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HIV-associated neurocognitive disorders (HAND) affect up to 70% of HIV positive 
individuals and are the leading cause of dementia in patients under 40 years. Despite 
this, the molecular mechanisms involved in the onset of HAND are not well understood. 
Among a number of plausible etiological agents of HAND, HIV-Tat has been shown to be 
neurotoxic in vitro and in vivo, but the basis of its induced neuronal dysregulation 
remains relatively poorly characterised, giving rise to various competing theories. This 
thesis describes differential, quantitative proteomic analyses of HIV-Tat-treated neuronal 
cells in vitro, the goal being to gain deeper insight into the underlying molecular basis of 
this HIV-Tat-mediated dysregulation, as well as to potentially inform better patient 
treatments in the future. To achieve this goal, deep, quantitative proteomic analysis of 
HIV-Tat treated SILAC-labelled SH-SY5Y neuroblastoma cells was carried out, alongside 
transcriptomic analysis of the same system in which 3077 proteins were identified and 
quantified with 407 proteins and 1074 genes being differentially expressed. 
Subsequently, label-free proteomics analysis was used to study the ability of lithium – a 
proposed new treatment for HAND – to suppress the HIV-Tat induced dysregulated 
molecular phenotype in SH-SY5Y cells in which 3757 were identified and quantified with 
360 and 531 being significantly differentially expressed in HIV-Tat and HIV-Tat + lithium 
treated cells, respectively. 
Detailed analysis of all three datasets enabled delineation of a sequence of signalling 
events which not only lead to HIV-Tat-induced apoptosis but which also account for 
degeneration of neuronal cell function. Interestingly, this analysis identified 
dysregulation of neurodegenerative processes thought to be involved in other dementias 
such as Alzheimer’s disease and Parkinson’s disease and, usefully, also confirmed the 
dysregulated of numerous pathways known to be important to HIV replication. In 
particular, HIV-Tat induced activation of several proinflammatory pathways including 
Toll-like Receptor, Interferon Regulatory Factor, RIG-1 and MDA-5 signalling was 
observed. This implies involvement of a proinflammatory response in the dysregulation 
of cytoskeletal reorganisation pathways, attenuation of protein synthesis pathways and 
the induction of apoptosis. In cytoskeletal regulatory pathways, Rho, Rac and cdc42 
signalling were found to be dysregulated; in protein synthesis pathways, EIF2 signalling 
was attenuated, as seen by the inhibition of several critical eukaryotic initiation factors, 
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and mTOR and P70S6K were also dysregulated; & initiation of apoptosis could be 
attributed to the accumulation, and resultant signalling, of ceramide due to the 
proinflammatory response. 
Pathway analysis revealed that lithium activated AKT and reversed the activation of 
several pro-apoptotic pathways such as ceramide and TNFR1 signalling, but also showed 
that lithium did not ameliorate, but instead increased HIV-Tat induced protein synthesis 
attenuation. Furthermore, several key cytoskeletal regulatory factors, including RhoA and 
ARP proteins, remained dysregulated after lithium treatment. Importantly, while lithium 
was found to decrease the apparent overall dysregulation of most HIV-Tat dysregulated 
pathways, numerous proteins and pathways implicated in neurodegenerative processes 
remained dysregulated or were specifically newly dysregulated by lithium. 
While it is unlikely that HIV-Tat is the sole contributor toward HAND development, the 
data presented in this thesis provides considerable new understanding of the extent to 
which HIV-Tat is able to induce significant dysregulation of the neural proteome, 
ultimately contributing to the neurodegeneration and synaptodendritic injury associated 
with disease onset and progression. Furthermore, the work described in this thesis also 
suggests that lithium is not able to prevent the dysregulation which underlies the HIV-









Infection with human immuno-deficiency virus type 1 (HIV) is a significant global health 
concern and is known to have adverse neurological effects. A significant portion of 
HIV-infected patients develop some form of HIV-Associated Neurocognitive Disorder 
(HAND). HAND describes three formal disease classifications; asymptomatic 
impairment (ANI), mild cognitive disorder (MND) and HIV-associated dementia (HAD). 
Up to 70% of HIV+ patients develop HAND1 and 90% of patients display autopsy 
evidence of neuropathology. Although the incidence of HAD have decreased since the 
implementation of Highly Active Antiretroviral Treatment (HAART), the incidence of 
minor cases of HAND have increased.2,3 The high incidence of HAND poses significant 
socio-economic challenges to South Africa as it has negative implications for 
behavioural and health outcomes, adherence to medication, rates of employment, and 
functional impairment.4 There are no current treatment possibilities for HAND other 
than HAART. Several studies have shown that patients treated with HAART improve in 
their neurocognition scores, but never fully remit. This implies that patients have had 
either significant neurological damage before the commencement of HAART, or that 
the neurotoxic environment was not removed. Whether or not the former is true it can 
be difficult to assess while the latter is a definite possibility. 
There is, currently, no rapid test for HAND. Diagnosis relies on neuropsychological, 
psychiatric and medical evaluation. Several diagnostic approaches have been 
proposed, however, due to variability in disease presentation and possible limitation in 
busy or recourse poor medical centres, there is a need for standardisation. In 2007, the 
American Academy of neurology (AAN) updated their proposed diagnostic procedure 
and established criteria for the diagnosis of three HAND syndromes: ANI, MND and 
HAD. A notable improvement over the previous procedure is that neurocognitive 
impairment is now required for HAND diagnosis. Previously, HIV neurocognitive 
disorders could be diagnosed on the basis of neuromotor and non-cognitive psychiatric 
changes such as changes in personality or mood.5 HAND diagnosis also requires that all 
other possible sources of neurocognitive impairment. 
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HIV Life cycle 
As an obligate intracellular parasite, HIV requires a permissive human cell for most of 
the machinery involved in its life cycle. The factors required are recruited and 
manipulated in order to facilitate maximal viral replication. In response to the threat of 
viral infection, host cells have developed several physical and functional mechanisms 
in order to limit infection and replication. 
HIV’s initial requirement is a host cell; the infection of which is governed by the cells’ 
expression of CD4 and CXCR4 or CCR5 of their surfaces. CD4+ T-lymphocytes and cells 
of the monocytic lineage along with several smaller populations of cells such as 
dendritic cells are the predominant host cells. CD4+ cell state also plays a significant 
role in the HIV life cycle where both active and resting cells are permissive to infection, 
but only active cells are permissive to viral replication. Since the majority of CD4+ cells 
are resting, there is typically a large population of latently infected cells which can be 
activated. Once bound to the surface of permissive cells through GP120 interaction 
with the CD4, GP120 undergoes conformational changes. In this process, GP120 
engages with either CXCR4 or CCR5 which, in turn activate GP41 mediated fusion of 
the viral and cellular membrane. Fusion leads to the ejection of the viral capsid 
containing its nuclear material into the cytoplasm. At this point, the virus faces a 
physical barrier to infection in the form of a dense cortical actin mass below the cell 
membrane. It is believed that interaction of the viral Env protein with the chemokine 
receptors initiates a cascade leading to the activation of actin depolymerising protein, 
cofilin, which degrades the cortical actin barrier. Once beyond the cortical actin barrier 
the capsid is transported along the cytoskeleton toward the nucleus. During this time, 
the viral genome is reverse transcribed and the preintegration complex is formed. 
Premature uncoating may be facilitated by the host cellular restriction factor, TRIM5α, 
and results in aborted infection.6 Once at the nuclear surface, the viral pre-integration 
complex (PIC) must traverse the nuclear membrane; a significant challenge as the PIC 
is 56 nm in diameter while the nuclear pore has a 28 nm central channel.7 Although it 
is not well defined, several factors including importin 7, histone H1, HIV-Vpr, matrix 
and integrase are required for importing the PIC into the nucleus.8,9 Following entry 
into the nucleoplasm, the PIC releases the viral DNA and integrase to allow 3’ 
processing and covalent strand transfer into the host genome. While integrase co-
ordinates the process, several host proteins such as DNA repair enzymes are 
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required.10,11 Although several genes have been expressed from the incoming 
cytoplasmic genome copies, transcription of the full genome only takes place after 
integration. Transcription of the HIV genome is primarily driven by HIV-Tat and several 
recruited host proteins such as RNA polymerase II. Once viral mRNA has been 
processed and exported to the cytoplasm by Rev, another major challenge is 
encountered. Viral protein synthesis relies entirely on the host translation machinery 
and, theoretically, has to compete with host transcripts for translation. Translation is 
also primarily co-ordinated by HIV-Tat through its binding to the 5’ HIV transactivating 
response element (TAR) mRNA sequence.12,13 There are several established examples 
of HIV actively dysregulating host protein synthesis machinery. 
One of the most studied and well recognised of these is the interaction between PKR, 
HIV-Tat and TAR. Briefly, PKR surveys the cytoplasm for viral replication and is 
activated by the resultant dsRNA. Through the phosphorylation of Eukaryotic initiation 
factor 2α (EIF2α), PKR is able to induce a global attenuation of protein synthesis. This 
process limits of completely inhibits the translation of most host mRNA’s but also 
serves to prevent active viral replication. To prevent this, it is reported that HIV-Tat 
binds and prevents the phosphorylation of EIF2α. There is, however, significant 
uncertainty about the mechanisms of this process in HIV-infected cells. The HIV mRNA 
translation process will be discussed in detail later. The final stage of the HIV life cycle 
is assembly, budding and maturation; each of which is co-ordinated by the polyprotein, 
gag, and its proteolytic products. The N-terminus of the Gag polyprotein, MA, targets 
and binds the plasma membrane and completely co-ordinates viral assembly by 
recruiting essential components such as Env, viral enzymes and the RNA genome. 
Although there is sufficient evidence that Gag and genomic RNA associates with actin 
structures, an intact actin cytoskeleton does not seem to be essential for assembly.14,15 
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Figure 1:A The figure represents brief depiction of the viral life cycle adapted from Sundquist and Kräusslich.16 A) 
During assembly, Gag polyproteins targets and binds the host plasma membrane via interaction with its N-terminal 
Matrix (MA). Gag continues to recruit essential components such as the viral RNA genome, Env products, gp120 and 
gp41 and the viral enzymes, IN, PR and RT. Gp120 and gp41 are impregnated into the plasma membrane and the 
RNA genome is packaged and bound the Gag C-terminal nucleoprotein, NC. As the budding process progresses, host 
ESCRT complex proteins are recruited to facilitate the membrane fission between the nascent virion particle and the 
plasma membrane. B) The Gag polyprotein and arrangement of the protein products within it. C) After fission, the 
immature virion then activates the viral protease which cleaves the Gag polyprotein into individual proteins which 
rearrange to form the mature, infectious virus (D). After Gag cleavage by the protease, MA proteins are structured 
below the membrane, the capsid protein arranges to form the core structure and the nucleocapsid (NC) associate 
with the RNA genome within the core. 
As the spherical immature virion is formed by co-ordinated Gag protein-protein 
interactions at the cell membrane, host ESCRT proteins are recruited to the budding 
particle and facilitates the fission between the nascent particle and the plasma 
membrane.17 Once budding is complete, unknown signals activate the viral protease 
which cleaves the Gag polyprotein into the individual proteins which rearrange to form 
the mature virus.16 The major steps in the HIV life cycle are illustrated in Figure 1. 
As neurons are not CD4+ and are, therefore, not typically infected by HIV, direct viral 
infection cannot be causative of neuronal degradation in HAND. The central nervous 
system (CNS) is, however, not immune to HIV. 
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HIV in the brain 
The blood-brain barrier (BBB) is a continuous layer of tightly linked brain microvascular 
endothelial cells tasked with separating the CNS from the periphery. The BBB is a 
selectively permeable membrane which regulates the tracking of molecules into and 
out of the brain parenchyma and the bloodstream. HIV has been shown to infect the 
brain very early after initial infection.18 While the mechanism is not entirely clear, HIV 
must have a means through which to cross the BBB in order to enter the brain. The 
Trojan horse theory suggests that HIV enters the CNS in infected monocytes migrating 
across the BBB into the brain parenchyma (Figure 2). 
 
Figure 2: Trojan horse theory: While there is evidence that HIV can migrate through BMVEC’s, it typically accepted 
that HIV initially enters the brain through invading, infected perivascular monocytes migrating across the BBB. 
These cells then shed replicative viral particles which go on to infect brain resident HIV permissive cells such as 
microglia. Once infected, microglia can be activated and induce and maintain an inflammatory environment in the 
brain.19 
Other work has shown that brain microvascular endothelial cells (BMVEC) in infected 
individuals contain HIV DNA which suggests that HIV may be couriered across the BBB 
through BMVEC’s. Invading virus or those shed from invading monocytes then infect 
resident brain cells, the majority of which are astrocytes and microglia, which then 
serve as both latent and active CNS reservoirs for HIV. Active or productive infection 
implies that HIV is constantly being shed from the cell surface whereas latent infection 
implies that the HIV genomic material is present, but is not being actively transcribed. 
It is believed that perivascular macrophages are the most common peripheral cell type 
to enter the CNS during infection. Together with microglia, these cells are capable of 
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forming multinucleated giant cells, or syncytia, which are a hallmark of HIV-
encephalitis. While astrocytes are typically not productively infected, latent infection 
leads to the secretion of monocyte chemoattractant protein, MCP-1, which contributes 
to the recruitment of activated macrophages into the CNS.20,21 Furthermore, the BBB is 
actively degraded during HIV infection which exposes the CNS to insults that it would 
not ordinarily encounter as well as increase the potential for continuous HIV entry.22 
Blood plasma molecules have access to the CNS via a disrupted BBB and have been 
shown to accumulate in neural tissues.23 This accumulation has a plethora of its own 
toxic effects. HIV has been shown to activate matrix-metalloproteases (MMP’s) which 
break down the BBB.24 Several mechanisms proposed to be involved in HIV induced 
BBB degradation are illustrated in (Figure 3). 
Due to unique selective pressure, the immune privileged environment in the CNS 
results in the accumulation of unique HIV genomic sequences in the CNS.25 HIV 
genomic sequences isolated post mortem from HIV Dementia patients’ brains have 
showed that CNS derived genomic sequences cluster separately from peripheral HIV 
genomic sequences relative to HIV-Tat.26 Furthermore, sequences also cluster relative 
to the brain area from which the sequences were isolated. This may be resultant of 
decreased immune surveillance in the CNS which alters the selective pressure and 
affects HIV genomic sequence evolution. 
As neurons are not productively infected by HIV, interaction with the infected cells or 
neurotoxic factors released by them must be causative of HAND pathologies. Infected 
microglia and brain resident macrophages can be activated by HIV infection itself, 
interaction with viral proteins or cytokine secretion by infected cells. Once infected 
and activated, these cells can secrete an array of neurotoxic factors including 
inflammatory cytokines IL-1β, IL-6, TNF-α, VCAM-1, ICAM-1, MCP-1 and PAF as well as 
excitotoxic amino acids.20,27,28,29,30 
Evidently, HIV induces significant alterations to cellular signalling during the infection 
and replication processes. To facilitate cell entry and movement through the cell, HIV 
modifies cytoskeletal regulation and structures. During replication HIV needs to hijack 
host protein translation machinery to ensure efficient synthesis of its proteins. 
Furthermore, these critical cellular functions need to be regulated by HIV despite the 
activation of innate antiviral response characteristic of HIV infection.31,32 
 




Figure 3: The mechanisms by which HIV exerts it toxic effects on the brain are numerous and complex. The image 
described several mechanisms through which HIV-Tat can alter the microvascular system and, ultimately, result in 
the degeneration of the BBB. Image adapted from Toborek et al.23 
Innate antiviral response and inflammation 
To successfully replicate in a human host, many viruses have developed means 
through which to modulate the host’s ability to activate the IFN mediated innate 
antiviral response. To achieve this, the activation of IFN regulatory factors by toll-like 
receptors, MDA-5 and RIG-1 are inhibited.33,34 No such ability has been reported for 
HIV. Ironically, sustained IFN production is characteristic of in vivo HIV infection. 
Although there are several different interferons, type-1 interferons of the alpha (IFNα) 
and beta (IFNβ) classes are the most studied and well characterised interferons 
released by host cells in response to viral infection. IFNα/β signals through a 
ubiquitously expressed receptor to activate a signal transduction cascade in response 
to viral infection. The specific antiviral response is mediated thereafter by any number 
of several hundred interferon response genes (ISG).35 
Given the diversity of potential human infective viruses present, it is no surprise that 
there is an array of distinct cell surveillance mechanisms by which the cell can detect 
viruses and mount a response. Interferon production through the recognition of 
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pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors 
(PRRs) is the first step in this process. While the specific mechanisms of activation vary 
between PRRs, they converge on downstream components. For example, the PRR’s 
RIG-I and MDA-5 are closely related in function but are non-redundant and induce 
interferon production by distinct means. Activated PRR’s induce the phosphorylation 
of the C-terminus of IFN regulatory factors (IRF) which then translocate to the nucleus 
where they induce the expression of IFNα/β. Activated PRR’s also result in the 
activation of the inhibitor of NF-κB kinase (IKK) and the subsequent phosphorylation, 
ubiquitination and destruction of inhibitor of NF-κB (IKβ) which results in the activation 
and nuclear translocation of nuclear factor kappa B (NF-κB) (Figure 4). Together with c-
Jun, each of these pathways can induce the transcription and subsequent production 
of IFNα/β. Through the subsequent IFNα/β activation, the antiviral pathways are 
engaged by specific compliments of ISGs being expressed. These ISGs number in the 
hundreds and are largely responsible for the innate antiviral effect of IFN.36,32 Since 
their discovery, much has been learned about the molecular cascades resulting in the 
activation of IFN and the subsequent antiviral pathways. However, much less is known 
about the specific genes being activated and their functions in the antiviral response.37 
The diverse array of functions of ISGs include cytoskeleton reorganisation, 38,35,39 
protein translation blockade 39,40,41 and apoptosis.42,43,44 
However, that some viruses are able to replicate despite the induction of a powerful 
antiviral response evidences the fact that they are able to overcome the intended 
inhibition caused. The mechanisms employed by viruses to overcome the antiviral 
response are diverse. Furthermore, there are several elegant descriptions of a viral 
requirement of the host antiviral response in order to replicate successfully. That the 
antiviral response primarily attenuates cellular protein translation evidences the 
importance of this system to viral replication. This also implies that viruses need to 
develop efficient means through which to overcome translational blockades. Indeed, 
several viruses are reported to not only antagonize the host’s efforts to inhibit viral 
protein synthesis but to require global protein translation suppression to replicate 
most efficiently. These include but are not limited to influenza, Hepatitis C virus (HCV) 
and dengue fever.45,46,47,48,49 
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Figure 4: Viral RNA binding induces the activation and subsequent signalling of RIG-1 and MDA-5. This activation 
cascade leads to NF-κB and IRF activation and nuclear translocation where they induce the expression of IFN-
stimulated, antiviral and various proinflammatory genes.50 
Primarily, the cytoskeletal effects of IFN play a role in barrier disruption and immune 
cell migration. It is well-documented that IFNα/β increase the permeability of 
epithelial barriers to facilitate immune cell migration into areas of inflammation. 
Similarly, IFN directly affects cytoskeletal reorganisation51 and its inflammatory effects 
are mediated by the cytoskeleton.52 The effects of IFN and inflammation on 
cytoskeletal reorganisation are discussed in detail by Ivanov et al.52 
Maintained activation of PRR’s, which results from the cells’ inability to effectively 
overcome the infection, the antiviral system induces apoptosis. Inflammation can 
induce apoptosis in many ways, through any of the stress responses it induces. The 
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involvement of viruses with the induction of apoptosis is not as much to do with 
replication directly but with prolonging access to replicative machinery. 
Neuroinflammation and neurodegeneration 
Inflammation creates a stress response in cells. If the inflammation is not resolved, this 
stress response persists and is associated with tissue damage and is involved in 
diseases such as asthma, Crohn's disease, rheumatoid arthritis, gastritis, otitis, celiac 
disease, and inflammatory bowel disease. Furthermore, many neurodegenerative 
diseases such as HAND, Alzheimer’s disease (AD) and Parkinson’s disease (PD) have an 
established inflammatory component.53 Since the acceptance that AD and PD patient 
brains contained an extensive milieu of proinflammatory molecules, extensive 
knowledge has been generated outlining the sources and some effects of this 
inflammation. In both AD and PD, the causative agents of this inflammation was fairly 
easy to discern; Aβ and α-synuclein deposits respectively.54 Furthermore, the resultant 
cell death in these diseases elicits an additional inflammatory response. However, 
teasing apart the effects of these deposits and the ensuing inflammatory response is 
more challenging. 
Aβ is neurotoxic and induces apoptosis when added to neuronal cultures alone, 
however, this effect is significantly increased when neurons are pre-treated with 
IFNγ.55 The inflammation resulting from Aβ and tangles further increases the 
expression of amyloid precursor protein (APP) which subsequently increases the 
formation of Aβ. A key marker of AD is tau hyperphosphorylation which is facilitated 
by CNS inflammation. Interestingly, acute and lasting increased cognitive impairment 
in AD patients have been correlated with peripheral infection events. The 
inflammatory events uncovered in AD brains are well-documented to be cytotoxic in 
the periphery; it is therefore improbable that they would be neurotoxic as well. 
Furthermore, upregulated inflammatory markers localize within areas of the brain with 
high AD pathology. Several clinical trials have provided evidence that classic anti-
inflammatory treatment delay the onset or progression of AD.56 
There is significant evidence for the involvement of inflammatory markers in PD. 
Studies have shown that both TNFα and IFNγ levels are altered in PD brains post 
mortem. Proinflammatory cytokines also correlate with disease severity in PD patients. 
Patients receiving therapeutic IFNα have been reported to exhibit a PD-like syndrome 
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including tremors, muscle rigidity and a generalized paucity of movement. Similarly, PD 
patients exhibit fewer infections and malignancies which may stem from increased 
systemic inflammation.57 The effects of IFN on neurons is predominantly thought to be 
exacted through microglia, however, IFN also has direct effects on neurons. IFN 
treatment increased calcium influx and nitric oxide production which subsequently 
depleted cellular ATP which lead to dendritic beading.58 While there may be 
significantly more biochemical events which are not outlined in this study, it provides 
evidence for the neurotoxicity of proinflammatory cytokines. 
Given the evidence that inflammation can cause neurodegeneration in well studied 
diseases, the inflammatory environment present in HAND patient brains likely plays a 
role in disease as well. Thus, it is reasonable to assume that the same effects elicited 
by inflammation in AD and PD are taking place in HAND. Although both PD and AD are, 
evidently, very complex diseases, HAND might be even more so. While there are 
certainly genetic predispositions involved in PD and AD, HAND has the additional 
complexity of a replicating virus within the CNS. A virus which is known to alter host 
biochemistry in order to favour its replication and which produces and secretes many 
non-host proteins, many of which are known to have deleterious effects on cells. 
To assess the inflammatory involvement in neurodegenerative disease, one must also 
consider the involvement of the brain resident macrophage: microglia. In common 
with other viral infections in other tissues, HIV infection induces an inflammatory 
response in the CNS. This response is typically beneficial and helps in the removal of 
the offending antigens. However, in the case of HIV infection, the virus persists and 
results in chronic inflammation in the CNS and periphery. Then, considering the 
cytotoxic environment induced by inflammation, it is not surprising that chronic CNS 
inflammation would have deleterious effects on CNS cells and, importantly, neuronal 
function. In healthy, non-inflamed brains, resting microglia are dominant with small 
cell bodies and many branched processes. Upon activation by various PAMPs or 
damage-associated molecular pattern molecules (DAMPs), microglia begin actively 
producing proteins such as iNOS and COX-II together with proinflammatory cytokines 
such as IFN and TNFα. These not only affect local neurons but also activate other 
microglia and astrocytes. This active state is maintained as long as antigen is present. 
Activated microglia can kill pathogens but are also capable of killing neurons directly.59 
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Possible origins of disease 
HIV, even when well managed, is a chronic disease which elicits an inflammatory 
response. In addition, viral proteins are present and circulating throughout the entire 
infection. Compounding this, HIV antiretroviral (ARV) treatments are inherently 
cytotoxic. ARV’s are certainly not required for HAND onset and progression, although, 
they do not inhibit the progression. Therefore, it is reasonable to suggest that HAND is 
caused by either the secretion of viral products interacting with neurons, the secretion 
of neurotoxic inflammatory molecules from infected or non-infected immune cells or a 
combination of these. 
ARV therapy and HIV Dementia 
The increase in minor HAND cases in the post HAART era raised questions pertaining to 
the involvement of ARVs in the development of HAND. HAND has been shown to 
persist while patients are on treatment despite supressed CNS viral loads.60 These 
observations have raised the simple question as to why HAND is persisting and 
increasing in incidence. Here, several possibilities may be causative: 1. HIV may be 
protected from the ARVs by the BBB. This would result in the unchallenged replication 
of HIV in the CNS facilitating continued CNS exposure to neurotoxins resultant of HIV 
infection. 2. ARVs themselves may be neurotoxic, thus eliciting similar symptoms to 
HIV-mediated toxicity. 3. Patients have suffered irreversible neuron loss before the 
commencement of HAART. 
Patients with advanced HIV being treated with drug cocktails with higher CNS 
penetrating effectiveness (CPE) values have lower CNS viral loads. However, patients in 
this cohort with higher CPE scores performed lower on neurocognitive tests.61 This 
trend was also found in patients treated with a greater number of drugs within their 
regiments.61 Higher CPE scores were also correlated with decreased or undetectable 
CNS viral counts which suggests that uncontrolled CNS replication of HIV is unlikely the 
cause of the persistence of HAND. Studies in developed countries have shown that 
patients on treatment do improve in their neurocognitive scores, although the 
symptoms sometimes do not fully remit. This suggests that either significant neuronal 
loss was present before the commencement of treatment or that the treatment is 
facilitating HAND development.60 Since the BBB is often severely compromised in HIV+ 
patients,62 it is not inconceivable that the levels of ARVs in the CNS rise considerably. It 
has been shown that several proteins achieve plasma levels in the CNS when the BBB is 
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compromised.63,64 Since the hypothesis that ARVs may be neurotoxic is relatively new, 
very little information is available on the topic. Consequently, we have not found 
possible mechanisms through which ARVs might be neurotoxic, although, it is widely 
accepted that ARVs are toxic to peripheral tissues. 
HAND is clearly a highly multifactorial disease. HIV is the most common form of 
encephalitis and neuroinflammation. Since viral burden does not correlate well with 
disease severity, it is most likely that secondary products of infection are key disease 
agents. This alone introduces a vast array and possible combinations of neurotoxic 
proinflammatory cytokines and viral proteins. The most prominent of the latter group 
would be GP120 and HIV-Tat as both are neurotoxic and secreted into the CNS despite 
undetectable viral replication,65,27,66,67 although, other viral proteins certainly have 
effects as well. As is evident in other well studied neurodegenerative diseases; there is 
scope for a large number of cellular functions to be dysregulated in HAND and 
contribute to the phenotype of neurodegeneration. 
Neuroinflammation in HIV infection 
Microglia can become activated in response to viral infection, viral proteins such as 
GP120 and HIV-Tat or factors released by other activated cells. It is known that HIV 
enters the brain early after infection and infected microglia have been detected 15 
days after infection; suggesting that the brain is exposed to early inflammation. A 
prominent feature of microglial infection by HIV is the development of microglial 
nodules. HIV patients who developed HAND showed increased microglial density, 
decreased synaptic and dendritic density and neuronal loss between successive follow-
ups. Cases with severe HAD suffered a 40% loss of dendritic area in frontal cortex and a 
40–60% loss of dendritic spine density in comparison with non-demented controls.68 
Several studies, however, showed that neuronal loss was not correlative with viral 
burden and apoptotic neurons did not localize with infected microglia but were 
topographically associated with markers of microglial activation. Furthermore, the 
cytotoxic cytokine, TNFα and its receptor, TNFR, are elevated in microglia in HAD 
patients. TNFα affects neurons in many ways including cytoskeletal reorganisation, 
protein translation modulation and inhibition of neurite outgrowth.69 HAD patient 
microglia also contain increased levels of IL-1B which is can induce the expression of 
TNFα and iNOS. NO regulates the release of many neurotransmitters such as 
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acetylcholine, catecholamines, excitatory and inhibitory amino acids, serotonin, 
histamine, and adenosine.70 Therefore, the release of NO may further contribute to 
neuronal dysfunction and injury. 
Inflammation in the brain is associated with impaired neural plasticity.71 The term 
“neural plasticity” encompasses an array of mechanisms, from the birth, survival, 
migration, and integration of new neurons to neurite outgrowth, synaptogenesis, and 
the modulation of mature synapses. Impairment in neuronal plasticity is an early 
hallmark of neurodegeneration and is intimately linked to the symptoms of 
neurodegeneration. High degrees of neuronal plasticity are particularly important in 
brain areas involved in regulation of memory, learning, perception, self-awareness, 
consciousness, and higher brain functions as these require a life-long re-fitting of 
connectivity. By extension, these are the first functions affected by impaired neural 
plasticity.72 
In general, inflammation brings about many cellular changes in order to respond to 
viral infection. The effects influence regulation of protein synthesis replication and 
cytoskeletal regulation. Attenuation of protein synthesis is the primary means through 
which cells counter viral replication before the initiation of apoptosis. Cytoskeletal 
reorganisation is essential for immune cells to travel toward site of inflammation. 
Similarly, epithelial cells need to increase membrane permeability which is primarily 
induced through cytoskeletal regulation. 
Neurotoxic viral proteins 
GP120 
Glycoprotein 120 is the envelope protein of HIV and functions in the attachment and 
penetration of HIV into host cells. HIV-1 cell entry is initiated by the interaction 
between gp120 and CD4, and chemokine coreceptors C-X-C chemokine receptor 4 
(CXCR4) and C-C chemokine receptor type 5 (CCR5). Although they typically referred to 
as immune receptors on CD4 cells, neurons also express both coreceptors; where they 
have been reported to be involved in neuronal migration 73 and proliferation.74 
Exogenous GP120 binding to these receptors induces apoptosis in neurons which can 
be blocked by inhibitors to the receptors. Interestingly, pre-treatment with brain-
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derived neurotropic factor (BDNF) protects against GP120 induced apoptosis, 
mediated by BDNF-induced internalization of CXCR4.75 
HIV Transactivator of transcription 
HIV-Tat function 
HIV-Tat is the most important regulator of HIV gene regulation and expression.76 HIV-
Tat has been shown to activate Long Terminal Repeat (LTR) directed transcription. It 
performs this function by binding a Transactivating Response Region (TAR) RNA stem 
loop immediately downstream of the initiation sequence. This is followed by the 
assembly of the positive transcription elongation factor b (p-TEFb) containing Cyclin 
Dependant kinase-9 (CDK9) and Cyclin T1.77,76 The HIV-Tat/p-TEFb complex then 
phosphorylates the C-terminus of RNA polymerase II (Figure 5).78 In phosphorylating 
RNA polymerase II, both its initiation and elongation functions are enhanced resulting 
in the rapid transcription and translation of its RNA genome. Although HIV-Tat forms 
complex interactions with host cellular machinery to achieve HIV replication, it does 
not interact only with them. Many of HIV-Tat deleterious effects are resultant of its 
ability to bind many host proteins, transcription factors and promoters.79,76,80,81,77,78 
HIV-Tat Protein structure 
HIV-Tat consists of two exons, the first of which composes of the functional domains 
while the functions of exon two are possibly situation specific  and complimentary to 
the functions of exon 1.82 Exon 1 codes for 72 amino acids while exon 2 has a highly 
variable length.83 The crystal structure of HIV-1 Tat complexed to human p-TEFb has 
recently been determined.84 Although these domains, illustrated in Figure 6, have 
been studied before, the crystal structure aided in understanding the roles of these 
domains regarding both structure and function. The determination of the structure 
emphasised the role of the cysteine-rich region in the structure of HIV-Tat as well as 
the recruitment and binding of P-TEFb, which is essential to HIV-Tat’s transactivation 
function.84 
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Figure 5: Showing the p-TEFb complex formation initiated by HIV-Tat. Once the p-TEFb complex is assembled, the C-
terminus of RNA polymerase II is phosphorylated (b) which increases the rate of initiation and elongation. Image 
adapted from Karn, 2000.85 
The seven cysteines in the cysteine-rich region help coordinate the formation of a 
novel zinc finger like structure with two Zn2+ molecules.84 Previous work has shown 
that oxidising conditions destroy HIV-Tat function and result in aggregation.86 
HIV-1 Tat protein is extremely variable in its peptide sequence which results from viral 
replication by the error prone Polymerase II.87 HIV-Tat is reported to tolerate ~40 % 
mutations overall without losing biological activity.84 This high tolerance for mutation 
supported by the high mutation rate of HIV replication results in an enormous diversity 
in HIV-Tat genomic sequences found in vivo. It also promotes the selection of viruses 
able to exploit any tissue it may infect. This mutation rate also affects the length of 
exon two which results in variant proteins with 72aa, 86aa and 101aa being the 
commonly referred to lengths, though HIV-Tat proteins larger than 101aa have also 
been reported.82,86 
 
Figure 6: A linear representation of the functional domains of HIV-Tat protein. Exon 1 is thought to contain all the 
functional domains while exon two functions are unclear. Image adapted from Tahirov et al.84 
While they retain their transactivation function, the different lengths of HIV-Tat 
protein have significantly different properties such as cellular localization, 
transactivation and membrane transduction.88,89 Based on current knowledge of 
protein function, it is conceivable that different sequences of HIV-Tat have diverse in 
b) HIV-Tat activated elongation 
  a) HIV-Tat binds pTEFb and TAR 
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vivo characteristics. Since HIV can infect a variety of cells in different tissues,90,91,92,93,94 
it is also conceivable that various protein sequences arise to exploit different tissues. It 
is possible that the diversity in protein sequences add to HIV-Tat’s ability to bind a 
variety of host molecules 95,96 and therefore its toxicity. 
HIV-Tat toxicity 
While HIV-Tat acts as a pro-survival factor in many tissues,97,98 it induces apoptosis in 
neurons.99,98 Despite extensive research efforts and suggested mechanisms by which 
HIV-Tat causes apoptosis in neurons, there is no consensus. One commonality in the 
suggestions is that it acts through the activation of Glycogen Synthase Kinase-3β (GSK-
3β) to induce apoptosis.100,101,99 In addition to being directly neurotoxic, HIV-Tat has 
various other effects such as promoting the production of cytokines65 and cytokine 
receptors,102 proliferation and migration of different cell types and exerting angiogenic 
activity in vitro and in vivo. 
The specific mechanisms of these phenotypes are unclear but may result from either 
HIV-Tat’s protein binding characteristics through which it may directly alter protein 
function or transactivating activity by altering expression patterns. HIV-Tat protein has 
been shown to activate many host genes as well as bind to many host proteins. Each of 
these genes and proteins may have an effect on the cell state. Additionally, HIV-Tat is 
able to bind to many cytokine receptors, which may result in signal cascades having 
significant effects.21,103 
A likely in vivo candidate pathway is the platelet activating factor (PAF) pathway.101 In 
an HIV-infected brain, infected and activated microglia, macrophages and neurons all 
release TNF-α.104 TNF-α in turn initiates the proinflamatory release of PAF from 
microglia and macrophages.105,101 Through the activation of PAF receptors on neurons, 
AKT and PI3K are inactivated.106 This results in active GSK-3β which is able to activate 
caspase mediated apoptosis pathways.107,108 This proposed pathway requires PAF 
production by microglia and macrophages. It has, however, been shown that HIV-Tat is 
able to stimulate apoptosis in vitro without the involvement of PAF.65 These studies 
have also shown an increase in GSK-3β activity when treated with HIV-Tat,27 suggesting 
that there are other pathways activated by HIV-Tat that can lead to apoptosis. Two 
popular mechanisms proposed are the production of reactive oxygen species (ROS) 
and an increase in cellular calcium levels. 
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The generation of ROS and the increase in cellular calcium are interlinked and are 
resultant of one another. HIV-Tat induces the release of ROS in neurons and microglia, 
which in turn induces oxidative stress in neurons.105,65 HIV-Tat has been shown to 
induce mitochondrial membrane hyperpolarisation (MMHP) and calcium influx.109 
MMPH possibly results in increase proton-motive activity and therefore, increased ATP 
production.105 This process in turn results in increased oxidative stress and neuronal 
toxicity.110 Increased Ca2+ has an additional effect on astrocytes’ cytokine production. 
It has been shown that increased astrocyte intracellular Ca2+ can activate NF-κB.110 This 
in turn increases the production of neurotoxic cytokines such as TNF-α by 
Astrocytes.105 TNF-α increases ROS production in microglia,111 thus, perpetuating the 
neurotoxic effects due to chronic exposure to HIV-Tat. 
While HIV-Tat may have direct effects influencing neuronal survival, it also indirectly 
affects neurons through NF-κB. Astrocytes induce the activation NF-κB as a 
neuroprotector in response to stress in the CNS.99,112 During HIV infection, HIV-Tat 
decreases the neuroprotective activity of NF-κB through the activation of GSK-3β via 
the PI3K/AKT pathway. GSK-3β phosphorylates serine 468 on NF-κB subunit rel-A 
which decreases its transactivation activity and limits its ability to initiate pro-survival 
expression within neurons. 99,113 This is surprising as NF-κB is a transcription factor 
controlling TNF- α expression. TNF- α increases the production of HIV virions in cells of 
monocytic lineages114 as well as activate GSK-3β. There is certainly a very delicate 
equilibrium between GSK-3β and NF-κB activity resulting in the expression of various 
proinflammatory cytokines. 
HIV and protein translation 
Due to the activity of the antiviral inflammatory response in attenuating protein 
synthesis so as to combat viral replication, HIV’s obvious ability to thrive under or 
circumvent the intended effects are being investigated. There are four mammalian 
kinases capable of phosphorylating and inactivation eukaryotic initiation factor 2α 
(EIF2α): general control nonderepressible 2 (GCN2), double-stranded RNA-activated 
protein kinase (PRK), PKR-like endoplasmic reticulum-resident kinase (PERK) and 
heme-regulated inhibitor kinase (HRI).115 Of these, PKR is activated through 
inflammation and the presence of dsRNA, thus, it is the primary means through which 
cells attempt to attenuate viral replication in virally infected cells. PKR would, 
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therefore, be an obvious target of investigation in HIV related protein synthesis 
research. However, there seems to be contention over the role of PKR during HIV 
infection. 
A common opinion is that PKR autophosphorylation and, thus, activation, is inhibited 
by binding to HIV-Tat, thus, it is unable to phosphorylate its target, EIF2α. However, it 
is evident that HIV-Tat requires phosphorylation by PKR for maximal activity. This, 
therefore, suggest that PKR is not inhibited, but that it may be modulated by 
competitive binding with HIV-Tat. This is further supported by the evidence that HIV 
replication is strongly inhibited in PKR knockout cells. It is, therefore, clear that HIV 
replication requires some level of PKR activity. Contradictory to this, however, is 
research suggesting that any PKR activity is inhibitory to HIV replication.116 In their 
review, Clerzius et al, also claim that PKR is strongly inhibiting of HIV replication and 
that PKR is inactivated during late stage infection, due to high levels of TAR RNA which 
inhibit PKR and then allow for HIV replication.117 This model assumes that HIV 
transcription can proceed while PKR is actively inhibiting protein synthesis until 
sufficient TAR RNA can be accumulated. This work, however, was performed in vitro 
and without directly measuring the resultant HIV replication rates. Furthermore, the 
authors propose that, due to dsRNA binding and PKR dimerization requirements, high 
concentrations of TAR would inhibit PKR activation.118,119 Similar work, but including 
HIV-Tat, shows that the concentration of dsRNA required to activate PKR in vitro 
increases with HIV-Tat concentration present.120 Furthermore, if HIV required 
inhibition of PKR, its replication would not be strongly inhibited in PKR knockout 
models. It is clear that there is significant confusion over the role of the most studied 
antiviral protein, PKR, and its regulation and requirement during HIV infection. 
Mammalian protein translation is a sequential, multi-step process which begins with 
the formation of the preinitiation complex. The initiator Met-tRNAiMet is bound by EIF2 
to initiate the formation of an eIF2/GTP/Met-tRNAi complex which is delivered to the P 
site of the 40S ribosomal subunit to form the 43S preinitiation complex. The 43S 
preinitiation complex must then be recruited to the mRNA. EIF4E binds the m7GpppX 
5’ cap sequence and forms the EIF4F complex with EIF4G and EIF4A. EIF4EBP bind and 
inactivates EIF4E which inhibits protein synthesis by preventing cap recognition.EIF4A 
helicase activity is increased 10 fold when increasing its affinity for ATP when bound to 
EIF4B. Additionally, EIF4B promotes the formation of the 48S complex. EIF3 plays a role 
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in the formation of the preinitiation complex as well as the 43S complex. Following the 
recruitment of the 43S complex to the mRNA, the AUG codon needs to be located by 5' 
untranslated region (UTR) scanning. Beginning at the 5’ cap, the 43S complex scans the 
UTR for the AUG and translation is initiated when a favourable pairing between Met-
tRNAiMet and AUG forms which completes the formation of the 48S complex. EIF1 and 
EIF1A also function to promote the formation of the 48S complex at the AUG 
codon.121,122,123 
While PKR and its phosphorylation of EIF2α are likely the most studied relationships 
between HIV and host protein translation, HIV is known to affect other Eukaryotic 
initiation factors and ribosomal proteins. Since many proteins and protein complexes 
are required to initiate and maintain protein synthesis, dysregulation of any required 
protein would dysregulate the entire process. HIV protease has been shown to cleave 
EIF4G and, thereby, inhibit cap-dependant mRNA translation; upon which host mRNA 
translation is dependant. 
HIV and the cytoskeleton 
Cytoskeletal components play a major role in the execution of a diverse array of 
cellular functions including cell shape maintenance, cell polarity and movements as 
well as cytoplasmic trafficking of molecules determining cell fate and including 
apoptosis. As a result, the cytoskeleton plays a role in the entire life cycle of HIV. 
Cytoskeletal dynamics are controlled by the Rho small GTPases composed of the Rho, 
Rac and cdc42 protein superfamilies. Since HIV modulates cytoskeleton dynamics, 
these cytoskeletal regulating proteins are a potential source of the HIV induced 
cytoskeletal dysregulation, through either direct or indirect activity. It has been 
suggested that actin microfilament redistribution and cytoskeletal contraction 
facilitate receptor clustering in the cell membrane.124,125 HIV entry is dependent on the 
process or co-receptor clustering by Rho-dependant cytoskeletal reorganisation which 
is responsible for the process of receptor clustering. Statins, which inhibit Rho activity 
block HIV envelope fusion with the target cell and, thereby, reduces cell infection. 
Cells have a physical barrier against viral and endocytic vesical entry below the cell 
membrane known as the cortical actin network. For viruses to infect the cell, they 
must overcome this barrier.126 It is believed that HIV Nef protein binding and activating 
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Rho GTPases dysregulates the cytoskeleton and allows HIV to circumvent this barrier 
during infection. Furthermore, Nef induces actin reorganisation such as to facilitate the 
movement of the viral core 127 which makes use of dynein to move toward the nuclear 
pore complex.128 A Nef binding domain was identified in SH3-domain containing 
proteins and is believed to be required for its Nef mediated inhibition.129 
Viral assembly and budding also require specific cytoskeletal reorganisation. Although 
the mechanism is not clear, virion self-assembly occurring at the plasma membrane is 
thought to induce the formation of a cellular protrusion.130 The formation of a cellular 
protrusion requires the formation of a focal adhesion and actin polymerisation behind 
the focal adhesion. This process would, presumably, be controlled by the cytoskeletal 
regulators, Rho, Rac and cdc42. The protrusion formed continues to grow until the 
virion is released from the membrane. The final release is mediated by proteins 
traditionally involved in the generation of endosomal compartments called 
multivesicular bodies.131 
Glycogen Synthase Kinase in HAND 
Glycogen Synthase Kinase (GSK) is expressed in many tissues with particularly high 
levels in the brain and phosphorylates over 40 target substrates.132 It functions as a key 
component to several pathways including cell fate regulation. GSK homologs are found 
in all eukaryotes with high degrees of homology. Protein function is also conserved 
across all eukaryotes. Two isoforms with over 98% conservation in their kinase 
domains have been isolated: GSK-3α and GSK-3β. Despite the high levels of similarity, 
their functions are non-redundant in vivo. 133 It is believed that GSK-3α and GSK-3β are 
inhibited by S21/S9 phosphorylation respectively by Phosphoinositol-3-Kinase 
(PI3K).134 Mutation studies substituting S21/S9 for alanine have since revealed that 
these are less important than previously thought. This was supported when Y216 was 
identified as being phosphorylated in vivo which was later shown to increase GSK kcat 
fivefold.135 The mechanism responsible for GSK tyrosine phosphorylation is currently 
controversial.136 
HIV-Tat was shown to increase GSK-3β activity but not protein levels in vivo. Although 
HIV-Tat does co-precipitate with GSK-3β, it does not directly dysregulate its activity 
which suggests that its dysregulation is resultant of dysregulation induced in upstream 
pathways.27 While no data is available pertaining to in vivo GSK-3β activity in HAND 
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patients, data regarding AD patients has been reported. These studies have shown a 
correlation between GSK-3β activity and AD development.137 In AD, GSK-3β is of 
particular importance as it directly phosphorylates tau protein and its inhibition 
inhibits Aβ induced neuronal apoptosis. Similarly, its inhibition by lithium inhibits HIV-
Tat induced neuronal apoptosis.27 
Lithium 
Lithium has been prescribed for the treatment of Bipolar Disorder (BD) for nearly 60 
years.138 Despite having received approval for treatment of BD, the molecular targets 
and mode of action responsible for the behavioural alterations remains poorly 
understood. 
Very little is known about lithium molecular targets other than its activation of AKT. 
Several phosphorylation events such as tau phosphorylation, have been shown to be 
inhibited by lithium. The effect on tau protein is predicted to be via the inhibition of 
GSK-3β as it is a tau kinase. A mechanism for the lithium-induced inactivation of GSK-
3β is outlined in the review by Freland and Beaulieu.139 In addition to direct GSK-3β 
inhibition, lithium also activates AKT by promoting the dissociation of its inhibitory 
complex composed of AKT:βArr2 and PP2A.139 Lithium is also reported to favour the 
dissociation of the PP2A regulatory subunit which abolishes its activity.140 The work by 
Chen et al, does not address lithium’s effect on other PP2A regulatory subunits but it 
may be that they are similarly affected. In addition to its effects on GSK-3β, AKT and 
PP2A, lithium has also been shown to inhibit inositol monophosphatases, bisphosphate 
3’-nucleotidase and cyclooxygenase. Whether or not these effects are linked is not 
known. 
Since its initial use as a mood stabiliser, lithium has found therapeutic value in many 
neurodegenerative and neurotoxic settings. While lithium is certainly able to inhibit 
apoptosis induced by a variety of neuronal insults, it has not produced particularly 
promising results in vivo.141,142,143 
Due to lithium’s apparently safety as chronic treatment and its inhibition of HIV-Tat 
induced neuronal apoptosis in vitro, it has been proposed as a treatment for HAND. 
While it is widely accepted that lithium has several cellular targets beyond GSK-3β, an 
exhaustive list of targets has not been generated. Whether or not lithium’s mood 
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stabilising ability is due to GSK-3β inhibition or not is still unclear. In spite of this, 
several small trials have been performed to test lithium’s efficacy as a HAND 
therapeutic agent. While one prominent and often cited publication by Letendre et al, 
show neurocognitive improvement by HAND patients treated with lithium over 10 
weeks, they do not rule out the possibility of practiced effects, spontaneous remission 
and test error due to the uncontrolled study design.141 Others suggest that lithium is 
safe to use and propose further studies, but they do not report significant 
improvements in HAND patients.142 However, an early study reported that lithium was 
not well tolerated by HIV positive men and that most patients did not complete the 
study due to toxicity.143 
Lithium was essentially proposed as a treatment possibility due to the involvement of a 
single molecule, GSK-3β and its role in HIV-Tat induced neuronal apoptosis. 
Considering the results of previously performed clinical trials, it is clear that the 
involvement of GSK-3β and the subsequent use of lithium should be carefully 
evaluated. In addition, it is clear that the molecular aetiology responsible for HAND 
onset and progression is poorly understood. HAND mechanisms have been studied for 
many years, yet there are still a great many contradictions and even greater 
uncertainty in the molecular events facilitating HAND onset and progression as well as 
the possible cellular effects they induce or contribute to. While understanding the 
basic molecular dysregulation that occurs in and contributes to HAND is interesting 
and important, we also need to link these molecular events to cellular functions and 
resultant phenotypic alterations which ultimately lead to the symptoms. Given the 
probable complexity present in HAND onset and progression, it is becoming imperative 
that we study these multifactorial diseases in a manner that allows us to view the 
interactions of multiple cellular systems together. This would allow us to gauge the 
contributions and interplay between many systems in disease development and, 
thereby, generate new models which take the complexity into account and allow us to 
better identify drug targets which may be more specific for dysregulations contributing 
to disease. In addition, it is important to understand the effect of lithium on HAND 
beyond its effect on GSK-3β. Such a study might allow us to gauge the involvement 
GSK-3β in the dysregulation of cellular functions responsible for disease onset and 
progression. 
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Unfortunately, typical biochemistry approaches to identifying dysregulation induced by 
potential causative agents require a hypothesis. This limits the scope of the work to 
identifying disease contributors which were previously implicated. This approach is 
unable to identify novel outcomes nor is it able to consider any proteins and pathways 
not specifically targeted in the experiment. To understand a disease as complex as 
HAND is proving to be, viewing a snapshot of the dysregulated cell state in comparison 
to a healthy cell may allow us to provide a comprehensive overview of the 
dysregulation underlying disease as well as to better describe those molecular features 
in the context of disease onset and development. Such an analysis would require the 
analysis as large a proportion of the cells’ machinery as possible and identify 
differences between a ‘disease’ and ‘healthy’ state. 
Teasing apart the Differences 
The determination of specific pathways integral to the development of HAND is 
hindered by the intricate interactions and, often, conflicting pathways implicated to 
date. An all-encompassing explanation of these interactions has not yet been 
presented. It is likely that a global “snap shot” of these pathways interacting with one 
another will identify specific pathways central to the development of HAND. Such a 
snapshot would compose all the cellular proteins presents in forms and levels relevant 
to the physiological stress being studied. Generating such data is possible through 
mass spectrometry (MS) based techniques. Using MS, researchers are theoretically 
able to identify all forms and levels of all proteins representing the exact state of the 
cell. Computational differential analysis between stressed and unstressed sample 
groups allows the identification of differentially expressed or activated proteins 
between the two states. Using gene ontology, it is possible to use this information to 
identify pathways activated during the particular stress. 
Assaying complex biology using proteomics 
To begin assessing the complexity present in a biological system, we need to be able to 
measure as many contributory components as possible, simultaneously. Genome 
sequencing has revealed that the human genome is composed of approximately 20, 
000 genes, a subset of which is actively transcribed in individual cells. Current 
technology already allows us to determine the transcription rates of the entire human 
genome in single experiments. The proteome, however, is significantly more complex 
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and is incongruent with transcription levels. While the true values are not known, 
there are an excess of 1 million individual functional protein species that can 
theoretically be formed from the ~20 000 human genes.144,145 This is due to alternate 
splicing, post-translational modifications and cleavage products. This is to say that 
singly, doubly or triply phosphorylated versions of the same primary amino acid 
sequence with the same fold are in fact different proteins as they potentially have 
different functions. Complimentary to genomics, proteomics enables the high 
throughput analyses of the protein complexity representing a snapshot of the cell state 
at any point in time. 
Two-dimensional gel electrophoresis 
Classically, proteomics has entailed the analysis of complex protein samples by two-
dimensional gel electrophoretic (2D-PAGE) methods which relies on two dimensions of 
protein separation. The first is separation performed by loading proteins on isoelectric 
focusing (IEF) strip which contains regions of varying pH. As proteins migrate along the 
strip under the influence of an electric current, they reach their isoelectric pH at which 
they carry no charge, and stop migrating. The strip is then placed lengthwise atop an 
SDS-PAGE gels and resolved in the second dimension as per standard SDS-PAGE 
methods. The resultant protein ‘spots’ can then be quantitated by densitometry. Based 
on this quantitation, spots of interest are excised and the proteins identified by MS. A 
drawback of this technique is that it is time-consuming and poorly reproducible. The 
most modest shifts in mobility in either dimension can result in spot mismatching 
during quantitative analysis and identification.146 Furthermore, it is unable to 
efficiently resolve the complexity of whole proteomes due to multiple proteins 
migrating together. This meant that the densitometric quantitation was of undefined 
protein mixtures rather than a single protein. This made differential analysis between 
samples troublesome and relatively few proteins could feasibly be identified in an 
experiment.147,148,149 As a result, 2DE is an inefficient means with which to analyse 
proteome complexity.150  
A major advancement in 2D-PAGE technology was the development of 2D-DIGE. One 
of the major advantages of 2D-DIGE over 2D-PAGE is that samples can be analysed 
together on the same gel; this mitigates the possibility of spots in one sample shifting 
 
28 | P a g e  
 
its relative position compared to the other.151 In addition, spots can be quantitated 
and directly compared between samples. 
The spot position variability between 2D-PAGE gels is eliminated by the addition of a 
differential labelling step followed by sample mixing prior to IEF focusing. Up to three 
samples can be compared by labelling proteins with different, spectrally resolvable 
cyanine dyes (CyDyes). Once labelled, equal protein quantities of each sample are 
mixed and loaded onto a suitable IPG strip for IEF focusing as in 2DE. After separation 
in the first and second dimensions is complete, the gels are analysed by CyDye specific 
scanners which are able to differentiate between fluorescence from each CyDye. This 
allows for direct relative quantitative comparison between samples for each spot.152 
Both 2D-gel methodologies rely on MS to identify proteins within each spot. Spots of 
interest are excised from the gel and subjected to in-gel digestion which is a common 
process employed to extract proteins from PAGE gels for MS identification. Despite 
addressing the reproducibility of 2DE, 2D-DIGE was inherently low throughput. The 
requirement for every spot of interest to be excised from the gel and processed for MS 
identification could not be avoided and was labour intensive. In addition, there was 
still a high possibility that each spot of interest contained many proteins and that 
neither of them are significantly differentially regulated. Over time, advances in MS 
and protein/peptide ionisation techniques, MS-based proteomics emerged as an 
answer to the limitations of gel based proteomics. 
A new ‘proteomics’ 
As proteomics was being ported from gel-based methods to MS-based methods, 
another important reform occurred. Gel based methods typically analysed intact 
proteins whereas MS methods typically analysed the peptides resultant from chemical 
or enzymatic cleavage of those intact proteins. Intact protein analysis became known 
as top-down proteomics, which contrasted bottom-up proteomics, which refers to the 
analysis of protein derived peptides in order to extrapolate the data generated to 
identify and quantify proteins in a given sample. Both techniques rely on direct 
intensity measurements and protein/peptide sequencing for quantification and 
identification, respectively. Modern MS based bottom-up proteomics proved capable 
of significantly higher throughput and reproducibility than top-down methods and 
quickly dominated proteome analysis workflows. Despite its advantages, top-down MS 
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is typically limited to the analysis of single proteins or simple mixtures. One caveat of 
bottom-up vs top-down approaches is that bottom-up analysis, unlike top-down 
experiments, very rarely yields 100% protein sequence coverage of individual proteins. 
Coupled to inherent variability in peptide ionisation efficiencies, this creates a problem 
for quantification and identification. Data analysis for bottom-up proteomics will be 
discussed in more detail later.  
Mass spectrometry 
Modern advancements in proteomics, specifically the capabilities of MS, have allowed 
for the side-by-side quantitative comparison of a large proportion of proteins within a 
biological sample. MS has fast become an invaluable tool in the proteomic analysis of 
complex protein samples ordinarily used for biomarker discovery. 
Shotgun proteomics is a method of identifying proteins in complex mixtures using a 
combination of high performance liquid chromatography combined with MS.153 By 
definition a mass spectrometer consist of an ion source, mass analyser and a detector 
which records data allowing the mass and abundance of each ion species present to be 
determined. MS has a lower detection limit than any other high-throughput discovery 
technique.154,150 MS provides an unrivalled platform from which to perform an in depth 
proteomic analysis of a complex biological sample. 
There are several mass analysers used in an array of mass spectrometers, but the most 
popular are time-of-flight (TOF), Fourier-transform ion cyclotron resonance (FTICR), 
linear ion trap (LIT) and Orbitrap mass analyser. Each operates by different physical 
principles to achieve the same basic function; to separate ions according to their 
mass/charge ratio. The TOF instrument is essentially a long tube into which ions 
uniformly accelerating toward a detector. Due to the uniform acceleration, larger ions 
travel slower than smaller ions with the same charge and are, therefore, separated in 
time. A modification of this is TOF/TOF which increases resolution by increasing the 
flight path with a second TOF tube. 
FTICR-mass analysers differ from TOF instruments in that the ions are not separated in 
time; instead, ions are maintained within a strong radial magnetic field and an axial 
electric field applied by trapping plates (Figure 7). Ions are briefly excited upon 
entering the magnetic field; when the excitation is removed, the ions are rotating in 
phase at their cyclotron frequency. The ions are, thereby, maintained in an orbital 
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motion within the magnetic and retained axially by the electric field. As all ions 
entering are excited together, ions with higher m/z values adopt different rotation 
patterns to those with lower m/z.155,156 
 
Figure 7: Schematic FTICR-cell. Ions are injected coaxial to the magnetic field. Excitation and detection plates can be 
seen with the trapping plates at each end of the cell. (Image adapted from: http://what-when-
how.com/proteomics/ft-icr-proteomics/) 
The linear quadrupole ion trap consists of four rods with hyperbolic inner surfaces 
arranged to create a hollow central channel. In addition, each rod consists of three 
regions; front, centre and back (Figure 8). This design allows ions to be contained and 
controlled radially in the central channel by applying a radio frequency (RF) voltage 
across the four rods and axially by applying DC potentials in the front and back of each 
rod. In order to facilitate mass selection and MS/MS, additional AC voltage is applied 
across x-rods.157 
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Figure 8: A schematic diagram of the linear quadrupole ion trap.157 
The orbitrap mass analyser is relatively comparable to the FTICR in principle. Orbitraps 
also maintain ions in orbital motion, but this motion is maintained by an electrostatic 
field generated between an outer barrel and an inner spindle-like electrode. Unlike 
FTICR, ions don’t require excitation to assume a harmonic oscillation pattern in the 
electric field after being squeezed into the orbitrap perpendicular to the inner spindle.  
 
 
Figure 9: A cutoff representation of the Orbitrap analyser. The inner (a) and outer (b) electrodes can be seen with 
the amplifying detector (c) situated in the outer electrode. (Image adapted from: 
https://en.wikipedia.org/wiki/Orbitrap)   
The oscillating ions induce an image current which is detected via a differential 
amplifier positioned between the two halves of the outer electrode (Figure 9). Each 
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ion rotation induces an image current which is recorded into a frequency spectrum 
and, using fast fourier transformation, is converted into a mass spectrum. 158,159,160, 
FTICR detectors work on the same principle where ions create an image current on the 
amplifying detector plate. In contrast to the differential amplifying, non-destructive 
detectors present in the FTICR and orbitrap mass analysers, destructive electron 
multipliers, are another common detector used in MS. In electron multipliers, the ions 
impacting the first dynode generate secondary electrons which are accelerated to a 
secondary dynode where each electron generates several more electrons. As this 
process is repeated, the original sample is multiplied, thereby, increasing sensitivity.161 
Mass spectrometry-based proteomics 
Since its entry into the proteomics arena, MS has become an indispensable technology 
in the analysis of complex protein samples. A mass spectrometer is typically composed 
of three parts, an ion source to produce the gas phase ions, a mass analyser to 
separate the ionised analytes according to their mass-to-charge ratio (m/z), and a 
detector that records the number of ions at each m/z value. Two main achievements 
have facilitated MS based proteomics: the availability of genome sequence databases 
to provide the means by which to identify and peptides and proteins; and the 
development of soft protein ionisation methods for which the 2002 Nobel Prize in 
Chemistry was awarded. Since then, two primary means of ionisation were developed 
and are widely used today; matrix assisted laser desorption ionisation (MALDI) and 
electrospray ionisation (ESI). In MALDI-MS, the samples to be analysed are co-spotted 
onto a target plate with a suitable matrix. While there are an extensive variety of 
MALDI matrices, each with specific uses, they serve a common purpose; to ionise and 
facilitate vaporization of the analyte. Once dried on the target plate, matrix-analyte 
mixtures are ionised softly by laser radiation which is absorbed by the matrix leading 
to desorption and ionisation of the analytes. Ions are then accelerated by an 
electrostatic field generated around the target (Figure 10).162 MALDI has historically 
been used in conjunction with 2DE to identify excised spots by peptide mass 
fingerprinting.163,164 However, a powerful use has arisen from MALDI’s ability maintain 
the spatial distribution of the sample. Thus, MALDI is increasingly being used for 
imagining experiments where, for example, a tissue section is laid onto a target plate 
and overlaid with a suitable matrix. Protein spatial distribution across the section can 
then be determined by selectively ionising specific areas of the section.165 
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Figure 10: A simplified representation of MALDI ionisation. Once the mixture of analyte and matrix have dried on 
the MALDI target, laser pulses are used to excite the matrix which impart a charge onto the analyte. The charged 
analytes are then accelerated into the mass spectrometer by an electrostatic field generated around the target 
plate. Image adapted from Demartini.166 
ESI is characterised by the ionisation of a sample in liquid phase and its subsequent 
transfer into the gas phase. Due to the pressurised flow through the LC emitter and 
acidified mobile phase, tiny positively charged, analyte containing droplets are 
propelled toward the MS by a charge imparted onto the emitter. The positively 
charged droplet shrinks due to solvent evaporation once exposed to the atmosphere. 
As the droplet shrinks, it becomes increasingly unstable due to increasing density of 
positive charges on the droplet. These droplets break up due to coulombic explosions 
to form smaller droplets which continue to evaporate and break up into exponentially 
smaller droplets. This process continues until the charged analyte is released from the 
droplet and available for analysis in the gas phase (Figure 11). However, the process by 
which the charged analyte is released is poorly understood and discussed in detail by 
Konermann et al.167 
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Figure 11: In source dynamics of analyte entry into the gas phase: As charged droplets are released from the LC 
emitter, they begin to reduce in size due to solvent evaporation. As the droplet shrinks, the density of charges 
increases which results in coulombic explosions. This process occurs until charged analytes are released and 
become available for MS analysis. The image is adapted from the university of Bristol (http://www.bris.ac.uk/). 
As ESI requires the analyte to be in a liquid phase, it is particularly amenable to 
coupling with liquid chromatography (LC) systems; however, MALDI MS can also be 
coupled to offline LC systems. The practical limitation of MS with regard to sample 
complexity is that there is a dynamic range of two-three orders of magnitude 
detectable per spectrum. This is insufficient to analyse any complex, raw biological 
sample in its entirety. The dynamic range of proteins in serum spans twelve orders of 
magnitude 168 with cell culture and tissue samples spanning 5 – 6 orders or magnitude. 
Together with the dynamic range, typical mammalian cell lysates contain 500 000+ 
protein species after alternative splicing and post-translational modifications (PTM). 
Typically, proteomic analysis of these complex samples is performed at the peptide 
level which compounds the challenge. As a result, protein/peptide separation 
methodologies are essential for the analysis of most complex protein mixtures. 
Peptide fragmentation and, subsequently, using peptide fragmentation patterns to 
generate a peptide primary sequence through which it can be identified is not a trivial 
matter. Two common MS/MS fragmentation methods are used in proteomics; collision 
induced dissociation (CID) and electron transfer dissociation (ETD). As the name 
suggests, ETD relies on the transfer of electrons from radical anions such as 
anthracene or azobenzene to the peptide. ETD typically results in peptide breakage on 
the N-terminal side of the primary carbon which produces c and z ions (Figure 12). A 
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powerful advantage of ETD is that it has a greater capability of maintaining labile 
PTM’s such as phosphorylation and is, therefore, favoured for PTM analysis.169 Under 
ideal CID conditions, charged peptides break along the backbone at amide bonds and 
produce b and y series ions as illustrated in Figure 12. The fragmentation pattern 
generated from a peptide depends on many factors such as the peptide size, charge 
state, collision energy, collision gas and collision gas pressure.170 The resultant 
fragments masses and intensities are measured by the detector and, together with 
MS1 mass and intensity data, account for the majority of the data in MS raw files. 
 
Figure 12: Nomenclature of peptide fragment ions. Image adapted from Harrison.170 
Limitations of MS 
Although researchers are able to detect low fmol quantities of protein with high 
confidence using shotgun MS technology and methodology, MS has several limitations. 
One of the greatest limitations facing current methodologies is the limited dynamic 
range of detection per spectrum.171 This means that abundant analytes will 
overshadow the less abundant analytes. This poses a significant problem as most 
proteomes are dominated by a small subset of proteins 171 which effectively renders 
the remainder of the proteome “invisible” to MS. Two methods for overcoming this 
are depletion and fractionation. The depletion route aims to remove the most 
abundant analytes before analysis, thereby enriching the less abundant analytes for 
MS analysis.172 The use of depletion in shotgun proteomics is currently limited by 
insufficient selectivity and specificity.173 This means that many non-targeted molecules 
are removed from the sample either by non-specificity or by being bound to target 
molecules. Fractionation on the other hand is based on producing many less complex 
fractions of the original sample, ideally with a lower dynamic range per sample.174 
After being analysed individually, all fractions can be compiled to represent the original 
complex sample. However, fractionation on its own may still be plagued by the 
“dynamic range” problem as the abundant molecules will still be present in select 
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fractions. Fractionation can be performed both online and offline. Offline fractionation 
strategies produce multiple individual samples, which need to be combined 
bioinformatically to represent the whole, original sample. Online fractionation may be 
coupled to offline fractionation and will be discussed later. 
Current bottom-up shotgun proteomics requires that protein samples are digested, 
fractionated and then analysed by MS. This is the preferred route as sequencing intact 
high molecular weight proteins using high-throughput shotgun proteomics 
methodologies is extremely challenging.175 bottom-up methodologies, however, pose 
an inherent bioinformatic challenge where peptides from a single protein are spread 
across any fractions due to fractionation. This complicates analysis as splice variants or 
activity states of proteins cannot be elucidated unless specific spliced or post 
translationally modified peptides are identified.176 
Decreasing biological complexity for MS analysis 
Protein separation ahead of MS has is a critical and indispensable component of high-
throughput MS-based proteomics. To address this, various gel and liquid based 
methods have been developed to fractionate complex protein samples into several 
less complex samples which, together, represent the full complexity of the original 
sample in more manageable portions. 
In light of this challenge, LC techniques have earned an unrivalled position in MS based 
proteomics. Typically, reverse phase (RP) chromatography is used for peptide 
chromatography with octadecyl bonded silica (c18) used as the solid phase packing 
material. RP separation is based on the partitioning of peptides between the non-polar 
solid phase and the polar liquid phase. RP chromatography is not only favoured as a 
peptide separation method in proteomics due to its high resolving power, but also for 
its compatibility. The mobile phase typically contains water and a water soluble 
organic solvent such as acetonitrile. This solution is typically acidified with low 
concentrations of formic, acetic or triflouroacetic acid to ensure all peptides are 
positively charged. Despite the high resolving power of RP-HPLC, the complexity of 
biological samples has demanded even more. It has been shown that ultra-high 
pressure HPLC (uHPLC) outperforms HPLC by increasing separation speed and, thereby, 
decreasing analysis time. A further benefit of uHPLC is reduced sample requirement 
due to lower column volumes and flow rates. The increased pressure tolerance of 
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uHPLC’s has allowed for longer columns and has typically resulted in increased 
resolution and identification rates. Column lengths cannot be increased indefinitely, 
however. Several phenomena affecting chromatographic resolution occur inside a 
column. The most important of these is the effect of mobile phase diffusion into the 
chromatographic particles. As chromatographic particles are typically hollow, the 
mobile phase can enter the particle as well as travel passed it unrestricted. Mobile 
phase entering the particle is slowed and takes a longer time to exit the end of the 
column. If the column length is increased, the time delay is increased proportionally to 
the column length and this decreases resolution as peak width increases. This inherent 
limitation of chromatographic separation and means to mitigate it will be discussed in 
greater detail later. 
To achieve additional fractionation ahead of LC-MS analysis, samples can be 
fractionated at the protein level before digestion. This simplifies the samples even 
further by decreasing the number of proteins from which peptides can be generated in 
each fraction. Jafari et al, performed a comparison between various whole protein 
fractionation techniques and found 1D-PAGE gels to yield the highest protein 
identifications.177 Although 1D SDS-PAGE gels have relatively low resolution, they are 
capable of efficiently gross separation of a protein sample and have successfully been 
used as a fractionation technique upstream of LC-MS analysis. The major limitation of 
this, however, is that it decreases the reproducibility of the workflow. While LC-MS is 
capable of very high reproducibility, PAGE coupled with in-gel digestion is significantly 
less reproducible. Reports of protein and peptide loss during PAGE and in-gel digestion 
vary between 15% and 50%.178 This inconsistency makes limits the quantitative 
capacity of such experiments. However, labelling and combining samples before PAGE 
separation mitigates the possibility of differential sample loss between control and 
experimental samples. 
Chromatographic particle/bead size 
Typically, increasing the length of the analytical column on nLC systems results in 
increased sample separation and a resultant increased identification rate. The column 
lengths are, however, limited by the resultant system pressure increases. Theoretically, 
resolving power increases with an increased chromatographic surface area until a 
critical limit is reached whereby peaks widths begin to broaden, thus, beginning to 
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increase the chromatographic area occupied by highly abundant peaks masking low 
abundant peaks. In part, this phenomenon is caused by the diffusion required for 
peptides bound inside beads to transfer from the solid phase to the mobile phase. 
Larger beads also create larger spaces between beads which creates turbulence in the 
column and decreases the chromatographic surface area to column volume ratio. 
Together, these serve to increase eddy diffusion inside the column and, thereby, 
decrease performance (Figure 13). To counter this effect, solid core beads with 
increasingly small diameters were developed. This decreases the effect of diffusion in 
the analytical column and increases the theoretical plate count. Low diameter, solid 
core beads have a relatively thin surface coating into which peptides can diffuse and 
be bound to. Coupled to optimal pore sizes of ~100Å, peptides are transferred from 
solid phase to mobile phase much faster which results in smaller peak widths and 
higher theoretical plate counts.179,180 
 
Figure 13: Depiction of eddy flow and its effects on peak width. Adapted from 
http://community.asdlib.org/imageandvideoexchangeforum/ (access date: 27.09.2015) 
However, using smaller beads results in dramatic increases in the system pressure, 
which prohibits the use of small beads in long columns. The advent of nUHPLC systems 
which tolerate pressures up to and exceeding 800 bar has removed this limitation. 
Thus far, these systems have out-performed lower pressure nHPLC systems in 
literature. The increased performance is not a function of increased pressure but of 
the capabilities the increased pressure bestows: decreased bead size and increased 
column length. 
Bottom-up proteomics data processing 
Protein identification 
The aim of proteomics is to generate meaningful data about a biological system with 
the aim of increasing our understanding of that system. To acquire this information, 
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however, the raw MS data needs to be transformed into a validated list of quantified 
proteins which can then be used in further analyses. Possibility-based database 
searches remain the most efficient means through which to identify MS/MS spectra. 
This, however, depends on the presence of a suitable database containing the proteins 
being analysed. Thus, large scale, high-throughput proteomics absolutely depends on 
the availability of fully sequenced genomes. From these, theoretical proteins and 
proteolytic peptides can be generated in silico. These in silico peptides are then used 
to create in silico fragmentation spectra based on the fragmentation patterns 
discussed earlier. Experimental MS/MS spectra are compared and scored based on 
their similarity to the theoretical spectrum. Several free and commercial software 
packages available make use of algorithms employing this approach, such as 
Andromeda and Mascot.181,182 SEQUEST makes use of the same principle of matching 
experimental spectra to theoretical spectra, but it first reduces the size of the database 
against which it searches each spectrum. Based on the precursor mass, SEQUEST 
creates a list of possible peptide matches with similar masses. Theoretical spectra are 
generated from this reduced list and compared to the experimentally derived spectra 
to produce a list of 500 best fit sequences. These 500 possible matches are subjected 
to a correlation-based analysis to generate a final probability score where the best 
score is selected.183 Andromeda is based on the mascot algorithm and assesses two 
basic criteria; precursor mass and the number and masses of MS/MS fragment masses. 
Based on the overlap between the experimental and theoretical spectra, the 
algorithms score the spectra with a possibility score indicating the likelihood of a 
positive match which also considers the likelihood of the match occurring by random 
chance. Furthermore, higher scores are assigned if the matched peaks are higher 
intensity.182 Probability-based searches, however, are only applicable when the 
peptide is present in a database. However, if peptides are not in an available database, 
de novo sequencing of MS/MS spectra is possible, as it does not require prior 
knowledge of the proteins being identified. De novo sequencing makes use of the 
same MS/MS spectra generated and used in probability-based searches, but instead of 
matching to theoretical spectra, peaks are assigned amino acids based on the mass 
differences between peaks. However, the sheer quantity of data and possible MS/MS 
spectra which may arise creates significant challenges for de novo sequencing entire 
shotgun experiments. A major challenge in this approach is the ability of algorithms to 
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correctly distinguish peaks from noise. Added to this, missing peaks and PTM’s merely 
compound the problem.184,185,186 Due to the high possibility of false positives, stringent 
criteria are required to obtain sufficiently high confidence peptide and protein 
identifications. Criteria stringency aiming to decrease false positives needs to be 
balanced by the likelihood of excluding false negatives. A minimum list of protein 
identifications are then inferred from the peptides identified. Since many proteins 
share non-proteotypic peptides, if proteotypic peptides are not identified in the 
experiment, it is impossible to assign a single protein identification with certainty. As a 
result, protein groups which contain all proteins which may have contributed the 
peptides identified are reported. 
Protein quantitation 
Rather than just produce a list of protein identified in a sample, proteomics also aims 
to quantify those proteins in the sample. An unfortunate drawback of shotgun 
proteomics is that it only allows for confidence in proteins identified, but cannot assign 
confidence in the absence of a protein which is not detected. Due to this limitation, 
shotgun proteomic analyses typically entail comparing proteins identified and 
quantified in all conditions being tested. To facilitate the comparison of two or more 
physiological states in a biological setting, the proteins present must be accurately 
quantitated. The quantitation method may either be absolute or relative. Absolute 
quantitation allows for the exact molar amount of each peptide to be determined. Far 
more commonly, however, peptides and proteins are quantified such as to facilitate 
relative quantitation. Absolute quantitation requires that known amounts of MS 
discernible isotopes of the target peptide be quantitated simultaneously with the 
target peptide. Two common methods for absolute quantification are AQUAtm and 
PSAQ.187,188 
Several labelling techniques have been developed to increase the accuracy of relative 
quantitation. Of those, labelling techniques such as Stable isotope labelling by amino 
acids in cell culture (SILAC), Isobaric tags for relative and absolute quantitation (iTRAQ) 
and Tandem Mass Tags (TMT) are the most popular. iTRAQ and TMT are similar in that 
they are both isobaric mass tags with which peptides can be labelled after digestion. In 
both techniques, the tags make use of N-hydroxy-succinimide (NHS) chemistry which 
permits near complete tagging of peptide amine groups. As the tags are isobaric, the 
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same peptide labelled with the different tag masses would have the same precursor 
mass. This allows peptides from different samples to be selected together during the 
MS1 precursor scan and during MS/MS. Peptides from different samples are 
discernible only upon peptide fragmentation in MS/MS, during which the relative 
ratios of each samples’ contribution is identified. iTRAQ and TMT allow for the analysis 
of up to eight and ten samples simultaneously, respectively.189,190 The rationale behind 
using labelling techniques is that samples being compared can be mixed together and 
analysed together. This serves to eliminate any sample specific variability introduced 
after labelling and subsequent sample mixing. Following this, the sooner samples can 
be mixed together, the further one can reduce the technical variability introduced by 
sample processing. To date, SILAC is the gold standard for labelling techniques as 
samples can, theoretically, be combined immediately after harvesting cells from 
culture. These benefits can be realized in the detection of smaller biological 
differences present between two cell states. These differences might otherwise be 
missed by techniques with greater inherent variability. SILAC labelling makes use of 
isotopically labelled amino acids in which certain nuclei are replaced with their heavy 
isotopes (deuterium, 13C and 15N). To SILAC label cells in culture, cells are grown in 
chemically identical media, except that each contains heavy or light isotopes of specific 
amino acids. Typically, heavy lysine and arginine are used as they ensure that efficient 
tryptic digestion results in a single heavy amino acid per peptide, although, many 
others are available. Cells typically require ~5 passages to achieve near complete label 
incorporation, although, incorporation efficiency should be tested before using the 
cells experimentally. Although the technique is typically restricted to cell culture, larger 
organisms can be labelled and are available; albeit at very high cost.191,192 While the 
technique is very powerful when applicable, it can be difficult or impossible to label 
certain samples due to the size of the animal or metabolic inactivity of the target cells 
and tissues.193 In order to address this limitation, CDIT and, more recently, super-SILAC 
have been developed.194,195 Both techniques employ metabolically labelled proteins 
from a related cell culture mixed with the unlabelled tissue as an internal standard. As 
opposed to CDIT, super-SILAC makes use of multiple cell lines in the SILAC labelled 
internal standard which results in greater coverage of the proteome being analysed. 
Due to methodological and instrumentation developments in proteomics, many of the 
benefits endowed by labelling methodologies have been offset relative to label-free 
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approaches. As the name suggests, label-free quantification does not involve any 
labelling of peptides/proteins before analysis and each sample is analysed individually. 
Label-free approaches are, therefore, not necessarily quantified as a ratio between 
experimental conditions. Two approaches exist for label-free quantification; spectral 
counting and ion intensity. Spectral counting functions on the assumption that the 
number of peptide spectrum matches, total number of peptides identified and the 
sequence coverage correlates with protein abundance. Since this method relies on 
simple counting of spectra rather than measuring physical data, it has remained 
controversial.196 The second method calculates the cumulative area under the curve 
for the monoisotopic mass for each precursor ion. The area under the peak has been 
shown to correlate linearly with peptide abundance which makes the method highly 
amenable to quantitative proteomics.197 Despite relatively higher systematic error 
being introduced to label-free approaches, there are several advantages as well.198 
Since samples are analysed individually, label-free samples are significantly simpler 
which equates to a greater analysis depth in single MS runs. Increased analysis depth is 
also facilitated by a higher dynamic range of quantification. Additionally, there is no 
limit of the number of biological comparisons that can be made in an experiment. 
While always important, a stable LC-MS system is integral to label-free experiments. 
Changes to the system during the course of an experiment could render the resultant 
data incomparable. 
Understanding the biology 
Currently, the challenge to understanding biological systems is no longer our ability to 
generate data representative of the system. The challenge lies in our ability to 
understand those massive datasets and draw biologically meaningful information from 
them. Proteomics is inherently a systems science that studies not only proteins and 
their expression levels but the interplay between proteins, complexes and the 
pathways they function in. However, after the database search, we have a list of 
proteins rather than information about the protein and pathway interactions. These 
lists then contain extensive potential information which may not be immediately 
apparent as a mere protein list with quantitation. Pathway and gene ontology analyses 
are typically used to view the data within the biological context. Before the widespread 
usage of MS and genome-wide gene expression methodologies to assay biological 
systems, significantly fewer proteins were identified in experiments. In those 
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instances, it was feasible to search each differentially regulated protein individually 
and determine a biologically relevant explanation for its dysregulation as well as 
postulate about its effect. In some cases, a few proteins/genes signifying the most 
differentially regulated elements of the data are individually analysed. This, however, 
has a major limitation in that it can miss important regulatory information and 
intermediates in signalling. Furthermore, modest changes in multiple proteins in a 
pathway can have a large effect on the overall activity of the pathway. Thus, making 
use of as much of the dataset as possible infers obvious advantages. Analysing single 
proteins/genes individually is, however, impossible when thousands of proteins are 
identified and quantified and hundreds are significantly dysregulated. Furthermore, 
most pathways function with incredible complexity and significant cross talk with other 
pathways that it is simply not feasible to attempt to understand the interactions one 
protein at a time. In addition, this approach can be very subjective. 
One means through which to analyse large datasets for biological significance is 
through gene ontology (GO) analysis. GO analysis attempts to identify biologically 
meaningful functions taking place in the biological system. It does this by assigning one 
or more functional term to each queried gene or protein, then identifies statistically 
significant enrichment of terms within the dataset against a background dataset. This 
approach, however, considers each query as a separate event and, thereby, decouples 
pathways and networks. This means that individual proteins are not validated by the 
presence of interacting partners. In addition, many proteins have multiple functions 
and, analysing each individually does not necessarily identify the specific functional 
role in which that protein is being dysregulated. Perhaps the biggest drawback of GO 
annotation and enrichment analyses is that they do not make use of quantitative data. 
Pathway and network analysis helps simplify unwieldly amounts of data by grouping 
proteins into smaller functional compartments. These compartments may be defined 
by interaction in a function or canonical pathway. Many pathways may work together 
in complex networks to bring about certain biological functions. Data can, therefore, 
be analysed in increasing complexity in order to understand the activity of pathways 
and their relationship to the biological system. An advantage of pathway and network 
analysis over GO analysis is that pathway and network analysis allows for direct 
visualisation of proteins with their interaction partners and regulatory elements. 
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Furthermore, many knowledge bases, such as Ingenuity Pathway Analysis (IPA) 
contains information upon which biological implications of protein, pathway and 
network information can be made with respect to a functional outcome. 
An inherent problem with all automated analyses, however, is that they rely on 
incomplete knowledge.199 Firstly, our knowledge of protein/gene functions and their in 
vivo interactions, regulation, functions and localization is incomplete. Secondly, as the 
knowledge bases are manually curated, the curators may miss some already published 
information. More commonly, however, there is a lag in incorporating newly published 
data into the knowledge bases. Thus, it will always be the responsibility of the user to 
evaluate the data, and understand the basis of predictions made by automated 
software. The user will also be required to understand and address the functional 
implication of all possible interactions within pathways as well as across different 
pathways. It is a common assumption that pathways function linearly and each 
pathway produces and ‘output’ which then goes on to interact with other pathways. In 
reality, individual proteins within canonical pathways are constantly being regulated by 
external and internal proteins. Therefore, despite the use of extensive and very well 
constructed and curated knowledge bases, there will always be a need to manually 
assess the data output of pathway analyses. Furthermore, many proteins are 
ubiquitously expressed in many different cell types. They may not have identical 
functions due to PTM’s and cellular localization. Where they do have the same 
function, their functional outcomes may vary. A simple example can be made with the 
cytoskeleton. Neurons and macrophages have highly overlapping cytoskeletal 
regulatory mechanisms and proteins. However, in macrophages, cytoskeletal 
projections are the basis for pseudopodia. In neurons, however, they are the initial 
structure in a developing neurite, axon, dendrite and, ultimately, a neuronal synapse. 
Thus, downstream bioinformatic analysis of the primary quantitative data is a critical 
part of the overall results obtained from proteomic experiments today. 
Despite the overwhelming research efforts into understanding HIV-Tat mediated 
neuronal dysregulation, the mechanisms involved remain poorly understood. This is, in 
part, due to the nature of classical mechanistic experiments, which require a 
hypothesis to be tested. The limitation of this approach is that the proteins or 
pathways of interest must be specifically targeted while concurrently ignoring the vast 
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majority of processes taking place. This limitation is compounded by the apparent 
complexity of the mechanisms involved in HIV-tat treated neurons. High throughput, 
hypothesis generating MS analyses coupled to detailed pathway analysis may be 
capable of providing a global view of the mechanisms underlying HIV-Tat induced 
neuronal dysregulation. Furthermore, by using these techniques, the potential 
therapeutic value of drugs could be assessed by characterising the effects they have on 
the dysregulated pathways and their ability to restore normal signalling. 
 
Aims of This Thesis 
In this work, the goal was to use shotgun proteomics to understand and describe the 
molecular mechanism of HIV-Tat induced neuronal apoptosis. The achieve these, the 
aims of this thesis were: 
1. To develop an in vitro model system for HAND. 
2. To perform quantitative differential genomic and proteomic analysis to 
characterise the perturbation of the model system by HIV-Tat. 
3. To perform quantitative differential proteomic analysis to characterise the 
effect of lithium on HIV-Tat dysregulated neuronal proteome. 
4. To perform detailed pathway analysis of the data generated in (2) and (3) to 
identify the underlying mechanisms of HIV-Tat induced neurotoxicity and the 
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Chapter 2 
Establishing a model for HIV-Tat induced 
neuronal cell death 
 
Introduction 
There are approximately 36.9 million people living with HIV (WHO, 2014, 
http://www.who.int/hiv/en/), up to 70% of whom develop HIV-associated 
neurocognitive disorders (HAND). HAND describe three formal disease classifications; 
asymptomatic impairment (ANI), mild cognitive disorder (MND) and HIV-associated 
dementia (HAD).5 Before the widespread implementation of HAART, disease onset and 
progression was associated with neuronal apoptosis which resulted in neurological and 
cognitive impairment. However, in the post HAART era, HAD incidence has decreased 
while the incidence of milder forms has increased. This phenomenon is associated with 
patients living longer with varying degrees of viral replicative suppression. As a result, 
patients are exposed to decreased levels of the causative agents over an extended 
period. HAND progression is, therefore, no longer associated with apoptosis but with 
synaptodendritic loss. Despite significant research efforts, molecular mechanism 
underlying the neurodegeneration evident in HAND brains remains poorly understood. 
To identify molecular cascades in an array of diseases, in vitro cell culture models have 
been invaluable. 
Currently, the biomedical research field relies on appropriate models to study disease 
states and develop therapies for many human diseases. Furthermore, the CNS is 
composed of a heterogeneous cell population predominantly composed of neurons 
and glia (astrocytes, dendritic and microglia). The difficulties of molecular analysis in 
heterogeneous organs are compounded when dealing with complex, multigenic 
diseases such as neurodegenerative diseases. When analysing molecular responses, it 
is nearly impossible to delineate the responses within individual cell population. In 
comparison to this, in vivo cell culture allows the analysis of a homogeneous cell 
population. As HIV is not known to directly infect neurons, it is feasible to assume that 
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the neurodegeneration is due to the host response, secreted viral factors or a 
combination of the two acting on neurons. 
Several HIV proteins, including gp120 and HIV-Tat have been shown to be neurotoxic. 
One critical feature unique to HIV-Tat is that it is continually secreted from infected 
cells despite replicative suppression. HIV-Tat primary sequence is highly variable and 
reported to tolerate ~40% mutations while maintaining function and occurs in many 
active length variants in vivo. Typically, cysteine comprises ~2.26% of amino acids in 
mammalian proteins.200 Although the HIV-Tat primary sequence is highly variable, 
seven cysteines are maintained within a 16 amino acid cysteine-rich motif201 which 
equates to at least 7% cysteine occupancy across the entire protein (ignoring any 
cysteines outside the cysteine-rich region). This region is believed to be integral to HIV-
Tat structure, function and toxicity through the formation of specific disulphide 
bonds.202,203 
The SH-SY5Y neuroblastoma cell line has long been used as a model human neuronal 
cell line and is widely used in HAND mechanistic studies involving HIV-Tat.204,205 An 
ever present and legitimate concern about using cell lines is their ability to adequately 
represent and replicate in vivo tissue responses. Unfortunately, cell lines will never 
replicate complex human tissues; however, work by Krishna et al assessed the validity 
of SH-SY5Y as an appropriate cell line for studying neurodegenerative diseases. After 
analysis of genomic, transcriptomic and proteomic data derived from the cell line and 
performed disease specific network analysis. The concluded that most genes involved 
in PD, AD, Huntington’s disease and Amyotrophic Lateral Sclerosis were intact.206 
Herein, we provide a brief description of the establishment of an SH-SY5Y model for 
HIV-Tat induced neuronal dysregulation. In particular, the maintenance of monomeric, 
active HIV-Tat required particular attention. We show that multimeric HIV-Tat is 
unable to induce cell death and that the buffer used to resuspend lyophilized HIV-Tat is 
critical to its long-term in vitro activity. As many publications fail to identify the 
resuspension buffer used, this may be the source of the conflicting information 
present in literature. Furthermore, we show that the inclusion of a wash step, not 
present in many MTT protocols, is required for accurate MTT data. 
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Materials and Methods 
Cell culture 
The SH-SY5Y neuroblastoma cell line was kindly provided by Dr. K. Wilkinson (IIDMM, 
University of Cape Town Faculty of Health Sciences). Cells were expanded in 
Dulbecco’s modified Eagle’s medium (DMEM) - high glucose (Sigma-Aldrich D6429), 
supplemented with Penicillin-Streptomycin (100 units/ml penicillin and 0.1 mg/mL 
streptomycin (Sigma-Aldrich D4333)) and 10% (v/v) heat-inactivated foetal calf serum 
(FCS) (Sigma-Aldrich F7524). Cells were seeded on 10 cm Greiner adherent cell culture 
plates (Lasec SA, South Africa) at 1.5 X 106 cells/plate and maintained at 37 °C in a 
humidified atmosphere containing 5% CO2. 
Subculture 
Cell culture media was removed and cells are gently washed with warmed PBS. After 
removal of the wash buffer, 1.25 ml of trysin solution was added to the 10 cmØ culture 
dish and spread evenly across the surface. The plate was then incubated for 
approximately 1 minute or until cells have visibly lifted from the dish. Once cells are 
loosened from the plate, the trypsin was immediately quenched with trypsin inhibitor. 
20 µl of well mixed cell suspension was mixed with 20 µl of trypan blue and loaded into 
a cell counting slide and viable cells are manually counted using a microscope. 
Depending on the application, specific amounts of cells are then diluted in 10% FBS, 
DMEM and aliquoted into appropriate dishes and incubated the 5% CO2, humidified 
37oC incubator. 
MTT assay 
Following treatment, cell culture media was removed and the cells are gently washed 
with warmed 0% FBS, DMEM. After the wash buffer was removed, 0% FBS containing 
0.5 mg MTT/ml was added and cells are incubated in the 5% CO2, humidified 37oC 
incubator for approximately 30 minutes or until formazan crystals are visible. All 
treatments were performed when cells were at ~80% confluence in three biological 
replicates while MTT assays were measured in two technical replicates.  
To evaluate our ability to detect changes in cell viability using the MTT assay, we 
performed dose response tests with staurosporine. While maintaining a constant 0.2% 
DMSO in all wells, we treated the cells with a range on staurosporine concentrations 
(100 nM, 50 nM and 25 nM) suspended in 100% DMSO as well as a 0.2% DMSO 
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control. We then also tested the effect of washing the cells in warmed DMEM media 
prior to treatment with 0.5 mg/ml MTT reagent. Briefly, after treatment, the culture 
media was removed and warmed media was added very gently over the cells. After a 
gentle swirl, this media was again removed and media containing 0.5 mg/ml MTT 
reagent was added to the cells gently. 
After sufficient formazan crystals formed, the media was removed. We then added 200 
µl 100% DMSO and incubated the dishes at room temperature with gentle agitation for 
10 minutes. Thereafter, 80 µl of the suspended formazan was added to clear, flat 
bottomed 96 well plates and analysed by iMARK (BIORAD) plate reader at 595 nm. If 
the highest A595 ≥ 1, mixtures were diluted equally until the highest A595 < 1. 
Results and Discussion 
HIV-Tat was suspended in sterile PBS and diluted to a range of concentrations such 
that the volume added to each well remained constant. Cells were treated with HIV-
Tat for 24 hours then assayed for cell death using the MTT assay Figure 14. A wide 
range of HIV-Tat toxic concentrations have been reported in literature and our CD50 fell 
within the reported range. 
 
Figure 14: A dose response assay perfomed using indicated concentrations of HIV-Tat. The data was expressed as 
the number of live cells as a percentage of PBS treated control cells. Based on the trend line fitted to the data, the 
CD50 was calculated to 575 ng/ml. 
Following this result, we performed ELISA assays to determine cellular expression 
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the ELISAs were in accordance with expected results as it was previously reported that 
the activity and not expression levels of GSK-3β is altered by HIV-Tat.27 Before 
continuing with ELISAs to determine the levels of phosphorylated, activeGSK-3β and 
MS analysis of perturbed cells, I attempted to confirm the results in Figure 14 were 
reproducible. 
Remnants of apoptotic cells produce formazan 
Using HIV-Tat from the same source suspended in the same manner, we were unable 
to reproduce these results. To confirm that the cell culture and assay technique 
applied was capable of accurately and reproducibly detect and measure cell death, we 
tested the protocol using a known apoptotic agent, staurosporine. 207,208 To do this, we 
performed a dose response experiment using staurosporine (Figure 15). Staurosporine 
was suspended in 100% DMSO which served as the control. Following treatment, we 
determined that the MTT assay was capable of identifying dose dependant cell death 
induced by staurosporine.  
 
Figure 15: Staurosporine dose response showing that the MTT assay was able to detect cell death in SH-SY5Y. The 
data is expressed as a percentage of the carrier (DMSO) treated control. 
Satisfied that our MTT assay was able to detect and quantify cell death in SH-SY5Y 
reproducibly, we determined whether our technique was producing accurate data. 
Given that cells are undergoing cell death, it is to be expected that cell debris will be 
present during the MTT assay. To determine whether dead cells influenced the result, 
we tested the effect of washing the cells prior to performing the MTT assay. Figure 16 
shows that the dead cells do contribute significantly and cause the assay to 
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We are unable to find any literature reference to this drastic effect of dead cells 
present in the MTT assay but we hypothesize that this effect is due to lactate 
dehydrogenase (LDH) which is not degraded during cell death and is present and active 
in the cell bodies and culture media after cell death.209 LDH is able to convert the 
soluble MTT to the same insoluble formazan salt formed by live, intact 
mitochondria.210 The presence of active LDH therefore skews the result by increasing 
the amount of insoluble formazan formed. We therefore concluded that it is important 
to remove dead cells and replace the media prior to performing the MTT assay. 
 
 
Figure 16: Determining the effect of removing dead cells prior to the MTT assay. Cells were treated with either 50 
nM staurosporine (s+) or DMSO (control) (s-). Cells were then either washed (w+) or not washed (w-) prior to 
performing the MTT assay. 
After refining the assay using staurosporine, we attempted to induce cell death with 
HIV-Tat again. Using up to 10, 000 ng/ml HIV-Tat, we were unable to show any cell 
death in SH-SY5Y cells (data not shown). Despite acquiring several new vials (all from 
the same batch) we were not able to reproduce the data in Figure 14. Following this, 
we shifted our focus to determining why the HIV-Tat we received was inactive. 
Reduced, monomeric HIV-Tat is essential for the induction of cell death 
We separated the HIV-Tat suspended in PBS by 12% SDS-PAGE. This revealed that the 
sample consisted of proteins larger than the expected monomeric mass of 9.7 kDa 
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Figure 17: A 12% SDS-PAGE of NIH supplied HIV-Tat (1 µg, 4 µg and 2 µg)(lanes 2-4) and ubiquitin at 8.5 kDa (1 µg) 
(lane 5). It is clear that there are no bands in lanes 2, 3 and 4 close to the expected molecular mass of 9.7 kDa. Only 
high molecular mass proteins are present in the sample. 
We then analysed that same sample by MALDI-MS, which revealed the presence of 
only high molecular mass proteins (Figure 18). The mass spectrum consisted of a series 
of peaks ranging from 39.657 – 78.457, each separated by ~9.7 kDa. This suggested 
that these peaks represent high order structures of HIV-Tat protein. While this 
spectrum does not confirm multimeric HIV-Tat, it does support the gel data showing 
high molecular weight proteins which are likely HIV-Tat multimers. 
 
Figure 18: A mass spectrum of NIH HIV-Tat showing the high order HIV-Tat structures with peaks 9.7 kDa apart. 
We then wanted to determine why the protein was predominantly represented by 
multimeric forms. Additionally, we acquired another HIV-Tat variant (HIV-Tat from 
Clade-B) from a different source (Diatheva, Italy). Notably, DTT was used in their 
isolation protocol, which raised a concern because the cysteines are highly important 
to HIV-Tat confirmation and activity 211,84. DTT is well known to oxidise rapidly and 
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spontaneously in solution, so it seemed plausible that by the time the HIV-Tat was 
resuspended for use, no effective reducing agent was present which enabled the 
formation of inter-molecular disulphides. To test this hypothesis, we treated an aliquot 
of the same HIV-Tat used in Error! Reference source not found. and Figure 18 with 200 
M β-mercaptoethanol (βMe), 10% SDS; after thorough mixing, this mixture was heated 
to 95oC for 15 minutes. As can be seen in Figure 19, this reversed most of the high 
order structures present in the sample. Lanes 2 and 4 are clade-B HIV-Tat and it can 
clearly be seen that nearly all the multimers have been reduced to monomers. We also 
tested lower concentrations of βME but these had no effect on reversing multimers, 
even after boiling. Since 200mM βME alone (i.e. without 10% SDS and heating) was not 
sufficient to restore the monomeric form (data not shown), we generated a βME dose 
response curve for SH-SY5Y to determine the highest possible concentration of βME 
tolerated by the cells (data not shown). 
 
Figure 19: HIV-Tat superstructures reversed by 200 mM βME treatment. Lanes 2 and 3 are treated with 200 mM 
βME, 10% SDS and heating. Lanes 4 and 5 are suspended in plain strerile water. Lane 2 shows significantly reduced 
compared to lane 4. Lane has no visible multimers, though there are fewer multimers in lane 3 without βME. 
From this, we determined that we could treat the HIV-Tat stocks with up to 350 mM 
βME which would result in 3.5 mM final βME concentration when diluted to working 
HIV-Tat concentrations in cell culture. Unfortunately, 350 mM βME was not enough to 
reverse multimers that have already formed (Data not shown). 
Since the formation of disulphide bonds requires alkaline pH and oxygen,212 we 
suspended new vial of clade-B HIV-Tat in a nitrogen bubbled, degassed solution of 
0.05% TFA in water. However, this HIV-Tat was still unable to induce cell death and 
was multimeric (data not shown). However, when we resuspended clade-B and C HIV-
Tat in degassed, 0.05% TFA containing 350 mM βME the resultant solution was able to 
induce cell death (Figure 20). The presence of monomeric HIV-Tat upon resuspension 
was confirmed by MALDI-MS as can be seen in Figure 21 along with an SDS-PAGE (not 
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shown). A single clear, defined peak is present at ~9.7 kDa, while a doubly charged ion 
can be seen at ~4.8 kDa along with an SDS-PAGE (not shown). 
 
Figure 20: SH-SY5Y cells treated with two variants of HIV-Tat (clade-B and C) resuspended in degassed water 
containing 350 mM βME, 0.05% TFA. The final concentration of βME in cell culture was 3.5 mM which was also used 
as the control. All data is expressed as percentage of control live cells. 
 
Figure 21: MALDI mass spectrum of singly and doubly charged monomeric HIV-Tat. 
We also showed that clade-B HIV-Tat resuspended in this manner was able to induce 
cell death both when used immediately upon resuspension, as well as after three 
months of storage at -800C, with the same level of activity at both time points (Figure 
22). 
 
55 | P a g e  
 
 
Figure 22: Clade-B HIV-Tat resuspended in 0.05% TFA, 350 mM βMe degassed water after 3 months of storage at -
800C. 
Our model was, therefore, one in which 1 ug/ml HIV-Tat reproducibly induced ~20% 
neuronal cell death as measured by MTT. Using this model, we were then able to 
pursue more advanced proteomic analyses. Despite 3.5 mM βMe not inducing any 
measurable cell death, we wanted to reduce its concentration so as to have as little 
effect as possible in cell culture. Toward this, we tested using 50 mM βMe in the 
resuspension buffer as opposed to 350 mM and found the resultant HIV-Tat 
suspension to be monomeric (Figure 23A) and able to induce 20% cell death at 1 µg/ml 
(Figure 23B). 
 
Figure 23:  HIV-Tat resuspended in 0.05% TFA, 50 mM βMe degassed water induced cell death as effectively as 
earlier experiments using higher βMe concentrations. 
This work confirms that HIV-Tat must be in its monomeric form to induce cell death. 
Since establishing the cell culture model and reproducibly inducing ~20% cell death, 
we progressed on to MS analysis of this model. 
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Chapter 3 
Quantitative proteomic analysis of HIV-1 Tat-
induced damage in SH-SY5Y neuroblastoma cells 
Abstract 
Despite affecting up to 70% of HIV+ patients and being the leading cause of dementia in 
patients under 40 years, the molecular mechanisms involved in the onset of HAND is 
not well understood. To this end, we performed SILAC-based quantitative proteomic 
analysis on HIV-Tat treated neuroblastoma (SH-SY5Y) cells. Isolated protein was 
fractionated by SDS-PAGE and analysed by nLC-MS/MS on a Orbitrap Velos. Using 
MaxQuant, we identified and quantitation 3077 unique protein groups. Using the 
student’s t-test, we identified 407 differentially regulated proteins of which 29 were 
identified as highly significantly and stably dysregulated using an additional 2sd cutoff. 
GO-term analysis shows dysregulation in both protein translation machinery as well as 
cytoskeletal regulation which have both been implicated in other dementias. In 
addition, several key cytoskeletal regulatory proteins such as ARHGEF17, the Rho 
GTPase, SHROOM3 and CMRP1 are down-regulated. Together, we that HIV-Tat can 
dysregulate neuronal cytoskeletal regulatory proteins which leads to the major HAND 
clinical manifestation; synapse loss. 
  
Keywords: Proteomics , SILAC, HIV dementia, pathway analysis, neurodegeneration   
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Introduction 
A major complication of human immunodeficiency virus type-1 infection, affecting 70% 
of HIV positive individuals in South Africa in its more severe form, is HIV-associated 
neurocognitive disorders (HAND).213 HAND encompasses a set of neuropathological 
disorders characterised by varying degrees of cognitive, motor and behavioural 
dysfunction as a result of HIV infection in the central nervous system (CNS).5 HAND 
comprises an array of conditions that range from asymptomatic neurocognitive 
disorder (ANI) and mild neurocognitive disorder (MND) to the most severe form, HIV-
associated dementia (HAD).5 Since the implementation of highly active antiretroviral 
therapy (HAART), the life expectancy of HIV+ patients has increased. As a result, more 
patients have presented with HAND. The incidence of HAD has decreased since the 
implementation of HAART, however HAND cases have increased. 
HIV has been shown to enter the brain during early infection214 which results in 
significant alterations in the volumes of various brain regions.215 HAND patients 
generally present with minor cognitive and motor disorders as well as depressive 
disorders.216 Studies have shown that neurocognitive and psychiatric scores of 
HAND/HAD patients correlate most strongly with loss of synapses rather than neuronal 
loss or encephalitis.217 
The causative agent for the development of HAND must be considered as either an HIV 
protein or a host response to HIV infection. In reality, it is most likely that the exact 
pathology involves a combination of HIV and the host inflammatory response to HIV. 
However, a great wealth of information has been published which shows that HIV 
transactivator of transcription (HIV-Tat) alone is capable of causing neuronal damage 
and eliciting an inflammatory response in vivo and in vitro. However, the deregulatory 
effect of HIV-Tat protein in the CNS has been studied extensively, the underlying 
molecular mechanism involved remain to be elucidated. There is, therefore, no 
complete mechanism describing the proteomic changes in neurons when treated with 
HIV-Tat. In addition, despite the large amount of work dedicated to this area, no 
diagnostic nor prognostic markers have been used clinically.218 
Lately, there has been increased evidence suggesting that the HIV-1 Tat has a major 
impact at the gene and protein levels of infected host cells. For example, a recent 
study has demonstrated that Jurkat cells treated with HIV-Tat resulted in the 
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dysregulation of 49 host proteins involved in diverse functions such as protein 
metabolism, energy and amino acid metabolism. 219 In another similar study it has 
been suggested that HIV-Tat is responsible for changes in expression pattern of 
proteins relevant for the integrity of endothelial tight junctions, interestingly those 
changes result in increased permeability of blood-brain barrier.220–222 In neuronal cells, 
such as SH-SY5Y cells it has been reported that HIV-Tat is responsible for the 
differential expression of multiple MicroRNAs. 223 HIV-Tat is a highly variable protein 
derived from a two-exon HIV-Tat gene. The first, 72bp, exon is stable in its length while 
exon 2 may be completely absent to 39+bp in length. It is reported that HIV-Tat can 
remain functional with ~40% variability in its primary sequence.84 While its primary 
function relative to HIV is simple; transactivation of the viral genome,76 its highly 
variant sequence lends itself to performing a vast array of secondary biological 
functions 95,224,102. These functions may or may not be targeted functions of the HIV life 
cycle. Added to its protein binding capacity, HIV-Tat has been shown to bind the 
genome of a human cell line at 2074 discreet sites.225 Taken together, this suggests a 
startlingly high capacity for HIV-Tat to influence host signalling pathways and cellular 
functions. 
In lieu of the disparity in our understanding of HAND molecular mechanisms of onset 
and HIV-Tat’s apparent ability to affect host biological functions, we have performed a 
global quantitative proteomic analysis of SILAC labelled SH-SY5Y neuroblastoma cells 
treated with HIV-Tat. We present a rigorous bioinformatics approach capable of 
identifying gross proteomic changes in the cell. Using this approach, we were able to 
quantitate 3077 proteins and identify 407 proteins as stably and significantly 
differentially regulated with 29 passing an additional standard deviation (sd) test and 
being deemed highly dysregulated. We have, to our knowledge, for the first time, 
identified the molecular basis for HIV-Tat induced neuronal degradation. Several 
proteins identified can be linked to the major clinical manifestation of HAND, synaptic 
degeneration. Additionally, we have identified several secretory proteins which 
deserve further study as putative diagnostic or prognostic markers. 
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Materials and Methods 
Cell culture and SILAC labelling 
The SH-SY5Y neuroblastoma cell line was kindly provided by Dr. K. Wilkinson (IIDMM, 
University of Cape Town Faculty of Health Sciences). Cells were expanded in DMEM - 
high glucose (Sigma-Aldrich D6429), supplemented with Penicillin-Streptomycin (100 
units/ml penicillin and 0.1 mg/mL streptomycin (Sigma-Aldrich D4333)) and 10% (v/v) 
heat-inactivated FCS (Sigma-Aldrich F7524). Cells were seeded on 10 cm Greiner 
adherent cell culture plates (Lasec SA, South Africa) at 1.5 X 106 cells/plate and 
maintained at 37 °C in a humidified atmosphere containing 5% CO2. 
Cells were expanded for a minimum of five passages (>15 doublings) in arginine and 
lysine deficient high glucose DMEM (Sigma-Aldrich) supplemented with Penicillin-
Streptomycin and 10% dialysed heat-inactivated FCS (Thermo Fisher Scientific 88212) 
and containing the respective concentration of L-lysine and L-arginine isotopes 
(Thermo Fisher Sientific): light 0.8 mM 6C122N14 (K0) and 0.2 mM 6C124N14 (R0) or heavy 
0.8 mM 6C132N15 (K8) and 0.2 mM 6C134N15 (R10). Incorporation efficiency and Arg – 
Pro conversion was tested through analysis of the heavy labelled sample as described 
in Soares et al. 2013.226 
Treatment with recombinant HIV-1 Tat CLADE-B: 
HIV-1 Tat (rec-HIV-1 Tat CLADE-B, Catalogue # REP0002B, Lot 013-0511, Diatheva, 
Fano, PU, Italy) was reconstituted at a concentration of 0.1ug/µl in 50 mM βMe, 
nitrogen bubbled water acidified with 0.01% TFA. βMe was essential to maintain HIV-1 
Tat functionality by preventing disulphide bond formation which created inactive 
multimeric HIV-1 Tat. Cells at 80% confluence were incubated for 24 hours in DMEM 
(no FCS) with Tat (1ug/ml HIV-Tat and 0.5mM βMe final concentration) or only 0.5mM 
βMe (vehicle). 
In parallel with experiments for protein extraction, cell viability was determined using 
the [4,5-Dimethylthiazol]-2,5-diphenyltetrazolium (MTT) (Sigma, M2128) cell 
proliferation assay in 24 well plates. After 24 hours of HIV-Tat treatment, wells were 
washed with DMEM and incubated in 0.5 mg/mL MTT in DMEM for 30 – 90 minutes. 
The resultant formazan crystals were solubilised in dimethyl sulphoxide (DMSO) 
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(Sigma-Aldrich), and measured at 560 nm using a BioRad iMARK™ Microplate Reader 
UV-Vis Spectrophotometer (BioRad Laboratories Pty Ltd, Parklands, Johannesburg). 
Sample preparation 
K0/R0 labelled cells were treated with vehicle, whereas K8/R10 cells with HIV-Tat on 10 
cm dishes in triplicate (8x106 cells per dish). After dead cells were washed away with 
heated phosphate buffer saline (PBS), the remaining attached cells were lifted with 
trypsin (Sigma-Aldrich, T4049) which was immediately quenched using trypsin inhibitor 
(T6522). Cells were pelleted at 600 g and washed in Tris-HCl Wash Buffer (50 mM Tris-
HCl, 10 mM NaCl, pH 7.5) before lysis. After washing, cells were counted using the 
trypan blue assay and mixed in a 1:1 ratio. The pellet was then lysed at <4oC according 
to the QIAGEN Phosphoprotein Kit (Catalogue #37101). Briefly, the washed pellet, 
containing 16 x 106 cells was resuspended by gentle pipetting, and incubated for 40 
minutes with occasional vortexing in cold 5 mL PhosphoProtein Lysis Buffer containing 
protease phosphatase inhibitors (provided in the kit), 10 µL of 25 units/µL Benzonase® 
Nuclease Stock, and 0.25% (w/v) CHAPS ). The suspension was then clarified by 
centrifugation at 14,000 g, and the clarified supernatant was transferred into a clean 
vial for further processing. 
Following the lysis protocol, the clarified lysate was quantitated and passed through 
the PhosphoProtein Purification Columns (QIAGEN, Catalogue #37101) at room 
temperature as per the manufacturer’s instruction. Briefly, total protein was 
quantitated using the Bradford Protein Quantiation Assay following manufacturer’s 
instructions, the total lysate diluted to 0.1 mg/mL with PhosphoProtein lysis Buffer. 
The diluted lysate was then passed through the column and the flow through was 
retained as the phosphodepleted (PD) sample. The column was then washed with 6 mL 
PhosphoProtein Lysis Buffer and retained. Thereafter, bound phosphorprotein was 
eluted using four 500 µL volumes of phosphoprotein elution buffer (50 mM K2PO4, pH 
7.5 , 50 mM NaCl, 0.25% CHAPS) pooled and labelled phospho-enriched (PE). PD and 
PE were then concentrated using 3 kDa molecular weight cutoff (MWCO) filtration 
columns (Nanosep®) to final volumes of ~1 mL and ~100 µL respectively. Bradford 
protein quantitation showed that PE contained ~180 µg each, whereas the PD 
contained ~1.8 mg each. 
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100 µg of protein from each of the three PE and PD replicates were fractionated by 1D-
SDS-PAGE, ten gel slices were cut from each lane, and subjected to in-gel digestion. 
Proteins were reduced with 10 mM DTT, alkylated with 55 mM iodocetamide and 
digested with 200 ng Trypsin (Promega). Peptides were extracted twice with 70% 
Acetonitrile (ACN), 0.1% Formic Acid for 30 minutes, cleaned using stage tips then 
dried. Briefly, ziptips where equilibrated using 80% ACN acidified with 0.1% TFA then 
washed twice using 5% ACN, 0.1% TFA. Peptides were loaded onto the column and 
washed using 5% ACN, 0.1% TFA. Peptides were there eluted from the column using 
two volumes of 80% ACN, 0.1% TFA and dried down. Peptides were reconstituted in 
5% ACN, 0.1% formic acid for LC injection. 
Mass spectrometry 
 The LC-MS/MS was performed on a Proxeon EASY-nLC II system (Proxeon Biosystems, 
Odense, Denmark now Thermo, Bremen), which was coupled in-line via a 
nanoelectrospray (nESI) source to a LTQ-Orbitrap Velos™ instrument (Thermo Fisher 
Scientific) for MS analysis. 10 µL The peptide mixtures were applied onto a 10 cm 
ProxeonEASY column (ID 75 µm, 3 µm, C18-A2 medium) analytical column and peptide 
elution was achieved at a flow rate of 300 nL/minute with a linear gradient of 5-40% 
Solvent B (95%Acetonitrile, 0.1% formic acid) for 60 minutes (samples were injected in 
duplicate). 
Data dependent mass spectral acquisition was programmed on Xcalibur as follows: 
precursor MS1 scans from m/z 380 – m/z 1600 acquired in the Orbitrap mass analyser 
with a resolution of 60,000 (at full-width half-maximum at m/z 400) with lock mass 
option enabled for the m/z 445.120025 ion. For full scans, 1 x 106 ions were 
accumulated within a maximum injection time of 150 ms. The ten most intense ions 
with a minimum charge state of +2 were then sequentially isolated with a 2 m/z 
isolation window and an AGC target of 30000 with a maximum injection time set to 
100 ms. Higher energy collisional dissociation (HCD) fragmented was performed at a 
normalized collision energy (NCE) of 35. The corresponding MS/MS scans were 
acquired and detected in the Orbitrap mass analyser at a resolution of 7500. Precursor 
masses were placed on a dynamic exclusion list for 70s following MS/MS selection.  
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Data processing and bioinformatic analysis 
The raw data files were searched using MaxQuant (1.3.0.5) against the Human Uniprot 
Global Proteome, (12 January 2013, taxonomy id 9606) and the MaxQuant built in 
common contaminant database, using a reverse decoy database with global FDR set at 
5%. Trypsin was used as the protease, allowing two missed cleavages and a fixed 
modification of Carbamidomethyl (C) and variable modifications of Oxidation (M) and 
Acetyl (Protein N-term). Only unique, unmodified peptides were used for quantitation. 
MaxQuant assigns detected peptides to proteins, however, proteins that are not 
identified by proteotypic peptides are reported in protein groups. All files were run 
simultaneously to ensure all protein groups were the same across samples and 
normalized together. Replicates were separated through the MaxQuant experimental 
design facility. 
The text outputs from MaxQuant (proteingroups.txt, peptides.txt, evidence.txt, 
paramters.txt, summary.txt) were imported into the statistical language R 
(http://www.r-project.org/). Decoy Hits (Rev) and Contaminants (Con) were removed. 
Data was further curated by removing any protein with an H/L variability greater than 
300, indicating greater than 3 sd across all redundant quantifiable peptides for the 
protein within a sample, thereby removing inaccuracies in protein quantitation from 
the data. A two-tailed t-test was then performed on the entire dataset, using a subset 
of the entire dataset, those proteins within 1sd and with a variance below 0.25, against 
which to assess differential regulation of the dataset. Proteins with a t-test p-value 
below 0.05 were identified as significantly differentially expressed and those with a t-
test p-value below 0.05 and average expression above the 2SD cutoff were deemed 
highly and significantly differentially expressed. 
Functional enrichment analysis 
To identify the biological processes altered by HIV-Tat treatment, we assessed the 
significantly differentially expressed proteins (by t-test only) for GO-term enrichment 
using the PANTHER online software suite.227 For each core analysis investigated, GO-
terms identified with less than Three proteins were ignored. 
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Results 
Given the unavailability of diseased primary neuronal tissue, establishing models of 
disease are a necessity for studying causative pathway dysregulation in disease. To 
identify pathways responsible for HIV-Tat mediated neuronal dysregulation, we SILAC 
labelled and treated the commonly used neuroblastoma cell line, SH-SY5Y, with 
recombinant HIV-1 Tat protein. The resultant isolated proteins representing the 
proteomic state of the cell under both control and treated conditions were mixed and 
analysed by Orbitrap Velos mass spectrometer. The resultant data was analysed to 
identify and quantify proteins prior to differential bioinformatic analysis to identify 
dysregulated proteins. These dysregulated proteins were then further analysed in 
order to elucidate the pathways and cellular functions dysregulated by HIV-1 Tat. 
Monomeric HIV-Tat is required to induced cell death in SH-SY5Y cells 
Previous studies described the identification of several oligomerization forms of HIV-
Tat protein spontaneously forming in solution and particularly stable to denaturing and 
reducing conditions.228 Accordingly, our SDS-PAGE based assay revealed that HIV-Tat 
multimeric form was highly stable once formed and it remains stable after treatment 
with high concentrations of βMe (Chapter 2). However, HIV-Tat multimer formation 
was prevented when lyophilized HIV-Tat is suspended in milliQ water with 50 mM 
βMe, 0.05% TFA and deoxygenated by nitrogen bubbling. Earlier evidences indicate 
that the monomeric form of exogenous HIV-Tat is the only functional form capable of 
transactivating the HIV-1 LTR. This prompted us to investigate the effects of different 
forms of HIV-Tat (monomeric or multimeric) on SH-SY5Y cell viability in vitro. Our 
results confirmed that the multimeric form of HIV-Tat had no effect on cell viability, 
whereas monomeric HIV-Tat suspended in deoxygenated 50 mM βMe, 0.05% TFA 
resulted in 20% cell death. Therefore, in order to treat SH-SY5Y cells with exogenous 
active HIV-Tat protein, the latter conditions were used for further experiments 
involving HIV-Tat treatment. Here, SH-SY5Y cells were treated with 1µg/mL of 
monomeric HIV-Tat, which is within the range of in vivo HIV-Tat levels229 and we chose 
to harvested HIV-Tat treated cells at 80% viability assuming that most of the cells 
would be highly stressed but alive and intact. We reason that this would allow us to 
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have a snap shot of late stage molecular events preceding, but ultimately resulting in 
apoptosis. 
Proteome dynamics 
We performed a typical SILAC experiment that compared two differentially labelled 
cell cultures: SH-SY5Y untreated cells (Arg0; Lys0) and treated with HIV-Tat (Arg10; Lys8) 
with three biological replicates. The incorporation efficiency of the SILAC amino acid 
was greater than 99.9 % (Identified peptides: Appendix 1) and the Arg –Pro conversion 
was calculated as 6.5%. For the subsequently analysis, we employed 1D SDS-PAGE 
protein separation, and subsequent in-gel protein digestion of 10 fractions from each 
biological replicate. After MS analysis and MaxQuant STY phosphorylation 
identification, we saw no evidence of phospho-enrichment (Data not shown). We, 
therefore, treated the phospho-enrichment as a further fractionation step in 
downstream analysis. Combined proteome of the SILAC experiments resulted in the 
identification of 1348896 MS/MS spectra corresponding to 19672 non-redundant 
peptides sequences and 3077 protein groups. The false discovery rate (FDR) was set at 
1% at the peptide level and 5% at protein group level. In order to determine the extent 
of relative expression changes in proteome, a histogram was generated to determine 
the distribution of the data, due to there being outliers in the data, the histogram was 
trimmed including everything within 2SD and regenerated returning a normally 
distributed data set, shown in Figure 24. 
 
Figure 24: A histogram of protein H/L ratios showing a normal distribution of H/L ratios across the dataset after 
highly variant data was removed. 
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The reproducibility of quantitation between biological replicates was assessed by a 
Pearson Correlation analysis and was found to be between 0.75 and 0.96 as shown in 
Figure 25. 
A two-tailed student’s t-test was then used to test each protein against a stably 
expressed set of the data defined as those proteins within 1sd of the mean with a 
variance below 0.25 between replicates. A total of 407 protein groups scored a t-test 
p-value below 0.05 and were identified as significantly differentially expressed. Of 
these, 29 displayed a greater than 2SD variance from the data mean and were deemed 
highly and significantly differentially expressed (Table 1).  
 
Figure 25: Reproducibility of quantitation between biological replicates. Despite the extensive fractionation 
performed, the biological replicates retain high correlations which will allow for more sensitive significance analysis 
downstream.  
Of these, six proteins were upregulated and 23 were downregulated in response to 
HIV-Tat treatment. In order to have an overview of the potential biological processes 
affected by HIV-Tat infection, differential and highly differentially expressed proteins 
 
66 | P a g e  
 
were analysed by GO-term enrichment or individually classified by their putative 
function respectively. 
Table 1: The set of 29 stably and highly significantly differentially regulated proteins as well as number of 






Change p-value Protein Names 
ARHGEF17 1 0.011871 -8.56 0.035 Rho guanine nucleotide exchange factor 17 
BPIFA1 5 7.9E-109 -26.41 0.009 BPI fold-containing family A member 1 
CASP14 3 2.16E-25 -2.45 0.028 Caspase-14 
CDO1 1 0.012644 1.45 0.005 Cysteine dioxygenase type 1 
CHGA 6 2E-173 2.10 0.009 Chromogranin-A 
CRMP1 7 1.1E-152 -1.75 0.026 Dihydropyrimidinase-related protein 1 
CSTA 3 9.71E-23 -4.74 0.037 Cystatin-A 
DBH 15 6E-193 1.67 0.028 Dopamine beta-hydroxylase 
DCD 4 4.77E-43 -10.77 0.002 Dermcidin 
DSP 28 1.1E-106 -5.51 0 Desmoplakin 
IGHA1 8 1.17E-72 -9.97 0.022 Ig alpha-1 chain C region 
IGLL5 1 5.21E-26 -5.04 0.001 Immunoglobulin lambda-like polypeptide 5 
KCTD15 7 2.98E-17 -1.33 0.026 BTB/POZ domain-containing protein KCTD15 
KIAA1429 2 0.000126 -1.45 0 Protein virilizer homolog 
KRT2 1 0 -6.46 0.031 Keratin, type II cytoskeletal 2 epidermal 
LRMP 2 0.001908 -418.48 0 Lymphoid-restricted membrane protein 
MUCL1 2 0.000325 -6.65 0.001 Mucin-like protein 1 
PITPNB 10 3.74E-35 1.39 0.02 Phosphatidylinositol transfer protein beta isoform 
PRRC2C 3 9.04E-05 -31.89 0.019 Protein PRRC2C 
PRSS3 1 2.46E-46 -10.90 0.043 Trypsin-3 
PSME2 12 1.2E-174 1.40 0 Proteasome activator complex subunit 2 
S100A8 5 6.84E-18 -5.53 0.021 Protein S100-A8 
SHROOM3 1 0.000739 -103.75 0.002 Protein Shroom3 
SLC2A1 2 0.000103 -1.34 0.02 Solute carrier family 2 
SMYD5 3 7.99E-14 -1.37 0.013 SET and MYND domain-containing protein 5 
TFPI2 1 0.034087 6.52 0.028 tissue factor protease inhibitor 2 
TOMM34 3 1.71E-09 -1.30 0.014 Mitochondrial import receptor subunit TOM34 
UBXN7 3 1.48E-08 -3.56 0.004 UBX domain-containing protein 7 
ZG16B 4 1.37E-34 -11.81 0.023 Zymogen granule protein 16 homolog B 
 
Using the full complement of 407 differentially regulated proteins, we performed GO-
term enrichment analysis using PANTHER.227 Figure 26 shows that the most highly 
enriched functions are catalytic activity and binding. In our data, catalytic activity 
describes a vast array of enzyme mediated cellular functions which are dominated by 
 
67 | P a g e  
 
hydrolase activity. More interestingly, however, is that the second most enriched 
function is the GO-term, binding (GO:0005488). In our data, this function is dominated 
by nucleic acid as well as protein binding, the components of which can be seen in 
Figure 27A and Figure 27B, respectively. 
 
 
Figure 26: PANTHER GO-term, molecular functions components. 
 
 
Figure 27: PANTHER GO analysis of the respective component functions of nucleic acid and protein binding. 
A B 
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Discussion 
HIV-Tat has been known to cause varying degrees of neuronal damage in vivo and in 
vitro. Due to the subjective nature of many of these past experiments, clear, conclusive 
mechanisms by which this damage takes place has remained elusive. To this end, we 
have performed a quantitative global proteomic analysis of HIV-Tat treated SILAC 
labelled SH-SY5Y human neuroblastoma cells. With this data, we were able to attribute 
HIV1-Tat specific proteomic dysregulation to the most prominent clinical feature 
correlating with disease severity; synapse degradation and loss. 
HIV clade-B Tat as an HIV dementia causative agent 
Despite HIV clade-B being most associated with HIV dementia worldwide, South 
Africa’s burden is most associated with clade-C.230 This was recently attributed to the 
HIV-Tat S31C mutation, most associated with clade-B HIV-Tat, being present in South 
African isolates.231 Furthermore, CNS derived sequences from HIV dementia patients 
typically contained the S31C mutation. However, clade-C HIV-Tat with the S31C 
mutation was, to our knowledge, not commercially available at the time of this study. 
For these reasons, we chose to use clade-B HIV-Tat in our studies. Current studies 
using HIV-Tat to induce neuronal apoptosis use varying concentrations of HIV-Tat and 
culture conditions and rarely confirm the HIV-Tat to be monomeric. 
Bioinformatic identification of dysregulated proteins upon HIV-Tat treatment 
In the current study we have identified a total of 3077 protein groups; a significant 
proportion of the SH-SY5Y proteome and overall this study resulted in one of the 
largest proteomic data reported in SH-SY5Y published to date. We selected the 
unconventional use of an FDR of 5%  as our peptide and protein identification because 
we reasoned that any false positives would become evident in downstream analysis by 
our use of pathway analysis. Our reasoning is that all protein entries in the UniProt 
database used in our MaxQuant searches have an equal opportunity of being identified 
as a false positive in our final protein lists. Furthermore, pathway analysis relies on 
associated proteins being present in the given dataset. The basis of the non-real 
protein assignments dictate that there is a very low possibility that a non-real protein 
identified will fall into a pathway with many other members selected by our 
bioinformatic analysis. Therefore, most, if not all, false positive proteins selected by 
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our differential analysis should not fall into pathways and can thus be excluded from 
further analyses on that basis. Highly dysregulated proteins which do not fall into 
known pathways selected for further analysis will be analysed using targeted MS 
methods 
Conventionally, any proteins with greater than 2SD variance from the dataset mean 
are considered differentially expressed. 2SD is, however, a completely arbitrary value 
as it has no biological relevance when used on its own. We also deemed that the 
commonly used 2X fold change was also not a reliable nor acceptable criterion as the 
cellular relevance of any change in protein abundance would surely be dependent on 
the cell state and would be highly variable between proteins. Furthermore, the 2SD 
average variance from the mean criterion does not take variance among samples into 
account. 
 
As can be seen in Figure 28, we present two examples of proteins with a greater than 
2SD variance from the mean, but they have large variability between samples. These 
two proteins are, therefore, excluded from further analysis due to their high inter-
sample variance Alternatively, differentially expressed proteins which have a greater 
than 2SD variance and small inter-sample variance as determined as a function of a 
significant p-value in the two-tailed students t-test are deemed significantly 
differentially regulated. While we have not presented the data, 2X fold change would 
suffer similar short falls since it too will not take inter-sample variance into account. To 
this end, we argue that any protein with a significant difference as determined by a 
two-tailed students t-test is stably and significantly different and should not be 
ignored. We included the 2SD cutoff as described in order to generate a high 
confidence list of differentially expressed proteins with both a significant and large 
difference between treated and untreated samples which could highlight the most 
significant cellular changes brought about by HIV-Tat treatment (Figure 29). 
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Figure 29: Two examples of proteins which have an average expression greater than 2SD with sufficiently small variation, therefore, selected as significantly differentially regulated 
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HIV-Tat alters protein translation and cytoskeletal regulation 
Using the full complement of 407 differentially regulated protein groups, we 
performed GO-term enrichment analysis using PANTHER.227 Other publications 
performing large scale discovery work to identify HIV-Tat induced dysregulation have 
identified similar dysregulated pathways to those identified in this study. Liao et al 232 
performed qRT-PCR on selected few amino acid metabolism enzymes and, while we 
did not identify differential regulation specific enzymes analysed, we did identify 
differential regulation of 13 amino acid metabolism proteins. Alteration of amino acid 
metabolism is possibly due to altered energy metabolism as a result of HIV-Tat 
treatment. Additionally, among the array of observations outlined in Jarboui et al, 219 
ribosomal biogenesis and the ubiquitin proteasome pathway were noted. Our data 
also shows a dysregulation in the ubiquitin proteasome pathway and we see increased 
expression of a wide array of ribosomal proteins. Following from this, the PANTHER 
molecular functions enriched in the differential data highlight HIV-Tat’s ability to 
dysregulate several key cellular functions is apparent. In our data, the GO-term, 
binding, predominantly describes nucleic acid and protein binding functions. HIV-Tat’s 
ability to alter nucleic acid metabolism is not at all surprising given that its primary 
function relative to HIV is to increase the HIV genome transcription through 
established mechanisms.233 Complementary to this, HIV-Tat is, evidently, capable of 
altering the expression of a vast array of eukaryotic initiation factors (EIF) and 
ribosomal proteins; these form the bulk of the GO-term, RNA binding within the 
nucleic acid binding description. HIV-Tat has been shown to bind 2074 discrete DNA 
loci within the human genome.225 It is, therefore, not surprising to see an increase in 
DNA binding in our data and it serves to validate our findings. In addition to the 
dysregulation seen by the downregulation of EIF’s, we also see the opposite, 
upregulation of ribosomal proteins. From the findings, it is clear that HIV-Tat is able to 
effectively alter neurons’ ability to regulated protein translation. 
The protein binding term is dominated by cytoskeletal protein and receptor binding 
(Figure 27B). The purpose, relative to HIV, of dysregulating receptor proteins is not 
immediately clear and requires further investigation. However, it may be that HIV-Tat 
is capable of modulating the cellular antiviral response as these cellular cascades are 
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primarily initiated by ligand-receptor binding (INF, TNFα, TLR3 etc.).234,235,29 
Furthermore, HIV is known to bind and signal through integrin receptors. Thus, HIV1-
Tat may be capable of increasing these proteins’ abundance such as to provide HIV 
with greater effective binding on cell surfaces. Given that the dominant clinical 
manifestation of HAND is the loss of synapses, it is very interesting to see that the actin 
cytoskeleton, its inner and outer membrane binding partners and regulators are 
dysregulated within the protein binding term. Establishing and maintaining synapses 
relies heavily on the cytoskeleton, not only for structural support, but also for guidance 
queues.236 As the cytoskeleton is a dynamic structure, dysregulation of its subunits and 
regulatory proteins will undoubtable impede the neurons’ ability to maintain and 
establish properly functioning synapses or may lose them entirely. 237 Furthermore, 
analysis of the protein classes in PANTHER provides further support of HIV-Tat’s ability 
to impede proper synapse function. 
Cytoskeletal dysregulation features prominently in highly differentially regulated 
dataset 
 After applying the 2SD cutoff to the 407 significantly dysregulated proteins, we 
identified 29 as highly and stably differentially regulated as a result of HIV-Tat 
treatment. While classical pathway analysis was not feasible for such a small dataset, 
following from the GO-term analysis of the entire dysregulated set, we were able to 
postulate as to the biological impact of these highly differentially regulated proteins. 
We have identified eight proteins, which we believe are indicative of synaptic damage. 
The process of building and maintaining synapses involves several cellular functions 
such as cell – cell adhesion, cytoskeletal reorganisation and axonal and synaptic 
guidance.236 The maintenance of these is essential to the maintenance of synapses. 
Interestingly, each of these functions are represented in our list of highly significantly 
dysregulated proteins and were all down-regulated. 
PRSS3 is a form of trypsin expressed in neural tissue and released into the extracellular 
space as a stress response. PRSS3 then specifically cleaves proteinase activated 
receptor 2 (PAR2) which is a G protein coupled receptor. Among others, PAR2 functions 
to alter cell adhesion by activating Rho. Interestingly, we also identified the Rho 
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guanine nucleotide exchange factor 17 as being down-regulated in our data. As the 
name suggests, this protein controls the activity of Rho by regulating its access to GTP. 
Together, this suggests a decrease in Rho activity. Decreased Rho activity is further 
supported by the decrease in SHROOM3 which is a potent Rho recruiting protein.238 
Rho is the primary co-ordinator of the actin cytoskeleton which forms the structural 
basis of neural extension and, thus, synapses.239,240 If Rho activity is decreased, it is 
feasible to assume that the cells’ ability to maintain synapses is decreased as well since 
Rho is a major cytoskeletal regulator in synapses.237 In addition to providing structural 
support for cell extensions, the cytoskeleton also plays a role in cell adhesion, which is 
important for synapse stability as well. S100-A8 is involved in a multitude of cellular 
functions including but not limited to oncogenesis, signal transduction and energy 
metabolism.241 While some of these activities may be relevant in HAD, its role in the 
modulation of the actin dependant cytoskeleton 241,242 is particularly interesting and 
relevant. There is limited information regarding its involvement in the cytoskeleton, 
however, its decrease seems relevant in lieu of the decreases of other observed 
cytoskeletal proteins. Its calcium binding properties are important to the 
polymerisation of actin 243,244 and they may be structurally important to desmosomes. 
245 There are a multitude of cell adhesion molecules present in synapses and axons 
including the integral desmosome protein, desmoplakin. Desmoplakin is most well-
known for its role in epidermal and cardiac cell adhesion but has also been identified in 
hippocampal granular cell synapses 246,247 where it functions in cell adhesion. 
Interestingly, the hippocampus is one of the most notably damaged areas in HAD 
patients with respect to synapse loss.248 The desmoplakin binder, CSTA 249,250, and 
regulator, SHROOM3 238,251, were also found to be down-regulated in our data. A 
decrease in the Rho-dependant CRMP1 has been shown to result in a loss of 
hippocampal synapses.252 CRMP1 is known to function in axonal outgrowth and 
guidance via its interaction with Rho-dependant Semaphorins.253 PSME2 belongs to a 
family of proteasomal proteins shown to be involved in synaptic regulation and 
neuronal plasticity.254 
A surprising find was that two Immunoglobulin-like proteins, IGHA1 and IGLL5 were 
identified as being severely decreased. While we cannot draw any firm conclusions 
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about their involvement, it is interesting to note that Ig-like proteins have now been 
shown to be involved in synapse adhesion.255 It is plausible that IGHA1 and IGLL5 are 
yet to be discovered neuronal adhesion molecules. 
HIV-Tat affects key systems seemingly unrelated to protein translation or cytoskeletal 
regulation 
Several other interesting and relevant dysregulated proteins were identified; however, 
further analysis will be required to speculate about their function in HIV-Tat induced 
neuronal toxicity as they seem to appear to function independently of the other 
dysregulated proteins identified in this study. Both PITPB and its isoform, PITPa with 
which it shares 77% sequence and 94% structural homology are expressed in the 
hippocampus. 256 However, only PITPa is known to contribute to axonal guidance and 
synaptic establishment.257 Increased PITPb has been known to inhibit cells growth and 
a complete loss results in nonviable cells 258 and plays a role in neuronal vesicular 
trafficking.259 An increase in Dopamine B-hydroxylase (DBH) results in increased 
norepinephrine (NE) production which has been shown to increase infectivity and 
replication of HIV in immune cells. 260,261 Consequently, increased DBH and production 
of NE may be depleting CNS dopamine levels. 262,263 Our data suggests that KCTD15, a 
TFAP-2α suppressor, expression is decreased by HIV-Tat treatment. TFAP-2α is a 
transcription factor capable of transcribing several known viral enhancer elements in 
the human genome. 264,265 This, therefore, suggests that HIV-Tat is promoting the 
transcription of host viral enhancer elements. Along with the above mentioned 
functional alterations induced by HIV-Tat, several proteins identified to be 
dysregulated are secreted (TFPI2, CHGA, MUCL1 ) and certainly warrant further 
investigation as putative diagnostic or prognostic markers for HAD. Furthermore, 
CHGA 266 and PRRC2C are thought to be diagnostic in AD; these too, certainly require 
further investigation using targeted methods. 
In Summary, the data presented here provide clear evidence for HIV-Tat’s ability to, at 
least in part, contribute to the major clinical HAND phenotype; synapse loss. Go-Term 
enrichment analysis in PANTHER reveals that several well established 
neurodegeneration and axonal guidance pathways are dysregulated. Furthermore, we 
have identified several other dysregulated cellular functions which undoubtedly 
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contribute to the overall phenotype of HAND. Protein translation dysregulation has not 
previously been implicated in HAND, but is known to contribute to other 
neurodegenerative diseases such as AD, Huntington’s, Schizophrenia, PD.267,268,269 
While we report direct evidence for synapse dysregulation via cytoskeletal 
dysregulation, dysregulation of protein translation may also play a significant role in 
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Chapter 4 
Extensive pathway analysis of SILAC labelled 
proteomic and transcriptomic data from HIV-Tat 
treated SY-SY5Y neuroblastoma cells 
Abstract 
Despite affecting up to 70% of HIV+ patients and being the leading cause of dementia in 
patients under 40 years, the molecular mechanisms involved in the onset of HAND is 
not well understood. To this end, we performed SILAC-based quantitative proteomic 
and transcriptomic analysis of HIV-Tat treated neuroblastoma (SH-SY5Y) cells. We 
identified 407 proteins and 1074 transcripts as significantly differentially regulated. In 
depth analysis of the dysregulated pathways identified by pathway analysis tools 
revealed overwhelming evidence that HIV-Tat activates numerous antiviral and 
inflammatory response pathways. In other cell types, these may aid in the specific 
dysregulation of the protein synthesis and cytoskeletal functions to aid efficient HIV 
replication. In neural cells, dysregulation of these pathways likely have a profound 
effect on the neurons’ ability to maintain synapses, which can lead to neuronal loss of 




78 | P a g e  
 
Introduction 
HIV-1 infection can induce an array of neurocognitive impairments termed HIV-
associated neurocognitive disorders (HAND). The HAND complex describes three 
standardised measures of dysfunction; asymptomatic impairment (ANI), mild cognitive 
disorder (MND) and HIV-associated dementia (HAD).271 Currently, there are no 
biomarkers to predict or diagnose the disease and there are no specific treatments for 
HAND. Initially, the disease was classified as being the result of neuronal loss in various 
brain regions. Recently, however, it has been shown that cognitive scores correlate 
most closely with synapse loss rather than neuronal loss.217 This switch in the disease 
profile may be directly linked to the advent and availability of highly active 
antiretroviral treatment (HAART). Indeed, since the implementation of HAART, there 
has been a decrease in the incidence of HAD but an increase in MND.1,272 This can be 
attributed to increased life expectancy of HIV patients. In this model, however, a 
source of neurotoxic agents must still exist which leads to a slower but notable 
neurocognitive decline in patients. HAND has been shown to persist and progress 
despite undetectable CNS viral loads.273,60 It was showed that HIV-Tat protein is still 
secreted and detectable in blood despite HIV-treatment and undetectable CSF and 
serum viremia in the majority of patients.274 Depending on the specific Antiviral 
regiment being administered, this may be even more pronounced within the brain 
which may serve as a viral reservoir of actively replicating virus.275 None the less, it is 
highly likely that the CNS and other tissues are exposed to HIV-Tat in most HIV patients 
despite controlled HIV replication. 
HIV-Tat has been studied as a possible HAND causative agent for many years and has 
been shown to dysregulate neurons in several ways. The most prominent of these has 
been the induction of apoptosis.276 As HIV-Tat has been shown to induce apoptosis in 
neuronal cells, significant efforts have gone into elucidating a molecular mechanism of 
this apoptosis induction. However, given the multifunctional nature of HIV-Tat and the 
myriad of cellular pathways that can result in apoptosis, it is not surprising that several 
different pathways have been implicated. One undeniable, central feature is that GSK-
3β activity is increased.27 A popular proposed mechanism demonstrates that, upon 
HIV-Tat treatment, TNFα and PAF function to inhibit the PI3K/AKT pathway, thereby, 
 
 
79 | P a g e  
 
resulting in active GSK-3β which is then capable of facilitating apoptosis 
induction.106,101 However, the upstream source of TNFα upregulation is not elucidated. 
A popular alternative to this involves increased cellular calcium and ROS production. It 
has been shown that HIV-Tat treatment results in increased cellular calcium in neurons 
as well as mitochondrial dysfunction. When cellular calcium increases as a result of 
Endoplasmic reticulum (ER) calcium efflux, mitochondrial calcium influx in increased. 
This calcium influx results in mitochondrial membrane hyperpolarisation (MMHP).109 
This, in turn, results in increased ATP and ROS production. ER stress and subsequent 
calcium induced MMHP are known to induce apoptosis in neurons.277 Normal et al 
present excellent work demonstrating that this is possible by HIV-Tat binding to the 
Ryanodine receptor and inducing ER stress.229 
While, in their isolation, all these pathways are seemingly able to induce apoptosis, we 
do not yet know how all of these pathways contribute, if they do at all, to the HIV 
dementia phenotype. Added to that, HIV dementia has been show to correlate most 
closely with synapse loss rather than neuronal apoptosis. Based on this, together with 
the observation that HIV-Tat is able to bind 2074 sites in the human genome,225 there 
are other possible molecular events taking place in response to HIV-Tat. Together with 
this wealth of literary information about the cellular dysregulations induced by HIV-
Tat, unfortunately, there exists contradictory data; much of which can be attributed to 
work being done in different cell types. These contradictions exist on so grand a scale 
that HIV-Tat is reported to be both pro and anti-apoptotic.278 Understanding these 
dysregulated pathways may allow us to inform better treatments for HAD patients. To 
identify as many of these events as possible, we need to circumvent a downfall 
inherent to classical molecular biology techniques used to identify pathway 
involvement in a particular setting which is that it ignores all non-target molecules and 
pathways. As a result, for one to present a unified set of molecular events to 
consolidate the great wealth of information published in this area, one has to rely on 
conjecture of possible outcomes of interactions. 
Such a proposal can only be realized by a few high-throughput cell state analysis 
techniques such as MS and gene expression analysis. These two incredibly powerful 
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platforms allow us to take a snapshot of the cell state at a chosen time and identify 
non-targeted, global dysregulation in the cell. Along with identifying currently 
unknown functions, these platforms could allow us to determine the pathways 
ultimately responsible for apoptosis and whether those are also responsible for other 
clinical symptoms observed. Such a global analysis would also provide insight into 
additional, unknown, pathways HIV-Tat might be dysregulating. 
A key requirement for any global MS experiment seeking to perform a differential 
analysis is sound statistical methodology. Typically, a fold change approach is used to 
identify differentially regulated proteins. However, given the recent advancements in 
peptide mass spectrometry and nanoLC allowing highly reproducible data generation, 
new statistical approaches are being explored. Recently, several publications have 
employed a t-test based statistical differential analysis. 279 In comparison to a fold 
change based approach, the t-test allows for much smaller changes in protein 
abundance to be deemed significant which equates to greater sensitivity and 
specificity in identifying differential expression. 
In this Chapter, we describe the analysis of both the SILAC-labelled proteome and 
complimentary transcriptome of HIV-Tat treated SH-SY5Y neuroblastoma cells. We 
identify and quantitate 3077 SILAC protein group pairs, of which 407 were identified as 
statistically significantly dysregulated. Additionally, we identified 1074 differentially 
regulated transcripts. Pathway analysis on both these datasets reveal rather 
interesting cascade of pathways. It is apparent from the gene expression analysis that 
HIV-Tat activates pattern recognition receptors (PRR) such as RIG-1 and TLR’s which 
are cellular dsRNA sensors. These can be seen to activate an antiviral response via the 
activation of INFα/γ. A primary means by which the antiviral system resists viral 
infection is to modulate the protein synthesis pathways but it also signals through and 
alters cytoskeletal regulation. Both of these are evidenced in the proteomic data. 
Together, these data provide a cascade map of the dysregulation induced by HIV-Tat 
and can be seen to adversely affect neuronal synapse maintenance and apoptosis. 
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Materials and Methods 
Proteomic data used for pathway analysis 
The highly significantly dysregulated proteomic data presented in Chapter 3 was 
generated by applying an additional 2 SD cutoff to the significantly dysregulated data 
identified by t-tests (as described in Chapter 3, section: Data processing and 
bioinformatic analysis). In this chapter, the t-test derived significantly dysregulated 
data was further analysed using IPA (QIAGEN Redwood City, 
www.qiagen.com/ingenuity). 
RNA extractions 
Since SILAC has no impact on cellular functions, RNA was extracted from unlabelled, 
HIV-tat treated cells. The cells were treated identical to those used to generate the 
data represented in Chapter 2, Figure 23B. 
RNA extractions were performed using the QIAzoltm (QIAGEN) reagent and a modified 
manufacturer’s protocol. The entire protocol was completed as per the manufacturer’s 
instructions except that all incubation steps were performed on ice and all 
centrifugations were performed at 4oC. We found that this yielded higher quality RNA.  
Briefly, cells were removed from the plate by removing media and washing the cells in 
warmed PBS. Trypsin was then used to detach cells from the culture dish and was then 
immediately quenched with trypsin inhibitor once cells are visibly lifted. The cell 
suspension was then transferred to a 2ml vial and centrifuged and 600g for 10minutes. 
The cells are then washed with warmed PBS and centrifuged at 600 g for 10 minutes. 
The cell pellet was the suspended in 500 µl of QIAzoltm reagent and was incubated on 
ice for 25 minutes with occasional gentle end over end mixing. I then added 100 µl of 
cold chloroform and shaken vigorously for 15 seconds. The tube was then incubated 
on ice for 3 minutes followed by centrifugation at 12000 g for 15 minutes at 4oC. The 
upper aqueous phase was transferred to a clean vial and 250 µl ice-cold isopropanol 
was added to the aqueous phase and mixed by vortexing. The mixture was then 
incubated on ice for 10 minutes followed by centrifugation at 12000g at 4oC for 10 
minutes. The RNA pellet was then recovered by removing the supernatant, washed 
with 1 ml of ice-cold 75% absolute ethanol and centrifuged at 7500 g at 4oC for 5 
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minutes. The RNA pellet was the air-dried completely and suspended in RNA free 
water for quantitation and quality assessment by UV spectroscopy using a nanodrop 
instrument. 
Affymetrix Gene array analysis 
Samples were analysed on two separate occasions where four samples (2 treated and 
two untreated) were run initially and two samples (one treated and one untreated) 
were analysed at a later date. The gene expression analysis was performed using the 
Affymetrix platform and HuGene-1_0-st-v1. The quality and concentration of the 
samples were assessed using the Nanodrop (spectrophotometer) and the RNA 
integrity determined using the Agilent Bioanalyser. Using the Ambion WT Expression 
assay the samples were labelled in accordance with the protocol. A control RNA 
sample was included to monitor the assay performance. For the purpose of ensuring 
sufficient labelled target for hybridisation to the Human Gene ST array, 200ng of RNA 
was used for cDNA synthesis. Following cDNA synthesis, in vitro transcription was 
carried out to generate antisense RNA (cRNA). The cRNA was cleaned up in accordance 
with the protocol and the concentration and assessment of size distribution 
determined using the Nanodrop spectrophotometer and Agilent Bioanalyser 
respectively. Using 15μg of cRNA, 1st strand cDNA synthesis was carried out followed 
by cRNA hydrolysis. The sense strand cDNA was cleaned up in accordance with the 
protocol and the concentration and the size distribution determined using the 
Nanodrop spectrophotometer and Agilent Bioanalyser respectively. In order to 
proceed with labelling, 5.5μg of sense strand cDNA was fragmented, assessed on the 
Agilent Bioanalyser for complete fragmentation and subsequently end-labelled. The 
prepared targets were hybridised to the arrays for 17 hours. After the hybridisation 
period, the arrays were washed and stained using the GeneChip® Fluidics Station 450 
and scanned using the GeneChip® Scanner 3000 7G. 
Gene expression data analysis 
The data analysis including the differential analysis of the transcriptomic data was 
performed by Katie Viljoen, a fellow PhD student at the time. Although, I will include a 
brief description of the raw data analysis performed. I performed the pathway analysis 
of the differentially expressed data. 
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The data was preprocessed in R using the Bioconductor packages,280 frma281 and 
ComBat282 for normalization and batch correction respectively. The data was 
generated in two separate experiments in which the cell culture, RNA extractions and 
Affymetrix array hybridisation were duplicated. However, batch effects were identified 
and corrected for using ComBat. Differential expression analysis was performed using 
the Bioconductor package, Limma. Limma uses a moderated t-test to compute p-
values in which both the standard error and the degrees of freedom are modified. A p-
value cutoff of 0.01 was applied in the selection of significantly differentially regulated 
transcripts. 
Pathway analysis 
Pathway analysis for both gene expression and proteomic data were performed in the 
IPA software package. Significantly dysregulated gene names and log-fold or ratios for 
each gene/protein, respectively, were submitted into the IPA core analysis function. 
The IPA core analysis function generates an activity profile for the pathways and 
functions dysregulated in HIV-Tat treated cells. Dysregulated genes/proteins were 
used as overlays on pathways to easily identify and display significantly dysregulated 
pathway members. Biological significance of the data was determined by comparing 
the differences in dysregulation induced by both experimental conditions. Briefly, the 
pathways were grouped into common functions and matched to dysregulated 
functions identified by IPA. Based on literature and the IPA analyses, the dysregulation 
induced was interpreted relative to HIV replication as well as neurodegenerative 
functions. Where possible, mechanisms underlying the dysregulation as well as their 
implications are proposed. 
Pathway maps displaying dysregulated genes are generated from transcriptomic data 
while all pathway maps displaying dysregulated proteins are generated from 
proteomic data. 
Results 
HIV-Tat induces cell death and widespread functional dysregulation 
We elected to harvest protein when approximately 20% cell death was reached as 
determined by MTT assay on parallel experiments (data shown in Chapter 2). The 
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proteomic (Dysregulated SILAC proteins; Appendix 2) and transcriptomic (Genes 
dysregulated in transcriptomic analysis: Appendix 3) analysis identified 1074 and 407 
proteins as differentially regulated respectively. Although some overlap in 
gene/protein identifications was observed, the large majority were restricted to one 
dataset or the other. A similar observation was reported by Woodhouse, et al.283 
Despite several cellular functions and pathways being specifically or better 
represented in one dataset over the other, there was a large overlap between 
dysregulated pathways and functions. Obvious trends in the pathway can be discerned 
from the most highly dysregulated aspects of the data. The proteomic pathway 
analysis displayed a wider variety of cellular effects with the most highly dysregulated 
canonical pathways indicative of protein translation dysregulation (EIF2 signalling, 
mTOR signalling and the regulation of EIF4 and p70S6K signalling), protein degradation 
(protein ubiquitination pathway) and cytoskeletal regulation (remodelling of epithelial 
adherens junctions) (Table 2A). The transcriptomic pathway analysis also provided 
evidence for functions highlighted in the proteomic data, but was dominated by 
pathways indicative of an immune activation (Table 2B). 
However, all the dysregulated pathways, their interactions with each other and their 
contributions to the dysregulated functions should be analysed for a deeper and more 
meaningful analysis. Given HIV-Tat’s function as a transactivator of transcription, it is 
unsurprising that fewer pathways are inhibited (Figure 30) than activated (Figure 31). 
As the primary regulator of protein synthesis, the inhibition of EIF2 signalling at the 
gene level is interesting. Similarly, the inhibition of several cell-surface receptors 
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Table 2: An IPA generated summary of the pathways, disease and cellular functions dysregulated in the proteomic 
(A) and transcriptomic (B) data respectively. While the most highly dysregulated pathways do not overlap, the 
functional implications do. Both datasets are indicative of neurological disease and cell survival deficits.
 
The regulation of DARPP-32 is very complex and relies on many kinases and 
phosphatases,284 however, the inhibition of Dopamine-DARPP32 Feedback in cAMP 
Signalling is significant as it is associated with traumatic brain injury and executive 
function, learning, and memory deficits.285 The inhibition of death receptor signalling is 
counter intuitive given that HIV-Tat is known to induce apoptosis. A strong activation 
of immune functions can be seen in the activation of Role of RIG1-like Receptors in 
Antiviral Innate Immunity, Role of Pattern Recognition Receptors in Recognition of 
Bacteria and Viruses, Activation of IRF by Cytosolic Pattern Recognition Receptors, 
TNFR1 and TNFR2 Signalling and many others. The activation of inflammatory 
pathways is complimented by the predicted activation and recruitment of many 
immune cell types (Figure 32) In the discussion of the apparent activation of an 
inflammatory response, it is not being suggested that these neuroblastoma cells have 
the ability to induce a classical inflammatory response as would be produced by cells 
of the immune system. Instead, the inflammatory and antiviral responses described 
herein are those typical of non-immune cells, which are capable of producing and 
responding to inflammatory cytokines in order to recruit immune cells and mount an 
initial response to a cellular stress such as viral infection. The induction of apoptosis 
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can be seen in the activation of apoptosis and ceramide signalling as well as induction 
of apoptosis by HIV1. In conjunction with the inhibition of one G protein subunit 
(Gai3), Gα12/13 and Gαi signalling is activated. 
Transcriptomic data identified a comprehensive inflammatory response 
Pathway analysis of the transcriptomic data revealed strong activation of several 
inflammatory antiviral pathways and molecules. We see a strong upregulation of 
Interferon regulatory factor (IRF) 7 as well as type-1 interferon-α and type-2 
interferon-γ (Figure 33A). These are likely functions of the activated PRR pathways 
such as TLR or RIG-1 activation as displayed in (Figure 33B). The activation of the 
cytoplasmic dsRNA receptors, RIG-1 and MDA5 lead to the activation of IRF and a 
subsequent activation of an interferon mediated inflammatory response.286 This is 
accompanied by activation of several other antiviral, proinflammatory pathways such 
as TWEAK signalling which activates and signals through FADD and TRAF which are 
both pro-apoptotic (Figure 34A). Complimentary to an inflammatory activation, 
several TNFα family members are upregulated along with their receptor signalling; 
TNFR1, TNFR2 and TREM1. Central to immune activation and many other cellular 
processes, NF-κB is strongly activated. NF-κB plays a role in a diverse array of cellular 
pathways and functions as it regulates the transcription of many genes. Since NF-κB is 
such a multifunctional transcription factor, we wanted to determine which aspects of 
the data are being influenced by its activation. Figure 34B shows that dysregulated 
proteins involved in NF-κB also signals in a host of antiviral inflammatory pathways. As 
may be expected given the inflammatory environment predicted in the HIV-Tat treated 
cells, NF-κB is also signalling in a pro-apoptotic capacity. The antiviral response brings 
about several alterations in cellular dynamics; most importantly, its effects on protein 
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Figure 31: HIV-Tat activated canonical pathways identified in the transcriptomic data evidences a comprehensive inflammatory activation 
 
 




Figure 32: Cell - Cell signalling functions predicted by IPA analysis of the transcriptomic data. Some of the most dramatic function activation occurs in functions related to immune 
activation in the recruitment of immune cells. 
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Figure 33: Pathway maps of differentially regulated genes in the (A) Interferon regulatory factor (IRF) and (B) Pattern 
recognition receptor pathways. These pathways show the activation of a vast array of proinflammatory cytokines as well as 
the activated receptors which mediate and regulate the inflammatory response. Green shaded proteins are identified and are 
decreased compared to the control while red shaded proteins have increased abundance. 
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Figure 34: A) Dysregulated genes identified in the transcriptomic data overlaid onto the TWEAK pathway. TWEAK 
regulated the induction of several inflammatory cytokines and can induce apoptosis. B) Dysregulated NF-κB 
associated genes identified in the transcriptomic data overlaid. NF-κB activation is central to the inflammatory 
response activation as seen in the transcriptomic data. Several pathways, in which NF-κB plays a central signalling 
role have been overlaid onto the NF-κB associated proteins identified. Green shaded proteins are identified and are 
decreased compared to the control while red shaded proteins have increased abundance. 
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Inhibition of several EIF’s indicate attenuation of protein synthesis 
EiF2 signalling was the pathway most highly dysregulated by HIV-Tat treatment. From 
the pathway map in Figure 35A it is evident that all but two eukaryotic initiation factor 
(EIF3H and EIF4B) were upregulated in the differentially expressed dataset. Ribosomal 
protein expression is less uniformly affected with ~60% being decreased with the 
remainder increased in the differentially regulated set of proteins. Although EIF2 
signalling pathway receives regulatory input from a host of pathways, it remains the 
master regulator of protein synthesis.287 It is therefore the primary pathway by which 
to assess the regulation of protein within the cell. Protein synthesis is, however, 
influenced by a number of other pathways which cascade onto the EIF2 signalling 
pathway. Together with this, it must be noted that loss of individual proteins in the 
protein translation pathways can offset increases of other proteins. Along with the loss 
of EIF3H and EIF4B, the increase in EIF4E inhibitor, 4EBP would serve to inhibit 40s 
ribosome binding and scanning. 
Since the EIF2 signalling pathway describes only protein synthesis, the physiological 
implications are not easily discernible from this data alone. The functional implications 
of the dysregulation of protein synthesis can be seen in Figure 35B which shows that 
functions related to protein synthesis are seemingly activated by HIV-Tat treatment 
despite the observed decrease of several EIF and ribosomal proteins. 
Endoplasmic reticulum stress could account for the attenuation of protein synthesis 
 As can be seen in Figure 35A the ER, via PERK, is one of four major protein synthesis 
regulators capable of inhibiting global protein synthesis. Coupled to the activation of 
the unfolded protein response (UPR) (Figure 36A), IPA diseases and functions analysis 
predicts general ER stress. This serves as another means through which HIV-Tat can 
attenuate global protein synthesis. As part of UPR, protein degradation is also 
increased by proteasomal activation which is evidenced in the data by the 
upregulation of several proteasomal proteins and protein ubiquitination in (Figure 
36B). 
Attenuated protein synthesis is associated with other neurodegenerative diseases 
Defects in the regulation of protein translation has been linked to an array of 
neurodegenerative diseases including AD, Huntington’s, PD, Schizophrenia. 267,268,269 
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The importance of the dysregulation of protein synthesis in neurological and 
psychological diseases as well as neuronal cell death which share 17, 13 and 5 
dysregulated proteins with protein synthesis pathways respectively can be seen in 
Figure 38. This serves to highlight the relationship between individual dysregulated 
pathways and functions and phenotypic manifestation of disease. 
Endoplasmic reticulum stress could account for the mitochondrial dysfunction 
An additional consequence of ER stress and the reported interaction between HIV-Tat 
and the Ryanodine receptor, is that cytoplasmic calcium levels increase.229 This is 
further evidenced by the increase in calcium signalling (Figure 31). The mitochondria 
are particularly sensitive to cellular calcium where increases result in mitochondrial 
membrane hyperpolarisation (MMHP) and altered energy production. As with protein 
synthesis, energy production is tightly controlled by many pathways and proteins. Our 
data not only shows dysregulation of proteins related to mitochondrial dysregulation, 
but we also see dysregulation of the function, energy production. All cellular functions 
rely on energy, thus, dysregulation in energy production may have significant effects 
on cellular homeostasis. Once more, the complex cellular interplay and regulatory 
systems involved in energy production share many proteins which play a role in known 
neurological and psychological diseases. An additional consequence of MMPH is the 
increased generation of ROS.288 Figure 37 shows that the production of ROS is not only 
altered, but also shares proteins with, and is therefore associated with infectious 




94 | P a g e  
 
 
Figure 35: A) Proteins dysregulated in the proteomic data overlaid onto the EIF2 signalling pathway. Green shaded proteins 
are identified and are decreased compared to the control while red shaded proteins have increased abundance. B) 
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Figure 36: Proteins dysregulated in the proteomic data overlaid onto the (A) unfolded protein response pathway and (B) protein 
ubiquitination pathway. Most of the dysregulation occurs in protein chaperones and ATPases. UPR initiation typically occurs together with 
increased protein ubiquitination which functions to target proteins for degradation. Green shaded proteins are identified and are decreased 
compared to the control while red shaded proteins have increased abundance. 
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Figure 37: Functions and dysregulated proteins identified in the proteomic data relating to the production and 
metabolism of ROS. ROS plays a role in several cellular functions and diseases, some of which are overlaid to 
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Figure 38: Protein synthesis functions identified in the proteomic data overlaid with proteins associated with 
psychological disorders, neurological disease and neuronal cell death. This serves to illustrate the involvement of 
dysregulation in protein synthesis and the development of neurodegenerative diseases. Green shaded proteins are 
identified and are decreased compared to the control while red shaded proteins have increased abundance. Orange 
and blue shaded functions are predicted to activated and inhibited, respectively. 
Major cytoskeletal regulatory pathways and proteins are dysregulated 
The differentially regulated data presented here enriched for canonical pathways 
involved in cytoskeletal regulation. Most proteins relating to cytoskeletal regulation 
are upregulated with notable exceptions being the RhoGDI nucleotide exchanger and 
the cdc42 family of proteins. Cdc42 proteins are strong positive regulators of actin 
reorganisation. Thus, their loss may be related to a cells inability to regulate its actin 
 
 
99 | P a g e  
 
cytoskeleton. It is similarly interesting to note that all the actin related proteins (ARP) 
as well as cofilin are upregulated. These directly facilitate the polymerisation and 
depolymerisation of F-actin respectively (Figure 39).289 Given that integrins function as 
mediators between the external and internal cellular environment, the activated 
integrin signalling may play a role in regulating the cytoskeleton. Among others, ezrin, 
cdc42, Rho, Rac and ARP family proteins function downstream of integrins239,290,291 
(Figure 40).Given that cytoskeletal dysregulation has been implicated in many diseases 
including neurodegenerative disease, it is interesting to note that dysregulated 
proteins involved in the cytoskeleton and its dysregulation signal in other important 
pathways as well (Figure 41). Several pathways relating to the cytoskeleton, but more 
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Figure 39: Dysregulated proteins identified in the proteomic data overlaid onto the (A) RhoGDI and (B) RhoA signalling pathways. These pathways play a role in signal transduction between the 
external and the internal cellular environment. Primarily, they regulate the cytoskeletal response in accordance with those signals plays integral roles in many pathways and cellular functions. Green 
shaded proteins are identified and are decreased compared to the control while red shaded proteins have increased abundance. 
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Figure 40: Proteins identified in the proteomic data overlaid onto the Integrin signalling. Integrins serve as connections between the exterior and interior of the cell and the subsequent signalling 
dictates the cellular response to the exterior environment. Additionally, integrins are partially responsible for cell adherence to the extracellular matrix which is of importance to the development and 
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Figure 41: Dysregulated proteins involved in cytoskeletal regulation identified in the proteomic data have been plotted in an 
interaction map with several functions overlaid to highlight the relationship between cellular functions. The cytoskeleton plays a 
role in many cellular functions, thus its dysregulation influences those functions as well. Notably, many cytoskeletal proteins are 
associated with neurological disease. Green shaded proteins are identified and are decreased compared to the control while red 
shaded proteins have increased abundance. 
HIV-Tat induced dysregulation is strongly associated with increased cell death and 
decreased cell survival 
While there are classical apoptotic pathways and markers, they are the end-points of 
other cascades which regulate the initiation of apoptosis. In this study, we believe that 
tracking and understanding the upstream regulators of apoptosis which ultimately 
result in that final end-point decision are more important. The wealth of literature as 
well as our own data showing that HIV-Tat induces apoptosis in neurons is sufficient 
evidence of the event. Since the regulation of apoptosis cannot be described using a 
specific canonical pathway, it can be described only as a cellular function resultant of 
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several pathways and other functions; thus, we will present it as such. IPA analysis has 
revealed connections with cell death and apoptosis in a variety of cell types; however, 
we have chosen to only present those related to neuronal cell loss and apoptosis in 
general (Figure 42). Due to the cell wide regulation of apoptosis, we sought to identify 
the pathways and functions which, in our data, contribute to the apoptotic phenotype. 
Dysregulation in these functions are, therefore, the strongest contributors to apoptosis 
induced by HIV-Tat. The large dysregulation of gene expression proteins is not 
surprising given the HIV-Tat function in the HIV life cycle. 
 
Figure 42: Cell death and survival functions. Several relevant functions depicting evidence for cell death and survival 
based on the proteomic data. Cell death and apoptosis are predicted as activated while cell survival and cell viability 
are predicted to be inhibited as a result of HIV-Tat treatment 
To assess the interplay between apoptosis and other functions we have described 
which are known to play a role in neurodegenerative diseases, we overlaid those 
functions onto a network map of proteins and functions involved in apoptosis (Figure 
43). It is, therefore, clear that dysregulation of any single function affects many others. 
Such complex interactions also highlights the value of a global approach such as this as 
it is not possible to predict the extent of these interactions based on the expression of 
just a few proteins. 
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Figure 43: Functional network map generated from proteins identified in the proteomic data showing the involvement of various 
cellular functions in the dysregulation and apoptosis of neurons via proteins shared by the different cellular functions depicted. The 
network contains 166 proteins related to cell death or apoptosis; of these, 157 are shared by Gene Expression functions, 49 to 
infectious disease, 45 to protein synthesis, 22 to energy production, 11 are cytoskeletal and 4 to mitochondrial dysfunction. Green 
shaded proteins are identified and are decreased compared to the control while red shaded proteins have increased abundance. 
Orange and blue shaded functions are predicted to be activated and inhibited, respectively. Yellow, orange and blue dotted lines 
show connections between dysregulated proteins and the neuronal apoptotic functions they are known to contribute to. Grey lines 
denote involvement of these proteins to other important cellular functions. 
Discussion 
The most widely studied neurodegenerative disease is AD. From this wealth of 
knowledge, it is clear that neurodegenerative diseases are multifactorial. The list of 
molecules, pathways and risk factors implicated in the onset of disease is extensive. 
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Thus, it is becoming increasingly important to address these multifactorial diseases in a 
manner that allows us to view as many of these factors as possible. Within the HAD 
research sphere, neuronal cell culture experiments treated with HIV-Tat allow for the 
presumption that gross cellular changes resulting in neurite retraction and apoptosis 
are taking place.105 This approach, however, cannot divulge any information about the 
specific pathway dysregulation resulting in these changes. While there is a great 
wealth of information published in this area, the data is often derived in a wide array 
of cell types with inconsistent experimental methodologies. This created difficulty in 
linking these studies and postulating about the involvement of different proteins and 
pathways. To unravel the molecular basis of HAD, an all-encompassing experiment was 
performed in which the involvement of each protein, pathway and function could be 
determine simultaneously. While proteomic and transcriptomic approaches do not 
allow us to identify external triggers of the disease, they do allow us to discern the 
means by which these external triggers dysregulate a cell and, thereby, bring about the 
disease phenotype. This approach is particularly useful when attempting to uncover 
underlying molecular phenotypes which later manifest as a disease phenotype. This is 
especially important given that the disease of interest is multifactorial and that the 
molecular events being analysed are multifunctional. This is to say that neither of the 
factors implicated in these diseases functions independently. Thus, it is of critical 
importance to view them synchronously so as to elucidate the means by which they 
interact and co-regulate specific cellular functions which foster disease progression 
and onset. In order to delve deeper into the molecular milieu responsible for the 
pathway dysregulation and ultimately, the gross phenotypic changes observed, we 
performed rigorous proteomic and gene expression analyses on HIV-Tat treated 
neuroblastoma cells. From this data, we identified genes and proteins that are 
differentially regulated by HIV-Tat treatment. Using IPA, we performed pathway 
analysis on these and, thus, identified cellular functions linked to and possibly 
responsible for HIV dementia development. 
An important realization to maintain throughout this pathway analysis is that 
pathways act to bring about one specific action. Typically, many pathways are involved 
in executing a particular cellular function. For this reason, one cannot engage in 
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pathway analysis with the view that pathways are static such as to assume that 
pathways function independently to bring about cellular functions. Pathway analysis 
requires understanding of each pathway’s contribution to bringing about a function 
and the hierarchy of those contributions. Similarly, it is important to note that 
pathways share members; some more than others. This seems to be particularly true 
for pathways linked to multiple cellular functions. Furthermore, multiple cellular 
functions can act synchronously to bring about a single or few phenotypic changes in 
the cell. 
Cytoplasmic dsRNA sensors contribute to the Inflammatory response 
The antiviral response is, imaginably, the cells’ first line of defence against viral 
infections. This response is primarily instigated and maintained by the upregulation of 
type-1 interferon (IFN) and its response genes, ISG’s. IFN expression is rapidly induced 
by IRF’s after the activation of PRR. PRR’s are predominantly composed of RIG-1, 
MDA5 and toll-like receptors (TLR).292 Upregulation of all of these proteins and 
pathways provides significant support that inflammation and the antiviral response are 
initiated. As RIG-1, MDA5 and TLR-2 are activated by dsRNA or viral 
components,293,294,295 this observation would be expected in a virus infected cell, but 
not so where no exogenous nucleic acids are present. This then presents the 
interesting question as to whether HIV is specifically activating the host’s inflammatory 
and antiviral response via HIV-Tat. It seems apparent that, in HIV permissive cells, HIV 
replication requires the cellular alterations we have presented here for efficient 
replication. It is also interesting that the attenuation of protein synthesis296 and 
cytoskeletal regulation297,52 are both functions of inflammation and the antiviral 
response. The activation of several proinflammatory TNFα family cytokines as well as 
their receptor, TNFR1, is congruent with an antiviral response.298,299 Several 
downstream effects of this activation can be seen in the data, among which is a strong 
NF-κB activation, upon which an inflammatory response is dependant.300 The 
dysregulation of PKR is indicative of the activation of NF-κB and may be the result of 
the upregulation of TNFα.301 None the less, PKR associated pathways have been 
dysregulated in the transcriptomic data. PKR is a particularly interesting kinase as it is 
the source of much controversy within literature regarding HIV-Tat function. Some 
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reports show PKR being inactivated by HIV-Tat binding while others report its 
activation and function to be highly important to HIV-Tat function.302,303,304,305 It may 
be that both are true and that the means by which the results are obtained are 
responsible for the contradiction. It seems clear that HIV-Tat binding to TAR RNA as 
well as LTR activation is improved by PKR phosphorylation of HIV-Tat.303 Also, it is 
reported that HIV-Tat inhibits the activation of PKR by dsRNA304 and that this inhibition 
is competitive with dsRNA binding.120 This implies that PKR is not inhibited such that it 
cannot phosphorylate EIF2α but that this function may be decreased. Furthermore, 
interferon-α directly activates PKR.306 This interplay likely results in our reported 
dysregulation without a specific directionality. It is also likely that there is some PKR 
phosphorylation activity toward its targets. It is interesting to note that complete loss 
of PKR results in a potent inhibition of HIV replication.307 Primarily, PKR antiviral 
activity functions to inhibit global protein translation once activated by dsRNA so as to 
limit viral protein synthesis. Although many inflammatory regulating pathways can 
alter the regulation of protein synthesis, PKR is likely the most widely studied. TNFα 
induced inflammation is known to result in the global attenuation of protein synthesis 
via PKR activation and phosphorylation of EIF2-α.301 This effect would be compounded 
by the activation of several IFN genes which are also known to attenuate protein 
synthesis via modulation of EIF activity.306 
The HIV-Tat induced inflammatory response favours HIV replication 
There are several antiviral responses initiated by host cells upon viral infection or pre-
emptively when neighbouring cells are infected. These systems illicit a variety of 
cellular responses including the initiation of cytokine release, blockade of protein 
translation and preparation for apoptosis. Intuitively, these measures should decrease 
or abolish the rate of viral replication in cells. Counter intuitively, however, we and 
others show that HIV-1 activates NF-κB which is a potent antiviral transcription factor, 
307,308,309 although it has a wide variety of transcription targets. Interestingly, the HIV-
LTR contains flanking NF-κB binding domains310,311 and an inhibition of NF-κB activation 
by various means leads to a decrease in HIV-1 transcription.312 It is also feasible that 
HIV-Tat can alter the function of active NF-κB since it has been shown to bind NF-κB 
directly.76 Thus, it is reasonable to assume that HIV has the means to overcome the 
blockade intended by the host antiviral response. 
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There is significant evidence in the literature that other viral as well HIV infections still 
trigger the antiviral inflammatory response. However, despite this, HIV and other 
viruses are still able to replicate very efficiently inside host cells. This, therefore, 
implies that efficient strategies have been developed by the various viruses in order to 
overcome any intended replicative impedance by the antiviral and inflammatory 
systems. This does not exclude the possibility that these viruses succeed in spite of the 
antiviral response. However, HIV may be specifically evolved to replicate maximally in 
the cellular environment created by inflammation. It is not impossible to envisage a 
situation whereby HIV-Tat can prime cells to this state in preparation for HIV Infection; 
especially in lieu of the data presented here. HIV may be initiating the inflammatory 
response as a simple means to bring about cell wide environment conducive to its 
replication which is typically initiated by this system. It may then specifically alter the 
expression of a few genes to bring about a favourable replicative environment. Or, it 
may have altered its life cycle such that it thrives in an otherwise classical antiviral 
environment. 
The inflammatory response attenuates protein translation 
Our data does not allow us to conclusively determine the purpose of HIV-Tat 
stimulating the antiviral response, but we can speculate based on knowledge of other 
viral mechanisms of overcoming the host antiviral response. It is well established that 
the induction of the antiviral response induces a cell wide blockade on protein 
synthesis. This blockage includes most, but not all, host transcripts.313 Many 
publications state that HIV prevents this blockade via inhibition of eukaryotic initiation 
factor 2α kinase, PKR. This work proposes that HIV-Tat binds and is phosphorylated by 
PKR and, in this process, blocks EIF2α phosphorylation and inactivation. While our data 
does not allow us to see PKR activity specifically, its signalling is dysregulated by HIV-
Tat treatment. Despite little literature evidence for a cellular shutoff induced by HIV, 
there is significant evidence for the process in other viral infections.46,314,315 Influenza is 
known to decrease both host transcription and translation and, thereby, favour 
synthesis of its own proteins.45,316 Evidence for exactly this is seen in our data whereby 
mRNA transcription and translation is predicted to be decreased. If, in our model, 
protein translation is not inhibited by PKR activity, as is the case in influenza shutoff, 
the entire PRR antiviral system can induce a protein translation blockade. Interestingly, 
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like HIV-Tat, influenza induces the degradation of EIF4B in order to attenuate host 
protein synthesis.45 Specifically, activation of RIG-1, MDA-5 and TLR’s induce the rapid 
production of interferon. The resultant interferon mediated antiviral inflammatory 
response induces a global protein translation blockade. 
The inflammatory response is a potent cytoskeletal regulator 
Similarly, inflammation is known to affect the regulation of the cytoskeleton from the 
altered membrane permeability due to alterations in cellular adhesion52 to altered 
neuronal migration.317,318 This can easily be rationalised due to the fact that the 
immune system cells are typically recruited to sites of inflammation; This recruitment 
relies on a cytoskeletal response to chemotactic signals in order to direct cellular 
movement. Furthermore, inflammatory agents such as TNFα and IFN increase Rho-
dependant signalling and disassembly of cellular junctions which increases membrane 
permeability. Inflammation is also attributed to increased F-actin disassembly due to 
increases cofilin activity.52 Classically, the renin-angiotensin (RAS) system is involved in 
the regulation of blood pressure. More recently, however, basic research and animal 
studies have implicated the RAS as an important proinflammatory mediator in 
response to TNFα stimulation.319,320 Furthermore, the RAS system is known to be 
activated in HIV-infected podocytes and is associated with a compromised actin 
cytoskeleton.321 The RAS has been shown to be capable of mediating cytoskeletal 
reorganisation by signalling through RhoA and Rac via Ezrin.322 Thus, the dysregulated 
cytoskeletal reorganisation in our study is possibly directly due to the proinflammatory 
environment. Furthermore, the dysregulation identified in this work is capable of 
altering neuronal cytoskeletal reorganisation pathways such that cellular extensions 
such neurites and dendrites cannot be initiated nor maintained.323 
Protein translation blockade favours replication in many viruses 
The dysregulation in the EIF2 signalling pathway and general dysregulation of the 
protein synthesis functions seen are very interesting not only because it is the most 
highly dysregulated system, but because of its importance to viral infection. Since 
viruses rely entirely on the host cell for its translation machinery, cells have, therefore, 
appropriately developed an array of mechanisms through which to inhibit viral 
replication once infected. Similarly, successful viruses have developed mechanisms 
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with which to overcome the efforts by their hosts to stifle their replication. It is, 
therefore, well established that viruses specifically target and dysregulate host protein 
translation in an effort to subvert the effects of the host antiviral system in order to 
specifically translate their RNA’s while inhibiting the translation of host RNA.49 
Protein translation is attenuated in AD 
Interestingly, dysregulation of protein synthesis is known to play a role other 
neurodegenerative diseases such as AD and PD.324,325 In AD patients’ brains, inhibition 
of global protein synthesis was elevated compared to non-AD age matched patients.326 
This inhibition was associated with activated PKR.327 In another study, knockout of ER 
resident EIF2α kinase, PERK, ameliorated the inhibitory effects of Aβ on LTP in 
hippocampal slices.270 This is likely because LTP requires de novo protein synthesis, 
thus, inhibition of protein synthesis inhibits long lasting LTP is blocked.328,329 
Activated UPR attenuates protein synthesis 
PERK is one of four master regulators of EIF2α activity and responds to various ER 
stresses; specifically, the UPR which requires modulation of protein synthesis.330 The 
primary function of UPR is to reduce the influx of protein due to the presence of 
unfolded protein in the ER/cell. While attenuating protein synthesis, protein 
degradation is also increased by proteasomal activation.331 Norman, et al, 2008, 
reports that HIV-Tat can indeed activate UPR in neurons through binding to and 
activation of ryanodine receptors in the ER.229 However, why HIV would evolve a 
function which places additional stress on cellular protein synthesis is not apparent 
from this work. Work in other RNA viruses including, but not limited to, West Nile 
Virus, Coronavirus and Influenza A virus shows that they too activate UPR upon 
infection and require UPR activation for optimal replication.332,333,334,335 In addition, 
global protein translation is also attenuated in those cells. Another UPR function is to 
increase levels of protein folding chaperones. HIV makes extensive use of the ER for 
protein folding, glycosylation and disulphide formation, possibly due to its ideal folding 
environment.336 Despite this, a large proportion of synthesized GP160 is retained in the 
ER in insoluble aggregates.337 Given this, it seems plausible that HIV-Tat activates the 
UPR in cells such that the ER becomes better equipped for large scale, rapid viral 
protein production. However, the UPR is a stress response and, therefore, induces 
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several negative effects inside the cell, not least of which is the suppression of protein 
synthesis. Additionally, chronic UPR activation leads to apoptosis via the activation of 
CHOP. Following from the work by Norman, et al, ryanodine receptor activation leads 
to ER calcium depletion 229 and, consequently, cytoplasmic calcium enrichment. Given 
that mitochondria are highly sensitive to cytoplasmic calcium, this may explain the 
mitochondrial dysfunction we report. 
Our data shows a decrease in PPP2CA which is a catalytic subunit of the 
multifunctional phosphatase, PP2A, forming part of the core enzyme and Holoenzyme. 
It has been shown that the ratio between core enzyme and holoenzyme are important 
for the HIV-Tat mediated HIV-LTR transcription. Ruediger et al, showed that by 
increasing levels of core enzyme, HIV-LTR transcription was inhibited 5-fold.338 
Conversely, it is feasible to assume that by decreasing the levels of the core enzyme, 
HIV-LTR transcription would be increased. Our data shows that HIV-Tat is capable of 
decreasing the levels of PPP2CA which, following from Ruediger et al, 1997, would 
decrease the levels of core enzyme.338 PP2A is one of four major cellular phosphatases 
and is a negative regulator of cell cycle and survival. It responds to many pathways; of 
interest to us are protein synthesis regulators such as PKR and mTOR where it 
regulates the activities of AKT/PI3K and EIF4B. In addition, HIV protein Vpr has been 
shown to bind with PP2A subunits which affirm PP2A as a target for dysregulation by 
HIV. Our data, thus, shows that HIV-Tat is capable of decreasing its level in the cell as 
well. Furthermore, as is outlined in the review by Ruediger et al, many viruses target 
and dysregulate PP2A in their life cycles.339 Targeted PP2A dysregulation may be a 
means by which HIV-Tat can alter the protein synthesis machinery to suit HIV 
replication. Interestingly, PP2A is also responsible for the synaptodendritic regulation 
of EIF4B mediated mRNA translation and is essential for neuronal plasticity.340 
Our data shows an bidirectional expression effect on dysregulated ribosomal proteins. 
It is known that several ribosomal proteins are members of a diverse range of 
signalling pathways, although, little is known about this. It may be that HIV requires a 
specific ribosomal expression pattern for protein synthesis modulation as well as other 
functions. It may be that those ribosomal proteins activated are specifically required to 
translate HIV mRNA while maintaining suppression of host mRNA translation. Jarboui 
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et al, also reported dysregulation of several ribosomal proteins as well as HIV-Tat 
trafficking to the nucleolus; the site of ribosomal protein synthesis.219 
EIF4B is responsible for the recruitment of the 40s ribosome to the translation 
initiation complex. Thus, loss of EIF4B will result in impaired 40s ribosomal 
recruitment, mRNA scanning and subsequent translation initiation.121 Interestingly, 
Influenza A also decreases levels of EIF4B in order to inhibit host mRNA translation 
which dramatically increases IAV replication.45 Similarly, the decrease in EIF3H would 
attenuate translation initiation due to its core role in recruiting and stabilising the 40s 
ribosome preinitiation complex. Thus, its loss would either compound or further 
facilitate the protein translation attenuation caused by EIF4B. It is important to note 
that this is most important for the vast majority of mammalian mRNA transcripts as 
they contain 5’ structured untranslated region (UTR) which would result in the global 
attenuation of translation.341 Cimermancic et al identified 497 HIV protein-host 
interactions involving 435 host proteins including many EIF3 subunits.342 
Given the integral involvement of EIF4B in the recruitment of the 40s ribosome to 
mRNA, its loss would certainly attenuate the translation of all transcripts requiring it. 
While the exact mechanism by which IAV overcomes the loss of EIF4B is not known, 
HIV may employ a similar mechanism or, at least, the effect may be for a similar 
reason. Most human mRNA initiation begins by the 40s scanning which is already 
attenuated by the loss of EIF4B. It is likely that the highly structured 5’ UTR prevents 
40s access to the UTR and thus scanning may not be possible. Indeed, the TAR 
secondary hairpin structure decreases EIF4B access and mutation studies removing the 
hairpin structure increased EIF4B access343 and, presumably, 40s pre-scanning. The 
TAR hairpin sequence and structure in HIV mRNA is absolutely required for efficient 
transcription and translation in infected cells. This implies that the TAR specifically 
prevents EIF4B dependent translation of HIV RNA. 
When the TAR sequence is removed, basal HIV protein translation increases 190 fold in 
healthy cells. However, logic dictates that under cellular conditions present during HIV 
infection and replication, the TAR sequence results in greater or more efficient viral 
protein translation. Following this logic, it may be that there is a translational blockade 
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within infected cells and that HIV has developed a means through which to efficiently 
translate its own proteome. Furthermore, the HIV-Tat bound TAR sequence was shown 
to sequester EIF2s1 with greater affinity that mammalian mRNA sequences.344 This 
would allow HIV mRNA transcripts to outcompete host mRNA for translation even 
further under compromised cellular conditions. 
It is feasible to assume that HIV-Tat might use the antiviral and inflammatory systems 
to bring about a favourable environment in which it can replicate. By our analysis, this 
would involve the removal of host mRNA’s ability to compete with HIV transcripts for 
translation machinery. It has been shown that HIV protease cleaves EIF3D342 and that 
interferon induced the suppression of EIF3’s ability to bind the 40s ribosome for 
translation initiation. Thus, interferon functions to suppress global protein upon viral 
infection.345 Similarly, HIV-Tat has decreased the levels of EIF4B which is essential for 
cap-dependent mRNA translation. Furthermore, higher EIF4B levels promote cap-
dependent translation over internal ribosome entry site (IRES) translation.346 Thus, a 
reduction of EIF4B would favour IRES translation. Taken together, a reduction in EIF3H 
and EIF4B would severely decrease the efficacy of cap-dependent mRNA scanning and 
translation and would favour IRES translation. Indeed, HIV translation has been shown 
to make use of the cap-independent translation, IRES.347 Ventoso, et al, show that HIV 
protease cleaves EIF4G and, in doing so, attenuates host cap-dependent protein 
synthesis and favours and IRES mechanism. To our knowledge, HIV-Tat has not 
previously been shown to attenuate EIF functions or protein synthesis. Via this 
mechanism, HIV can effectively decrease competition from host capped mRNA’s and 
thus promote its own translation. 
HIV’s biological purpose is to replicate itself. The requirements for replication are 
energy in the form of ATP and GTP, monomers for its protein and genetic material and 
replication machinery. By limiting the cells’ ability to use these recourses, viral 
replication has access to them with decreased competition. Toward this, a human cell 
likely has several thousand mRNA transcripts present and competing for translation at 
any point in time. If these were to be translated along with the HIV transcript species 
with the same efficiency, HIV replication would be sorely hampered. 
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Figure 44: Psychological disorders. Associated proteins don’t match known disease patterns. This, however, also 
serves to show that HIV-Tat dysregulates proteins implicated in other similar diseases but is molecularly distict from 
them. Green shaded proteins are identified and are decreased compared to the control while red shaded proteins 
have increased abundance. 
Cytoskeletal dysregulation underpins synaptic degradation 
We tend to believe that a pathway has a loss of function when its members’ 
expression is decreased and a converse increase in function when its members’ 
expression is increased. However, any dysregulation should be seen as a loss of 
function especially when the function is regulation. This is due to the fact that cells can 
no longer regulate these key functions to the same degree as in healthy cells. This 
problem likely becomes exacerbated when dealing with such an important, tightly 
controlled and multifunctional cellular systems as the cytoskeleton. 
Cytoskeletal components play a major role in the human immunodeficiency virus-1 
(HIV-1) infection.348 A wide variety of molecules belonging to the microfilament 
system, including actin filaments and actin binding proteins, as well as microtubules 
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have a key role in regulating both cell life and death.349,350 Cell shape maintenance, cell 
polarity and cell movements as well as cytoplasmic trafficking of molecules 
determining cell fate, including apoptosis, are regulated by the cytoskeleton.351 
Additionally, cytoskeletal dysregulation plays a role in the development of many 
diseases including many neurodegenerative diseases like AD, PD and Huntington’s 
Disease.352 While the cytoskeleton plays a role in many cellular functions such as cell-
cell communication, attachment, cellular transport, etc., in neurons, it is also plays a 
central role in the establishment and maintenance of synapses.237,353 
Neuronal synapse maintenance and function relies heavily on the neurons ability to 
accurately regulate its actin remodelling pathways.354,240 Synaptic actin spans a wide 
array of functions including pre and post synaptic shape, restraining and directing 
synaptic vesicles toward the synapse and maintaining the entire synapse in its specific 
space. The roles of specific actin structures within synapses are largely unknown, 
however, despite this, it is known that dysregulation of actin remodelling pathways 
can disrupt synapse function and integrity. Several actin reliant pathways are 
dysregulated in our proteomic data and they are united in their ability to regulate actin 
remodelling. Our proteomic data show that ARP proteins are being upregulated. 
Interestingly, Korobova and Svitkina, 2009, report that ARP2/3 is integral to both 
stable and dynamic actin fibres in post synaptic boutons.240 While we can see that 
actin remodelling is dysregulated by HIV-Tat, our proteomic data does not allow us to 
speculate about the source of the dysregulation. The gene expression data, however, 
does provide insight into the upstream regulators of the dysregulated actin 
remodelling pathways. 
Cofilin activity promotes the depolymerisation of actin and an increased production of 
free barbed ends from F-actin chains. Conversely, these free barbed ends provide 
binding sites for ARP2/3 and subsequent actin polymerisation.289 This process inhibits 
the formation of stable long F-actin filaments. Furthermore, induction of long-term 
potentiation requires stabilisation of F-actin chains; A process is facilitated by the 
inhibition of cofilin.355,356 Overexpression of cofilin results in the formation of 
actin/cofilin rods and is thought to be an early event in the neurodegeneration 
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associated with AD and PD. The actin/cofilin rods are also reported to impede distal 
neurite function without killing the neuron.352 
Along with the maintenance of LTP, stabilisation of the F-actin in synapses plays 
several other roles such as dendritic spine and post synaptic bouton density and 
morphology which are important to their function.357 While we cannot be sure about 
the effect of increased ARP proteins along with increased cofilin, it is certain that the 
cytoskeletal role in synapse function and maintenance is impaired. In addition to this, 
the observed decreased cdc42 correlated with increased cofilin and ARP activity. Cdc42 
is a known cytoskeletal regulator and its loss in neurons was shown to result in gross 
brain abnormalities as well as, but not limited to, impaired abilities to form axons. 358 
Wegner, et al, 2008, showed that ARP2/3 function was critical to the formation of 
dendritic spines and synapses. Similarly, decreased cdc42 levels reduced the number 
of synapses and dendritic spines on neurons via impedance of ARP2/3 function.359 
Relative to HIV replication, the observed dysregulation of the actin cytoskeleton can be 
explained. HIV requires the cytoskeleton to be reorganised such as to allow efficient 
transportation of its components through the cell throughout the infection, replication 
and release process. In addition, cortical actin structures present an initial, physical 
barrier to HIV infection. Active cofilin and ARP2/3 loosen this barrier and allow release 
of the viral core into the cytoplasm.15 Furthermore, the transport of viral cores from 
the membrane to the nucleus is facilitated by free barded ends and actin 
polymerisation.15 This may explain HIV’s need for the production of free barded ends 
by cofilin and the polymerisation functions of ARP’s. This same process of removing 
actin structures likely aids in the disruption of neuronal cytoskeletal structures as well 
as function.360 Protein kinase C (PKC) is known to regulate cofilin and is an important 
cytoskeletal mediator.361 Active cofilin is also associated with increases membrane 
permeability which would allow HIV greater and faster infiltration into tissues. 
Additionally, activation of the multifunctional NF-ΚB is critical to HIV replication where 
its loss decreases replication. Furthermore, NF-ΚB activation in HIV was shown to be 
reliant on the activation of the RAS system. Chandel et al, showed that the activation 
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As has been mentioned, the regulation of protein synthesis plays a role in cytoskeletal 
regulation and synapse maintenance and function. In addition to its effects on protein 
synthesis, a further consequence of decreased EIF3H may be due to it having several 
regulatory functions beyond protein translation. It is reported to be important for 
brain development in zebrafish.363 Sertie et al, showed a further neuron-specific 
interaction whereby EIF3H interacts with the neuron-specific GDP/GTP exchange 
factor, Collybistin, which plays a role in cytoskeletal regulation via Rho, Rac and cdc42. 
This interaction was shown to include the receptor-anchoring protein, gephyrin, which 
plays a role in the maintenance of synapses. They further propose that this interaction 
may regulate synapse specific protein translation.364 It is known that long-term 
potentiation in neurons requires de novo protein synthesis and that this process needs 
to be very tightly regulated. Interestingly, HIV has been reported to alter the 
expression of BDNF which is known to be a powerful regulator of synapse specific 
protein translation and well as many other neuronal and synaptic functions.365,366 HIV 
decreases the levels of BDNF in synapses and consequently increase the levels of its 
antagonist, pro-BDNF. Additionally, the predicted decrease of BDNF activity further 
supports impaired LTP where sustained BDNF activity is shown to be critical to LTP 
induction and maintenance.367 Furthermore, MEK and protein kinase A (PKA) are 
critical to BDNF-induced LTP, 368,369 thus, their inhibition seen in our gene expression 
data would function to further hinder LTP induction. PKA is well known as a 
cytoskeletal regulator and its decrease in the data correlates with the loss of cdc42 
proteins and increase in Rho, both of which are central cytoskeletal regulators.370 
BDNF is thought to regulate synaptic protein synthesis through regulation of 
eukaryotic elongation factor 2 (EEF2) which is decreased in our data. Interestingly, 
EEF1A is the only upregulated EEF in our data and is known to be important for the 
reverse transcription complex. Reduction of EEF1A levels resulted in a significant 
decrease in HIV reverse transcription.371 BDNF promotes expression of certain mRNA’s 
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Apoptosis 
Apoptosis is a well-documented end result of HIV-Tat treated neurons with a wealth of 
literature on the topic. Due to a wealth of literature on the subject, it is indisputable 
that GSK-3β activity is responsible for or at least greatly involved in apoptosis in HIV-
Tat treated neurons and that apoptosis can be inhibited by activating the PI3K/AKT 
pathway by lithium. What is not known, however, is what molecular events lead to the 
sustained inactivation of the PI3K/AKT pathway, and therefore, the activation of GSK-
3β. While the downstream effectors in this model are known and described, the 
upstream effectors are not clear and their elucidation is certainly more pertinent. 
As mentioned previously, apoptosis is regulated by a fine balance between anti and 
pro-apoptotic stimuli contributed by external or internal stimuli which signal through a 
vast array of pathways. By extension, these pathways regulate an array of cellular 
functions including protein synthesis and cytoskeletal reorganisation. Similarly, due to 
the wide scope of apoptosis regulating proteins, it is not surprising that proteins and 
pathways implicated in diseases such as neurodegeneration also contribute to 
apoptosis regulation. Following this, we were interested to see how the pathways and 
cellular functions dysregulated in our datasets contribute to or may initiate apoptosis. 
What was of interest was the relationship between the dysregulation of other 
pathways and cellular functions and apoptosis. As mentioned above, there is no single 
pathway that leads to apoptosis; instead, it is mediated by several pathways. 
Literature has shown that TNF-α exacerbates the apoptotic effect of HIV-Tat 
treatment.65 The cause of this, however, remains unknown. The IPA analysis of the 
data we present shows that TNFR, TNFR2 and strong TREM1 signalling is activated by 
HIV-Tat treatment in addition to upregulation of several TNF family genes. Since TNFa 
signals through both pro and anti-apoptotic TNFR1 and TNFR2 respectively, further 
cellular input is required to favor cell survival or death.298,373,374,375 TNFα treatment 
typically increases the activity of GSK-3β via PI3K/AKT inhibition. HIV-Tat is reported to 
increase phosphatase, PTEN, expression which, therefore, increases PI3K/AKT 
dephosphorylation and results in dephosphorylated and, therefore, active GSK-3β. 
Several publications have shown that HIV-Tat treated neurons exhibit increased PTEN 
levels, which, when inhibited, inhibits apoptosis. Increased hippocampal PTEN activity 
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has been shown to be responsible for AKT mediated apoptosis.376,377 PTEN activity may 
also be a direct effect of HIV-Tat’s ability to bind its promoter.378 Along with PTEN, 
fellow phosphatase, PP2A, are central inflammatory mediators in the cell whereby 
PTEN favours inflammation and PP2A is inhibitory.379,380,381 There is, however, some 
contradiction within literature as to the activity of PP2A. PP2A inhibition can function 
as a pro-survival mediator due to its phosphatase activity toward PI3K/AKT.339 This 
mechanism should function to decrease GSK-3β activity. Conversely, decreased PP2A 
activity in an AD brain model correlated with neurodegeneration and increased GSK-3β 
activity.382 Despite the obvious complexity of PP2A activity, we believe PP2A to 
function in a pro-apoptotic and neurodegenerative capacity in our model due to 
possible regulatory mechanisms outlined below. Furthermore, a decrease in PP2A 
activity is paramount to the induction and maintenance of an inflammatory 
response.383,384 Thus, despite the complexity of PP2A activity, the use of additional 
proxy pathways makes it feasible to conclude that PP2A is functioning in a pro-
apoptotic and cellular degenerative capacity. 
There is a very significant interplay reported between PP2A, BDNF, GSK-3β and NF-κB. 
NF-κB is a highly complex transcription factor with multiple levels of regulation, some 
of which is controlled by GSK-3β and PTEN.385,386,387 While the regulatory functions of 
each of these phosphorylation events remains unclear, they must be tightly regulated 
as NF-κB can be both pro and anti-apoptotic.388 The exact activity likely depends on the 
cellular localization together with the specific phosphorylation status and subunit 
composition; all of which would influence binding partners. GSK-3β has been shown to 
activate NF-κB via Rel-A subunit phosphorylation.389 Activation of TNF-like weak 
inducer of apoptosis (TWEAK) signalling correlates with the phonotypic apoptosis. 
Although the TWEAK signalling cascade is poorly understood, it is known to activate 
and signal through the NF-κB pathway and inhibit the AKT/PI3K pathway, thereby 
activating GSK-3β.390 Given that HIV-Tat induced GSK-3β is pro-apoptotic, it may be fair 
to assume that its activation of NF-κB in this state is also pro-apoptotic. Following from 
this, PP2A may be a potent regulator of apoptosis in HIV-Tat induced neuronal 
apoptosis and several other functions. Despite massive complexity in NF-κB signalling, 
many pro-apoptotic NF-κB activators are known; among them is TNFα signalling 
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through TNFR1. This pro-apoptotic event is known to be inhibited by PP2A activity. It is 
important to note here that the specific compliment of cellular stimuli will define the 
activation status of each of these factors and thereby, ultimately, decide the cells 
apoptotic status. Interestingly, PKC and PKA show decreased expression and are PP2A 
regulators. Both PKA and PKC are reported to activate PP2A 391, 392 thus, their loss could 
explain the loss in PP2A. 
While NF-κB can be either pro or anti-apoptotic, it seems clear from both the data 
presented here and literature, that HIV-Tat mediated apoptosis is NF-κB dependent. It 
is also likely that, given the multifunctional nature of NF-κB, chronic pro-apoptotic 
signalling from multiple pathways is required for an apoptotic phenotype. In our 
description of HIV-mediated neuronal apoptosis, TNFR1/2, UPR, PKR/pEIF2α and 
TWEAK together with other proinflammatory signalling seem to contribute to 
apoptosis. It is certainly feasible that chronic activation of the inflammatory, antiviral 
pathways by HIV-Tat would result in apoptosis. 
Since the implementation of HAART, the disease has changed significantly such that 
HAND correlates less with neuronal cell loss and more so with synapse loss. Our data 
clearly shows how pathways and cellular functions we have shown to be involved in 
neuronal degeneration are also involved in apoptosis. Thus, given that this study made 
use of stressed but live, intact cells, the apoptotic signals from these proteins must still 
be offset by anti-apoptotic signals in the cell. The in vivo, pro-apoptotic signals may be 
further offset by local support cells such as the astrocytes and microglia. Using stressed 
cells, however, does allow us to isolate candidate systems and pathways that may 
ultimately lead to apoptosis as those systems are likely active and dysregulated in the 
stressed cells. 
Conclusion 
It is undeniable that HIV is an incredibly efficient replicator within its target cells. 
Furthermore, the HIV genome is highly error prone; errors that the virus relies on for 
its ability to overcome the immune system and ARV treatments through rapid 
evolution. Thus, any cellular environment present during HIV infection is likely as a 
result of HIV influence or HIV has managed to overcome any intended inhibitory 
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effects; the latter of which is evidenced by the global HIV pandemic. Therefore, it is no 
mere coincidence that the transcriptomic and proteomic data presented here evidence 
favourable dysregulation of so many pathways integral to HIV replication within 
permissive cells. That a large portion of this data can be explained within the context 
of HIV replication lends additional support for the validity of those pathways described 
as playing a role in the most studied synaptopathy, AD. As such, this work has 
highlighted the similarity in molecular mechanisms responsible for neurodegeneration 
in HAND and AD. Indeed, Perry et al also suggest that HAND and AD 
neurodegeneration may be via similar mechanisms.105 The causative agents certainly 
are different, but the pathways dysregulated share many similarities. However, we 
show that the pattern of dysregulation induced by HIV-Tat does not match that of any 
other neurodegenerative disease. This means that, although proteins and pathways 
implicated in other neurodegenerative diseases are dysregulated by HIV-Tat, the 
patterns of dysregulation differ in those diseases. 
Despite HIV not typically infecting neurons, many ubiquitous cellular functions share 
very similar cellular machinery. Thus, although HIV-Tat has likely evolved to specifically 
target systems to enable maximal replication within host cells, if the machinery is the 
same, it will have the same effects in neurons. In the model we propose, HIV-Tat 
inhibits the translation of host cellular mRNA in order to favour the translation of its 
own transcripts via cap-independent mechanisms despite global translation 
attenuation. HIV is known to disrupt cytoskeletal signalling in order to facilitate 
infection and transport of its components throughout the cell during replication. Not 
only does this work show that HIV-Tat is capable of inducing the cytoskeletal 
dysregulation, but that it is likely responsible or, at least, contributory to synaptic 
degradation in HAND. This work serves to highlight the strength of global protein and 
transcription analyses and subsequent pathway analysis to unravel and visualise 
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Chapter 5 
The effect of lithium on HIV-Tat dysregulated 
SH-SY5Y Neuroblastoma cells 
Abstract 
One of the few molecular hallmarks of HAND is the activation of GSK and its inhibition 
rescues neurons from HIV-Tat induced apoptosis. Additionally, activation of GSK is 
strongly associated with other neurodegenerative diseases such as AD. Not 
unexpectedly, the widely described neuroprotector and potent GSK inhibitor, lithium, 
was proposed as a treatment for HAND. However, several clinical trials have shown 
limited success. To this end, we sought to characterise the effect of lithium on HIV-Tat 
dysregulation of neuronal proteins, pathways and cellular functions. In addition to 
identifying known effects of lithium such as the activation of the PI3K/AKT pathway, 
many previously undescribed effects on protein translation and cytoskeletal 
regulation, which are known to play a role in neurodegenerative diseases, are 
described in detail. Additionally, prominent features of the cytoskeletal dysregulation, 
such as RhoA and Rac, involved directly in the development of dendrites and synapses 
correlate strongly with the observed inhibition of NGF signalling which is maintained 
after lithium treatment. Interestingly, NGF modulates inflammatory signalling and 
inhibits HIV replication. It is, therefore, feasible that NGF inhibition facilitates the 
inflammatory signalling required for HIV replication and, consequently, results in the 
loss of synaptodendritic density in HAND. While lithium reverses the dysregulation of 
several HIV-Tat dysregulated proteins, many are specifically or further dysregulated by 
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Introduction 
HIV-1 infection can induce an array of neurocognitive impairments termed HIV-
associated neurocognitive disorders (HAND). The HAND complex describes three 
standardised measures of dysfunction; asymptomatic impairment (ANI), mild 
cognitive disorder (MND) and HIV-associated dementia (HAD).271 Although HAD was 
fairly common, its incidence has decreased since the widespread implementation of 
highly active antiretroviral therapy (HAART). However, the incidence of milder forms 
of the disease has increased.1,272 Furthermore, the disease has persisted in such cases 
where the peripheral and CNS viral loads were undetectable.273 It is, therefore, clear 
that frontline anti-retrovirals (ARV) are not a sufficient treatment for HAND complex 
diseases. Given that disease progression may continue despite undetectable virus in 
the CNS and that neurons are very rarely infected with HIV, the whole virus is not 
likely to be the primary cause of disease.393 An effective treatment would, therefore, 
have to nullify or reverse the cellular dysregulation induced during HIV infection. 
Furthermore, HIV transactivator of transcription (Tat) protein remains detectable 
despite undetectable viral load.274 This, therefore, implies that viral proteins and the 
host response to them are capable of inducing disease onset and maintain its 
progression. 
While the molecular dysregulation underpinning the functional dysregulation leading 
to HAND progression is not well understood, a key molecular event in HIV-Tat induced 
neurotoxicity is the activation of GSK-3β which, when inhibited by lithium, protects 
against apoptosis.276,394 Lithium is a commonly prescribed bipolar treatment which has 
well-documented GSK-3β inhibitory activity.395 However, it has a variety of other 
protein targets and likely many unknown as well.396 The inhibition of GSK-3 along with 
that of other pro-apoptotic genes and the activation of bcl-2 is proposed as its primary 
means of cytoprotection in neurodegenerative diseases.397 It is not known whether 
lithium’s inhibition of apoptosis is solely responsible for its therapeutic effects in BD 
patients, nor whether the other targets have beneficial or adverse effects in patients. 
Lithium has been reported to induce a wide variety of dysregulations in cellular 
functions such as dendritic density, protein synthesis, immunity and inflammation398 
and neuronal signalling.399,400 It has been shown to both increase and decrease 
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dendritic densities in vitro and in vivo. These contradictions may be related to the cell 
type and underlying disease state being tested. Despite the therapeutic mechanisms 
being poorly understood,139 lithium is being studied for efficacy in a variety of 
neurodegenerative diseases including HAND.401,402 Several short term studies have 
previously investigated lithium as a treatment for HAND and have, to some degree, 
found the drug to have had little effect.402 This has led some of them to suggest further 
trials as lithium produced no negative effects in their trials. Such studies have also 
been performed in other disease states such as AD and produced similar conclusions. 
However, what has not yet been determined is the extent to which lithium 
dysregulates cells in these disease states. 
GSK-3β plays a role in a diverse array of cellular functions such as cell survival and 
proliferation, development and an array of neuronal functions including aspects of 
neuronal function, such as gene expression, neurogenesis, synaptic plasticity, neuronal 
structure, and neuronal death and survival403 and phosphorylates a range of targets 
including CREB, NF-κB, AP-1, HSF-1, β-catenin and p53.404 Its inhibition, therefore, may 
affect these processes as well. Despite much research toward identifying the molecular 
aetiology of HAND, little is known about the cellular dysregulations that lead to disease 
onset.405,406 While apoptosis is a central feature in many neurodegenerative diseases, 
HAND prognosis and symptom progression correlates most closely with synapse 
loss.217 While GSK-3β does play a role in the synaptic plasticity, its inhibition has not 
been shown to restore normal plasticity. In BD, GSK-3β inhibition reduces dendritic 
density. In contrast, fragile X syndrome (FXS) is associated with increased dendritic 
spine density. 
The functional implications of impaired synaptic plasticity are however, not simply 
equivalent to the number of dendrites and functional synapses present. Synapses need 
to be both formed and destroyed adequately for normal neuronal/brain function. If 
either function is sufficiently dysregulated, impairment will ensue. With up to 70% of 
patients showing partial or no response to lithium,407 it is feasible to assume that the 
underlying aetiology is different, if only modestly. Additionally, 37 single nucleotide 
polymorphisms (SNPs) were weakly associated with increased risk of BD.408 Added to 
the variability contained within the BD pathology, BD is vastly different to dementia’s. 
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It is, therefore, not possible to predict whether lithium would have a positive effect on 
HAND patients. To evaluate the effects lithium might have on HIV-Tat induced 
neuronal dysregulation, we designed a MS-based cell culture experiment to ascertain 
the effects of lithium on HIV-Tat dysregulated neuroblastoma cells. 
Herein, we describe the analysis cell cultures treated with HIV-Tat and HIV-Tat + 
lithium as well as their controls using label-free MS techniques. We identified and 
quantitated 3757 proteins with 360 and 531 being significantly dysregulated in HIV-Tat 
and HIV-Tat + lithium respectively. With this data, we aimed to determine whether the 
cellular dysregulation we previously identified and described (Chapter 4) could be 
reversed by lithium. To do this, we preformed pathway analysis using IPA and 
evaluated the effects on individual key proteins, pathways identified as well as activity 
predictions of the cellular functions. While the dysregulation of several pathways such 
as PTEN and IL-1 signalling were decreased or removed, most remained dysregulated 
after lithium treatment. To our knowledge, this is the first global proteomic analysis of 
lithium’s effects on HIV-Tat induced neuronal dysregulation and may be the first global 
proteomic analysis of any lithium-induced dysregulation. 
Materials and Methods 
Label-free method development 
Given the challenges regarding quantitation in label-free proteomics, we performed 
extensive tests to determine whether a label-free approach was sufficient for our 
work. We prepared samples with the FASP protocol.409  Both, technical and biological 
replicates were analysed on 180 minute gradients. The most important factors to test 
were the reproducibility of technical as well as biological replicates with regards to the 
stability of protein quantitation as well as ID’s. With this approach, we were able to 
test our entire label-free workflow, from cell culture to MS data acquisition. Of 
importance one sample was run in triplicate, which allowed us to assess the stability of 
our LC-MS workflow, and the remaining samples analysed once. 
LC and Q-Exactive method optimisation 
This work was done in conjunction with Shaun Garnett and Dr. Nelson Soares.  
After using standard protocols provided by Thermo Scientifictm during the Q-Exactive 
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installation as well as another in-house method, we began a series of experiments to 
test effect of each parameter in the MS method setup on the rate of MS and MS/MS 
acquisition and protein an peptide identifications per time. To this end, our starting 
point was a set of settings published by, Pirmoradien et al.410 To get an accurate 
understanding of the effect of all the settings, we both increased and decreased the 
respective settings and then tried combinations that yielded the best results. 
After identifying optimal MS methods to use, we also developed new LC methods. To 
do this, we maximised sample elution time by determining the lag time as well as 
identifying the sample elution range such that we can focus on this area with an 
appropriate gradient. Following the development of optimal linear gradients, we 
developed new non-linear gradients. Briefly, the entire sample elution range is not 
occupied by the same number of peptides/time. Thus, all areas of the chromatogram 
are not used to the same efficiency. To this end, we increased the gradient in the 
beginning and end of the chromatogram and decreased it in the centre. 
Lithium treatment 
In order to determine the toxicity of lithium on SH-SY5Y cells, we performed a dose 
response assay. We then used to 10mM lithium chloride in subsequent experiments 
with HIV-Tat. When cells have grown to approximately 70% confluency, cells are 
washed twice with heated DMEM and cultured in 0% FBS, DMEM for 24hours prior to 
treatment. After 24 hours, cells are treated with 10mM LiCl and/or HIV-Tat suspended 
in 0.01% TFA, 50mM βMe and N2 bubbled water to 100ng/µl was added to 1µg/ml and 
mixed gently. HIV-Tat treated cells are then incubated 5% CO2, humidified 37oC 
incubator for 24 hours. 
Label-free sample processing 
After cells are washed with warmed DMEM, they are immediately treated with 1ml of 
ice-cold RIPA lysis buffer (150mM NaCl, 50mM Tris-HCl pH 8, 0.1% SDS, 0.5% sodium 
deoxycholate with protease and phosphatase inhibitors). The lysate was then removed 
and the culture dish was washed with an additional 500 µl and added to the lysate to 
which 250 units of benzonase was added and mixed. This lysate was incubated, mixing 
end over end, at 4oC for 24hours. After 24 hours, the SDS concentration was increased 
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to 1% and mixed thoroughly. Protein was then quantitated in duplicate using the 
micro-BCA method with a 7-point BSA standard curve. After quantitation, 100 µg was 
prepared and digested using the Filter Aided Sample Preparation (FASP) protocol.409 
Briefly, approximately 100 µg of protein was added to a 30 kDa microcon filter and 
diluted to 450 µl with 8M urea and centrifuged at 14000g for 15minutes. 200 µl 
100mM DTT was added to the filter, mixed and incubated at room temperature for 
30minutes in the dark. Following the incubation, samples are centrifuged at 14000g for 
15minutes. 100 µl of 8M urea was added and the filters are centrifuged at 14000g for 
15minutes. Thereafter, 200 µl of 50mM IAA was added, mixed and incubated in the 
dark at room temperature for 30 minutes. The filters were centrifuged at 14000g for 
15 minutes. This was followed by the addition of 200 µl of 8M urea and centrifuged at 
14000g for 15minutes; this step was repeated twice. Following this, 200 µl of 50mM 
ammonium bicarbonate (ABC) was added and centrifuged at 14000g for 15minutes; 
this step was repeated twice. Filters were then transferred to fresh, clean tubes and 20 
µl of 0.06µg/µl Trypsin (Promega gold) suspended in ice-cold 50mM ABC was then 
added to the filters at a 1:75 trypsin to protein ratio. The digests were then mixed and 
incubated in a humidified 37oC chamber for ~16hours. Following the incubation, the 
filters are centrifuged at 14000g for 10minutes. 50 µl of 50mM ABC was added to the 
filter followed by centrifuging at 14000g for 10minutes; this step was repeated twice. 
Peptides were then acidified with 5 µl 1% formic acid. 
Reverse phase peptide clean-up 
In-house packed stage tips are used for peptide clean-up. Briefly, ~1mmØ disks are cut 
and packed into 200 µl plastic pipette tips. Columns are activated by adding 100 µl 80% 
acetonitrile (ACN), 0.1% formic acid (FA) and centrifuging at 5000g for 1 minute; this 
was repeated thrice. The column was then washed by adding 100 µl 2%, 0.1% FA and 
centrifuged at 5000g for 1 minute; this was repeated twice. 10 µg of peptide (assuming 
no loss through digestion) was loaded onto the column, diluted to 100 µl in wash 
buffer (2% ACN, 0.1% FA) and centrifuged at 500g for 5 minutes. The column was then 
washed by adding 50 µl wash buffer and centrifuging at 5000g for 1 minute; this was 
repeated thrice. After washing, a tapered glass vial was added such that the stage tip 
was inside the vial. Peptides are eluted into the glass vial by adding 50 µl of 60% ACN, 
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0.1% FA and centrifuging at 5000g for 1 minute; this was repeated thrice. Samples 
were then dried completely in a speedyVac. 
Q-Exactive settings 
Standard settings were used for all Q-Exactive analyses unless otherwise mentioned. 
Spectra were captured in a data dependant manner with automatic switching between 
MS and MS/MS scans using a top 10 method. MS spectra were acquired at a resolution 
of 70000 with and AGC of 3X106 with a maximum fill time of 250ms with an underfill 
ratio of 1%. The MS scan range was 400m/z to 1750m/z with a fixed first mass of 
100m/z. MS/MS spectra were acquired at a resolution of 17500 with a AGC target of 
2X105 with an underfill ratio of 1% and a maximum fill time of 120ms. Peptide 
fragmentations were performed by high-energy collision dissociation with the NCE set 
to 25. MS/MS ion selection was performed using a 4m/z window including only 6≤ z 
≥2. 
Label-Free data analysis 
Raw files are analysed in MaxQuanttm 279, version 1.5.1.2 applying a 1% peptide and 
protein FDR, a maximum of two missed cleavages, LFQ based quantitation and the 
MaxLFQ algorithm for normalization. To assess LC and MS reproducibility, shared 
proteins’ LFQ values in the technical replicate data where compared to each other 
using regression curves. Regression curves were plotted and Pearson’s correlation 
calculations were used to assess reproducibility between biological and technical 
replicates. Although these samples were not SILAC labelled, we wanted to compare 
the data to the SILAC labelled data presented in Chapters 3 and 4 respectively. To do 
this, we generated ratios between randomly selected pairs of HIV-Tat : βMe and HIV-
Tat + lithium : βMe treated cells, respectively. These ratios were then tested for 
significance using the t-test method as described in Chapter 3 (section: Data processing 
and bioinformatic analysis). However, only t-tests and not a 2sd cutoff were applied to 
identify significant dysregulation. 
Ingenuity Pathways Analysis 
Total proteins identified and significantly dysregulated lists were submitted for IPA 
(QIAGEN Redwood City, www.qiagen.com/ingenuity) analysis. Gene names and ratios 
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for each protein were submitted into the IPA software package and analysed by the 
core analysis function. The IPA core analysis function generates an activity profile for 
the pathways and functions dysregulated by HIV-Tat and HIV-Tat + lithium treatment 
relative to the control. Significantly dysregulated proteins and their log- mean ratios 
were also analysed by the core analysis function. These were used as overlays on 
pathways annotated with all proteins identified for that pathway to easily identify 
significantly dysregulated pathway members. Biological significance of the data was 
determined by comparing the differences in dysregulations induced by both 
experimental conditions. Briefly, the pathways were grouped into common functions 
and matched to dysregulated functions identified by IPA. Based on literature and the 
IPA analyses, the dysregulations induced were interpreted relative to HIV replication as 
well as neurodegenerative functions. Where possible, mechanisms underlying the 
dysregulations as well as their implications are proposed. 
Results 
Non-linear LC gradients produce higher identifications 
When starting this work, our group was routinely using linear LC gradients across the 
entire peptide elution range. However, linear gradients tend to produce TIC profiles 
such as is depicted in Figure 45 which have a steep slope up to a peak which then 
slopes back down to baseline. The downfall of this approach is that fewer peptides are 
eluted at the base of the peak, which underutilises the mass spectrometer. Conversely, 
too many peptides are co-eluted around the peak of the chromatogram, which can 
result in a greater proportion of peptides not being selected for MS/MS analysis. This 
was confirmed by determining the identifications per time window across the 
chromatogram. To address this, the gradient was decreased over the centre of the 
chromatogram and increased at the start and end (Figure 46). An additional benefit of 
running non-linear gradients is that the sample load could be increased significantly. 
Adopting non-linear gradients increased our peptide identifications from ~9000 to 
~16000 and protein identification rates from ~2700 to ~3400 per 120 minute gradient. 
These results were obtained using an earlier version 1.3; if reanalysed, these 
identification rates will likely decrease as identification rates tend to decrease when 
using the latest version. 
 
 
130 | P a g e  
 
 
Figure 45: A representative TIC generated from a 120 minute linear LC gradient 
 
Figure 46: A representative TIC generated from a 120 minute non-linear LC gradient 
 
Similar 180minute, non-linear gradients were used to analyse the label-free HIV-Tat 
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Figure 47: A representative TIC generated from a 180 minute linear LC gradient used to analyse the label-free HIV-
Tat and HIV-Tat + lithium samples. 
Label-free peptides generated from HIV-Tat and HIV-Tat + lithium treated cells were 
analysed on 180 minute gradients on a Q-Exactive Orbitrap. The resultant raw files 
were analysed using the MaxQuant software package; the results of which are 
summarised in Table 3. 
Table 3: A summary of the Label-free metadata obtained from the MaxQuant analysis. 
MS spectra 134643 
MS/MS Spectra submitted 755896 
MS/MS Spectra Identified 304637 
Total unique peptides identified 29817 
Total protein groups 3757 
0 missed cleavages 86% 
1 missed cleavage 13% 
2 missed cleavage 1% 
 
Differential analysis performed on the quantitated 3757 proteins identified in the 
label-free experiments identified 360 (Dysregulated-LF_TatvsBme proteins; Appendix 
4) and 531 (Dysregulated LF_TatLivsBme proteins; Appendix 5) being significantly 
dysregulated in HIV-Tat and HIV-Tat + lithium, respectively, when compared to the 
βMe treated control. 
Label-free experiments were highly reproducible 
One of the primary concerns in applying label-free proteomics techniques is that they 
are inherently less reproducible than labelling techniques such as SILAC, it was 
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important for us to assess the quantitative reproducibility of the methodology. To 
assess reproducibility, we performed Pearson’s correlation tests on the three biological 
replicates as well as three technical replicates. Technical replicates achieved Pearson’s 
correlation scores above 0.98 (Figure 48). Pearson’s correlation scores for biological 
replicates were above 0.98 for twelve comparisons and 0.94 and 0.95 for the 
remaining two (Figure 49). As MaxQuanttm normalizes the data,279 LFQ intensities were 
used for the Pearson’s correlation scores and significance analysis with no further 
normalization applied. 
 
Figure 48: Regression curves and Pearson's correlations of three technical replicates of TatLi1; Pearson’s 
correlations above 0.98 suggest that the LC-MS were operating stably. 
 
Figure 49: Regression curves and Pearson’s correlation scores for biological replicates show that the sample 
preparation was highly reproducible within each set of biological replicates. 
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Lithium inhibits HIV-Tat induced neuronal apoptosis 
To determine the effect of lithium on HIV-Tat treated neuroblastoma cells, we 
performed a dose response experiment using a range of lithium concentrations and 1 
µg/ml of HIV-Tat (Figure 50). HIV-Tat induced cell death was completely inhibited by 5 
mM – 20 mM lithium whereas 2.5mM had minimal effect. 
 
Figure 50: Cell viability of HIV-Tat treated cells with a range of lithium concentrations. HIV-Tat induced apoptosis 
can be inhibited by lithium at various concentrations with no lithium-induced cell death evident. 
Lithium alters the gross dysregulation induced by HIV-Tat 
To determine gross effects lithium had on HIV-Tat induced dysregulation, we 
determined the directionality of dysregulation across all the pathways significantly 
dysregulated in the HIV-Tat and HIV-Tat + lithium experiments (Figure 51). HIV-Tat + 
lithium had 81 while HIV-Tat treated had 93 dysregulated pathways and 79 were 
shared between both experimental groups. There were 65 and 49 (55 and 48 shared) 
inhibited pathways and 24 and 20 (20 and 19 shared) activated pathways in HIV-Tat 
and HIV-Tat + lithium treated experiments respectively. HIV-Tat has fourteen unique 
dysregulated pathways while HIV-Tat + lithium has two. 
To more directly compare the effects on shared dysregulated pathways, we assessed 
the directional and magnitude effects of those pathways which are dysregulated in 
both experiments (Figure 52). Of the 79 shared pathways that were dysregulated, 47 
maintained the directionality of the dysregulation induced by HIV-Tat after lithium 
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treatment and 30 changed. Of those inhibited, the magnitudes of 11 were increased 
and 22 were decreased. Of those activated, the magnitudes of two were increased and 




Figure 51: Gross pathway dynamics within each experiment. All pathways with activation scores in IPA were used 
irrespective of whether information was available for the pathway in the reciprocal experiment. 
Lithium altered HIV-Tat induced dysregulated in a pathway dependant manner 
The dysregulatory effect of lithium varies between pathways from a very modest effect 
seen in relaxin and IL-8 signalling to for more drastic effects seen in cdc42 Signalling 
and eNOS signalling (Figure 53). The inhibition of ERK/MAPK signalling in both 
treatments is significant as ERK activity is needed for BDNF control of dendritic density 
and in the establishment and maintenance of LTP/LDP which is essential to learning 
and memory functions.411 
HIV-Tat dysregulation of cdc42 signalling is one of the most strongly affected by 
lithium. Not only is cdc42 known to be specifically decreased during latent HIV 
infection, 412 as a Rho regulator, it plays a central role in the regulation of F-actin and 
the cytoskeleton.237 In addition, the cytoskeleton regulating pathways, RhoGDI 
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Signalling, Signalling by Rho Family GTPases and Regulation of Actin-based Motility by 




Figure 52: overview of lithium’s effect on HIV-Tat induced dysregulation. Of those pathways where lithium 
treatment maintained the directionality of dysregulation, lithium tended to decrease the dysregulation. Lithium had 
no effect of the activation of six pathways. The dysregulation directionality of 30 pathways was reversed by lithium. 
8 pathways activated by HIV-Tat were inhibited by lithium while 10 inhibited by HIV-Tat were activated by lithium. 
10 pathways dysregulated by HIV-Tat are normal in lithium treated cells while 2 are uniquely dysregulated by 
lithium. 
There are ten instances where lithium has completely abrogated the dysregulation 
induced by HIV-Tat; of these PTEN is likely directly related to its effect on apoptosis. A 
general observation is that lithium decreases the dysregulation in most HIV-Tat 
dysregulated pathways. Interestingly, although lithium inhibition of apoptosis is well 
established to act via the activation of AKT, there is little effect seen on the AKT 
signalling pathway. This may suggest that HIV-Tat dysregulation of the pathway is not 
via direct inhibition of the AKT, but rather that AKT is inhibited through a molecular 
cascade initiated by HIV-Tat. Furthermore, together with Figure 57, this data supports 
the direct activation of AKT by lithium. Although the immune activation previously 
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reported in Chapter 4 is less abundantly represented in Figure 53, Activation of IRF by 
Cytosolic Pattern Recognition Receptors is activated by HIV-Tat and, interestingly, this 
activation is decreased, but not abrogated by lithium. IRF7 activation has been shown 
to increase HIV replication.413 Similarly, the Induction of Apoptosis by HIV1 is activated 
by HIV-Tat and is appropriately inhibited by lithium. Dysregulation of Dopamine 
receptor signalling is important as it is one of the major neurotransmitters. Lithium 
decreases the magnitude of HIV-Tat induced activation. PCBD, a regulator of the 
Tyrosine hydrolase (TH) cofactor, BH4, which is critical to the production of 
dopamine414,415 is significantly decreased in HIV-Tat treated cells but not in HIV-Tat + 
lithium treated cells. 
The inhibition of ceramide and TNFR1 signalling correlates with apoptosis inhibition 
Further involvement if HIV-Tat and lithium’s effects on apoptosis are evident in Figure 
54. Ceramide and TNFR1 signalling activation by HIV-Tat are both strongly inhibited by 
lithium and may, therefore, play prominent roles in HIV-Tat induced neuronal 
apoptosis. It is interesting to note that Apoptosis signalling is inhibited by HIV-Tat and 
that that inhibition is decreased by lithium. The protein synthesis regulators, EIF2, 
mTOR and p70S6K signalling as well as Regulation of eIF4 and p70S6K Signalling are all 
inhibited by HIV-Tat and activated by lithium. The cell cycle is also affected by HIV-Tat 
and can be seen in the dysregulation of Cell Cycle: G2/M DNA Damage Checkpoint 
Regulation, Cell Cycle: G1/S Checkpoint Regulation, Role of CHK Proteins in Cell Cycle 
Checkpoint Control and CDK5 Signalling in Figure 53 and Figure 54. HIV-Vpr but not, 
HIV-Tat, has previously been described as stalling the cell cycle in the G2/M phase.416 
The strong inhibition of nerve growth factor (NGF) signalling in HIV-Tat treated cells is 
highly significant in relation to neurodevelopment and synaptic loss associated with 
HAND. By regulating the activity of cytoskeletal reorganisation machinery, NGF 
signalling regulates microtubule dependant axonal extension and maintenance in 
many neuronal types.417 While the majority of pathways were identified in both 
experiments, several were unique to an experiment (Figure 55). Several significant 
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Figure 53: Radial plot showing the z-scores of both, HIV-Tat and HIV-Tat + lithium on pathways where the 
directionality of dysregulation was maintained. All pathways presented are, therefore, either inhibited further by 
lithium (red line outside) or the magnitude of the inhibition is decreased by lithium (blue line outside) but they 
remain inhibited. Each cluster of pathways is arranged from the most to least affected by HIV-Tat + lithium 
treatment relative to HIV-Tat treatment in a clockwise fashion. 
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Figure 54: Shared pathways where lithium reversed the directionality of the dysregulation induced by HIV-Tat. Both 
pathway clusters are arranged from the largest to smallest difference between HIV-Tat and HIV-Tat + lithium z-
scores for each pathway in a clockwise fashion. Thus, the largest effects of lithium can be seen in ceramide and EIF2 
signalling respectively. 
Lithium increases the extent to which most pathways are dysregulated 
As the magnitude of dysregulation varied between pathways and treatments so did 
the extent to which members of each pathway were dysregulated. Based on IPA 
canonical pathway outputs, the percentage of significantly dysregulated proteins in 
each pathway verses the total proteins identified for that pathway was calculated. Of 
the pathways the rate of dysregulation could calculated, 65 were common between 
both HIV-Tat and HIV-Tat + lithium treated analyses (Figure 56). The percentage of 
identified proteins of each pathway in each experimental condition that was 
dysregulated varied between 12.9% and 53.6%. As a general observation, lithium 
increased the rate of dysregulation in pathways when compared to HIV-Tat treated 
cells. A notable exceptions to this, however, are insulin growth factor-1 (IGF-1) and 
PI3K/AKT Signalling which are, unsurprisingly, decreased by lithium. Their decreased 
rate of dysregulation may be a result of lithium’s known effects on GSK-3β and AKT, 
respectively, which are regulators in those pathways. 
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Figure 55: Several pathways with z-scores in each experiment were not found in the reciprocal experiment. These 
were not necessarily found in the reciprocal experiment, but did not have a uniform directionality to their 
dysregulation. HIV-Tat treated cells have many more dysregulated pathways than HIV-Tat + lithium treated cells. 
 
 
Figure 56: Rate of dysregulation. The percentage of proteins significantly dysregulated in each of the common 
pathways varies between 12.9% and 53.6%. 
Lithium reverses the molecular signature of apoptosis 
The effects of lithium on HIV-Tat induced apoptosis is the most important feature to 
characterise as it is the most documented feature in literature. While the molecular 
regulation of this effect is unknown, the phenotypic effect is well characterised. We 
see a predicted HIV-Tat induced decrease in AKT activity which correlates with the 
increased GSK3β activity (Figure 57A). Following lithium treatment, AKT activity is 
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predicted to increase which would signify a decrease in GSKβ activity due to increased 
ser9 phosphorylation (Figure 57B).418 
The cell culture evidence showing that lithium is able to inhibit HIV-Tat induced cell 
death is clearly evident in the functional network analysis as well (Figure 58). The 
protein expression pattern induced by HIV-Tat is indicative of activated cell death and 
inhibited cell survival. Not unexpectedly, lithium treatment reversed almost all these 
effects such that cell death is predicted to be almost completely inhibited. 
Interestingly, however, cell survival and viability functions are inhibited further by 
lithium. Proteins involved in cell death and survival functions remain dysregulated 
despite lithium treatment and the inhibition of apoptosis; both, phenotypically and 
molecularly. Figure 59 contains 106 dysregulated proteins involved in various cell 
death and survival functions as well as an array of other relevant pathways that they 
contribute to. This highlights the interconnectivity of pathways and cellular functions 
which further supports the need for detailed pathway analyses as dysregulation in 
individual pathways likely has widespread functional implications beyond those 
expected for a particular pathway. 
Lithium specifically dysregulated several EIF proteins 
Once more, EIF2 signalling was one of the most dysregulated pathways in both HIV-Tat 
and HIV-Tat + lithium treated cells. However, the effect of lithium on the pathway is 
qualitatively evident in that a greater proportion was significantly dysregulated in the 
HIV-Tat + lithium treated cells verses HIV-Tat treated only. While the directionality is 
reversed for some proteins, it is not for many others. HIV-Tat induced dysregulation of 
many EIF’s was eliminated by lithium; however, most ribosomal proteins were 
dysregulated by lithium only. Interestingly, two specific EIF’s discussed in Chapter 4, 
EIF4B and EIF3H which play a significant role in the regulation of protein synthesis 118 
were inhibited in HIV-Tat and returned to normal levels in HIV-Tat + lithium treated 
cells. However, several EIF3 proteins, EIF4E and EIF4C remain significantly inhibited 
after lithium treatment. Nine phosphatases in EIF2 signalling were dysregulated; five in 
HIV-Tat and four in Tat + lithium treated cells respectively. Additionally, lithium inhibits 
the GTP-binding EIF2 subunit, EIF2β. The Full effects of lithium treatment on the EIF2 
signalling pathway can be seen in (Figure 60). 
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HIV-Tat treated cells exhibit a marginal increase in initiation of translation of protein 
with 32 proteins identified as contributing to the function. Similarly, 29 proteins 
related to initiation of translation of protein were identified in HIV-Tat + lithium 
treated cells; 28 of which are shared with HIV-Tat treated cells. However, IPA reports 
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Figure 57: AKT signalling. AKT phosphorylates a diverse array of protein substrates; typically in a pro-survival, proliferative manner. Most importantly in this setting, AKT 
phosphorylates and inhibits GSK-3β. All proteins identified in the pathway are displayed with significantly dysregulated proteins and complexes highlighted in magenta. Green shaded 
proteins are identified and are decreased compared to the control while red shaded proteins have increased abundance. Additionally, blue shaded proteins and complexes are 
predicted to be inhibited while those predicted as activated are shaded in orange. A) HIV-Tat treated cells, B) HIV-Tat + lithium treated cells.  
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Figure 58: Cellular functions related to Cell death and survival depicting significant functions. IPA analysis predicts 
that Li+ ameliorates most of the cell death functions and shows a clear relative decrease in cell death and an 
increase in cell survival. While lithium has a clear inhibitory effect on cell death and apoptosis, it also further inhibits 
cell survival and viability functions. 
 
Figure 59: Cell death and survival functions: 106 significantly dysregulated proteins involved in cell death and 
survival functions in neuronal cells as well as an array of other important pathways. This indicates that many 
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Although the EIF2 signalling pathway is the most influential in the regulation of protein 
synthesis,118 there are other pathways involved as well. The multifunctional mTOR 
pathway is involved in the regulation of many other pathways and functions including 
protein synthesis and cytoskeletal regulation.419 
Given that protein synthesis occurs ubiquitously in all cells using conserved 
mechanisms, a great wealth of regulatory information exists with which to interpret 
the pathway data in (Figure 60). Protein synthesis occurs in three defined steps with 
temporally and spatially defined requirements for each step. Thus, disruption of any 
step disrupts progression to subsequent steps and attenuates protein synthesis. 
Despite this, however, it was useful for us to analyse the IPA predictions of protein 
synthesis related functions based on expression patterns of proteins related to those 
functions. This analysis shows that functions related to protein synthesis are largely 
unchanged or decreased in HIV-Tat + lithium treated cells relative to HIV-Tat treated 
cells (Figure 61). 
Along with the activation of several ER stress functions, Calpain (Capn1) signalling is 
inhibited by HIV-Tat treatment and is reversed by lithium. Calpain1 is known to 
associate with Pi3K 420 and its decrease led to decreased AKT activity and increased 
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Figure 60: EIF2 signalling pathway; the primary protein synthesis regulator which integrates a diverse array of stress and proliferative signals to regulate the global and specific rates of protein synthesis. All 
protein identified in the pathway are displayed with significantly dysregulated proteins and complexes highlighted in magenta. Green shaded proteins are identified and are decreased compared to the control 
while red shaded proteins have increased abundance. A) HIV-Tat treated cells, B) HIV-Tat + lithium treated cells. 
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Figure 61: IPA predictions of shared protein synthesis functions. Functions related to protein synthesis shared HIV-
Tat and HIV-Tat + lithium show the functional implication of the patterns of protein expression. Functions are 
plotted with IA calculated activation scores showing the extent of either activation or inhibition 
 
 
Figure 62: Cellular compromise functions: evidence for the activation of cellular stress functions. Functions related 
to the cellular stress response shared by HIV-Tat and HIV-Tat + lithium show the functional implication of the 
patterns of protein expression. Functions are plotted with IPA calculated activation scores showing the extent of 
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Figure 63: Unfolded protein response; A cellular stress response activated in response to ER stress and unfolded 
protein accumulation. All protein identified in the pathway are displayed with significantly dysregulated proteins 
and complexes highlighted in magenta. Green shaded proteins are identified and are decreased compared to the 
control while red shaded proteins have increased abundance. A) HIV-Tat treated cells, B) HIV-Tat + lithium treated 
cells. 
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Figure 64: Protein Ubiquitination Pathway; protein ubiquitination functions as a post-translational modification which primarily 
targets proteins for proteasomal degradation. All protein identified in the pathway are displayed with significantly dysregulated 
proteins and complexes highlighted in magenta. Green shaded proteins are identified and are decreased compared to the control 
while red shaded proteins have increased abundance. A) HIV-Tat treated cells, B) HIV-Tat + lithium treated cells.  
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Lithium does not abrogate endoplasmic reticulum stress nor UPR activation 
As was highlighted previously, global protein synthesis can be regulated by the 
endoplasmic reticulum resident kinase, PKR-like endoplasmic reticulum kinase, 
PERK.115 PERK is phosphorylated and activated by endoplasmic reticulum stress 
resultant from, among others, unfolded protein accumulation.423 The ensuing stress 
response then functions to decrease or completely inhibit global protein synthesis, 
increase protein ubiquitination and degradation and to increase levels of protein 
folding chaperones.424 ER stress is activated by HIV-Tat treatment and is modestly 
attenuated by lithium (Figure 62). Interestingly, fragmentation and degradation of 
mitochondria are strongly inhibited by HIV-Tat with the former being activated by 
lithium. Functionally, ER stress induces protein ubiquitination and the UPR primarily to 
decrease the rate of protein synthesis and increase the clearance of unfolded protein 
by degradation and refolding. Interestingly, we see dysregulatory effects resultant 
from both HIV-Tat and HIV-Tat + lithium treatment in these cellular functions. 
Two prominent unfolded protein response (UPR) induced ER chaperones, BiP and 
CANX and are significantly dysregulated by HIV-Tat. BiP is significantly upregulated in 
HIV-Tat treated cells but not Tat + lithium treated cells. HIV-Tat induced activation of 
CANX is maintained in HIV-Tat + lithium cells. Furthermore, while lithium does reverse 
the dysregulation of the chaperone, HSP90AA1, more remain dysregulated (Figure 63). 
Despite the large representation of chaperones in the UPR pathway, the majority were 
not differentially dysregulated by HIV-Tat (Figure 63A) nor by lithium (Figure 63B). 
Protein ubiquitination and proteasomal activity function together and are represented 
in Figure 64, we see that many protein folding chaperones such as members of the 
DNAJ and HSP families are differentially regulated by HIV-Tat (Figure 64A). In some 
cases such as with HSPA5, lithium normalizes their abundance (Figure 64B). However, 
other chaperones are either specifically dysregulated by lithium or their dysregulation 
is maintained by lithium. Within the protein ubiquitination pathway, E2 ligases are 
responsible for actively ubiquitinating and targeting proteins for proteasomal 
degradation.425 Our data shows that HIV-Tat dysregulates one E2 ligase and lithium 
maintains its dysregulation and additionally dysregulates another. In addition E1 and 
E3 are significantly dysregulated in lithium treated cells; both are important for protein 
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ubiquitination. As is the case in other elements of this pathway, several proteasome 
subunits are dysregulated by either or both treatments. As a general observation, most 
significantly dysregulated proteasomal proteins are activated. 
Lithium effects on HIV-Tat induced Cytoskeletal dysregulation 
The cytoskeleton is involved in many cellular functions beyond the structural integrity 
of the cell. Many cellular processes communicate with the exterior environment 
through the cytoskeleton as it extends throughout the cell, through the membrane and 
makes direct contact with the cell exterior and ECM. Its contacts with the ECM guide 
cellular movement and cell projections. Furthermore, synapse loss is an integral part of 
HAND pathology. Therefore, understanding the means through which HIV is able to 
dysregulate and destabilize synapses is paramount to understanding the disease and 
to guiding therapeutic intervention.426 
The dysregulation of the cytoskeleton is likely the most important feature of HIV-Tat 
induced neuronal dysregulation as it is directly responsible for the degradation of 
neuronal dendrites and synapses. While the dysregulation of protein synthesis is 
certainly important as it is involved in many neurodegenerative diseases and is a 
prominent feature in our work, its dysregulation is likely not directly responsible for 
the loss of synapses although it may be contributory. To assess the impact of lithium 
on the regulation of the cytoskeleton, we investigated pathways involved in 
cytoskeletal functions as well as the functional implications of cytoskeleton regulating 
pathways. 
Many cytoskeletal regulatory proteins are specifically dysregulated by lithium 
Integrin signalling and the member proteins are major cell-surface proteins responsible 
for cell-ECM and cell-cell adhesion and interaction. They also function as binding sites 
for extracellular ligands and transduce signals to the cell interior. They can, however, 
transduce signals to the exterior as well. Many of these signalling events serve as 
regulators driving cytoskeletal reorganisation guided by extracellular cues.427,428 
HIV-Tat induces significant dysregulation in many key proteins involved in integrin 
signalling such as ITGB1, PTPN11, ARF4, cdc42 and RhoA (Figure 65A). After lithium 
treatment, all but PTPN11 are maintained and others such as RhoG, CrkL, TSPAN6 and 
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ARP were significantly dysregulated in response to lithium (Figure 65B). As a central 
upstream regulator of many Rho-dependant cytoskeletal regulatory functions, RhoA 
and RhoG dysregulation may have a significant impact on cytoskeletal dynamics. 
TSPAN6 is associated with AD pathology429 while loss of CrkL inhibits 
dendritogenesis.430 
Key phosphatases are dysregulated by lithium 
Actin nucleation by ARP-WASP complex (Figure 66) is primarily responsible for 
regulating actin polymerisation in several actin filaments and are critical in the 
development, establishment and maintenance of dendritic spines and synapses.359 The 
process of actin polymerisation is primarily controlled by the ARP-WASP proteins. This 
is responsible for many functions including cell motility and plasma membrane 
protrusions in the formation of lamellipodia and filopodia. Lamellipodial and filopodial 
protrusions from neurons are integral to axon extension, guidance, the formation of 
axon branches, and synaptic structures.323,354 ARP are responsible for polymerising 
and, therefore, lengthening F-actin filaments.323 Loss of ARP2/3 proteins or its 
activators alters spine morphology and reduces their number.431 Many cytoskeletal 
regulatory elements such as RhoA and an array of phosphatases such as PP2A and PP1 
family members are dysregulated as well. A PP2A regulatory subunit (PPP2R) 
dysregulated by HIV-Tat is maintained by lithium while an additional subunit and 
several other phosphatases are dysregulated. The HIV-Tat induced dysregulation of 
growth factor receptor-bound protein 2 (GRB2) is inhibited by lithium. GRB2 is known 
to inhibit HIV induced activation of toll-like receptor (TLR) signalling. 
Lithium dysregulates cytoskeletal regulatory G protein coupled receptor subunits 
GTPases are small signalling molecules involved in the regulation of diverse cellular 
functions including reorganisation of the actin cytoskeleton,432,251 morphogenesis,251 
transcriptional regulation,432 cell-cell junctions,251,433 vesicle trafficking,237,432 
neutrophil activation, phagocytosis, activation of the NADPH oxidase, mitogenesis, 
apoptosis and tumorigenesis.434 Along with the already mentioned RhoA and RhoG 
dysregulation, we see differential GNAI dysregulation between HIV-Tat and HIV-Tat + 
lithium treated cells (Figure 67). GNAI3 is activated by HIV-Tat; this, along with the 
inhibition of GNAS, is maintained in lithium treated cells. Similarly, GNB1, GNB2, 
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GNB2L1 are specifically activated by lithium. These G-proteins are upstream regulators 
of the major cytoskeletal regulators, cdc42, Rac and Rho.435,436 Although not 
significantly dysregulated, the increase in cofilin activity in Figure 67B results in the 
prediction of increased actin polymerisation, likely, by increasing barbed ends which 
are required for ARP2/3 mediated actin polymerisation. Cofilin is responsible for 
severing F-actin filaments and its increase leads to synaptic loss in AD.437 Lithium 
maintains the HIV-Tat induced dysregulated Septins, Sept9 and Sept11 and additionally 
dysregulates Sept2 and Sept7. Septins not only regulate the cytoskeleton,438 but have 
been found to play a role in AD.439 ARP2/3 family proteins play major roles in synaptic 
plasticity359 as they are the major actin polymerising proteins and are further 
dysregulated by lithium. Their dysregulation would result in the cell’s inability to 
regulate the growth of actin filaments which are paramount to the structural integrity 
of synapses. 
Neuronal cell protrusion functions remain dysregulated in lithium treated cells 
Given the importance of the cytoskeleton and that it plays a role in many cellular 
functions and pathways, the specific functional implication of dysregulations in 
individual pathways may be difficult to assess. The IPA predicted effects of the 
cytoskeletal dysregulation induced in both HIV-Tat and HIV-Tat + lithium treated cells 
allows for comparison of the functional implication of the dysregulation (Figure 68). 
Despite the continued dysregulation of cytoskeleton regulating pathways with lithium 
treatment, the functional effects of those dysregulations are typically less pronounced 
when compared to HIV-Tat treated cells. Important functions such as neuritogenesis 
and morphogenesis of neurites predicted only in HIV-Tat treated cells are not evident 
in HIV-Tat + lithium treated cells. Similarly, among others, lithium induces the 
inhibition of extension of cellular protrusions. 
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Figure 65: Integrin signalling pathway; A major family of cell-surface proteins responsible for cell-cell and cell-surface adhesion. Along with their downstream signalling proteins, they are responsible for signal 
transduction through the cell membrane. All protein identified in the pathway are displayed with significantly dysregulated proteins and complexes highlighted in magenta. Green shaded proteins are 
identified and are decreased compared to the control while red shaded proteins have increased abundance. A) HIV-Tat treated cells, B) HIV-Tat + lithium treated cells. 
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Figure 66: Actin nucleation by ARP-WASP complex. Along with their regulators, such as WASP, ARP proteins are responsible for actin polymerisation during cytoskeletal reorganisation. All protein 
identified in the pathway are displayed with significantly dysregulated proteins and complexes highlighted in magenta. Green shaded proteins are identified and are decreased compared to the 
control while red shaded proteins have increased abundance. A) HIV-Tat treated cells, B) HIV-Tat + lithium treated cells. 
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Figure 67: Signalling by Rho family GTPases. Molecule Activity Predictor (MAP) shows the predicted effect of the given protein abundance pattern on both relevant cellular functions and proteins. Blue 
and orange indicate predicted inhibition and activation respectively. Green and red shaded proteins are identified and decreased or increased respectively compared to the control. Proteins and 
complexes highlighted in magenta are significantly dysregulated in the respective experiment. A) HIV-Tat treated cells, B) HIV-Tat + lithium treated cells. 
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Figure 68: Several dysregulated cellular functions related to the cytoskeleton that are contained within the Cellular Assembly and Organization description in the Disease and function 
utility in IPA. The Degree of dysregulation induced by lithium on the pathways dysregulated by HIV-Tat varies between pathways. The majority of pathways dysregulated by HIV-Tat 
remain dysregulated after lithium treatment (A). Several Important functions such as neuritogenesis and morphogenesis of neurites are only identified in HIV-Tat treated cells (B). 
Similar functions such as extension of cellular protrusions are, however, are identified in HIV-Tat + lithium treated cells (C). 
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Discussion 
Given the central and canonical role GSK-3β occupies in HIV-Tat mediated 
neurotoxicity, it is reasonable to investigate lithium for its therapeutic potential. 
However, despite the wide use of lithium, little is known about its molecular effects in 
a cell beyond that of inhibiting GSK-3β via AKT activation. We, therefore, aimed to 
elucidate the extent of the proteomic changes induced by lithium on HIV-Tat treated 
neuroblastoma cells as well as the functional implications of those changes. That 
lithium inhibited apoptosis in cell culture was clear, however, the mechanisms 
responsible are not well understood beyond the activation of AKT. With this data, we 
tried to further understand the cellular dysregulation induced by HIV-Tat as well as the 
mechanisms through which lithium alters that response. We also specifically aimed to 
determine the effect lithium has on the cytoskeletal dysregulation induced by HIV-Tat 
and whether that would affect neurite and, ultimately, synapse loss. Given that the 
current consensus is that HAND is the result of synaptic loss rather than neuronal loss, 
lithium’s ability to effect neurite maintenance and function is significant. Ochs et al, 
showed that GSK-3β knockout resulted in a decrease in dendritic spine density in the 
hippocampus.440 Takahashi et al investigated the effect of lithium on the development 
of primary rat hippocampal neurons. They found that the inhibition of GSK-3β and 
phosphorylated tau inhibited neurite growth and purpose that this would hinder axon 
and synapse formation.441 Work by Shah et al, however, shows that neurite growth can 
be improved by low doses of lithium such that GSK3β is attenuated rather than 
completely inhibited in primary murine neuronal cultures.442 The role of GSK-3β in 
neurodegenerative diseases is complex and often not well understood. FXS is 
associated with increased dendritic spine density and GSK-3β activation. Subsequently, 
GSK-3β inhibition in FXS alleviates behavioural deficits. 440 Thus, if the same trend is 
expected, GSK-3β inhibition in HAND may serve to further destabilize synapses. 
 From these, and many other works, it is clear that GSK-3β plays an important role in 
synapse formation and maintenance as well as being central to HIV-Tat induced 
apoptosis. Our previous work (Chapter 4) provides a detailed description of the 
proteomic alterations and the functional implications of HIV-Tat treatment in neurons. 
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We will, therefore, not detail the current data to the same extent, except for 
significant pathways and functions exclusive to this dataset. 
Initially, the observation that HIV-Tat and HIV-Tat + lithium experiments shared so few 
differentially regulated proteins despite the overlap in identification was unexpected. 
However, both lithium and HIV-Tat have an array of target molecules and there is no 
reason, biological or other, for those targets to overlap. The wide range of targets for 
both molecules is reflected in the number of differentially regulated proteins in each 
experiment. That many HIV-Tat induced changes were ameliorated would hold 
promise for lithium’s therapeutic benefit if not for the observation that lithium 
increased the dysregulation of many proteins and pathways as well as uniquely 
inducing an array of dysregulated proteins and pathways. Similarly, the vast majority of 
HIV-Tat dysregulated pathways remain dysregulated in lithium treated cells. Despite 
the observation that lithium generally increases the rate of dysregulation, a more 
detailed analysis of the proteins, pathways and functions dysregulated is required to 
gauge the effect of lithium on HIV-Tat treated cells. 
Pathway analysis overview 
It is well established that HIV-Tat is neurotoxic and induces gross neuronal 
morphological changes and apoptosis. It is also well established that Lithium treatment 
is able to protect neurons from HIV-Tat induced apoptosis. In the previous chapter 
(Chapter 4), several dysregulated pathways and cellular functions are described; these 
may or may not be consequent or causative of apoptosis and may, thus, be completely 
uncoupled from apoptotic signalling. Furthermore, it is accepted that in vivo neuronal 
apoptosis is not primarily responsible for the onset of HAND symptoms in patients. In 
this study, we aimed to ascertain whether lithium has any positive effects on the HIV-
Tat-induced dysregulation of key pathways and cellular functions which contribute to 
and ultimately result in synapse loss. 
It is well known that lithium treatment induces many unfavourable side effects along 
with the associated behavioural alterations.443 There are, however, very few studies 
attempting to document the molecular dysregulations induced by lithium or the 
molecular source of the behavioural alterations it induces. Since lithium’s effects are 
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non-specific, it is not unexpected that it induces cellular dysregulations of its own. It is, 
however, interesting that there are many HIV-Tat induced dysregulations which are 
ameliorated by lithium. 
The extent to which GSK-3β inhibition by lithium would benefit HAND patients is 
difficult to assess by merely considering its effect on apoptosis or neurite growth and 
maintenance. The brain has a significant level of redundancy in its structure and 
function. The exact pathology in HAND patients is not known, but it is feasible that 
significant loss of neuronal functionality must develop before symptoms manifest. 
Indeed, this is supported by the observation that ~90% of HIV+ patients display post 
mortem evidence of neuropathology whereas significantly fewer present with HAND 
during their lifetimes. It is undeniable that GSK-3β and its inhibition will affect the 
progression and development of HAND. As the dysregulated processes directly 
involved in the onset of apoptosis are likely not entirely responsible for the 
neurodegeneration seen in HAND patients, pathways intuitively related to other 
cellular functions may be more intimately involved. Given the previously discussed 
(Chapter 4) importance of cytoskeletal and protein synthesis regulation, their 
maintained dysregulation in HIV-Tat + lithium treated cells identifies them as targets 
for further investigation. The discussion will, henceforth, be focussed on proteins, 
pathways and functions which may directly influence neurodegenerative processes in 
HAND. 
HIV-Tat induced dopamine receptor signalling 
HIV replication is reported to increase when host cells are exposed to increasing 
dopamine levels444 Congruent to this, HIV patients have higher CFS dopamine levels 
and develop hypersensitivity to dopamine antagonists. In addition to HIV-Tat’s 
function as a HIV-LTR transactivator, it may increase dopamine signalling specifically to 
increase the rate of HIV replication. HAND affects patient brains asymmetrically with 
significantly more damage being caused in dopamine rich brain regions. Whether this 
results from increased sensitivity of these areas to HIV or whether HIV replicates more 
efficiently there and, therefore, the causative agents are in greater abundance is not 
known. Silver et al, show that inhibition of dopamine receptor, DR1, completely 
inhibited HIV-Tat induced apoptosis in rat midbrain primary neuronal cells but not in 
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hippocampal cells where DR1 expression is low.445 Given that lithium reduced 
dopamine receptor signalling activation induced by HIV-Tat may suggest that lithium’s 
activity on AKT/GSK-3β may be directed through the dopamine receptor. 
Lithium inhibition of HIV-Tat induced neuronal apoptosis 
HIV-Tat treatment induces dysregulation indicative of cell death and inhibits those of 
cell survival. Despite lithium’s complete inhibition of apoptosis in cell culture, it is 
interesting that it further inhibits cell survival functions. It may be that lithium is 
merely capable of blocking the execution of apoptosis but not the signals which induce 
apoptosis during HIV-Tat treatment. Indeed, there remains significant dysregulation in 
AKT, particularly with chaperones and the phosphatases, PP2A and PP1, as well as 
other cell survival pathways. The dysregulation of chaperones and proteasomal 
proteins are likely indicative of cellar stress such as ER stress which can induce 
apoptosis. 
Using global proteomic data as presented here to conclusively identify a molecular 
mechanism responsible for the induction of apoptosis is not trivial. This is especially so 
given the number of pathways and functions identified to be dysregulated. However, 
given that apoptosis is completely inhibited according to cell culture data as well as 
functional analysis of the resultant MS data, it is feasible to assume that the pathways 
and functions which are responsible for the execution of apoptosis should be activated 
in HIV-Tat treated cells and dramatically and notably inhibited by lithium. Following 
this reasoning, ceramide and TNFR1 signalling present themselves as obvious 
candidates. Both are strongly activated by HIV-Tat and inhibited by lithium treatment. 
Ceramide signalling induces apoptosis by activating PP2A phosphatase which 
dephosphorylates and inactivates Bcl-2. Both TNFR1 signalling446 and IL-1447 have been 
shown to accumulate ceramide and induce ceramide dependant apoptosis. 
Furthermore, lithium has been shown to inhibit ceramide induced apoptosis by 
decreasing Bcl-2 dephosphorylation via PP2A inhibition.140 While the proteomic data 
does not describe HIV-Tat effects on the inflammatory response as well as our gene 
expression data does, pathways such as Activation of IRF by Cytosolic Pattern 
Recognition Receptor IL-1 signalling, IL-8 signalling and TNFR1 signalling suggest that 
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lithium supresses the HIV-Tat induced activation of proinflammatory molecules, 
pathways and functions. Interestingly, PTPN11 (SHP-2) negatively regulates TLR 
mediated IRF-3 activation and proinflammatory cytokine (TNF-α, INF-β) production, 
and loss of the phosphatase exacerbates the proinflammatory response.448,449 As may 
be expected of its involvement in cytoskeletal reorganisation, PTPN11 regulates the 
formation of Lamellipodia.449 Furthermore, PTPN11 regulates cells adhesion and plays 
a role in hippocampal synapse formation.450 Its loss impairs learning and memory in 
mice and induces neuronal and behavioural deficits in mice.451 That lithium abrogates 
the significant decrease of PTPN11 induced by HIV-Tat supports proposition that the 
inflammatory response activated by HIV-Tat initiates pro-apoptotic signalling in HIV-
Tat treated neurons. Interestingly, TNFR1 along with Fas contribute to death receptor 
signalling. 
Inhibition of CREB blocks GSK-3β mediated inhibition of PP2A 452 which suggests that 
CREB is an intermediate between PP2A and GSK-3β activity. However, both seem 
capable of regulating each other; the outcomes of which are dependent on the 
stimulus. CREB activity is required for neuronal LTP and LTD in learning and memory 
functions.368,367,453 Furthermore, AKT phosphorylates and activates CREB.454 While 
CREB inhibition did decrease upon lithium treatment, it was not activated as would be 
expected from active AKT. Additionally, CREB activity is decreased in AD brains and 
Ameloid-β (Aβ) tangle treated neurons in cell culture.455 Hippo signalling is also known 
to negatively regulate AKT signalling 456 and is known to be upregulated in HIV-infected 
CD8 T cells, but the exact role in HIV infection is not known.457 Hippo activation, 
therefore, promotes apoptosis in its primary function to regulate organ development 
and size.458 It is interesting that lithium further increases the HIV-Tat induced 
activation of Hippo signalling while concurrently activating AKT. This further supports 
our hypothesis that lithium merely disrupts the execution of apoptosis at the level of 
AKT while maintaining or exacerbating the original pro-apoptotic signals. While Hippo 
is activated during neuronal differentiation,459 its role in differentiated neuronal cells is 
unknown. Although the specifics are unknown, it is clear that dysregulated hippo 
signalling contributes to neurodegeneration. 
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The relationships between and contributions of pathways to seemingly unrelated 
cellular functions is often overlooked in pathway analyses, although, they cannot be 
ignored. The attributed functions of canonical pathways are rarely their sole function 
in cells. The extent of inter-pathway relationships likely varies between pathways and 
may be dependent to some degree on the complexity of the pathway. As a practical 
example, EIF2 signalling is best known for its regulation of protein synthesis; indeed, 
that is its primary function in the cell. However, protein synthesis can be regulated by 
countless other cellular systems and pathways and, therefore, by extension, signals in 
those pathways as well. This then implies that dysregulation in EIF2 signalling would 
affect the regulation of those pathways as well as pathways reliant on protein 
synthesis for their regulation. Indeed, one such mechanism is the relationship between 
EIF2 signalling and apoptosis. Briefly, if EIF2 signalling is inhibited sufficiently, which 
invariably indicates chronic cell stress, apoptosis is initiated.115,460 Therefore, pathway 
dysregulation, however small they may be, likely have far reaching effects on serveral 
other systems. Apoptosis is a cell function which must be tightly regulated and must be 
able to respond to a myriad of cellular stresses. Due to the obvious importance of tight 
regulation in apoptosis initiation and that it is a possible end-point function of chronic 
dysregulation of a vast array of pathways discussed; it is not surprising that it shares 
proteins with many important pathways. It is, therefore, feasible to postulate that any 
dysregulation in these pathways would ultimately contribute to and influence pro or 
anti-apoptotic signalling in cells. Thus, it is also feasible that all of the systems 
dysregulated by HIV-Tat or HIV-Tat + lithium contribute to the execution of apoptosis. 
Although apoptosis may have been inhibited by lithium, it is evident that many cell 
stresses induced by HIV-Tat are still present, even though the nature of the 
dysregulation may be altered after lithium treatment. There is, therefore, no doubt 
that lithium is merely altering the nature of the HIV-Tat induced dysregulation and not 
specifically alleviating all their effects. This may, however, have been expected as 
lithium does not have a specific, targeted function and is a broad spectrum inhibitor. 
That lithium protects against HIV-Tat induced neuronal apoptosis does not necessarily 
imply that lithium would be a viable treatment option for HAND as HAND is not 
primarily resultant of neuronal loss. It is clear that lithium’s effect on AKT and GSK-3β 
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are central to its inhibition of HIV-Tat induced apoptosis. However, what is not clear is 
whether the activation of AKT and GSK-3β inhibition play a role in the behavioural 
alterations induced by lithium in bipolar patients nor that they would alleviate HAND 
symptoms. 
Protein synthesis 
Although lithium evidently alters the dysregulation induced by HIV-Tat, the pathways 
and functions associated with protein synthesis and its regulation remain 
dysregulated. In this work and previously, we argued that protein synthesis is inhibited 
in HIV-Tat treated cells and that this would favour HIV replication. Briefly, protein 
synthesis takes place in several sequential stages; initiation, elongation and 
termination.122 Regulation of these stages effects the rate of protein synthesis 
sequentially as well. Therefore, increases in elongation and termination machinery will 
not significantly increase the rate of protein synthesis if the initiation machinery is 
inhibited. Furthermore, there are sequential steps within the initiation process 
whereby EIF2 functionality initiates the process such that inhibition of EIF2 functions to 
globally suppress protein synthesis irrespective of other components of the 
pathway.461,462 This observation is supported Bertsch et al, which showed that lithium 
reduced EIF2B activity and was ineffective at reducing the inhibition of protein 
synthesis.463 This data, however, is from an unrelated disease in muscle cells. Rats fed 
with lithium chronically showed significant decrease in active, phosphorylated EIF2B in 
brain tissue.464 Both FXS and BD are associated with increased protein synthesis rates. 
Lithium was shown to decrease the rate of neuronal protein synthesis in models of 
both these diseases.465 This further supports our view that lithium will further 
attenuate the protein synthesis dysregulation induced by HIV-Tat. 
Unlike BP and FXS, the rate of protein synthesis is decreased in AD and can be reversed 
by inhibition of the EIF2α kinases.270 The inhibition of protein synthesis was directly 
linked to deficits in synaptic plasticity and special memory in an AD mouse model.270 
This may be due to the need for de novo protein synthesis in synapses to initiate and 
maintain LTP. Not only does this affirm the importance of tightly regulated protein 
synthesis, but also highlights the implication of potentially further decreasing the rate 
of protein synthesis in HAND by lithium. Several EIF’s are dysregulated by HIV-Tat as 
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well as by the addition of lithium. Lithium would, therefore, likely serve to exacerbate 
the effects of a decreased rate of protein synthesis. Although Figure 54 shows that 
lithium increases EIF2 signalling dramatically, Figure 61 suggests that protein 
translation is decreased by lithium treatment. As we have previously argued (Chapter 
4) loss of specific individual EIF proteins can attenuate the entire process of protein 
synthesis. As the vast majority of mammalian mRNA’s requires binding and activity of 
multiple EIF’s in sequence, the loss of any of them would decrease the efficiency of 
protein translation initiation and global protein translation. This remains true despite 
upregulation of individual EIF’s and/or ribosomal components. 
Cytoskeletal Dysregulation 
Deficits in apoptosis signalling and protein synthesis are certainly involved in the 
dysregulation of synapse maintenance and their loss. In order to impair synapse 
structure, the structural components must be impaired. It is, therefore, reasonable to 
postulate that the elements regulating the synaptic structural components must be 
impaired. The structural component of the synapse is the cytoskeleton and its 
regulation forms the basis of synaptic plasticity. Functions that regulate synapse 
formation, maintenance and destruction must directly or indirectly influence the 
cytoskeleton. Therefore, discerning the effects on the cytoskeleton helps to gauge the 
state of the synapse’s physical structure irrespective of the source of the effect. 
Whether or not the deregulation of synaptic functions is decreased, exacerbated or 
maintained by lithium is difficult to gauge without functional studies on the synapses 
under different treatments. However, that elements of their cytoskeletal structure 
remains dysregulated is clear. 
One of the most prominent neuronal phosphatases, PP2A, along with PP1 show 
consistent dysregulation in many pathways, including those involved in cytoskeletal 
reorganisation, presented. In AD, PP2A and PP1 receive much attention due to their 
role as primary tau phosphatases as well as their ability to regulate microtubule 
structure and function. The involvement of tau hyperphosphorylation in HAND is 
debated, although, there are several publications showing increased tau 
phosphorylation in HAND patient brain tissue as well as CSF.466 Certainly, the increased 
GSK-3β activity does support the notion of increased tau phosphorylation.467 However, 
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while lithium does decrease the levels of phospho-tau in an AD mouse model, it did 
not improve their working memory.468 This may be due to the involvement of GSK-3β 
in LTP/LTP. GSK-3β inhibition is integral to the induction of LTP, however, the inhibition 
must end for normal LTP function; 469 thus, highlighting the importance of regulation 
as opposed to directionality. 
The specific functional implications of individual PP2A subunits is poorly understood, 
however, research by Martin et al shows the potential functional implication of the 
HIV-Tat induced loss PPP2R2A (PP2ABα). This work shows that loss of PP2Abα leads to 
hyperactivation of RhoA resulting in the cell’s inability to regulate its cytoskeletal 
rearrangement. PP2ABα loss also lead to dysregulated cell–matrix adhesion 
regulation.470 Synaptic plasticity relies on the cell’s ability to rapidly and reliably 
rearrange its cytoskeletal structure such as to destroy and rebuild synapses. Similarly, 
accurate axonal guidance is important for proper synapse formation and this would be 
hindered by poor cell–matrix adhesion and communication. Interestingly, the PP2ABα 
subunit is also known to interact with PKR in its regulation of EIF4E. The interaction of 
HIV-Tat with PKR and its regulation of protein synthesis was discussed in Chapter 4. 
Chen, et al, show that lithium inhibited the methylation of the PP2A subunit C which is 
required for subunit B recruitment.140 This would suggest that binding of all regulatory 
subunits would be inhibited by lithium. In either event, this may go toward explaining 
the array of side effects associated with lithium treatment. 
Although there is little information regarding specific activities PP2A subunit, PPP2R5C, 
as well as other phosphatases specifically dysregulated by lithium treatment, it is 
feasible to assume that they will have major effects on homeostasis. Irrespective of the 
source of dysregulation, they will have major effects on the regulation of the 
cytoskeleton and, in turn, on all cellular functions reliant on the cytoskeleton such as 
synapse maintenance and function. Neurite outgrowth is controlled by tight regulation 
of cytoskeletal functions such as focal point contact formation and guidance and actin 
polymerisation to drive the formation of cellular protrusions.471 RhoA inhibits neurite 
formation and is antagonized by Rac.237 However, dysregulation of Rac in either 
direction retards proper neurite formation suggesting that tight regulation is 
absolutely necessary.472 Additionally, Rac is required for the formation of point 
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contacts and the stabilisation of subsequent lamellar protrusions. Overexpression of 
Rac, however, does increase the frequency of protrusion formation but decreases the 
overall neurite outgrowth, thus, tight regulation is important. Furthermore, growth 
cone adhesion to the extracellular matrix (ECM) via point contacts which are enriched 
by molecules such as β1-integrin and paxillin.473,474,475 Our data, therefore describes 
the loss proteins and dysregulation of pathways required for the initiation, formation, 
stabilisation and guidance of neurites which would ultimately relate to neurons’ 
inability to form axons and synapses nor maintain them or their function. Furthermore, 
both Rho and Rac protein functions as well as their signalling pathways can be 
controlled through NGF signalling which promotes neurite outgrowth and, ultimately, 
synapse formation.476,477 The down regulation of NGF signalling correlates with the 
observed activation and inactivation of RhoA and Rac respectively in our data. This 
dysregulation also accounts for the observed HIV-Tat induced loss of neurites in 
neuronal cell cultures as well as the synapse loss in HIV+ patients.478 
Interestingly, NGF also functions in an inflammatory loop. TLR stimulation increases 
expression of NGF. In turn, NGF decreases the production of TLR induced 
proinflammatory cytokines, IL-1β, TNF-α, IL-6, and IL-8 and induces the release of anti-
inflammatory cytokines, IL-10 and IL-1 receptor antagonist.479 HIV-Tat may decrease 
NGF signalling in order to sustain the proinflammatory cellular environment. HIV 
infection is associated with chronic inflammation and maybe be due to inflammation 
resolution pathways being attenuated during HIV infection. While it is counter intuitive 
that HIV favours a proinflammatory cell state by activating antiviral mechanisms, HIV 
replication is dependent on this state. Equils et al show that LPS dependant activation 
of TLR-4 activates the HIV-LTR and that the inhibition of TLR-4 inhibits LPS induced HIV-
LTR activation. Furthermore, this HIV-LTR transactivation occurs via IL-1 signalling.480 
TLR agonist and TLR induced proinflammatory cytokine, TNF-α, increased HIV 
replication 481 
Given all the arguments presented for HIV’s dependence on a proinflammatory cell 
environment and the evidence presented showing that this proinflammatory 
environment may induce the cellular changes which ultimately result in synaptic loss, it 
is feasible that an anti-inflammatory drug co-treatment along with HIV-Tat could 
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protect neurons from the degeneration. However, a caveat to this is that it may prove 
dangerous to systemically treat HIV patients with anti-inflammatories. However, the 
NGF receptor, TrKA, agonists may prove sufficient to attenuate the HIV induced 
proinflammatory environment. Furthermore, it may serve to reverse the dysregulation 
seen in cytoskeletal regulatory pathways. 
The mechanism proposed for the activation of the inflammatory response is central to 
HIV’s ability to hijack the cell and replicate efficiently. TLR activation may be central to 
achieving the desired proinflammatory environment. That the inhibition of TLR 
activation inhibits HIV replication certainly supports this hypothesis. 
To our knowledge, this is the first proteomic analysis of the effect of lithium on HIV-Tat 
treated cells. While this was not intended to serve as a complete description of 
lithium-induced cellular dysregulation, it is possibly the largest such description 
produced. Based on the data presented here and the modest clinical trials testing 
lithium for HAND therapeutic potential, it is unlikely that lithium is able to completely 
restore the HIV-Tat induced neuronal cell to a normal cell state. Schifitto et al found 
that lithium had no beneficial effect on cognitive performance of HAND patients.402 It 
is, however, similarly clear that lithium is capable of abrogating or ameliorating several 
HIV-Tat induced dysregulations particularly regarding apoptosis and cytoskeletal 
reorganisation. Lithium may, therefore, have an effect over a significantly longer trial 
by slowing the rate of synaptic loss, thereby, slowing disease progression. However, in 
supporting the opinion that lithium is detrimental to neuronal regulation is a 
retrospective study performed on psychiatric patients in the Danish medical records. 
Although not intended to address lithium efficacy in HAND, they assessed the 
relationship between lithium usage and dementia onset. They identified all patients 
who had any exposure to lithium within the psychiatry registry and took a random 
sample of the rest of the population who had never taken lithium. Interestingly, the 
incidence of dementia was decreased to the same level as the rest of the population 
after a single lithium prescription. Unexpectedly, however, they report a slight increase 
in the incidence of dementia relative to subsequent prescriptions. This trend was not 
seen for other prescriptions such as anticonvulsants.482 Thus, continued lithium 
exposure is, seemingly, detrimental to neuronal regulation. This data may suggest that 
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lithium would compound HIV-Tat induced dysregulation. However, considering the 
alterations to HIV-Tat induced dysregulation by lithium, it is more likely that lithium 
will attenuate some functions but maintain and exacerbate others. These data may 
also serve to begin addressing the molecular dysregulations induced by lithium which 
leads to the array of side effects associated with its administration. Lithium is often 
said to be neuroprotective as it inhibits apoptosis induced by many insults. However, 
inhibition of apoptosis does not equate to proper neuronal function. Irrespective the 
original source of dysregulation, lithium seemingly merely prevents the execution of 
apoptotic signals but does not silence the original signal. This may indeed be a benefit 
in such diseases where neuronal apoptosis is primarily responsible for the patient 
decline. However, it is less important in cases, such as HAND, where apoptosis is not 
the primary disease contributor. Additionally, merely blocking the final signalling in the 
cascade does not necessarily inhibit the other effects induced by the original signal. 
Unfortunately, literature is very unclear about the specific regulation and function of 
many PP2A and PP1 phosphatases. Based on our data and literature, lithium’s 
functions may, at least in part, be due to the inhibition of phosphatases including the 
PP2A family. Given that PP2A accounts for 25% of cellular phosphatase activity, its 
general inhibition would have many side effects. In conclusion, we cannot rule out the 
possibility of therapeutic benefit to HAND patients, despite being certain that lithium 










HAND affects up to 70% of HIV patients, which equates to ~26 million of the 36.9 
million HIV-infected patients worldwide. Despite the prevalence of the disease and the 
continued global effort and research, we are as yet uncertain about the molecular 
mechanism of disease onset and progression. Humanised mouse studies have shown 
that HIV infection and HIV-Tat protein induces neurodegeneration. While HIV-GP120 is 
also neurotoxic, unlike GP120, HIV-Tat expression and secretion is not adversely 
affected by antiretroviral (ARV) therapy. 
Using shotgun proteomics and genome-wide transcriptomics, we profiled the 
molecular dysregulation of neuroblastoma cells treated with HIV-Tat and found that it 
is capable of inducing a wide array of cellular dysregulations. Of these, the 
dysregulation of the inflammatory response, protein synthesis, cytoskeletal 
reorganisation and apoptosis are most prominent and relevant. Although neurons are 
not typically infected, these dysregulations are likely induced to prepare a cell for HIV 
infection. In many cases, literature has shown that inhibiting the induction of these 
dysregulations in HIV-infected cells inhibited HIV replication. One of the most 
prominent features of HIV-Tat treatment in neurons is the activation of GSK-3β and 
subsequent apoptosis. Recently, lithium has been suggested as probable therapeutic 
candidate for HAND. Indeed, lithium has well-documented neuroprotective effects 
against various neuronal insults and is commonly prescribed to BD (BP) patients. The 
symptomatic presentation and pathologies of HAND and BP are, however, significantly 
different. Furthermore, only a subset of BP patients responds to lithium which 
highlights the impact of disease pathology on lithium efficacy. Thus far, very little is 
known about molecular mechanism involved in lithium-induced behavioural 
alterations nor have broader effects of lithium treatment beyond AKT activation been 
classified. 
In chapters 3 and 4, we described the proteomic alterations induced by HIV-Tat and 
linked these to HAND disease onset and progression. Following this, we wanted to 
determine whether lithium’s neuroprotection extended to abrogating all dysregulation 
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induced by HIV-Tat. We found that lithium very effectively reversed the molecular 
signature of apoptosis via activation of AKT. As a great deal of cross talk occurs 
between pathways, any imposed dysregulation, no less to such broadly functioning 
kinases as AKT/Pi3K, would have dysregulatory effects on downstream targets. We 
also show that AKT inhibition by HIV-Tat is likely via activation of PP2A phosphatases 
which are the primary AKT phosphatases. In the functional analyses, HIV-Tat was 
shown to strongly activate cell death and strongly inhibit reciprocal cell survival 
functions. Lithium, however, inhibited cell death functions and increased the inhibition 
of cell survival. This suggests that lithium merely intercepts apoptotic signalling at AKT 
while leaving upstream signalling unaffected. This is important since the upstream 
inflammatory dysregulation we see and describe induces dramatic molecular 
alterations to support their function with chronic activation resulting in apoptosis. 
Before initiating apoptosis however, the antiviral inflammatory response attempts to 
control viral growth by attenuating protein synthesis. Similarly, cells’ cytoskeletons 
respond to inflammation in a variety of ways such as epithelial cells decreasing 
adhesion in order to allow greater immune cell access to sites of inflammation. 
Similarly, immune cells respond by using their cytoskeletons to actively move toward 
sites of inflammation. Many publications highlight HIV’s need of dysregulated host 
cytoskeletal regulation throughout its life cycle. Similarly, it is not surprising that HIV 
requires alterations to host protein synthesis machinery to support its own protein 
synthesis while decreasing competition for host protein synthesis machinery. Lithium’s 
effects on protein synthesis and cytoskeletal reorganisation were, however, were not 
as promising as those seen in apoptotic pathways and functions. Prominent proteins 
and pathways contributing to both functions remained highly dysregulated. In 
addition, lithium induced the dysregulation of many novel proteins in these pathways. 
We have shown that HIV intends to attenuate global protein synthesis through other 
proteins and add that HIV-Tat is capable of inducing previously undescribed alterations 
to host protein synthesis machinery. Indeed, host protein synthesis attenuation is 
essential in many other viruses. Although not formally described, HIV likely has the 
same requirement and HIV-Tat plays a role in its implementation. While there is 
dispute in literature, we provide evidence in support of HIV mRNA translation 
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occurring via cap-independent protein translation. Global protein synthesis inhibition 
in neurons is known to play a role in synapse loss in AD but has not been described in 
HAND. Lithium treatment did not remove the inhibition of protein synthesis. 
While pro-apoptotic signalling and impaired protein synthesis certainly induce an 
unfavourable cellular environment within neurons, the loss of neuronal synapses is 
directly associated with dysregulated cytoskeletal reorganisation. We have explained 
the dysregulation of many of the associated functions with respect to their importance 
to HIV replication as well as their impact of synapse structure. Following from this, the 
roles of cdc42, Rho and Rac signalling and their dysregulation can be directly and 
unmistakably associated with impaired neurite outgrowth and stabilisation which 
ultimately corresponds with synapse dysregulation and loss. This, together with 
impaired lamellar protrusion, axonal guidance and cell adhesion functions, are entirely 
capable of inducing the synaptic loss observed in HAND patients. 
HIV-Tat, on its own, is capable of inducing many cellular dysregulations identified in 
HIV-infected systems. Furthermore, although unquantifiable, it supports the validity of 
the data we have generated and it adds support to the myriad of dysregulations not 
previously attributed to HIV or HIV-Tat. In addition to identifying functions known to 
be associated with HIV infection, we have identified and described many functions 
known to play a role in neurodegenerative diseases including AD, which has proved 
similar to HAND. 
Neuronal apoptosis, dysregulation of protein synthesis and cytoskeletal reorganisation 
can be explained as downstream effects of proinflammatory activity. Similarly, the 
described neurite and synaptic degradation can be attributed to RhoA and Rac 
dysregulation due to loss of NGF signalling. However, NGF loss cannot be explained by 
proinflammatory signalling. Interestingly, HIV replication decreases when host cells are 
treated with NGF. It is, therefore, feasible that HIV-Tat specifically and actively 
attenuates NGF signalling. As a consequence of this, not only are neurons unable to 
regulate their synapses properly, NGF attenuation of the proinflammatory response is 
also lost. NGF signalling remained strongly dysregulated after lithium treatment, as did 
RhoA and Rac signalling. 
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PP2A family phosphatases play diverse roles and regulate many proteins. The exact 
mechanisms through which the vast array of subunits are regulated is poorly 
understood. Thus, PP2A likely plays a very significant role in HIV-Tat induced 
dysregulation. However, we cannot, with certainty, identify the means through which 
specific subunits are dysregulated and it may be that HIV-Tat dysregulates them 
directly. Furthermore, lithium induced the significant dysregulation of additional PP2A 
and other phosphatases which certainly exacerbate HIV-Tat induced dysregulation. 
Together, the data presented herein not only describes a vast diversity of cellular 
changes induced by HIV-Tat and lithium’s effect on that dysregulation but also 
identifies a plausible and well supported mechanism of HAND onset and progression. 
In addition, the data provides insights into the wider functionality of HIV-Tat in its 
ability to transform healthy host cells into highly efficient HIV replicative machines. In 
using a virus free system, many dysregulated proteins and genes previously described 
only during HIV infection can be attributed to HIV-Tat function. It is important to note 
that although neurons are typically not infected by HIV, many of the systems we 
describe as dysregulated are ubiquitous to all cells and, therefore, HIV-Tat’s 
mechanism to dysregulate them may be generally effective in all cells. Although, 
differences in the specific molecular mechanism may vary between different cell types; 
this may induce variable functional outcomes of the initial dysregulation induced. Our 
use of lithium has not only allowed us to speculate about the possible efficacy of 
lithium as a treatment for HAND, but has evidenced the power of MS-based 
proteomics to identify, describe and quantify drug effects in a cell system. Whether 
that system is in a disease or healthy state, we have shown our ability identify 
expected effects as well as to extend the analysis and enable the identification and 
description of novel effects. To this end, the proteomic data showed that lithium 
induced the well-described and expected inhibition of cell death. However, lithium 
failed to abrogate all the dysregulation induced by HIV-Tat and even further 
dysregulated several of them. Importantly, lithium did attenuate much of the pathway 
and functional dysregulation to cytoskeletal reorganisation. Theoretically, this seems 
to suggest that HIV-Tat induced synaptic degradation in HAND patients may be 
attenuated. However, maintained or exacerbated dysregulation to any cytoskeletal 
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component may and likely will offset decreases in others. This is especially relevant in 
this work as the dysregulated NGF signalling was only modestly affected by lithium. As 
has been mentioned, synapse regulation is highly complex and dysregulation in any of 
the contributory pathways and functions will impair their stability and function. For 
example, dysregulation of protein synthesis alone can impair synaptic function due to 
the requirement of de novo protein synthesis for LTP induction and maintenance. 
Furthermore, several publications describe lithium as having little or no beneficial, and 
sometimes detrimental, effects in HAND and AD patients. This supports our finding 
that lithium is capable of dysregulating pathways already dysregulated by HIV-Tat and 
that it may well exacerbate HIV-Tat induced neuronal degradation. Despite this, we 
cannot, based on our data, dismiss the possibility that lithium may have modest long-
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SILAC incorporation test peptides 
 
Sequence Intensity Intensity L Intensity H 
AAAAAAALQAK 31983000 0 31983000 
AAAAVGAGHGAGGPGAASSSGGAR 2358900 0 2358900 
AAADLMAYCEAHAK 11847000 0 11847000 
AAAEAANCIMEVSCGQAESSEKPNAEDMTSK 4461600 0 4461600 
AAAEVNQDYGLDPK 3921900 0 3921900 
AAAGEFADDPCSSVK 55136000 0 55136000 
AAAGGGGGGAAAAGR 59439000 0 59439000 
AAAMDVDTPSGTNSGAGK 8302200 0 8302200 
AAAMDVDTPSGTNSGAGKK 1636200 0 1636200 
AAANFSDR 26771000 0 26771000 
AAASTDYYK 6348200 0 6348200 
AAATAEEPDPK 4593100 0 4593100 
AAATGPSFWLGNETLK 44271000 0 44271000 
AAAVSALAK 13317000 0 13317000 
AACDLVR 41071000 0 41071000 
AADIDQEVK 0 0 0 
AADIGVAMGQTGTDVCK 0 0 0 
AADTQVSETLKR 0 0 0 
AAEADGPLKR 26292000 0 26292000 
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AAECNIVVTQPR 69769000 0 69769000 
AAEDDEDDDVDTK 5326600 0 5326600 
AAEDLFVNIR 6192200 0 6192200 
AAESLADPTEYENLFPGLK 2887000 0 2887000 
AAFDDAIAELDTLSEESYK 7232100 0 7232100 
AAFGLELEEMK 65375000 0 65375000 
AAFNSGK 806630 0 806630 
AAFQLGSPWR 0 0 0 
AAGGDHGSPDSYR 3967900 0 3967900 
AAGPSLSHTSGGTQSK 9892900 0 9892900 
AAGTLYTYPENWR 10265000 0 10265000 
AAGVNVEPFWPGLFAK 6859400 0 6859400 
AAILPTSIFLTNK 17033000 0 17033000 
AALAGGTTMIIDHVVPEPESSLTEAYEK 41880000 0 41880000 
AALAPLPPLPAQFK 3027300 0 3027300 
AALEALGSCLNNK 2536400 0 2536400 
AALEALLPYTER 4227800 0 4227800 
AALETDENLLLCAPTGAGK 2232500 0 2232500 
AALEYLEDIDLK 30975000 0 30975000 
AALLELWELR 3748800 0 3748800 
AALNALQPPEFR 3468800 0 3468800 
AALQELLSK 91358000 0 91358000 
AALSALESFLK 85076000 0 85076000 
AAMEALVVEVTK 5544100 0 5544100 
AANDAGYFNDEMAPIEVK 31139000 0 31139000 
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AANGVVLATEK 20098000 0 20098000 
AANILVGENLVCK 3222600 0 3222600 
AANSLEAFIFETQDK 34043000 0 34043000 
AAQDFFSTCR 0 0 0 
AAQEEYVK 146680000 0 146680000 
AAQELQEGQR 48475000 2050100 46425000 
AAQGEPQVQFK 59656000 0 59656000 
AASDIAMTELPPTHPIR 1505000 0 1505000 
AASITSEVFNK 0 0 0 
AASLIQGYWR 867720 0 867720 
AATAAADFTAK 39164000 0 39164000 
AATASAGAGGIDGKPR 0 0 0 
AATQFWR 49972000 0 49972000 
AAVAWEAGKPLSIEEIEVAPPK 13171000 0 13171000 
AAVENLPTFLVELSR 4455700 0 4455700 
AAVPSGASTGIYEALELR 149490000 0 149490000 
AAYFGIYDTAK 70866000 0 70866000 
AAYFGVYDTAK 99519000 0 99519000 
AAYPDLENPPLLVTPSQQAK 0 0 0 
ACADATLSQITNNIDPVGR 30423000 0 30423000 
ACAEIAAQR 9596100 0 9596100 
ACANPAAGSVILLENLR 108510000 0 108510000 
ACGDSTLTQITAGLDPVGR 13026000 0 13026000 
ACGLNFADLMAR 113140000 2304200 110840000 
ACGLVASNLNLKPGECLR 20475000 0 20475000 
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ACGNFGIPCELR 62772000 0 62772000 
ACIDSNEDGDLSK 4751100 0 4751100 
ACIGDTLCQK 20590000 0 20590000 
ACLDYPVTSVLPPASLCK 11821000 0 11821000 
ACNPQPNGENAISAR 6699800 0 6699800 
ACYALENFVENLGPK 7169900 0 7169900 
ADAEEEAATR 5347100 0 5347100 
ADALQAGASQFETSAAK 35540000 0 35540000 
ADCASGIFLAAEK 0 0 0 
ADDYEQVK 5922600 0 5922600 
ADEASELACPTPK 14676000 0 14676000 
ADEGISFR 214610000 1659100 212950000 
ADFPAGIPECGTDALR 20258000 0 20258000 
ADFQGISPER 63516000 0 63516000 
ADGELNVDSLITR 14251000 0 14251000 
ADGGTQVIDTK 69659000 0 69659000 
ADGLLGMFLK 10521000 0 10521000 
ADGYVLEGK 15798000 0 15798000 
ADIFMFDEPSSYLDVK 5806300 0 5806300 
ADKEAAFDDAVEER 0 0 0 
ADLDKLNIDSIIQR 11841000 0 11841000 
ADLFPILMR 2245800 0 2245800 
ADLIAYLK 298630000 0 298630000 
ADLINNLGTIAK 41046000 0 41046000 
ADLLLSTQPGREEGSPLELER 22350000 0 22350000 
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ADLYLEGK 13226000 0 13226000 
ADMETLQR 21957000 1303200 20654000 
ADMGGAATICSAIVSAAK 31321000 0 31321000 
ADQIETQQLMR 7594400 0 7594400 
ADSWVEKEEPAPSN 6940900 0 6940900 
ADTLTLEER 67712000 0 67712000 
ADTLTLK 65029000 0 65029000 
ADTLTPEECQQFK 39379000 0 39379000 
ADTQTYQPYNK 18948000 0 18948000 
ADVIQATGDAICIFR 13099000 0 13099000 
AEAGGGWEGSASYK 2876000 0 2876000 
AEAGPEGVAPAPEGEK 10823000 0 10823000 
AEDGATPSPSNETPK 8127200 0 8127200 
AEDKEWMPVTK 149520000 0 149520000 
AEDNADTLALVFEAPNQEK 12126000 0 12126000 
AEEDEILNR 42976000 0 42976000 
AEEILEK 80385000 0 80385000 
AEEVATFFAK 3794900 0 3794900 
AEEYEFLTPVEEAPK 527740000 0 527740000 
AEFVEVTK 420680000 420680000 0 
AEGPGLSR 28167000 0 28167000 
AEGPQEWVFQECK 0 0 0 
AEGSDVANAVLDGADCIMLSGETAK 1949900 0 1949900 
AEGYEVAHGGR 13349000 382030 12966000 
AEHDSILAEK 3692300 0 3692300 
 
 
220 | P a g e  
 
AEKDEPGAWEETFK 11961000 0 11961000 
AELDDTPMR 5815600 0 5815600 
AELGEYIR 0 0 0 
AELLDNEKPAAVVAPITTGYTVK 21063000 0 21063000 
AELNEFLTR 0 0 0 
AELQLDPAMAGLGGGAGSR 19324000 19324000 0 
AELVQLVSPFLGK 828360 0 828360 
AEMDAAIASCK 14184000 0 14184000 
AEMVVPDFSELFK 2164600 0 2164600 
AENFFILR 110610000 2663400 107950000 
AENQVLAMR 51903000 0 51903000 
AENYDIPSADR 25284000 0 25284000 
AEPEDHYFLLTEPPLNTPENR 37550000 0 37550000 
AEQWNVNYVETSAK 0 0 0 
AESEEMETSQAGSK 28282000 0 28282000 
AESMLQQADK 8361100 0 8361100 
AESTPEIAEQR 16779000 0 16779000 
AEVAAEFLNDR 9699000 0 9699000 
AEVLSEEPILK 5335400 0 5335400 
AEVSIQNNK 5786400 0 5786400 
AEVSPMYGVQK 5573000 0 5573000 
AEYLASIFGTEK 871450 0 871450 
AFALEVIK 28900000 0 28900000 
AFAVGVQQVLLK 52810000 0 52810000 
AFCEPGNVENNGVLSFIK 0 0 0 
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AFCQEMLQEEPR 816340 0 816340 
AFDLIVDRPVTLVR 10249000 0 10249000 
AFDLVPPEAVPEQK 1873000 0 1873000 
AFDSGIIPMEFVNK 95893000 0 95893000 
AFDTAGNGYCR 14337000 0 14337000 
AFEPATGR 24896000 0 24896000 
AFFAGSQR 92043000 0 92043000 
AFFESHPAPSAER 3691200 0 3691200 
AFFSEVER 13950000 0 13950000 
AFGGQSLK 18078000 0 18078000 
AFGPGLQGGSAGSPAR 45265000 0 45265000 
AFHNEAQVNPER 30923000 0 30923000 
AFLADPSAFVAAAPVAAATTAAPAAAAAPAK 123090000 0 123090000 
AFLASGPYLTHQQK 77405000 0 77405000 
AFLASPEYVNLPINGNGK 124630000 3865600 120760000 
AFLEENNLDYIIR 76855000 0 76855000 
AFLLFPTIER 4988100 0 4988100 
AFLTLAEDILR 40600000 0 40600000 
AFNDPFIQK 0 0 0 
AFPAWADTSVLSR 6871600 0 6871600 
AFPMPGFDEH 0 0 0 
AFPNPYADYNK 11015000 0 11015000 
AFSGYLGTDQSK 24768000 0 24768000 
AFSPTTVNTGR 105380000 4041600 101340000 
AFTHTAQYDEAISDYFR 9149600 0 9149600 
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AFTYINLDK 27381000 0 27381000 
AFVDFLSDEIK 0 0 0 
AFVDFLSDEIKEER 17612000 0 17612000 
AFVEAQNK 0 0 0 
AFYGDTLVTGFAR 1417200 0 1417200 
AFYNNVLGEYEEYITK 4984500 0 4984500 
AFYYPEEAGLAFGGPGSSR 145810000 0 145810000 
AGAGSAAVSGAGTPVAGPTGR 0 0 0 
AGAGSATLSMAYAGAR 18115000 0 18115000 
AGALQCSPSDAYTK 20045000 0 20045000 
AGAVAEEVLAAIR 28904000 0 28904000 
AGAYDFPSPEWDTVTPEAK 977240 0 977240 
AGDEFVEK 56211000 0 56211000 
AGDEIDEPSER 1563200 0 1563200 
AGDISCNADINPLK 6058000 0 6058000 
AGDMENAENILTVMR 25906000 0 25906000 
AGDQIICMDDVYGGTNR 0 0 0 
AGDTVIPLYIPQCGECK 16706000 0 16706000 
AGELTEDEVER 168020000 6571300 161440000 
AGFAGDDAPR 2536500000 38362000 2498100000 
AGFFGTVVEYGAER 11356000 0 11356000 
AGGAAVVITEPEHTK 3647600 0 3647600 
AGGEAGVTLGQPHLSR 0 0 0 
AGGFLMK 22101000 0 22101000 
AGGSASAMLQPLLDNQVGFK 22128000 0 22128000 
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AGIISTVEVLK 13245000 0 13245000 
AGIPVYAWK 1287200 0 1287200 
AGLGSGLSLSGLVHPELSR 8363400 0 8363400 
AGLQFPVGR 855710 0 855710 
AGLQVYNK 21627000 0 21627000 
AGMSAEQAQGLLEK 24015000 0 24015000 
AGNEKEEGETADTVGCCSLR 16544000 0 16544000 
AGNELLESSAGDDASSLR 2403400 0 2403400 
AGNFYVPAEPK 91318000 0 91318000 
AGPESDAQYQFTGIK 7288000 0 7288000 
AGPIWDLR 15347000 0 15347000 
AGQLSQGAAEEDHGCR 32300000 0 32300000 
AGQPLQLLDASWYLPK 0 0 0 
AGQTTYSGVIDCFR 0 0 0 
AGQVFLEELGNHK 8413200 0 8413200 
AGSDGESIGNCPFSQR 22278000 0 22278000 
AGVLAHLEEER 31320000 0 31320000 
AGYAGEDCPK 5615600 0 5615600 
AGYGTCNCFPEEEK 4389200 0 4389200 
AGYIIPLQGPGLTTTESR 0 0 0 
AGYPQYVSEILEK 22638000 0 22638000 
AHIAQLCEK 27292000 0 27292000 
AHQVVEDGYEFFAK 36235000 0 36235000 
AHSSMVGVNLPQK 85578000 0 85578000 
AIADTGANVVVTGGK 17187000 0 17187000 
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AIAGVINQPYYNYEAGPDAVLGR 7626200 0 7626200 
AIDLFTDAIK 21010000 0 21010000 
AIEAVAISPWK 4492200 0 4492200 
AIEEQMVAAK 6442700 0 6442700 
AIELLQEFSDQHPENAAEIK 7559400 0 7559400 
AIENELLAR 7504600 0 7504600 
AIEPNDYTGK 13943000 0 13943000 
AIEPPPLDAVIEAEHTLR 8876200 0 8876200 
AIFENTLSTYPK 4708800 0 4708800 
AIFTGYYGK 10757000 0 10757000 
AIGAVPLIQGEYMIPCEK 44614000 0 44614000 
AIGNIELGIR 8192100 0 8192100 
AIGNTELENK 22028000 0 22028000 
AIGSASEGAQSSLQEVYHK 74511000 0 74511000 
AIITALGVER 0 0 0 
AIITDSVK 10977000 0 10977000 
AILILDNDGDR 4035300 0 4035300 
AILPCIK 29557000 0 29557000 
AILPCQDTPSVK 6039800 0 6039800 
AIMYEETTYSK 11849000 0 11849000 
AINNYNPK 5224000 0 5224000 
AINQGGLTSVAVR 9450500 0 9450500 
AINVQEEK 13768000 0 13768000 
AIPQLQGYLR 36576000 0 36576000 
AIQDPAFSDGIR 13163000 0 13163000 
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AISTTCIPNYPDR 13862000 0 13862000 
AITGASLADIMAK 18450000 0 18450000 
AITIANQTNCPLYITK 0 0 0 
AITIASQTNCPLYVTK 16700000 0 16700000 
AITSAYYR 0 0 0 
AIVAGDQNVEYK 84070000 0 84070000 
AIVAIENPADVSVISSR 534400000 0 534400000 
AIVDSPCIYEAEQK 2939900 0 2939900 
AIVQLVNER 43473000 0 43473000 
AIVQQWLEYR 0 0 0 
AIWGYCDQLK 0 0 0 
AIYDTPCIQAESEK 4759900 0 4759900 
AIYNNMK 70866000 0 70866000 
ALAAAGYDVEK 789680000 9221500 780460000 
ALADDDFLTVTGK 0 0 0 
ALADVATVLGR 26182000 0 26182000 
ALAEIAK 15485000 0 15485000 
ALAESWNAAFLESSAK 16723000 0 16723000 
ALAGCDFLTISPK 41598000 0 41598000 
ALANSLACQGK 203560000 0 203560000 
ALAPEYAK 44791000 0 44791000 
ALAYFEQLK 4051600 0 4051600 
ALCADLSPR 4634200 0 4634200 
ALCDLGPWVK 8184300 0 8184300 
ALCDVGTAISCSR 6147300 0 6147300 
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ALCEAAGCGSALLWPR 3449200 0 3449200 
ALDDMISTLK 21404000 0 21404000 
ALDFIASK 0 0 0 
ALDIAENEMPGLMR 145770000 0 145770000 
ALDIPLVK 21282000 0 21282000 
ALDLLYGMVSK 41564000 0 41564000 
ALDQFVNFSEQK 1222500 0 1222500 
ALDTMNFDVIK 26710000 0 26710000 
ALEAFETFK 27927000 0 27927000 
ALEDVDYVQTFK 1388400 0 1388400 
ALEEAGFK 11940000 0 11940000 
ALEHFTDLYDIK 24124000 0 24124000 
ALELCEILAK 11754000 0 11754000 
ALELDSNLYR 54906000 0 54906000 
ALELDSNNEK 8989400 0 8989400 
ALELNMLSLK 112210000 0 112210000 
ALELTGLK 18894000 0 18894000 
ALEPTGQSGEAVK 1357500 0 1357500 
ALEQFATVVEAK 25915000 0 25915000 
ALESDMAPVLIMATNR 2099800 0 2099800 
ALESGDVNTVWK 0 0 0 
ALESPERPFLAILGGAK 217420000 0 217420000 
ALESSIAPIVIFASNR 20424000 0 20424000 
ALFAVPK 4382400 0 4382400 
ALFNGAQK 7096800 0 7096800 
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ALGAQIEK 9162400 0 9162400 
ALGGLLK 46756000 0 46756000 
ALGTEVIQLFPEK 151190000 0 151190000 
ALIAAQYSGAQVR 0 0 0 
ALIEHEMK 0 0 0 
ALIEVLQPLIAEHQAR 11631000 0 11631000 
ALIQCAK 7452800 0 7452800 
ALLANALTSALR 48385000 0 48385000 
ALLEVVQSGGK 2844400 0 2844400 
ALLFIPR 146360000 0 146360000 
ALLFVPR 121000000 0 121000000 
ALLGSVK 4568600 0 4568600 
ALLIFLEK 4989000 0 4989000 
ALLLLCGEDD 0 0 0 
ALLNVVDNAR 0 0 0 
ALLQEMPLTALLR 3544400 0 3544400 
ALLQQQPEDDSK 16726000 0 16726000 
ALLQQQPEDDSKR 9936200 0 9936200 
ALLQSSASR 38556000 0 38556000 
ALLTPVAIAAGR 66725000 0 66725000 
ALLVTASQCQQPAENK 18805000 0 18805000 
ALMDEVVK 0 0 0 
ALMQVVDFLSR 4557600 0 4557600 
ALNEACESVIQTACK 0 0 0 
ALNMAIPGGPK 23354000 1305200 22049000 
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ALNSAANNVYQYGR 2196900 0 2196900 
ALPAVQQNNLDEDLIR 1519200 0 1519200 
ALPFWNEEIVPQIK 15217000 0 15217000 
ALPGQLKPFETLLSQNQGGK 269310000 0 269310000 
ALPIPAWESQPR 21666000 0 21666000 
ALQAAIQQLAEAQPEATAK 4627200 0 4627200 
ALQASALK 124850000 0 124850000 
ALQATVGNSYK 216490000 0 216490000 
ALQEGEGDLSISADR 9234400 0 9234400 
ALQSVGQIVGEVLK 10532000 0 10532000 
ALSEALTELGYK 0 0 0 
ALSPLEEWLR 24476000 0 24476000 
ALSQLAEVEEK 19069000 0 19069000 
ALSVETEK 20004000 0 20004000 
ALTGGIAHLFK 6814200 0 6814200 
ALTLIAGSPLK 78925000 0 78925000 
ALTLPGSSENEYIMK 8457900 0 8457900 
ALTTMGFR 0 0 0 
ALTVPELTQQMFDAK 3947400 0 3947400 
ALTVPELTQQVFDAK 60581000 0 60581000 
ALTYDEK 6911300 0 6911300 
ALVAYYQK 25649000 0 25649000 
ALVDILSEVSK 29983000 0 29983000 
ALVILAK 0 0 0 
ALVPFEDLFGQAPGGER 0 0 0 
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ALVSAQWVAEALR 6153000 0 6153000 
ALYLIATNGTPELQNPEK 0 0 0 
ALYTYESK 7833900 0 7833900 
AMADALLER 43123000 0 43123000 
AMDLVQEEFLQR 60239000 0 60239000 
AMDQVNALCEQLVK 2730900 0 2730900 
AMEAVAAQGK 36848000 0 36848000 
AMGAAQVVVTDLSATR 19235000 0 19235000 
AMGIMNSFVNDIFER 401570000 2791900 398780000 
AMGPLVLTEVLFNEK 3075100 0 3075100 
AMLESIGVPLEK 122650000 0 122650000 
AMQDAEVSK 47343000 0 47343000 
AMTEDGFLAVCSEAK 0 0 0 
AMTLMEYLIK 5900900 0 5900900 
AMVDPAQTVEQR 0 0 0 
ANCIDSTASAEAVFASEVK 9169000 0 9169000 
ANDDLADAGLEK 11350000 0 11350000 
ANDDVAQEIAER 5437500 0 5437500 
ANEAYPCPCDIGHR 0 0 0 
ANINIEK 57770000 0 57770000 
ANIQAVSLK 10218000 0 10218000 
ANIVHLMLSSPEQIQK 24154000 0 24154000 
ANNMQEVSR 0 0 0 
ANTFVAELK 0 0 0 
ANYWWLR 4315200 0 4315200 
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APDFVFYAPR 15818000 0 15818000 
APEAWDYGQGFVNEEMIR 5536100 0 5536100 
APFDLFENK 349770000 0 349770000 
APFDLFENR 225800000 0 225800000 
APGAEEYAQQDVLK 6466700 0 6466700 
APGAGLGQDR 40266000 0 40266000 
APGEQTVPALNLQNAFR 39422000 0 39422000 
APGFGDNR 69858000 0 69858000 
APGLGAFR 41606000 0 41606000 
APIIAVTR 0 0 0 
APIVTVGVNNDPADVR 550510 0 550510 
APPSVFAEVPQAQPVLVFK 12977000 0 12977000 
APQETYADIGGLDNQIQEIK 5900800 0 5900800 
APSDLYQIILK 27562000 0 27562000 
APSVPAAEPEYPK 10239000 0 10239000 
APTNIVYK 33150000 0 33150000 
APVAGTCYQAEWDDYVPK 34687000 0 34687000 
APVDITGQFEK 39276000 0 39276000 
APVLLSSLDR 5798400 0 5798400 
APVLSDSSCK 1315800000 1315800000 0 
APVPTGEVYFADSFDR 7765800 0 7765800 
APVSYPNTLPESFTK 0 0 0 
APWELLELR 65106000 0 65106000 
AQDGSHPLSLQDLIEK 18533000 0 18533000 
AQDPDQLR 0 0 0 
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AQDQGEKENPMR 19146000 0 19146000 
AQFAQPEILIGTIPGAGGTQR 14209000 0 14209000 
AQFEGIVTDLIR 76068000 0 76068000 
AQGPQQQPGSEGPSYAK 6691100 0 6691100 
AQLGPDESK 25651000 0 25651000 
AQQEFATGVMSNK 2192500 0 2192500 
AQQEQELAADAFK 169240000 0 169240000 
AQQLEQIR 20442000 0 20442000 
AQTEGINISEEALNHLGEIGTK 0 0 0 
AQVADVVVSR 0 0 0 
AQYYLPDGSTIEIGPSR 16833000 0 16833000 
ARFEELNADLFR 22228000 0 22228000 
ASADLMSYCEEHAR 24151000 0 24151000 
ASAELALGENSEVLK 23797000 0 23797000 
ASAETVDPASLWEY 0 0 0 
ASAFALQEQPVVNAVIDDTTK 9832600 0 9832600 
ASALEQFVNSVR 2647200 0 2647200 
ASANMDLMR 40697000 23764000 16933000 
ASAQGDPDVPECLK 6829500 0 6829500 
ASCLYGQLPK 0 0 0 
ASENAIVWK 0 0 0 
ASGPPVSELITK 51046000 0 51046000 
ASGTTTTAVK 2833800 0 2833800 
ASGTVYSGEEK 0 0 0 
ASIPFSVVGSNQLIEAK 10787000 0 10787000 
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ASLNGADIYSGCCTLK 3740900 0 3740900 
ASSAQSGGSSGGPAVPTVQR 5311300 0 5311300 
ASSGLLYPLER 89554000 0 89554000 
ASSLISLLK 15809000 0 15809000 
ASSTSPVEISEWLDQK 2926800 0 2926800 
ASVGFGGSCFQK 0 0 0 
ASVTVGGEQISAIGR 3967600 0 3967600 
ASWSSLSMDEK 0 0 0 
ATAAELLR 21256000 0 21256000 
ATAEQISSQTGNK 10082000 0 10082000 
ATAFNEQVDK 12503000 0 12503000 
ATAGDTHLGGEDFDNR 48378000 0 48378000 
ATAVMPDGQFK 873620000 0 873620000 
ATAVVDGAFK 319320000 0 319320000 
ATCAPQHGAPGPGPADASK 20353000 1140200 19212000 
ATCIGNNSAAAVSMLK 0 0 0 
ATDAQLCLESSPK 3638200 0 3638200 
ATDFVVPGPGK 35441000 0 35441000 
ATEGMVVADK 66939000 0 66939000 
ATENDIANFFSPLNPIR 2906500 0 2906500 
ATESGAQSAPLPMEGVDISPK 14478000 0 14478000 
ATGPPVSELITK 0 0 0 
ATIELCSTHANDASALR 0 0 0 
ATIGADFLTK 16782000 0 16782000 
ATLQEILPEVLK 5998800 0 5998800 
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ATLSSIR 38977000 0 38977000 
ATLYVTAIEDR 62214000 0 62214000 
ATNDEIFSILK 43463000 0 43463000 
ATPLAVNSAASLWGPYK 1832800 0 1832800 
ATQALVLAPTR 23283000 0 23283000 
ATQMPEGGQGAPPMYQLYK 7262300 0 7262300 
ATSFLLALEPELEAR 8985700 0 8985700 
ATSTATSGFAGAIGQK 1496600 0 1496600 
ATVLTTER 46019000 0 46019000 
ATVQQLEGR 6384500 0 6384500 
ATYDGNHDTFR 1922600 0 1922600 
AVAISLPK 8591200 0 8591200 
AVANYDSVEEGEK 10388000 0 10388000 
AVASQLDCNFLK 8311800 0 8311800 
AVAVVVDPIQSVK 0 0 0 
AVCMLSNTTAIAEAWAR 86954000 0 86954000 
AVDCLLDSK 31965000 1032900 30932000 
AVDIPHMDIEALK 301770000 0 301770000 
AVDLLYAMCDR 2243500 0 2243500 
AVDQSIEK 133110000 0 133110000 
AVDSQILPK 62351000 0 62351000 
AVEAVVNDTSGENK 0 0 0 
AVECPPPR 1501900 0 1501900 
AVELAANTK 28108000 0 28108000 
AVENSSTAIGIR 125680000 0 125680000 
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AVFPSIVGR 1536300000 62170000 1474100000 
AVFWDIK 15010000 0 15010000 
AVGPEITK 9969900 0 9969900 
AVGPSGGGGETPR 0 0 0 
AVGQGCVEIGSQR 8613600 0 8613600 
AVGWNELEGR 22620000 0 22620000 
AVLASTPR 6689400 0 6689400 
AVLCPPPVK 0 0 0 
AVLENNLGAAVLR 3739900 0 3739900 
AVLGTSNFK 64127000 0 64127000 
AVLIAGQPGTGK 20276000 0 20276000 
AVLLAGPPGTGK 5003400 0 5003400 
AVLLGPPGAGK 0 0 0 
AVLNPLCQVDYR 29783000 0 29783000 
AVLQEFGR 0 0 0 
AVMISAIEK 33983000 0 33983000 
AVNYFSK 42598000 0 42598000 
AVPETRPNHTIYINNLNEK 22092000 0 22092000 
AVPLALALISVSNPR 3721400 0 3721400 
AVQGMLDFDYVCSR 17846000 0 17846000 
AVQPTSGEPR 864480 0 864480 
AVSDWIDEQEK 5424900 0 5424900 
AVSDWLIASVEGR 9411700 0 9411700 
AVTELNEPLSNEDR 0 0 0 
AVTEQGAELSNEER 11680000 0 11680000 
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AVTEQGHELSNEER 5915200 0 5915200 
AVTHTSPEDVSFAESR 16750000 0 16750000 
AVTQALNR 0 0 0 
AVTVMMDPNSTQR 2455400 0 2455400 
AVVISGAGK 44390000 0 44390000 
AVVIVDDR 0 0 0 
AVVLMGK 27022000 0 27022000 
AVVVTDGER 19758000 0 19758000 
AVYEAVLR 27704000 0 27704000 
AVYMMPTEGDDSSK 10508000 0 10508000 
AVYTQDCPLAAAK 90221000 0 90221000 
AWDIAIATMK 77770000 0 77770000 
AWGAVVPLVGK 27788000 0 27788000 
AWGPGLEGGVVGK 0 0 0 
AWSATFDELIGR 10827000 0 10827000 
AYAALAALEK 8739500 0 8739500 
AYAALTDEESR 5426400 0 5426400 
AYADFYR 58016000 0 58016000 
AYAQGISR 97459000 1407600 96051000 
AYAYLFK 16075000 0 16075000 
AYDGTTYLPGIVGLNNIK 13669000 0 13669000 
AYEFAER 70055000 0 70055000 
AYGENIGYSEK 4296500 0 4296500 
AYGGSMCAK 23133000 0 23133000 
AYGPGIEPTGNMVK 14059000 0 14059000 
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AYGQALAK 38658000 0 38658000 
AYHSFLVEPISCHAWNK 4349700 0 4349700 
AYIDSFR 27303000 0 27303000 
AYILNLVK 39107000 0 39107000 
AYSEAHEISK 220790000 0 220790000 
AYVAVDGIPQGVLER 3382600 0 3382600 
AYVPALQMAFK 38212000 0 38212000 
CDKEFMWALK 16749000 0 16749000 
CTGGEVGATSALAPK 11808000 0 11808000 
DAASGEVVGK 18070000 0 18070000 
DAATIMQPYFTSNGLVTK 23083000 0 23083000 
DACDGHEIGR 946850 0 946850 
DADVQNFVSFISK 10957000 0 10957000 
DAEGILEDLQSYR 33785000 0 33785000 
DAEQESQMR 0 0 0 
DAFLGSFLYEYSR 93582000 93582000 0 
DAFVAIVQSVK 17556000 0 17556000 
DAGMQLQGYR 246040000 5089600 240950000 
DAGQISGLNVLR 0 0 0 
DAGTIAGLNVLR 703030000 0 703030000 
DAIAALGLLQK 8325300 0 8325300 
DAIAQAVR 9279000 0 9279000 
DAIPENLPPLTADFAEDK 54850000 54850000 0 
DAIPENLPPLTADFAEDKDVCK 145210000 145210000 0 
DAITQALFLR 8948100 0 8948100 
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DALSDLALHFLNK 50720000 0 50720000 
DAMQYASESK 98028000 0 98028000 
DANCSVMR 12261000 0 12261000 
DANGNSFATR 43810000 0 43810000 
DANNGNLQLR 20603000 0 20603000 
DAPQDFHPDR 27951000 0 27951000 
DAQQSSSPAADNLR 1736900 0 1736900 
DASQCYVK 2983800 0 2983800 
DATNVGDEGGFAPNILENK 386430000 0 386430000 
DATSRPTDNILIPQLIR 15037000 0 15037000 
DAVITVPVFFNQAER 4794900 0 4794900 
DAVLLLFANK 23987000 0 23987000 
DAVLLVFANK 8083200 0 8083200 
DAVTYTEHAK 228390000 0 228390000 
DAVVYPILVEFTR 3434400 0 3434400 
DCFTCSNCK 19345000 0 19345000 
DCGATWVVLGHSER 103550000 0 103550000 
DCLLELIEQK 9214700 0 9214700 
DCPDSAEEYER 1152100 0 1152100 
DCPLNAEAASSK 27537000 0 27537000 
DCVGPEVEK 0 0 0 
DDDIAALVVDNGSGMCK 420550000 3373000 417170000 
DDETMYVESK 16953000 0 16953000 
DDEYDYLFK 8961900 0 8961900 
DDFSSGTSSR 4689900 0 4689900 
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DDGEEEFAGAK 6228300 0 6228300 
DDGSWEVIEGYR 0 0 0 
DDIIENAPTTHTEEYSGEEK 16700000 0 16700000 
DDIPVFLR 18510000 0 18510000 
DDLLGFALR 18120000 0 18120000 
DDMIFEDCGDVPSEPK 0 0 0 
DDNMFQIGK 6328400 0 6328400 
DDPHACYSTVFDK 50185000 50185000 0 
DDPLTNLNTAFDVAEK 11776000 0 11776000 
DDPLVTPVPAAENPFR 131550000 5060700 126490000 
DDPSTIEK 23601000 0 23601000 
DDPVTNLNNAFEVAEK 5980500 0 5980500 
DDSPDLPK 88769000 88769000 0 
DEAAYGELR 31338000 0 31338000 
DEAQNEGPATESEAPLKEDGLLPK 12689000 0 12689000 
DECPEVR 27045000 0 27045000 
DEFEGLFK 9752800 0 9752800 
DEFLIQASPR 4923300 0 4923300 
DEIIWLLR 1752900 0 1752900 
DEILPTTPISEQK 0 0 0 
DELHIVEAEAMNYEGSPIK 7434200 0 7434200 
DENSVELTMAEGPYK 3310600 0 3310600 
DEPDTNLVALMK 51787000 0 51787000 
DEPSVAAMVYPFTGDHK 11494000 0 11494000 
DETLETEK 1404700 0 1404700 
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DETNYGIPQR 242010000 15797000 226210000 
DEVLYVFPSDFCR 127110000 4921700 122190000 
DFEEYPEHR 13594000 0 13594000 
DFFQSYGNVVELR 2286700 0 2286700 
DFIDSLGLLHEQNMAK 16653000 0 16653000 
DFIIFEAAPQETR 30482000 0 30482000 
DFINFISDK 31251000 0 31251000 
DFLAGGIAAAISK 113580000 0 113580000 
DFLAGGVAAAISK 121600000 0 121600000 
DFLIPIGK 11979000 0 11979000 
DFLLKPELLR 2264000 0 2264000 
DFLLQQTMLR 118750000 2559200 116190000 
DFLVQIK 22495000 0 22495000 
DFLYSYFK 22354000 0 22354000 
DFMIQGGDFTR 1114500000 10816000 1103700000 
DFPAMVQELHQGGR 8139400 0 8139400 
DFPLNDLLSATELDK 20834000 0 20834000 
DFQSGQHVIVR 3751500 0 3751500 
DFSPSGIFGAFQR 31289000 0 31289000 
DFSVFFQK 2344300 0 2344300 
DFTATDLSEFAAK 43628000 0 43628000 
DFTPVCTTELGR 0 0 0 
DFTVSAMHGDMDQK 24802000 0 24802000 
DFVQVMR 7697600 0 7697600 
DGATILTHAYSR 4491600 0 4491600 
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DGDILGK 16411000 0 16411000 
DGDSVMVLPTIPEEEAK 265520000 0 265520000 
DGEAVWFGCDVGK 36291000 0 36291000 
DGEDLMDESVLK 0 0 0 
DGENYVVLLDSTLPR 6063800 0 6063800 
DGETLEELMK 32771000 0 32771000 
DGETPDPEDPSR 3823600 0 3823600 
DGGAWGTEQR 0 0 0 
DGGFCEVCK 19861000 0 19861000 
DGIDDESYGQIFKPIISK 10424000 0 10424000 
DGIEPMWEDEK 0 0 0 
DGIVLGADTR 36272000 0 36272000 
DGLEMEK 16064000 0 16064000 
DGLILTSR 0 0 0 
DGMEYPFIGEGEPHVDGEPGDLR 10827000 0 10827000 
DGPGETDAFGNSEGK 3723700 0 3723700 
DGPNALTPPPTTPEWIK 13843000 0 13843000 
DGQAMLWDLNEGK 163790000 0 163790000 
DGQILPVPNVVVR 81719000 0 81719000 
DGSAFEDGLR 6601900 234280 6367600 
DGTACAEVSR 6009200 0 6009200 
DGTQCLSGSSDGTIR 4463300 0 4463300 
DGTVTAGNASGVADGAGAVIIASEDAVK 4931700 0 4931700 
DGVYVLDLAAK 80191000 0 80191000 
DHDTFLAVR 22165000 0 22165000 
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DHINLPGFSGQNPLR 19651000 0 19651000 
DIAAYIK 7356800 0 7356800 
DICNDVLSLLEK 62859000 0 62859000 
DIDDDLEGEVTEECGK 2856900 0 2856900 
DIDEVSSLLR 17913000 0 17913000 
DIDIHEVR 114210000 0 114210000 
DIELVMSQANVSR 4813200 0 4813200 
DIEREDIEFICK 0 0 0 
DIFQEIFDK 3543000 0 3543000 
DIFQEIYDK 43053000 0 43053000 
DIGEGNLSTAAAAALAAAAVK 2508900 0 2508900 
DIIACGFDINK 58686000 0 58686000 
DIICQIAYAR 52885000 0 52885000 
DIISIAEDEDLR 50370000 0 50370000 
DILADLIPK 42841000 0 42841000 
DILETHLR 0 0 0 
DILIDPIR 7213400 0 7213400 
DILIQYDR 0 0 0 
DILLRPELEELR 26660000 0 26660000 
DILPCLDGYLK 6590200 0 6590200 
DILQNVFK 34049000 0 34049000 
DINAVAASLR 12379000 0 12379000 
DINAYNCEEPTEK 314690000 1027900 313660000 
DINELNLPK 0 0 0 
DINQEVYNFLATAGAK 1428800 0 1428800 
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DIPNENEAQFQIR 0 0 0 
DIPNENELQFQIK 6213400 0 6213400 
DIQEDSGMEPR 20306000 0 20306000 
DIQENDEEAVQVK 25686000 0 25686000 
DIQTNVYIK 8295500 0 8295500 
DIREEAEK 0 0 0 
DISEASVFDAYVLPK 7890500 0 7890500 
DISLSDYK 74554000 0 74554000 
DISTTLNADEAVAR 0 0 0 
DIVQFVPFR 41390000 2862100 38528000 
DIVVQETMEDIDK 27285000 0 27285000 
DKDPPIPVAK 7369100 0 7369100 
DKLNNLVLFDK 11500000 0 11500000 
DKLSGEYEK 4665300 0 4665300 
DKYPNLQVIGGNVVTAAQAK 7614600 0 7614600 
DLAACIK 26161000 0 26161000 
DLADELALVDVIEDK 18755000 0 18755000 
DLAEITTLDR 6093700 0 6093700 
DLAPIGIR 0 0 0 
DLASVQALLR 9741800 0 9741800 
DLEALMFDR 15062000 0 15062000 
DLEGENIEIVFAKPPDQK 15304000 0 15304000 
DLEGSDIDTR 32445000 0 32445000 
DLFDPIIEDR 37688000 0 37688000 
DLFEDELVPLFEK 16815000 0 16815000 
 
 
243 | P a g e  
 
DLFLASCSQDCLIR 9763300 0 9763300 
DLFLQGAYDTVR 6177000 0 6177000 
DLFQVAFNR 38837000 0 38837000 
DLGEEHFK 68011000 68011000 0 
DLGFFGIYK 88980000 0 88980000 
DLGFNGAPYR 2217500 0 2217500 
DLGLAQDSATSTK 6764200 0 6764200 
DLGLSESGEDVNAAILDESGK 6614600 0 6614600 
DLGLSESGEDVNAAILDESGKK 259060000 0 259060000 
DLGREAWDIESTPIMMK 140500000 0 140500000 
DLGTESQIFISR 0 0 0 
DLIGIDNLVVPGR 2706400 0 2706400 
DLIGVQNLLK 3298000 0 3298000 
DLILADYGK 4128400 0 4128400 
DLILPTIQK 0 0 0 
DLILQCLDDKDESIR 6378600 0 6378600 
DLIPYLEK 9779600 0 9779600 
DLIQMLVQR 0 0 0 
DLISHDEMFSDIYK 54626000 0 54626000 
DLIVTPATILK 88598000 0 88598000 
DLKPQNILVTSSGQIK 6012900 0 6012900 
DLLGLCEQK 2725200 0 2725200 
DLLLTCAQDR 7168800 0 7168800 
DLLLTSSYLSDSGSTGEHTK 48088000 0 48088000 
DLLQSSYNK 9225100 0 9225100 
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DLNCVPEIADTLGAVAK 8997100 0 8997100 
DLNGIDLTPVQDTPVASR 0 0 0 
DLNSDMDSILASLK 4040600 0 4040600 
DLNSQADSLMTSSAFDTSQVK 3059700 0 3059700 
DLNSYLEDK 3401600 0 3401600 
DLPDVQELITQVR 6843400 0 6843400 
DLPLLLFR 28423000 731550 27692000 
DLPVSEQQER 0 0 0 
DLQMVNISLR 40939000 14170000 26768000 
DLSLDDFK 111320000 0 111320000 
DLSLLQIQMR 15442000 0 15442000 
DLSSQLLK 0 0 0 
DLSSVQTLLTK 22651000 0 22651000 
DLSTIEPLK 0 0 0 
DLSTIEPLKK 11756000 0 11756000 
DLSTVEALQNLK 94333000 0 94333000 
DLTDYLMK 11944000000 86976000 1.1857E+10 
DLTGQVPTPVVK 11481000 0 11481000 
DLTGVQNLR 0 0 0 
DLTLDQAYSYAVENAK 221720000 0 221720000 
DLTNVQNLQK 17263000 0 17263000 
DLTPEHLPLLR 3674400 0 3674400 
DLTSWVTEMK 7265900 0 7265900 
DLTTAGAVTQCYR 59059000 15234000 43825000 
DLTTGYDDSQPDKK 0 0 0 
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DLTYNITPTQVFK 3007000 0 3007000 
DLVGELGTALR 7290500 0 7290500 
DLYANNVLSGGTTMYPGIADR 3164500 0 3164500 
DLYANTVLSGGTTMYPGIADR 1099400000 0 1099400000 
DLYEDELVPLFEK 17060000 0 17060000 
DLYSALIK 36035000 0 36035000 
DMFQETMEAMR 7428800 0 7428800 
DMLLANK 0 0 0 
DMNQVLDAYENK 13523000 0 13523000 
DMSGTMGFNEFK 3263100 0 3263100 
DMSIIQWK 0 0 0 
DMVGIAQTGSGK 23391000 0 23391000 
DMYSFLQDMGLK 859690 859690 0 
DNFTAIPEGTNGVEER 66486000 396170 66090000 
DNFTLIPEGTNGTEER 0 0 0 
DNGNGTYSCSYVPR 9781700 0 9781700 
DNHLLGTFDLTGIPPAPR 78310000 0 78310000 
DNINIEEAAR 4179800 0 4179800 
DNIQGITK 131020000 0 131020000 
DNIQGITKPAIR 341600000 0 341600000 
DNLAEDIMR 33211000 0 33211000 
DNLEFFLAGIGR 29091000 0 29091000 
DNLQLPLQFLSR 2474700 0 2474700 
DNLTLWTSDMQGDGEEQNK 12236000 0 12236000 
DNMALQR 9351600 0 9351600 
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DNNLLGK 39656000 0 39656000 
DNNQFASASLDR 2963600 0 2963600 
DNPGVVTCLDEAR 0 0 0 
DNPNLLFNMCGFECR 1210100 0 1210100 
DNSGMIDKNELK 4987300 0 4987300 
DNTNEIYSGK 50088000 0 50088000 
DNVDDPTGNFR 61131000 0 61131000 
DNYTCPTEEEYK 5670900 0 5670900 
DPAEGDGAQPEETPR 14929000 0 14929000 
DPAQPMSPGEATQSGAR 11936000 0 11936000 
DPCAGPVCDCK 6009400 0 6009400 
DPEEIEKEEQAAAEK 80826000 0 80826000 
DPEFVFYDQLK 11977000 0 11977000 
DPENFPFVVLGNK 47025000 7572900 39452000 
DPETLVGYSMVGCQR 0 0 0 
DPFYMGLYQK 4031900 0 4031900 
DPGVITYDLPTPPGEK 7022500 0 7022500 
DPLLLAIIPK 5562600 0 5562600 
DPLNPIK 56479000 0 56479000 
DPMIDNNR 34585000 0 34585000 
DPNNLFMVR 81233000 0 81233000 
DPNTYFIVGTAMVYPEEAEPK 2443900 0 2443900 
DPPDPYVSLLLLPDK 0 0 0 
DPQHDLDR 4781900 0 4781900 
DPSTESGEEENEEQDELNEQILR 15084000 0 15084000 
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DPVQEAWAEDVDLR 26191000 0 26191000 
DQDLEPGAPSMGAK 8911400 0 8911400 
DQDNMQAELNR 7843000 0 7843000 
DQELSPR 5702000 0 5702000 
DQFTTTEVNMAR 0 0 0 
DQILTDSR 7475300 0 7475300 
DQIPSPGLMVFPK 0 0 0 
DQIYDIFQK 139050000 0 139050000 
DQLIYNLLK 336160000 0 336160000 
DQLLPNLR 0 0 0 
DQLQTFSEEHPVLLTEAPLNPR 10771000 0 10771000 
DQNIFVQK 55380000 0 55380000 
DQQEAALVDMVNDGVEDLR 25538000 0 25538000 
DQTVIQNTDGNNNEAWAK 0 0 0 
DQVANSAFVER 754980000 15846000 739130000 
DQVTAQEIFQDNHEDGPTAK 7482400 0 7482400 
DRDVTFSPATIENELIK 13928000 0 13928000 
DRPFFAGLVK 290590000 0 290590000 
DRPFFPGLVK 579160000 0 579160000 
DRPMEESLLLFEAMR 658180 0 658180 
DRPQEADGIDSVIVVDNVPQVGPDR 13123000 0 13123000 
DSAQCAAIAER 15050000 0 15050000 
DSAQNSVIIVDK 28368000 0 28368000 
DSAVNAICYGAK 12352000 0 12352000 
DSLIIIDELGR 8715500 0 8715500 
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DSLVYQYLQK 13850000 0 13850000 
DSPDLLLLLR 3547400 0 3547400 
DSPLETK 25495000 0 25495000 
DSPSVWAAVPGK 24451000 0 24451000 
DSQDAGGFGPEDR 0 0 0 
DSQICELK 0 0 0 
DSSQILSASFDQTIR 14093000 0 14093000 
DSSQSPSQVDQFCK 0 0 0 
DSTLIMQLLR 1035600000 26394000 1009200000 
DSWVDIFR 25704000 25704000 0 
DSYLILETLPTEYDSR 0 0 0 
DSYVGDEAQSK 3997300000 39752000 3957500000 
DSYVGDEAQSKR 44182000 0 44182000 
DTDIVDEAIYYFK 7067000 0 7067000 
DTDSINLYK 0 0 0 
DTEMLATGAQDGK 29964000 0 29964000 
DTFLGPVLK 0 0 0 
DTGNIGQER 2763900 0 2763900 
DTLDYSSNTMESALQYEK 2133300 0 2133300 
DTLYEAVR 48396000 0 48396000 
DTNFGTNCICR 913400 0 913400 
DTNGSQFFITTVK 487070000 0 487070000 
DTPGFIVNR 0 0 0 
DTPQEMEQTR 3098600 0 3098600 
DTQTSITDSCAVYR 13766000 0 13766000 
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DTSASAVAVGLK 47584000 0 47584000 
DTYMLSSTVSSK 0 0 0 
DVACGANHTLVLDSQK 113480000 0 113480000 
DVAIKEPLVDVVDPK 0 0 0 
DVATVCR 6683400 0 6683400 
DVAWAPSIGLPTSTIASCSQDGR 63605000 0 63605000 
DVCLYPR 50431000 0 50431000 
DVDFMYVELIQR 2742000 0 2742000 
DVFSPIGER 0 0 0 
DVIAQSQSGTGK 75772000 0 75772000 
DVIATDKEDVAFK 286600000 0 286600000 
DVIEEYFK 66214000 0 66214000 
DVIIADCGK 0 0 0 
DVLEVGELAK 0 0 0 
DVLLDVAYAYGK 7185400 0 7185400 
DVLSVAFSSDNR 196100000 0 196100000 
DVMDSTTTQK 28220000 0 28220000 
DVMPEVNK 82176000 2391500 79785000 
DVNAAIATIK 551890000 0 551890000 
DVNQQEFVR 195970000 6738400 189230000 
DVPNPNQDDDDDEGFSFNPLK 7300900 0 7300900 
DVQDSLTVSNEAQTAK 29906000 0 29906000 
DVQEIFR 0 0 0 
DVQELLTQYTK 0 0 0 
DVQIGDIVTVGECRPLSK 175560000 0 175560000 
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DVSELTGFPEMLGGR 20108000 0 20108000 
DVSGPMPDSYSPR 8378800 0 8378800 
DVTEAEQAEEQAR 2390500 0 2390500 
DVTFSPATIENELIK 17734000 0 17734000 
DVTNNVHYENYR 18563000 0 18563000 
DVTYEEAK 0 0 0 
DVVHTSEEAR 21486000 374450 21111000 
DVVICPDASLEDAKK 28036000 0 28036000 
DVVMEPTMK 3459700 0 3459700 
DVVQAYPEVR 76359000 0 76359000 
DVWGIEGPIDAAFTR 26846000 26846000 0 
DVYIVQDLMETDLYK 0 0 0 
DVYTGDALR 87773000 0 87773000 
DWNTLIVGK 23364000 0 23364000 
DWNVDLIPK 145770000 0 145770000 
DWTDTNYYSEK 1059000 0 1059000 
DYEILFK 17795000 0 17795000 
DYETATLSDIK 0 0 0 
DYFEEYGK 49757000 0 49757000 
DYFEQYGK 167040000 0 167040000 
DYFGAHTYELLAK 12001000 0 12001000 
DYFNVPYPLPK 17997000 0 17997000 
DYGNSPLHR 54073000 0 54073000 
DYGVLLEGSGLALR 75365000 0 75365000 
DYGVYLEDSGHTLR 1027000 0 1027000 
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DYIPVDQEELR 0 0 0 
DYIVVGSDSGR 0 0 0 
DYLEAAIR 0 0 0 
DYLHLPPEIVPATLR 9127000 0 9127000 
DYNVTANSK 68027000 0 68027000 
DYPFHEEF 0 0 0 
DYPLASK 5115800 0 5115800 
DYSGQGVVK 12372000 0 12372000 
DYSVTANSK 153520000 0 153520000 
DYTSGAMLTGELK 0 0 0 
DYTSGAMLTGELKK 2738400 0 2738400 
DYVAPTANLDQK 84333000 0 84333000 
DYVDLFR 45183000 0 45183000 
DYVQEVTK 13623000 0 13623000 
DYYINIR 0 0 0 
EAAENSLVAYK 312520000 0 312520000 
EAAEVLQNNR 45229000 890590 44338000 
EAALSTALSEK 32449000 0 32449000 
EAATQAQQTLGSTIDK 26819000 0 26819000 
EAAWAISNLTISGR 15239000 0 15239000 
EACFAVEGPK 42085000 42085000 0 
EADASPASAGICR 6178600 0 6178600 
EADDIVNWLK 11481000 0 11481000 
EAEILEVLR 8865000 0 8865000 
EAELLEPLMPAIR 23725000 0 23725000 
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EAEPDLLAVLR 3913900 0 3913900 
EAESLIAK 19502000 0 19502000 
EAESSPFVER 77308000 0 77308000 
EAFEISK 51073000 7073200 44000000 
EAFLQEVWK 39531000 0 39531000 
EAFSDGITSVK 11681000 1856400 9824600 
EAFSLFDKDGDGTITTK 3054900 0 3054900 
EAGAGGLAIAVEGPSK 10805000 0 10805000 
EAGEGGEAEAPAAEGGK 63304000 0 63304000 
EAGLAPVPMIIFAK 5714700 0 5714700 
EAGVEMGDEDDLSTPNEK 6827300 0 6827300 
EAHEPLAVADAK 4767300 0 4767300 
EAIEGTYIDKK 14090000 0 14090000 
EAIESAIGGNAYQHSK 45870000 0 45870000 
EAINLLEPMTNDPVNYVR 13676000 0 13676000 
EAINVEQAFQTIAR 34298000 0 34298000 
EAIQLIAR 9848100 0 9848100 
EALDVLGAVLK 11056000 0 11056000 
EALELTDTGLLSGSEER 3986900 0 3986900 
EALENANTNTEVLK 0 0 0 
EALENCITLQDFNR 3665100 0 3665100 
EALLELLR 12891000 0 12891000 
EALLGDTGTGDFLK 19486000 0 19486000 
EALLSSAVDHGSDEVK 17246000 0 17246000 
EALQDDLQR 2631600 0 2631600 
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EALQLMATYLPK 90565000 0 90565000 
EAMEADLK 4873200 0 4873200 
EAMEDGEIDGNK 14433000 0 14433000 
EAMMGLAQLYK 2223000 0 2223000 
EANNFLWPFK 59318000 0 59318000 
EANQQQQFNR 5496200 0 5496200 
EANSIIITPGYGLCAAK 40994000 0 40994000 
EAPAEGEAAEPGSPTAAEGEAASAASSTSSPK 33098000 0 33098000 
EAQELSQNSAIK 43714000 0 43714000 
EAQNLSAMEIR 15899000 0 15899000 
EASDPQPEEADGGLK 13869000 0 13869000 
EASFDGISK 19374000 0 19374000 
EATAGNPGGQTVR 2538200 0 2538200 
EATDAIGHLDR 100180000 0 100180000 
EATDEELEK 2311600 0 2311600 
EAVEAIQNSTSIK 14144000 0 14144000 
EAVLNAYR 10193000 0 10193000 
EAVTEILGIEPDR 25032000 0 25032000 
EAVTEILGIEPDREK 59475000 0 59475000 
EAYFWLR 1989800 0 1989800 
EAYMGNVLQGGEGQAPTR 26180000 0 26180000 
EAYPDHTQFEK 2360200 0 2360200 
EAYPEEAYIADLDAK 1510000 0 1510000 
ECCDKPLLEK 14647000 14647000 0 
ECCHGDLLECADDR 113130000 113130000 0 
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ECLPLIIFLR 102000000 2353100 99648000 
ECPSVLEYK 119220000 0 119220000 
ECVPNSNER 9299000 9299000 0 
ECVQQLAENTR 8309700 0 8309700 
EDCSPDEFIDVIVGNR 911550 0 911550 
EDDLNSFNATDLK 13831000 0 13831000 
EDEEESLNEVGYDDIGGCR 3664900 0 3664900 
EDFDSLLQSAK 353110000 1158900 351950000 
EDGLAQQQTQLNLR 3758300 0 3758300 
EDGSEVGVGGAQVTGSNTR 7746700 0 7746700 
EDGSGDRGDGPFR 10804000 0 10804000 
EDGTFYEFGEDIPEAPER 3530000 0 3530000 
EDIEFICK 0 0 0 
EDIQSVMTEIR 58206000 0 58206000 
EDITQSAQHALR 20319000 0 20319000 
EDIYAVEIVGGATR 49903000 0 49903000 
EDLECLIQEQMK 11018000 0 11018000 
EDLNCQEEEDPMNK 4430400 0 4430400 
EDLQLDKPASGVK 13237000 0 13237000 
EDLTEIR 88468000 2618200 85849000 
EDLVYQAK 24370000 0 24370000 
EDLYLKPIQR 8417600 0 8417600 
EDMAALEK 446150000 0 446150000 
EDPLIIPVPASENPFR 7493200 0 7493200 
EDPLLTPVPASENPFR 52823000 0 52823000 
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EDPTVSALLTSEK 6683600 0 6683600 
EDQSILCTGESGAGK 37437000 0 37437000 
EDQTEYLEER 162630000 6104100 156530000 
EDTEEYNLR 33444000 0 33444000 
EDTESLEIFQNEVAR 14725000 0 14725000 
EDVLTLLLPVMGDSK 8201600 0 8201600 
EEAADLSSLK 10594000 0 10594000 
EEACDCLFEVVNK 2730000 0 2730000 
EEAENTLQSFR 158390000 4042700 154350000 
EEASDYLELDTIK 46360000 1340700 45019000 
EEASGSSVTAEEAK 22025000 0 22025000 
EEDPATGTGDPPR 1515100 0 1515100 
EEEDVSGEPEASPSADTTILFVK 3928500 0 3928500 
EEEIAALVIDNGSGMCK 75469000 0 75469000 
EEEVTGPVIAPLFPQK 9719100 0 9719100 
EEIAQLAR 25967000 0 25967000 
EEIQSSISGVTAAYNR 0 0 0 
EELEALFLPYDLK 2628000 0 2628000 
EELEEVIK 4707600 0 4707600 
EELEEVIKDI 37687000 0 37687000 
EELFVTSK 5356200 0 5356200 
EELGLIEQAYDNPHEALSR 48955000 0 48955000 
EELQANGSAPAADKEEPAAAGSGAASPSAAEK 22309000 0 22309000 
EELVAEQALK 9717400 0 9717400 
EELVEESQTK 7223100 0 7223100 
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EEMIHNLQ 0 0 0 
EENAEQQALAAK 18688000 0 18688000 
EEPGSDSGTTAVVALIR 47673000 0 47673000 
EEQMDGTVTLK 6983000 0 6983000 
EESDDEAAVEEEEEEK 23897000 0 23897000 
EESGVSVSNSQPTNESHSIK 7117600 0 7117600 
EEVVTVETWQEGSLK 0 0 0 
EFADSLGIPFLETSAK 42220000 0 42220000 
EFAGEDTSDLFLEER 33447000 0 33447000 
EFCENLSADCR 91726000 0 91726000 
EFCQQEVEPMCK 7271200 0 7271200 
EFEDAFPADFIAEGIDQTR 6823000 0 6823000 
EFEEDLTGIDDR 51863000 0 51863000 
EFEENGLEK 10364000 0 10364000 
EFGATECINPQDFSK 17303000 0 17303000 
EFGEPWDLNSGDGAFYGPK 2894400 0 2894400 
EFGFSGLNVK 32117000 0 32117000 
EFGTNIK 141850000 0 141850000 
EFHLNESGDPSSK 92138000 0 92138000 
EFIQEPAK 40471000 0 40471000 
EFLPEGQDIGAFVAEQK 13116000 0 13116000 
EFLVAGGEDFK 4842600 0 4842600 
EFMWALK 3189600 0 3189600 
EFVICDK 5850100 0 5850100 
EGALCEENMR 394030000 0 394030000 
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EGATVYATGTHAQVEDGR 7092700 0 7092700 
EGDCGFGDGGPSGASGR 0 0 0 
EGEAVVLPEVEPGLTAR 2033700 0 2033700 
EGEEATAEAEEK 3517800 0 3517800 
EGFLLALTQGR 9613000 0 9613000 
EGFYDLSSEDPFGCK 11820000 0 11820000 
EGGDFVCCALSPR 13583000 0 13583000 
EGGGNNLYGEEMVQALK 18509000 0 18509000 
EGGLGPLNIPLLADVTR 1986200 0 1986200 
EGGTVVYGGK 10078000 0 10078000 
EGIAQTVFLGLNR 4969700 0 4969700 
EGIPALDNFLDK 54395000 0 54395000 
EGIPPDQQR 1430300000 33640000 1396700000 
EGITTYFSGNCTMEDAK 0 0 0 
EGIVTATEQEVK 6638200 0 6638200 
EGLELPEDEEEK 0 0 0 
EGLELPEDEEEKK 9953300 0 9953300 
EGLLAIFK 35794000 0 35794000 
EGLLFEGR 3748800 0 3748800 
EGLLGLQNLLK 2896000 0 2896000 
EGLLLWCQR 77737000 1768900 75968000 
EGMEAAVEK 0 0 0 
EGMNIVEAMER 379910000 10130000 369780000 
EGPAVVGQFIQDVK 22542000 0 22542000 
EGPLCDELIR 12818000 0 12818000 
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EGPYDVVVLPGGNLGAQNLSESAAVK 19384000 0 19384000 
EGPYSISVLYGDEEVPR 6607100 0 6607100 
EGQEIASVSDDHTCR 10620000 0 10620000 
EGQNYQQNCIK 25791000 0 25791000 
EGQTICVR 4160500 0 4160500 
EGSLVINSK 59587000 0 59587000 
EGSPVLLNCLMYK 31988000 0 31988000 
EGSQGELTPANSQSR 6158500 0 6158500 
EGTGTEMPMIGDR 0 0 0 
EGTLSDSTGSEK 2737100 0 2737100 
EGVECEVINMR 1669000 0 1669000 
EGVHGGLINK 57320000 0 57320000 
EGVVECSFVK 188610000 0 188610000 
EHALLAYTLGVK 113110000 0 113110000 
EHINSVSAMK 1986400 0 1986400 
EHVIEALR 71128000 0 71128000 
EHYVDLK 169790000 0 169790000 
EIAEAYLGK 11688000 0 11688000 
EIAQDFK 1406000000 3516500 1402500000 
EIAQEFKTDLR 41831000 0 41831000 
EIATVVK 126030000 0 126030000 
EICCYSISCK 15891000 0 15891000 
EIEDPEDR 78162000 0 78162000 
EIEQEAAVELSQLR 15183000 0 15183000 
EIEVGGGR 266330000 9038400 257290000 
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EIFNFVLK 102510000 0 102510000 
EIGSTMSGR 25883000 0 25883000 
EIIDLVLDR 3995300000 117580000 3877700000 
EIIEAMLK 83925000 0 83925000 
EIIQDVTLHDLDVANAR 23514000 0 23514000 
EILAELTGR 11791000 0 11791000 
EILETLIK 0 0 0 
EILGTAQSVGCNVDGR 150150000 966780 149180000 
EILIPVFK 56335000 0 56335000 
EILSEENEMQPNGK 0 0 0 
EILTLLQGVHQGAGFQDIPK 42425000 0 42425000 
EIQTAVR 50194000 1140200 49054000 
EIQTTTGNQQVLVR 3629300 0 3629300 
EIRPALELLEPIEQK 80344000 0 80344000 
EISYENTQISR 16641000 0 16641000 
EITALAPSTMK 5178000000 0 5178000000 
EIVESCDLK 33350000 0 33350000 
EIVLADVIDNDSWR 35491000 0 35491000 
EIVNNVR 17092000 0 17092000 
EIVPVLVSTR 2167800 0 2167800 
EIVQDGDHMIIR 44009000 0 44009000 
EKLQEEMLQR 7115700 0 7115700 
EKPYFPIPEEYTFIQNVPLEDR 11629000 0 11629000 
EKVESELR 32002000 0 32002000 
EKYIDQEELNK 3472100 0 3472100 
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ELAEDGYSGVEVR 147390000 0 147390000 
ELAESDFASTFR 0 0 0 
ELAFQISK 0 0 0 
ELAILLGMLDPAEK 3469000 0 3469000 
ELAILLGMLDPAEKDEK 28414000 0 28414000 
ELALQPK 45291000 0 45291000 
ELAMPGEDLK 22193000 5907500 16286000 
ELANSPDCPQMCAYK 28248000 0 28248000 
ELAPAVSVLQLFCSSPK 1006600 0 1006600 
ELAPLFEELR 9691600 0 9691600 
ELAPLQELIEK 21871000 0 21871000 
ELAPYDENWFYTR 19115000 0 19115000 
ELAQQIQK 162740000 602650 162140000 
ELATVLSDQPGLLGPK 36073000 0 36073000 
ELAVQIQK 27745000 0 27745000 
ELDALDANDELTPLGR 51237000 0 51237000 
ELDQWIEQLNECK 69563000 0 69563000 
ELDSLQTEAESLDNTVK 0 0 0 
ELEAENYHDIK 7666300 0 7666300 
ELEEESIR 15883000 0 15883000 
ELEEETGYK 9477000 0 9477000 
ELEEIVQPIISK 68301000 0 68301000 
ELEQVCNPIISGLYQGAGGPGPGGFGAQGPK 4326900 0 4326900 
ELEVLLMCNK 23868000 0 23868000 
ELFSNLQEFAGPSGK 10314000 0 10314000 
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ELFSPLHALNFGIGGDTTR 18181000 0 18181000 
ELGENLDQILR 19973000 0 19973000 
ELGIWEPLAVK 27018000 0 27018000 
ELGSECGIEFDEEK 0 0 0 
ELGSSTNALR 9251500 0 9251500 
ELHINLIPNK 5910200 0 5910200 
ELIDYLR 2685500 0 2685500 
ELIFEETAR 13618000 0 13618000 
ELISNASDALDK 143250000 0 143250000 
ELISNSSDALDK 397980000 0 397980000 
ELITILEK 0 0 0 
ELLAVPDNYK 9854200 0 9854200 
ELLEIVK 8315900 0 8315900 
ELLEQISAFDNVPR 10415000 0 10415000 
ELLESNFTLVGDDGTNK 13296000 0 13296000 
ELLGQGLLLR 5768200 0 5768200 
ELLLQPVTISR 150860000 0 150860000 
ELLNPVVEFVSHPSTTCR 54440000 0 54440000 
ELLSNVDEGIYQLEK 3689900 0 3689900 
ELLTLDEKDPR 8771400 0 8771400 
ELLVPLTSSMYVPGK 43744000 0 43744000 
ELLYFLDSCEPEFK 3687900 0 3687900 
ELMAWNQAENR 3850100 0 3850100 
ELNGTAPEEK 2822700 0 2822700 
ELNITAAK 168080000 0 168080000 
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ELNYFAK 103160000 0 103160000 
ELPAAVAPAGPASLAR 0 0 0 
ELPEQLQEHAIEDK 6412500 0 6412500 
ELQCLTPR 28578000 0 28578000 
ELQDSTQMNEK 7791600 0 7791600 
ELQEQLK 0 0 0 
ELQEQMSR 53451000 8164300 45287000 
ELQSMADQEK 5812900 0 5812900 
ELQSVEQEVR 32306000 0 32306000 
ELSDFISYLQR 17027000 0 17027000 
ELSDSVTLSSSDR 7836800 0 7836800 
ELSEALTR 69300000 0 69300000 
ELSEYVR 31674000 0 31674000 
ELSGTIK 93742000 0 93742000 
ELSNFYFSIIK 2864000 0 2864000 
ELSQIEACQGPMQMR 0 0 0 
ELSTTLNADEAVTR 14355000 0 14355000 
ELTAPDENIPAK 0 0 0 
ELTAVVQK 249610000 0 249610000 
ELTDEEAER 18944000 0 18944000 
ELTEEKESAFEFLSSA 9685100 0 9685100 
ELTGEDVLVR 0 0 0 
ELTIGSK 9006700 0 9006700 
ELTVSNNDINEAGVR 8466100 0 8466100 
ELVALMSAIR 0 0 0 
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ELVEGEMK 17443000 0 17443000 
ELVLDNSR 0 0 0 
ELVSCSNCTDYQAR 66359000 642880 65717000 
ELVSDANQHVK 10428000 0 10428000 
ELWDSIMTR 34715000 0 34715000 
ELYPVEFR 3009700 0 3009700 
EMDVVSQHK 0 0 0 
EMEENFAVEAANYQDTIGR 1138300 0 1138300 
EMFGSGTACVVCPVSDILYK 16923000 0 16923000 
EMLGGEIIPR 17770000 0 17770000 
EMLQQSK 15234000 0 15234000 
EMQNLSFQDCYSSK 1544300 0 1544300 
EMQPTHPIR 37096000 0 37096000 
EMQQLSGGQK 0 0 0 
EMTADVIELK 4186700 0 4186700 
EMVECFNK 63791000 0 63791000 
EMVELPLR 21389000 0 21389000 
EMVQNLMVLR 30668000 0 30668000 
ENCMYQACPTQDCNKK 4284900 0 4284900 
ENELTYYCCK 0 0 0 
ENFSCLTR 162460000 12452000 150010000 
ENGGYTGCPFPAK 780650 0 780650 
ENGLPLEYQEK 7647200 0 7647200 
ENILEEFSK 71437000 0 71437000 
ENITEDEAK 21061000 0 21061000 
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ENIVEAIIHSPELIR 7295700 0 7295700 
ENLATVEGNFASIDER 2937800 0 2937800 
ENLFMDLLR 15370000 3118000 12252000 
ENLISALEEAK 17739000 0 17739000 
ENLLDFIK 197560000 1719800 195840000 
ENLSYDLVPLK 7217500 0 7217500 
ENMTLQPK 8009600 0 8009600 
ENQTAVDVFR 8653100 0 8653100 
ENSETVVTGSLDDLVK 13608000 0 13608000 
ENTELVQK 3577200 0 3577200 
ENVNATENCISAVGK 2084500 0 2084500 
ENVSNCIQLK 55822000 0 55822000 
EPELGLEELLR 6379200 0 6379200 
EPESILQVLSQMEK 10138000 0 10138000 
EPEVLSTMAIIVNK 26056000 0 26056000 
EPFLQQLK 0 0 0 
EPLYVGVDDDK 21387000 0 21387000 
EPNPPIDEVISTPGVVAR 0 0 0 
EPNSENVDISSGGGVTGWK 2901900 0 2901900 
EPPYGADVLR 41903000 0 41903000 
EPVAVLK 12558000 0 12558000 
EPVETAVDNNSK 14230000 0 14230000 
EPVQLETLSIR 2205700 0 2205700 
EPWLLPSQHNDIIR 26768000 0 26768000 
EQADFAVEALAK 17475000 0 17475000 
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EQAYQER 5228700 0 5228700 
EQEAGLLQFLR 35158000 0 35158000 
EQESCNMANIR 0 0 0 
EQFLDGDGWTSR 144940000 1496100 143450000 
EQGFLSFWR 4989900 0 4989900 
EQGPYETYEGSPVSK 11465000 0 11465000 
EQGVLSFWR 295750000 1882100 293870000 
EQGVTFPSGDIQEQLIR 65918000 0 65918000 
EQICEVEEGDKPDVDK 6451000 0 6451000 
EQILEEFSK 23585000 0 23585000 
EQIYDVYR 31901000 0 31901000 
EQLAIAEFAR 10787000 0 10787000 
EQLDAFIDQLYK 4502200 0 4502200 
EQLDNQLDAYMSK 0 0 0 
EQLGEEIDSK 26701000 0 26701000 
EQLMSQEER 4686300 0 4686300 
EQLWLANEGLITR 12660000 0 12660000 
EQPEKEPELQQYVPQLQNNTILR 7594700 0 7594700 
EQPVFAMTGLR 30371000 0 30371000 
EQQEAIEHIDEVQNEIDR 0 0 0 
EQQIVIQSSGGLSK 4789200 0 4789200 
EQSGPSPLEETR 13853000 0 13853000 
EQSILELGSLLAK 7084400 0 7084400 
EQTADGVAVIPVLQR 47002000 0 47002000 
EQVANSAFVER 37877000 0 37877000 
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EQWDTIEELIR 2937500 0 2937500 
EQYGSVDQYAR 0 0 0 
ESALILLQTVPK 8052100 0 8052100 
ESCLEAYTGIVQGLK 101740000 0 101740000 
ESDYFTPQGEFR 0 0 0 
ESFAEMNR 168410000 3719100 164690000 
ESIEEPSAK 40130000 0 40130000 
ESISDVGFGMLK 13478000 0 13478000 
ESLDDLTNLVVK 0 0 0 
ESLPELSTAQQNK 11459000 0 11459000 
ESLVALLSR 0 0 0 
ESNCYDPER 122220000 0 122220000 
ESPFSTSASPLLSGSQHFDVPPR 16436000 0 16436000 
ESPNITDR 4323400 0 4323400 
ESQDTSFTTLVER 4560800 0 4560800 
ESSLTEPVIVGLLK 15148000 0 15148000 
ESSSEQYVPDVFYK 4172500 0 4172500 
ESSVPMCQGELR 0 0 0 
ESTAEKDEL 244740000 0 244740000 
ESTLHLVLR 44155000 0 44155000 
ESTSCPVVQK 13331000 0 13331000 
ESVVDYCNR 28404000 0 28404000 
ESYDYLK 7611900 0 7611900 
ESYSVYVYK 109160000 0 109160000 
ETAENYLGHTAK 4041600 0 4041600 
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ETAFILTGYCTDK 0 0 0 
ETANAIVSQQTPQR 4908400 0 4908400 
ETDLLILFK 3434100 0 3434100 
ETDLQELFR 9996200 0 9996200 
ETEEILADVLK 19364000 0 19364000 
ETEGDVTSVK 8819700 0 8819700 
ETENDDLTNVIQK 48396000 0 48396000 
ETENDDVTNVIQK 6694600 0 6694600 
ETGCMVYEK 0 0 0 
ETLAQLQQEFQR 12327000 0 12327000 
ETLIQFLR 4591200 0 4591200 
ETLLAMFK 41388000 0 41388000 
ETLLNGVGYLHEGLSPMER 11293000 0 11293000 
ETLPAEQDLTTK 28789000 0 28789000 
ETLVYLTHLDYVDTER 10178000 0 10178000 
ETMVTSTTEPSR 129290000 2701000 126590000 
ETQALILAPTR 9842800 0 9842800 
ETSGNLEQLLLAVVK 4097300 0 4097300 
ETSMVHELNR 9653900 4060700 5593200 
ETTGTGPNVYHENDTIAK 24097000 0 24097000 
ETTNIFSNCGCVR 0 0 0 
ETVDSFLDLAR 17514000 0 17514000 
ETVEEQASTTER 2864200 0 2864200 
ETVSEESNVLCLSK 2614500 0 2614500 
ETYGDMADCCEK 156900000 156900000 0 
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EVAALCR 6314200 0 6314200 
EVAEAATGEDASSPPPK 8220300 0 8220300 
EVATAIR 48440000 750470 47690000 
EVCFACVDGK 0 0 0 
EVDEQMLNVQNK 539740000 0 539740000 
EVDIYTVK 0 0 0 
EVEMGPFK 0 0 0 
EVEPALELLEPIDQK 15204000 0 15204000 
EVEQFTQVAK 0 0 0 
EVEQLIK 88138000 0 88138000 
EVFEMATR 21240000 0 21240000 
EVFLVMPTGGGK 60129000 0 60129000 
EVGSIIGK 37652000 0 37652000 
EVIAVSCGPAQCQETIR 0 0 0 
EVIDLLK 22407000 0 22407000 
EVLCPESQSPNGVR 2136900 0 2136900 
EVLDSFLDLAR 17980000 0 17980000 
EVLEGLEYLHK 5394000 0 5394000 
EVLEYNAIGGK 0 0 0 
EVLLEAQDMAVR 0 0 0 
EVLLPEVGAK 0 0 0 
EVLNEEDEVQPNGK 8348800 0 8348800 
EVLQNLGPK 18558000 0 18558000 
EVNEVIQNPATITR 0 0 0 
EVNLAVQNAK 54096000 0 54096000 
 
 
269 | P a g e  
 
EVPCYVFDEELR 2372100 0 2372100 
EVPGPDCR 29136000 0 29136000 
EVQVEHIK 2456500 0 2456500 
EVQYLLNK 16151000 0 16151000 
EVQYTLEMIK 0 0 0 
EVSEEQPVVTLEK 6926300 0 6926300 
EVSQPDWTPPPEVTLVLTK 18188000 0 18188000 
EVSSATNALR 74406000 0 74406000 
EVSSSFDHVIK 0 0 0 
EVSTYIK 941000000 0 941000000 
EVTPEGLQMVK 22270000 0 22270000 
EVVCTNCPTGTTGK 5274300 0 5274300 
EVVEAHVDQK 10292000 0 10292000 
EVVEEAENGR 736760000 20592000 716170000 
EVVEQGLLK 14890000 0 14890000 
EVWNTYELDLVNYQNK 26225000 0 26225000 
EWLNSCDLK 2840000 0 2840000 
EWLTELFQQSK 8180600 0 8180600 
EYAEDDNIYQQK 4241100 0 4241100 
EYCIQAFESFVR 14825000 0 14825000 
EYEATLEECCAK 234630000 234630000 0 
EYFGGFGEVESIELPMDNK 6156600 0 6156600 
EYGCGPSGQVVSR 4145400 0 4145400 
EYINCNR 4999100 0 4999100 
EYLLGSTAEEK 0 0 0 
 
 
270 | P a g e  
 
EYLPIGGLAEFCK 161010000 1436900 159570000 
EYLSEEVQAVHK 22322000 0 22322000 
EYNEFAEVFLK 32710000 0 32710000 
EYQDLLNVK 4026200 0 4026200 
EYQTQLIQR 51918000 0 51918000 
EYSLQVLK 5862300 0 5862300 
EYTAAVEAK 3653700 0 3653700 
EYTDVYPEIIER 30702000 0 30702000 
EYTLDVYR 2510000 0 2510000 
EYVTCHTCR 1241900 0 1241900 
FAAATGATPIAGR 389240000 9604600 379640000 
FAANPNQNK 5965200 0 5965200 
FAAQATQQR 0 0 0 
FAAYFQQGDMESNGK 27628000 0 27628000 
FADFMVK 3252000 0 3252000 
FADIGNTVK 6069200 0 6069200 
FAEALGSTEAK 32393000 1925900 30467000 
FAETQPK 0 0 0 
FAEVYFAQSQQK 3200700 0 3200700 
FAFQAEVNR 0 0 0 
FAIQDISVEETSAK 44940000 0 44940000 
FAMEPEEFDSDTLR 238650000 0 238650000 
FAMEQSFSADTGGGGR 0 0 0 
FASGGCDNLIK 51695000 0 51695000 
FATEYCNTIEGTAK 0 0 0 
 
 
271 | P a g e  
 
FAVALLDDSVR 14263000 0 14263000 
FAVFGLGNK 11901000 0 11901000 
FAVGSGSR 26926000 0 26926000 
FCANTCVECR 13250000 0 13250000 
FCDNSSAIQGK 2709200 0 2709200 
FCECDNFNCDR 79221000 2811200 76410000 
FCENTQAGEGR 1156400 0 1156400 
FCIWTESAFR 44059000 0 44059000 
FCNPGFPIGCYITDK 16887000 0 16887000 
FCNVDDDELR 39530000 0 39530000 
FCPEADSK 12204000 0 12204000 
FCPFAER 52317000 0 52317000 
FCQLLWR 6245500 0 6245500 
FCTGLTQIETLFK 35726000 0 35726000 
FDAGELITQR 0 0 0 
FDDAVVQSDMK 21867000 0 21867000 
FDDESAEEIR 7608000 0 7608000 
FDDPLLGPR 4685500 0 4685500 
FDEISFVNFAR 79109000 3583600 75525000 
FDGCYCDSLENLADGYK 2551100 0 2551100 
FDGILTEGEGPR 18671000 0 18671000 
FDLLGDFGR 5169200 0 5169200 
FDLMYAK 88640000 0 88640000 
FDLNSPWEAFPVYR 0 0 0 
FDNLYGCR 70179000 0 70179000 
 
 
272 | P a g e  
 
FDNPAAVSPTPTR 12286000 0 12286000 
FDQPLEASTWLK 33481000 25185000 8296100 
FDSNCITPGTEFMDNLAK 3093600 0 3093600 
FDSSLDR 67372000 2112500 65260000 
FDTEEEFK 9463300 0 9463300 
FDTGNLCMVTGGANLGR 16611000 0 16611000 
FDTQYPYGEK 3651600 0 3651600 
FDVPGDENAEMDAR 0 0 0 
FDVSGYPTLK 82372000 0 82372000 
FDYSGVGSSDGNSEESTLGK 0 0 0 
FEDENFILK 2107400000 0 2107400000 
FEDYLNAESR 0 0 0 
FEEAVEK 37911000 0 37911000 
FEEFLQR 18004000 0 18004000 
FEELGVK 30994000 0 30994000 
FEELNADLFR 154380000 2100400 152280000 
FEELTNLIR 44753000 0 44753000 
FEETGQELAELLEEEK 4769800 0 4769800 
FEETTADGR 13330000 0 13330000 
FEHCNFNDVTTR 4618400 0 4618400 
FEIWDTAGQER 67913000 0 67913000 
FELDTSER 20675000 0 20675000 
FENYGDK 35364000 0 35364000 
FESILPR 0 0 0 
FEVGDIMLIR 18288000 0 18288000 
 
 
273 | P a g e  
 
FEVNNTILHPEIVECR 0 0 0 
FEVQGLQPNGEEMTLK 60155000 0 60155000 
FEWELPLDEAQR 10753000 0 10753000 
FFDANYDGK 9584400 0 9584400 
FFDDPMLLELAK 4765500 0 4765500 
FFDGELTK 0 0 0 
FFEHFIEGGR 21857000 0 21857000 
FFEILSPVYR 0 0 0 
FFEVFDNSMK 2955000 0 2955000 
FFGGYVPEMVLTPDDQR 26823000 0 26823000 
FFGNLMDASK 0 0 0 
FFLSSGLIDK 12585000 0 12585000 
FFNVLTTNTDGK 59874000 0 59874000 
FFPASFPNR 0 0 0 
FFPLESWQIGK 48541000 0 48541000 
FFQEENTEK 16561000 0 16561000 
FFQPTEMASQDFFQR 4665000 0 4665000 
FFVAPFPEVFGK 9106600 9106600 0 
FFVGGNWK 0 0 0 
FFVSSSQGR 74848000 0 74848000 
FFYSDQNVDSR 0 0 0 
FGALTAEK 70766000 0 70766000 
FGAMLDMLTDR 9134400 0 9134400 
FGAPPHAGGGIGLER 9609100 0 9609100 
FGAVWTGDNTAEWDHLK 34749000 0 34749000 
 
 
274 | P a g e  
 
FGELVMTK 0 0 0 
FGEVTSASNCTDFQSR 2482800 0 2482800 
FGEVVDCTLK 26358000 0 26358000 
FGFEIIETK 21124000 0 21124000 
FGFPAFSGISR 19491000 0 19491000 
FGFPEGSVELYAEK 11311000 0 11311000 
FGFYEVFK 111070000 0 111070000 
FGGALDAAAK 103810000 0 103810000 
FGGGNPELLTQMVSK 108900000 0 108900000 
FGGLAAGEDNGQR 22998000 1353900 21644000 
FGGSGSQVDSAR 23760000 0 23760000 
FGIDDQDYQNSVTR 4922700 0 4922700 
FGIQAQMVTTDFQK 35316000 0 35316000 
FGNEITQLAR 0 0 0 
FGPYYTEPVIAGLDPK 17876000 0 17876000 
FGQVYTEAK 10276000 0 10276000 
FGSEFSPELQASFQK 87520000 87520000 0 
FGSLLPIHPVTSG 0 0 0 
FGTINIVHPK 0 0 0 
FGVIFAGAQK 117200000 0 117200000 
FGVLSDNFK 6937000 0 6937000 
FGVVLDEIKPSSAPELQAVR 5326700 0 5326700 
FGWDCHGLPVEYEIDK 23117000 0 23117000 
FGYVDFESAEDLEK 18121000 0 18121000 
FHEICSNLVK 23769000 0 23769000 
 
 
275 | P a g e  
 
FHMVDGNVSGEFTDLVPEK 10235000 0 10235000 
FHVEEEGK 5149000 0 5149000 
FIASTGMDR 58932000 0 58932000 
FIAYQFTDTPLQIK 7136100 0 7136100 
FIDDVVSAVLR 2797700 0 2797700 
FIEEHATK 39387000 0 39387000 
FIEIAAR 25912000 0 25912000 
FIGELFK 43075000 0 43075000 
FIHDQTSPNPK 1440000 0 1440000 
FIIPNVVK 999060000 0 999060000 
FIIPQIVK 2071000000 15505000 2055400000 
FIMESGAK 281100000 0 281100000 
FINDQYEK 29023000 0 29023000 
FIPCSPFSDYVYK 216360000 0 216360000 
FIPEGSQR 34442000 0 34442000 
FIPGSALNGMVEMMDR 6415200 0 6415200 
FIQLLSDQSDQSVLIQK 36448000 0 36448000 
FIQTFGK 23418000 0 23418000 
FISLASLEYSDYSK 21412000 0 21412000 
FITDNTVEER 14008000 0 14008000 
FKDIFQEIYDK 17184000 0 17184000 
FLAEEGFYK 20415000 0 20415000 
FLDGNELTLADCNLLPK 5084300 2607700 2476500 
FLEEYLSSTPQR 19815000 0 19815000 
FLELLPK 22452000 0 22452000 
 
 
276 | P a g e  
 
FLEMCNDLLAR 165510000 0 165510000 
FLEMHQL 0 0 0 
FLESPDFQPNIAK 3820200 0 3820200 
FLESQEFQPSIAK 9047800 0 9047800 
FLFDSVSSQNVGLR 0 0 0 
FLFSLFGQK 4965300 0 4965300 
FLFVDADQIVR 42454000 0 42454000 
FLGDIEVWDQAEK 45269000 0 45269000 
FLICTDVAAR 0 0 0 
FLILPDMLK 47396000 0 47396000 
FLINLEGGDIR 36972000 0 36972000 
FLIPNASQAESK 503920000 0 503920000 
FLIQNVLR 64842000 0 64842000 
FLITGADQNR 17766000 0 17766000 
FLIVAHDDGR 12737000 0 12737000 
FLLADNLYCK 34002000 0 34002000 
FLLDHQGELFPSPDPSGL 0 0 0 
FLLSESGSGK 0 0 0 
FLNAENAQK 46426000 0 46426000 
FLNEMIAPVMR 159390000 2142100 157240000 
FLNVPMFR 47490000 0 47490000 
FLPGYVGGIQEGAVTPAGVVNK 13088000 0 13088000 
FLPLFDR 52530000 0 52530000 
FLQDTIEEMALK 40591000 0 40591000 
FLQEVDFFQR 7397500 0 7397500 
 
 
277 | P a g e  
 
FLQFVTGTSK 0 0 0 
FLQMCNDDPDVLPDLK 10249000 0 10249000 
FLSAIVSSVDK 7058800 0 7058800 
FLSLYGDQIDMHR 88961000 0 88961000 
FLSNGYIPIPGQQDK 8947900 0 8947900 
FLTAVNLEHPEMLEK 13064000 0 13064000 
FLTVMMK 6213700 0 6213700 
FLVGFTNK 29872000 0 29872000 
FLVYVANFDEK 43314000 0 43314000 
FLYSELMK 79562000 0 79562000 
FMADIDLDPGCTLNK 27295000 0 27295000 
FMEQVIFK 70797000 0 70797000 
FMGTELNGK 54555000 0 54555000 
FMQASEDLLK 566180000 0 566180000 
FMQDPMEIFVDDETK 30519000 0 30519000 
FMQDPMEVFVDDETK 19616000 0 19616000 
FNADEFEDMVAEK 28601000 0 28601000 
FNAHGDANTIVCNSK 36772000 0 36772000 
FNEEHIPDSPFVVPVASPSGDAR 9572300 0 9572300 
FNESGDPSCVIMQNWAR 7813600 0 7813600 
FNLTYVSHDGDDK 21955000 0 21955000 
FNQVLDQFGEK 65022000 0 65022000 
FNTANDDNVTQVR 10946000 0 10946000 
FNTGPVGK 23190000 0 23190000 
FNVDEYSDLVTLTK 9702100 0 9702100 
 
 
278 | P a g e  
 
FNVEDGEIVQQVR 3967100 0 3967100 
FNVLQYVVPEVK 9515200 0 9515200 
FNVWDTAGQEK 43273000 0 43273000 
FNYGFEYLGVQDK 11865000 0 11865000 
FPAEQYYR 28094000 0 28094000 
FPDENFK 324570000 0 324570000 
FPEEEAPSTVLSQNLFTPK 9656600 0 9656600 
FPGQLNADLR 53528000 0 53528000 
FPLFGGWK 13194000 0 13194000 
FPSGNYPPCIGDNR 4469000 0 4469000 
FPSLLTHNENMVAK 214210000 0 214210000 
FPTLTNINENNPTLLNPIK 6100200 0 6100200 
FQASQGENLEGK 8335600 0 8335600 
FQDGDLTLYQSNTILR 112180000 0 112180000 
FQDGVLEPDFPR 15117000 15117000 0 
FQDLGAAYEVLSDSEK 19811000 0 19811000 
FQGEWNLQPLPK 10815000 0 10815000 
FQGQTCEMCQTCLGVCAEHK 14235000 0 14235000 
FQIATVTEK 0 0 0 
FQLLEGPPESMGR 7751300 0 7751300 
FQMPDQGMTSADDFFQGTK 87360000 0 87360000 
FQSGDFHVINGVLR 0 0 0 
FQSISTEFLALMK 4454100 0 4454100 
FQSIVIGCALEDQK 3470300 0 3470300 
FQTEIQTVNK 71723000 0 71723000 
 
 
279 | P a g e  
 
FQVDPSGEIVELAK 3233900 0 3233900 
FRIDELEPR 16984000 0 16984000 
FRPDMEEEEAK 50765000 0 50765000 
FSASGELGNGNIK 0 0 0 
FSDQFPLPLK 54086000 0 54086000 
FSDSYASVIK 4744200 0 4744200 
FSELTAEK 39726000 0 39726000 
FSFTLPYPVK 27434000 0 27434000 
FSGDLDDQTCR 21296000 0 21296000 
FSGGYPALMDCMNK 28218000 0 28218000 
FSGWYDADLSPAGHEEAK 22672000 0 22672000 
FSHEEIAMATVTALR 78341000 0 78341000 
FSHQGVQLIDFSPCER 6604100 0 6604100 
FSIEDLK 6012900 0 6012900 
FSIIAEPLVR 248840000 17100000 231740000 
FSIQTMCPIEGEGNIAR 108720000 0 108720000 
FSMVVQDGIVK 11267000 0 11267000 
FSPNSSNPIIVSCGWDK 90234000 0 90234000 
FSPTDFLAK 30748000 0 30748000 
FSSSSGYGGGSSR 11758000 11758000 0 
FSTIASSYEECR 4613200 0 4613200 
FSTVAGESGSADTVR 11204000 0 11204000 
FSVCVLGDQQHCDEAK 28221000 0 28221000 
FSWFAGEK 2911300 0 2911300 
FTADEAR 15759000 0 15759000 
 
 
280 | P a g e  
 
FTAGDFSTTVIQNVNK 1182600 0 1182600 
FTASAGIQVVGDDLTVTNPK 0 0 0 
FTAVEDQYYCVDCYK 8478700 0 8478700 
FTCSESQVNSR 5685300 0 5685300 
FTEYETQVK 28945000 0 28945000 
FTITPSTTQVVGILK 8926300 0 8926300 
FTNMLGQPGSTALDLFK 3431700 0 3431700 
FTPGTFTNQIQAAFR 73432000 0 73432000 
FTPLPEGK 58126000 0 58126000 
FVADGIFK 8371200 0 8371200 
FVASCGFTPDVK 1706800 0 1706800 
FVCAPPSR 6465600 0 6465600 
FVDGLMIHSGD 0 0 0 
FVEGLPINDFSR 135210000 0 135210000 
FVETPGQK 198070000 0 198070000 
FVFDRPLPVSR 33029000 0 33029000 
FVFSLVDAMNGK 104980000 0 104980000 
FVGQDVEGER 0 0 0 
FVIATSTK 35192000 0 35192000 
FVIGGPQGDAGLTGR 19045000 0 19045000 
FVIQGAGAK 48599000 0 48599000 
FVLSGANIMCPGLTSPGAK 44931000 0 44931000 
FVLSQAKDEL 0 0 0 
FVLSSGK 0 0 0 
FVPYYDLFMPSLK 11415000 0 11415000 
 
 
281 | P a g e  
 
FVSISDLLVPK 143010000 0 143010000 
FVTETLEDGSR 2754300 0 2754300 
FVTVQTISGTGALR 0 0 0 
FVVQNVSAQK 11006000 0 11006000 
FWEQSVR 24929000 0 24929000 
FWESPETVSQLDSVR 9966500 0 9966500 
FWPAIDDGLR 31682000 3292100 28390000 
FWQTYSSAEEVLQK 1775800 0 1775800 
FWSLEDGLNR 0 0 0 
FYALSASFEPFSNK 70885000 0 70885000 
FYDDAIVSQK 25999000 0 25999000 
FYEAFSK 1133200000 5408100 1127800000 
FYEQFSK 1693800000 0 1693800000 
FYFNGEYAGFDETQPTAESGGK 11364000 0 11364000 
FYGDEEKDK 21444000 0 21444000 
FYNLVLLPR 4881800 0 4881800 
FYPLEIDYGQDEEAVK 9817400 0 9817400 
FYQASTSELYGK 0 0 0 
FYSLPQSPQQFK 0 0 0 
FYSLWDTGYAK 5312700 0 5312700 
FYTEDSPGLK 58556000 0 58556000 
FYTQQWEDYR 5222800 0 5222800 
FYVEDLK 7440200 0 7440200 
FYVHNDIFR 0 0 0 
GAAGALLVYDITR 16617000 0 16617000 
 
 
282 | P a g e  
 
GACLLPK 218780000 218780000 0 
GACSVGTNVR 0 0 0 
GADCCVLVFDVTAPNTFK 2227900 0 2227900 
GADFCQFR 39719000 39719000 0 
GADFLVTEVENGGSLGSK 15080000 0 15080000 
GADIMYTGTVDCWR 21237000 0 21237000 
GAEDDLNTVAAGTMTGMLYK 11883000 0 11883000 
GAEEMETVIPVDVMR 51627000 0 51627000 
GAEILEVLHSLPAVR 4349200 0 4349200 
GAEYVSAR 30903000 0 30903000 
GAFASLSELHCDK 37969000 37969000 0 
GAFGKPQGTVAR 17494000 0 17494000 
GAGQQQSQEMMEVDR 2271400 0 2271400 
GAGSEETAAAAAPSR 1285600 0 1285600 
GAGTDDHTLIR 28809000 0 28809000 
GAGTDDSTLVR 6515500 0 6515500 
GAIILAK 51018000 0 51018000 
GALPLDTVTFYK 58160000 0 58160000 
GALQNIIPASTGAAK 1679700000 0 1679700000 
GANDFMCDEMER 3034700 0 3034700 
GATQQILDEAER 0 0 0 
GAVGALLVYDIAK 33827000 0 33827000 
GAVLVCDMSSNFLSK 30634000 0 30634000 
GAVLVCDMSSNFLSKPVDVSK 85347000 0 85347000 
GAVSAEQVIAGFNR 10236000 0 10236000 
 
 
283 | P a g e  
 
GAVWGATLNK 14780000 0 14780000 
GAVYSFDPVGSYQR 27295000 0 27295000 
GAWSNVLR 32058000 0 32058000 
GCALQCAILSPAFK 50546000 0 50546000 
GCDVVVIPAGVPR 92946000 0 92946000 
GCEVIQEIK 11933000 0 11933000 
GCEVVVSGK 225880000 0 225880000 
GCILTLVER 22748000 0 22748000 
GCITIIGGGDTATCCAK 37889000 0 37889000 
GCPEDAAVCAVDK 13947000 0 13947000 
GCTATLGNFAK 5155100 0 5155100 
GCVITISGR 3123100 0 3123100 
GDAMIMEETGK 88817000 0 88817000 
GDDQLELIKDDEK 49201000 0 49201000 
GDECGLALGR 2971400 0 2971400 
GDEELDSLIK 12820000 0 12820000 
GDFCIQVGR 404790000 8438200 396350000 
GDFDENLNYPEQK 0 0 0 
GDFILVGDLMR 3014800 0 3014800 
GDKVDILYNNIK 11797000 0 11797000 
GDLGIEIPAEK 26952000 0 26952000 
GDLLFLTNR 48322000 0 48322000 
GDPQVYEELFSYSCPK 4196000 0 4196000 
GDQENVHPDVMLVQPR 0 0 0 
GDQPAASGDSDDDEPPPLPR 5022300 0 5022300 
 
 
284 | P a g e  
 
GDTVATLSER 18926000 0 18926000 
GDVENIEVVQK 85299000 0 85299000 
GDVSNLDPNFSFEGTK 65835000 0 65835000 
GDVVNQDDLYQALASGK 5665000 0 5665000 
GDYPLEAVR 28971000 0 28971000 
GEAAAERPGEAAVASSPSK 27998000 0 27998000 
GEDEEENNLEVR 13369000 0 13369000 
GEDFPANNIVK 29965000 0 29965000 
GEDFYCVTCHETK 15478000 0 15478000 
GEEVDVAR 10816000 0 10816000 
GEEVGELSR 10176000 0 10176000 
GEFTIETEGK 15083000 0 15083000 
GEGQLGPAER 796890000 30286000 766610000 
GEHGFIGCR 38049000 0 38049000 
GEHPGLSIGDVAK 93421000 0 93421000 
GEIFLDEK 0 0 0 
GELLEAIK 8583700 0 8583700 
GELSGDFEK 7936200 0 7936200 
GEMMDLQHGSLFLQTPK 232530000 0 232530000 
GEMMDLQHGSLFLR 181980000 0 181980000 
GENLVSMTVEGPPPK 6271800 0 6271800 
GENSWFSTQVDTVATK 93072000 0 93072000 
GEPAAAAAPEAGASPVEK 16226000 0 16226000 
GEQGQYLQQDANECWIQMMR 5653300 0 5653300 
GESDPAYQQYQDAANNLR 0 0 0 
 
 
285 | P a g e  
 
GESLPCVK 4745900 0 4745900 
GESPVDYDGGR 69944000 0 69944000 
GETDLIQK 18466000 0 18466000 
GETLGLIGFGR 7686100 0 7686100 
GETVNDCHAEIISR 48799000 0 48799000 
GETVPLDVLQIK 20304000 0 20304000 
GEVDEEDAALYR 3682400 0 3682400 
GEVFNELVGK 25988000 0 25988000 
GFAFVQYVNER 104410000 0 104410000 
GFAFVTFDDHDSVDK 199140000 0 199140000 
GFAFVTFDDHDTVDK 113540000 0 113540000 
GFAFVYFENVDDAK 3246800 0 3246800 
GFALVGVGSEASSK 5108000 0 5108000 
GFAVSER 100660000 4013400 96649000 
GFCFITFK 65748000 0 65748000 
GFCFLEYEDHK 61178000 0 61178000 
GFDILGIKPVQR 18739000 0 18739000 
GFDQDMANK 26981000 0 26981000 
GFDVFNALDLMENK 1877700 0 1877700 
GFELTFK 1067300 0 1067300 
GFGFGLVK 38426000 0 38426000 
GFGFVDFNSEEDAK 214610000 0 214610000 
GFGFVLFK 7623800 0 7623800 
GFGFVSFER 12224000 0 12224000 
GFGFVTFDDHDPVDK 183170000 0 183170000 
 
 
286 | P a g e  
 
GFIGPGIDVPAPDMSTGER 49793000 0 49793000 
GFLNSSELSGLPAGPDR 10249000 0 10249000 
GFPTDATLDDIK 0 0 0 
GFQEDSEIR 2793100 0 2793100 
GFQEVVTPNIFNSR 7945400 0 7945400 
GFSIPECQK 27356000 0 27356000 
GFTIPEAFR 25593000 0 25593000 
GFVEIQTPK 7495200 0 7495200 
GFVPSPTSQPGGHESLVDR 0 0 0 
GFVQVDDGR 22808000 0 22808000 
GGADLFVENMPGFPDNIR 10444000 0 10444000 
GGADVNIR 22139000 0 22139000 
GGDCLTSQTR 6298900 0 6298900 
GGEIQPVSVK 106160000 0 106160000 
GGELVYTDSEAR 2683100 0 2683100 
GGGPAGAGGEAPAALR 14646000 0 14646000 
GGIMLPEK 45973000 0 45973000 
GGIVGMTLPIAR 70526000 0 70526000 
GGKPEPPAMPQPVPTA 29817000 0 29817000 
GGLGYVEETSEFEAR 0 0 0 
GGLQEVAEQLELER 0 0 0 
GGPEVQQVPAGER 27563000 0 27563000 
GGPNYQEGLR 39694000 0 39694000 
GGSWIQEINVAEK 47359000 0 47359000 
GGVVGIK 0 0 0 
 
 
287 | P a g e  
 
GGWGISPR 18314000 0 18314000 
GGYFDEFGIIR 8834900 0 8834900 
GHLENNPALEK 394780000 0 394780000 
GHYTEGAELVDSVLDVVR 0 0 0 
GIAAQPLYAGYCNHENM 0 0 0 
GIAPGDER 60432000 1445100 58987000 
GIATNDVGIQK 3447700 0 3447700 
GICECGVCK 3442700 0 3442700 
GIDPFSLDSLAK 36596000 0 36596000 
GIEMSEVR 0 0 0 
GIFGFTDSDCIGK 170040000 0 170040000 
GIFGSSAVPQPK 0 0 0 
GIIGYDV 0 0 0 
GILAADESTGSIAK 16088000 0 16088000 
GILEQGWQADSTTR 569580 0 569580 
GINAGQLPAPK 55674000 0 55674000 
GIQEEMEALVK 10827000 0 10827000 
GISCMNTTLSESPFK 38169000 0 38169000 
GISDPLTVFEQTEAAAR 0 0 0 
GISEETTTGVHNLYK 46567000 0 46567000 
GISLNPEQWSQLK 25678000 0 25678000 
GISQEQMQEFR 18648000 0 18648000 
GITFDSGGISIK 0 0 0 
GITPLLER 12763000 0 12763000 
GIVDQSQQAYQEAFEISK 971480000 6373000 965110000 
 
 
288 | P a g e  
 
GIVFEDVK 2034300 0 2034300 
GIVLLEELLPK 16591000 0 16591000 
GIVNEQFLLQR 31589000 0 31589000 
GIYAVGDVCGK 0 0 0 
GIYFADMVSK 74329000 0 74329000 
GLALGIAK 0 0 0 
GLALWEAYR 4801800 0 4801800 
GLAPDLPEDLYHLIK 43162000 0 43162000 
GLCAIAQAESLR 62907000 0 62907000 
GLDNTEFQGK 2210500 0 2210500 
GLEALLADPQQK 0 0 0 
GLEVTAYSPLGSSDR 9858000 0 9858000 
GLFDEYGSK 0 0 0 
GLFIIDDK 68952000 0 68952000 
GLFIIDGK 28870000 0 28870000 
GLFTGLTPR 0 0 0 
GLGAGAGAGEESPATSLPR 14433000 0 14433000 
GLGDCLVK 397250000 0 397250000 
GLGILSLK 0 0 0 
GLLLYGPPGTGK 0 0 0 
GLLPQLLGVAPEK 56817000 0 56817000 
GLLQTEPQNNQAK 61868000 0 61868000 
GLNVDQLNMLGEK 8140700 0 8140700 
GLQEGYENSR 0 0 0 
GLQQQNSDWYLK 0 0 0 
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GLQTSQDAR 1613500 0 1613500 
GLSEDVSISK 7041500 0 7041500 
GLSFSEATASNLVK 0 0 0 
GLSSLLCNFTK 53122000 0 53122000 
GLSSLLYGSIPK 6557000 0 6557000 
GLTPSQIGVILR 106780000 0 106780000 
GLTSVINQK 794440000 0 794440000 
GLVEPVDVVDNADGTQTVNYVPSR 0 0 0 
GLVGEIIK 64361000 0 64361000 
GLVGEIIKR 0 0 0 
GLVLGPIHK 15558000 0 15558000 
GLYCYELDEK 11588000 11588000 0 
GLYDGPVCEVSVTPK 28247000 0 28247000 
GMGLSLMR 0 0 0 
GMSAEYSFPIWK 4732900 0 4732900 
GMTSLQCDCTEK 6076600 0 6076600 
GMTTVDDFFQGTK 147100000 0 147100000 
GMYDGPVFDLTTTPK 164340000 0 164340000 
GNAGGIQPDLLISLTAPK 37678000 0 37678000 
GNDIIAAAK 14633000 0 14633000 
GNDISSGTVLSDYVGSGPPK 114280000 0 114280000 
GNDTPLALESTNTEK 6836000 0 6836000 
GNEFFCEVDEDYIQDK 5969100 0 5969100 
GNEIVLSAGSTPR 19359000 0 19359000 
GNENANGAPAITLLIR 18763000 0 18763000 
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GNILIPGINEAVAAVTEEEHK 4071500 0 4071500 
GNLANVIR 141560000 0 141560000 
GNPTVEVDLFTSK 65406000 0 65406000 
GNVGFVFTK 0 0 0 
GPAAAQGSAAAPAEPK 28762000 0 28762000 
GPCIIYNEDNGIIK 0 0 0 
GPCVSENEIGTGGTCQWK 2803500 0 2803500 
GPDGLTAFEATDNQAIK 8277200 0 8277200 
GPDWILGEIK 53112000 0 53112000 
GPFADENFK 24372000 0 24372000 
GPGDGAEEDEAASGGPGGR 11840000 0 11840000 
GPGLYYVDSEGNR 42160000 0 42160000 
GPLGPNWK 8995600 0 8995600 
GPLMMYISK 28965000 0 28965000 
GPNSEDLNR 917150 0 917150 
GPNVVGPYGLLQPFADAMK 6869500 0 6869500 
GPPCGPVNCNEK 4416000 0 4416000 
GPQLVCTGSDDGTVK 6374500 0 6374500 
GPSGCVESLEVTCR 4840300 0 4840300 
GPSGGGEEPALSQYQR 8000100 0 8000100 
GPSSVEDIK 86262000 0 86262000 
GPVEGYEENEEFLR 0 0 0 
GPVFAGDVSSSVR 6085400 0 6085400 
GPWTCVGDMNR 6593400 0 6593400 
GQAFVIFK 42173000 0 42173000 
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GQAVDYEGSR 56925000 0 56925000 
GQCDLELINVCNENSLFK 2235100 0 2235100 
GQESAGIVTSDGSSVPTFK 0 0 0 
GQEVETSVTYYR 11429000 0 11429000 
GQFSTDELVAEVEK 164740000 0 164740000 
GQFSTDELVAEVEKR 32562000 0 32562000 
GQGSMDEGTADER 7465300 0 7465300 
GQGSVSASVTEGQQNEQ 0 0 0 
GQISETLK 6895200 0 6895200 
GQLCELSCSTDYR 33682000 0 33682000 
GQLESIVENIR 40461000 0 40461000 
GQQQVFK 7576800 0 7576800 
GQTPGGAQFVGLELYK 15717000 0 15717000 
GQVLNIQMR 19242000 0 19242000 
GSAITGPVAK 52564000 0 52564000 
GSAPPGPVPEGSIR 85392000 0 85392000 
GSDFDCELR 100820000 0 100820000 
GSELQLPFQACLK 0 0 0 
GSELQNYFTK 0 0 0 
GSFSEQGINEFLR 220980000 0 220980000 
GSIDEVDKR 12222000 0 12222000 
GSIVWQEVFDDK 4976000 0 4976000 
GSLESPATDVFGSTEEGEKR 0 0 0 
GSLLFTAGPLEEER 15848000 0 15848000 
GSLVAPDR 10746000 0 10746000 
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GSNSLPLLR 19060000 0 19060000 
GSNTCELIFEDCK 2146200 0 2146200 
GSNTIASAAADK 62793000 0 62793000 
GSPLVVISQGK 45544000 0 45544000 
GSSASLVLK 162140000 0 162140000 
GSSDVDQLGK 13516000 0 13516000 
GSTAPVGGGAFPTIVER 139560000 0 139560000 
GSVSCPTCQAVGR 1555200 0 1555200 
GTAFGGWK 0 0 0 
GTAVAICR 0 0 0 
GTAVVNGEFK 115240000 0 115240000 
GTAYVVYEDIFDAK 24207000 0 24207000 
GTDIMYTGTLDCWR 32597000 0 32597000 
GTEASSGTEAATGLEGEEK 4934500 0 4934500 
GTEDITSPHGIPLDLLDR 34660000 0 34660000 
GTFDNAETK 25761000 0 25761000 
GTGGVDTAATGGVFDISNLDR 37784000 0 37784000 
GTGGVDTAAVGGVFDVSNADR 330400000 0 330400000 
GTGIVSAPVPK 161330000 0 161330000 
GTGLQPGEEELPDIAPPLVTPDEPK 20555000 0 20555000 
GTIQVITQGTSLK 14104000 0 14104000 
GTLDPVEK 51016000 0 51016000 
GTMVTIEGPR 13673000 0 13673000 
GTPLISPLIK 90586000 0 90586000 
GTQVYSPEK 13161000 0 13161000 
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GTRDDEYDYLFK 30251000 0 30251000 
GTTAVLTEK 50663000 0 50663000 
GTVEPQLEAR 69943000 1750400 68192000 
GTVQGQLQGPISK 10220000 0 10220000 
GTYQGLTATVLK 0 0 0 
GVAPLWMR 70405000 0 70405000 
GVDDLDFFIGDEAIEKPTYATK 13829000 0 13829000 
GVDIVMDPLGGSDTAK 165630000 0 165630000 
GVDLHEQSQQNK 20091000 0 20091000 
GVDLQENNPASR 191780000 0 191780000 
GVDLTEPTQPTR 26123000 0 26123000 
GVDLVLNSLAEEK 70053000 0 70053000 
GVEAVGSYAENQR 17176000 0 17176000 
GVEEEEEDGEMR 0 0 0 
GVEEEEEDGEMRE 15925000 0 15925000 
GVESVFDIMEMEDEER 1868300 0 1868300 
GVETIANDVVSLATK 8017000 0 8017000 
GVEWAAFGR 0 0 0 
GVIDLIFEK 46947000 0 46947000 
GVIQAIQK 116120000 0 116120000 
GVLFGVPGAFTPGCSK 67544000 0 67544000 
GVNEDTYSGILDCAR 9721700 0 9721700 
GVNLPGAAVDLPAVSEK 3337200 0 3337200 
GVNTDSGSVCR 95638000 691690 94946000 
GVPESLASGEGAGAGLPALDLAK 11565000 0 11565000 
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GVQVETISPGDGR 0 0 0 
GVSAIVYMVDAADQEK 4901800 0 4901800 
GVTCLSFSK 7655000 0 7655000 
GVTFNVTTVDTK 0 0 0 
GVTQYYAYVTER 3522500 0 3522500 
GVTSILPVLR 11856000 0 11856000 
GVVDSDDLPLNVSR 205470000 0 205470000 
GVVDSEDLPLNISR 2578800000 98630000 2480200000 
GVVEVTHDLQK 44678000 0 44678000 
GVVPLAGTDGETTTQGLDGLSER 2710700 0 2710700 
GVVPLAGTNGETTTQGLDGLSER 29873000 0 29873000 
GWDENVYYTVPLVR 13767000 0 13767000 
GWEEGVAQMSVGQR 9810600 0 9810600 
GWPLELLCEK 199990000 0 199990000 
GWPLYLSTK 19179000 0 19179000 
GYAFNHSADFETVR 10135000 0 10135000 
GYAVLGGER 94714000 0 94714000 
GYDVIAQAQSGTGK 48381000 0 48381000 
GYGFVHFETQEAAER 0 0 0 
GYGLFAGPCK 0 0 0 
GYIWNYGAIPQTWEDPGHNDK 3472600 0 3472600 
GYLGPEQLPDCLK 508450000 0 508450000 
GYPTLLLFR 5305500 0 5305500 
GYSFTTTAER 10388000000 0 1.0388E+10 
GYSYDLEVEQAYDLAR 3929400 0 3929400 
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HALIIYDDLSK 1772000 0 1772000 
HASNMLGELR 6876900 0 6876900 
HAYTLNNNSTTK 2154600 2154600 0 
HCECSTDEVNSEDMDAYCR 24737000 0 24737000 
HCLLTCEECK 0 0 0 
HCNMVLENVK 57986000 0 57986000 
HEEFEEGCK 23513000 0 23513000 
HEELMLGDPCLK 0 0 0 
HEGLGAFYK 28971000 0 28971000 
HELIEFR 22565000 0 22565000 
HEQEYMEVR 9855300 0 9855300 
HEQNIDCGGGYVK 277920000 0 277920000 
HESQMDSVVK 7171100 0 7171100 
HETLTSLNLEK 0 0 0 
HFCPNVPIILVGNK 1683200 0 1683200 
HFILDECDK 20105000 0 20105000 
HFIMQVVCEATQCPDTR 30659000 0 30659000 
HFVALSTNTTK 99138000 0 99138000 
HFVLDECDK 5543300 0 5543300 
HGDLPDIQIK 0 0 0 
HGESAWNLENR 50617000 0 50617000 
HGLYLPTR 32197000 0 32197000 
HGVESTLER 10207000 0 10207000 
HGVIVAADSR 6258900 0 6258900 
HIDLVEGDEGR 3770000 0 3770000 
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HIYYITGETK 385520000 99268000 286250000 
HLIPAANTGESK 441760000 0 441760000 
HLLPVETQR 46133000 0 46133000 
HLMDPQVLEFLGSR 31005000 0 31005000 
HLQLAIR 238730000 0 238730000 
HLSVNDLPVGR 0 0 0 
HLTDAYFK 80574000 0 80574000 
HLTGEFEK 444590000 0 444590000 
HLTYENVER 3727200 0 3727200 
HLVDEPQNLIK 67839000 67839000 0 
HLYTLDGGDIINALCFSPNR 715680 0 715680 
HMLPSGFR 18977000 0 18977000 
HNDLDDVGK 0 0 0 
HNDMPIYEAADK 5215100 0 5215100 
HNLQDFINIK 2084200 0 2084200 
HNQLPLVIEFTEQTAPK 68926000 0 68926000 
HPDASVNFSEFSK 2501300 0 2501300 
HPDSSVNFAEFSK 6809400 0 6809400 
HPHDIIDDINSGAVECPAS 0 0 0 
HPYFYAPELLYYANK 15568000 15568000 0 
HQAQIDQYLGLVR 23054000 0 23054000 
HQEGEIFDTEK 7855500 0 7855500 
HQGVMVGMGQK 1995000000 20551000 1974500000 
HQNVQLPR 194970000 0 194970000 
HQPTAIIAK 39922000 0 39922000 
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HSGNITFDEIVNIAR 29462000 0 29462000 
HSQFIGYPITLY 0 0 0 
HSSLAGCQIINYR 35532000 0 35532000 
HSSLITPLQAVAQR 2137400 0 2137400 
HSTENDSPTNVQQ 0 0 0 
HTGPGILSMANAGPNTNGSQFFICTAK 3176200 0 3176200 
HTLADNFNPVSEER 4204400 0 4204400 
HTLNQIDSVK 25877000 25877000 0 
HVFGESDELIGQK 121900000 0 121900000 
HVGMAVAGLLADAR 33100000 0 33100000 
HVMDGSLPTSLK 2771200 0 2771200 
HVQLLGR 20782000 0 20782000 
HVTFNQVK 95993000 0 95993000 
HVTNPAFTK 20864000 0 20864000 
HWGGNVLGPK 0 0 0 
HYFQNTQGLIFVVDSNDR 4315100 0 4315100 
HYGGLTGLNK 89662000 0 89662000 
HYGPGWVSMANAGK 24670000 0 24670000 
HYLFDVQR 20015000 0 20015000 
IAAAILNTPDLR 38886000 0 38886000 
IAAANGIGR 0 0 0 
IAAEIAQAEEQAR 5544400 0 5544400 
IAAYLFK 13181000 0 13181000 
IAAYLQSDQFCK 8891300 0 8891300 
IACTTLCPVDGR 4135400 0 4135400 
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IADDKYNDTFWK 11931000 0 11931000 
IADISQVYTQNAEMR 2385300 0 2385300 
IAEFTTNLTEEEEK 0 0 0 
IAEGAQQGDPLSR 4503200 0 4503200 
IAEVDCTAER 11999000 0 11999000 
IAFAITAIK 14365000 0 14365000 
IAFGGETDEATR 27698000 0 27698000 
IAGQVAAANK 15036000 0 15036000 
IAIPGLAGAGNSVLLVSNLNPER 0 0 0 
IAIVNHDK 9279900 0 9279900 
IAIYELLFK 14042000 0 14042000 
IALLPLLQAETDR 4751300 0 4751300 
IALTDNALIAR 150740000 0 150740000 
IALYETPTGWK 6232400 0 6232400 
IALYGLGSIPDER 4701400 0 4701400 
IANPDQLLTQDVEK 4973700 0 4973700 
IAPPEAPVTGYMFGK 3281400 0 3281400 
IAPYSVEIK 42372000 0 42372000 
IAQGVSGSIQDK 7308100 0 7308100 
IASPEGQDYLK 15571000 0 15571000 
IATEAIENFR 19944000 0 19944000 
IATGQIAGVDK 0 0 0 
IATGSFLK 130250000 1623100 128630000 
IAVAAQNCYK 329940000 0 329940000 
IAVEPVNPSELPK 2746500 0 2746500 
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IAVVGEGR 12006000 0 12006000 
ICDDELILIK 5619400 0 5619400 
ICDVYNAVMDVVK 18881000 0 18881000 
ICGDIHGQYTDLLR 0 0 0 
ICGDIHGQYYDLLR 9763800 0 9763800 
ICLDILK 18932000 0 18932000 
IDATSASVLASR 30891000 0 30891000 
IDDMTAAPMDVR 29852000 0 29852000 
IDELEPR 155960000 0 155960000 
IDFYFDENPYFENK 7714900 0 7714900 
IDGGITGNMR 19228000 0 19228000 
IDGLLIDQIQR 2687900 0 2687900 
IDIIPNPQER 58146000 0 58146000 
IDINMSGFNETDDLKR 0 0 0 
IDISNVK 114940000 0 114940000 
IDISPVLLQK 21756000 0 21756000 
IDKTDYMVGSYGPR 32032000 0 32032000 
IDNLDVNR 34777000 0 34777000 
IDNSQVESGSLEDDWDFLPPK 9176600 0 9176600 
IDNSQVESGSLEDDWDFLPPKK 29010000 0 29010000 
IDPLAPLDK 14984000 0 14984000 
IDTIEIITDR 95635000 1337000 94298000 
IDVFSPVEFNK 4577000 0 4577000 
IDYGEYMDK 40143000 0 40143000 
IEAINQAIANEYEVR 0 0 0 
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IEALQNHENESVYK 13728000 0 13728000 
IECDDKGDGSCDVR 44191000 0 44191000 
IEDFLER 0 0 0 
IEDGNDFGVAIQEK 20852000 0 20852000 
IEDGNNFGVAVQEK 8017100 0 8017100 
IEDLSQQAQLAAAEK 28675000 0 28675000 
IEDYFPEFAR 22957000 0 22957000 
IEEELGSK 0 0 0 
IEELDQENEAALENGIK 0 0 0 
IEESDQGPYAIILAPTR 0 0 0 
IEEVPELPLVVEDK 61564000 0 61564000 
IEFISTMEGYK 34731000 0 34731000 
IEGDETSTEAATR 24981000 0 24981000 
IEGDMIVCAAYAHELPK 150410000 0 150410000 
IEGLLAAFPK 2900700 0 2900700 
IEGTPLETIQK 20738000 0 20738000 
IEIEQNYAK 5301300 0 5301300 
IEISELNR 17695000 17695000 0 
IENLCAMGFDR 0 0 0 
IENSLTYSK 2336100 0 2336100 
IENVVLDANCSR 5517000 0 5517000 
IENVVLVVPVK 0 0 0 
IEPSPYK 7136600 0 7136600 
IEPSVNFLK 26549000 0 26549000 
IEQLQNHENEDIYK 38867000 0 38867000 
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IETIEVMEDR 71661000 0 71661000 
IETQDIQALR 0 0 0 
IEVEKPFAIAK 0 0 0 
IEVIEIMTDR 88862000 0 88862000 
IEVLQQHENEDIYK 11718000 0 11718000 
IEWLESHQDADIEDFK 123660000 0 123660000 
IEYDCELVPR 5879900 0 5879900 
IEYNDQNDGSCDVK 17665000 0 17665000 
IEYQFFEDR 926830 0 926830 
IEYVTVTPEGFR 1968000 0 1968000 
IFANTESYLK 15760000 0 15760000 
IFAPNHVVAK 14090000 0 14090000 
IFAQDGEGQR 34622000 1099100 33523000 
IFCCHGGLSPDLQSMEQIR 183520000 0 183520000 
IFFAGDTIPK 8619900 0 8619900 
IFFDDYVACCVK 1696900 0 1696900 
IFGGLDMLAEK 125550000 0 125550000 
IFGPIWNR 18144000 0 18144000 
IFGVTTLDIVR 427970000 9315400 418650000 
IFIGTFK 0 0 0 
IFNETPINPR 0 0 0 
IFNLYPR 10524000 0 10524000 
IFSIVEQR 5217200 0 5217200 
IFSQETLTK 15113000 0 15113000 
IFTSIGEDYDER 0 0 0 
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IFVFEPPPGVK 50850000 0 50850000 
IFVGGIKEDTEEYNLR 0 0 0 
IFVGGLSPDTPEEK 15392000 0 15392000 
IFYPETTDIYDR 2871100 0 2871100 
IGADFLAR 0 0 0 
IGAEVYHNLK 67657000 0 67657000 
IGAFGYMECSAK 15746000 0 15746000 
IGALEGYR 290030000 0 290030000 
IGASFLQR 40982000 2595600 38386000 
IGASTLLSDIER 0 0 0 
IGAVNCGDDR 8653600 0 8653600 
IGDEDVGR 447110000 12578000 434530000 
IGDELDSNMELQR 7618700 0 7618700 
IGDLQAFQGHGAGNLAGLK 106060000 0 106060000 
IGDTPMVR 75856000 0 75856000 
IGDVVGSSGANQQTSGK 2335700 0 2335700 
IGEHTPSALAIMENANVLAR 0 0 0 
IGFFQGDIR 2242300 0 2242300 
IGGIGTVPVGR 880980000 24288000 856690000 
IGGVQQDTILAEGLHFR 32024000 0 32024000 
IGHPAPNFK 10465000 0 10465000 
IGIFGQDEDVTSK 0 0 0 
IGIIDGEYVVNPTR 0 0 0 
IGIIGGTGLDDPEILEGR 0 0 0 
IGLETSLR 11256000 0 11256000 
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IGLFYMDNDLITR 4662300 0 4662300 
IGLGTLQPWLHAAAR 0 0 0 
IGLINDMVR 26343000 0 26343000 
IGNCPFSQR 10798000 0 10798000 
IGPITPLEFYR 102640000 0 102640000 
IGPLGLSPK 92047000 0 92047000 
IGPYQPNVPVGIDYVIPK 14085000 0 14085000 
IGSLIDVNQSK 109660000 0 109660000 
IGTDIQDNK 9060900 0 9060900 
IGTVTSGCPSPSLK 6224200 0 6224200 
IGVLDEGK 319830000 0 319830000 
IGVNQPK 6209400 0 6209400 
IGVVGGSDFEK 0 0 0 
IHCLENVDK 18553000 0 18553000 
IHFPLATYAPVISAEK 170130000 0 170130000 
IHPVSTMVK 251060000 0 251060000 
IHQETFGK 4729300 0 4729300 
IHQIEYAMEAVK 3902000 0 3902000 
IHVSDQELQSANASVDDSR 11987000 0 11987000 
IIAEGANGPTTPEADK 25537000 0 25537000 
IIAEGANGPTTPEADKIFLER 3440000 0 3440000 
IIAPPER 8041000000 241640000 7799400000 
IIAQCLNK 19843000 0 19843000 
IICAQQCSGR 10433000 616050 9817400 
IIDDSEITKEDDALWPPPDR 42053000 0 42053000 
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IIDGLLVMR 21274000 0 21274000 
IIDISDVFR 14819000 0 14819000 
IIDSLFNTVTDK 25014000 0 25014000 
IIDVVYNASNNELVR 85657000 0 85657000 
IIEDCSNSEETVK 3227500 0 3227500 
IIENELEGFGIR 4957400 0 4957400 
IIEVGDTPK 151370000 4283800 147080000 
IIEVSGQK 29841000 0 29841000 
IIFDDFR 49567000 0 49567000 
IIGLDQVAGMSETALPGAFK 1207400 0 1207400 
IIHEDGYSEDECK 15835000 0 15835000 
IIIPEIQK 17609000 0 17609000 
IILDLISESPIK 35823000 0 35823000 
IILLAEGR 30142000 0 30142000 
IINDLLQSLR 10764000 0 10764000 
IINDNATYCR 23774000 0 23774000 
IINEPTAAAIAYGLDK 171330000 0 171330000 
IINEPTAAAIAYGLDKK 44615000 0 44615000 
IINNTENLVR 116650000 2624200 114030000 
IINPMGLLVEELK 1332400 0 1332400 
IIPGFMCQGGDFTR 2558400000 69832000 2488600000 
IIPLVVK 0 0 0 
IIPTLEEYQHYK 0 0 0 
IIQFNPGPEK 20790000 0 20790000 
IIQLIEGK 20142000 0 20142000 
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IIQLLDDYPK 1039200000 1906700 1037300000 
IISDNLTYCK 22476000 0 22476000 
IISNASCTTNCLAPLAK 1099400000 1224500 1098200000 
IISSIEQK 0 0 0 
IITEGASILR 0 0 0 
IITHPNFNGNTLDNDIMLIK 184200000 184200000 0 
IITIPPFLAYGEDGDGK 1866600 0 1866600 
IITSELYR 0 0 0 
IIVDELK 0 0 0 
IIVDELKQEVISTSSK 222900000 0 222900000 
IIVLGLLPR 16015000 0 16015000 
ILADAAAEGVPVR 26153000 0 26153000 
ILADNPR 23899000 2939000 20960000 
ILAQVVGDVDTSLPR 0 0 0 
ILATPPQEDAPSVDIANIR 82145000 0 82145000 
ILCQEEQDAYR 2820800 0 2820800 
ILDAVVAQEPLHR 3641400 0 3641400 
ILDDWGETCK 17199000 0 17199000 
ILDGMFAICGVSDSK 20778000 0 20778000 
ILDIDNVDLAMGK 20193000 0 20193000 
ILDILGETCK 0 0 0 
ILDWHVANTDK 13412000 0 13412000 
ILDYSCSQDR 7883200 3364100 4519100 
ILEAHQNVAQMSLIEAK 16725000 0 16725000 
ILEAWEMNEK 0 0 0 
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ILEDDLK 6441900 0 6441900 
ILEFFGLK 159650000 0 159650000 
ILELDQFK 0 0 0 
ILEPPEGQDEGVWK 0 0 0 
ILFEDFR 10102000 0 10102000 
ILFFNTPK 65105000 0 65105000 
ILFIFIDSDHTDNQR 2419900 0 2419900 
ILFNNAVK 30821000 0 30821000 
ILGIPVIVTEQYPK 249670000 0 249670000 
ILGLLDAYLK 30873000 0 30873000 
ILGPGLNK 492960000 1072800 491880000 
ILGTAGTEEGQK 40855000 0 40855000 
ILIEDWK 6507300 0 6507300 
ILILGLDGAGK 48140000 0 48140000 
ILILQGLK 15537000 0 15537000 
ILITTVPPNLR 9850500 0 9850500 
ILLEAAR 12957000 0 12957000 
ILLLGLDNAGK 30244000 0 30244000 
ILLNYLPLER 1723100 0 1723100 
ILMLGLDAAGK 51696000 0 51696000 
ILMVGLDAAGK 215210000 0 215210000 
ILNPEEIEK 27332000 0 27332000 
ILPDILK 28758000 0 28758000 
ILPEQGLMLTGSADK 8448600 0 8448600 
ILPTLEAVAALGNK 135470000 0 135470000 
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ILQDIASGSHPFSQVLK 3892800 0 3892800 
ILQEDPTNTAAR 2528700 0 2528700 
ILQEYITQEGHK 0 0 0 
ILQVSFK 0 0 0 
ILSFIQDQEEDYLK 3028900 0 3028900 
ILSGVVTK 17411000 0 17411000 
ILTDYGFEGHPFR 35985000 0 35985000 
ILTFDQLALDSPK 97068000 0 97068000 
ILTGLNYEAPK 19255000 0 19255000 
ILTTSEDSNAQEIK 6803400 0 6803400 
ILVATNLFGR 35303000 0 35303000 
ILYLTPEQEK 24109000 0 24109000 
ILYMTDEVNDPSLTIK 49914000 0 49914000 
IMADNPSWDGEK 7290400 0 7290400 
IMASSPDMDLATVSALR 10114000 0 10114000 
IMCCVAQQASEK 14763000 0 14763000 
IMDCVGCFK 24295000 0 24295000 
IMEFTTTLLNTSPEGWK 4872500 0 4872500 
IMEIVDAITTTAQSHQR 18136000 0 18136000 
IMGPNYTPGK 45387000 0 45387000 
IMLEDGNLHVTQGAGR 0 0 0 
IMLGDEAALLEQK 37974000 0 37974000 
IMLPGVLR 56063000 0 56063000 
IMLPWDPTGK 28589000 0 28589000 
IMMLSVLK 11954000 0 11954000 
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IMQVVDEK 0 0 0 
IMVDMLDSDGSGK 0 0 0 
INDALSCEYECR 0 0 0 
INDFVLSPGPQPYK 9441300 7113300 2327900 
INELMPK 16174000 0 16174000 
INEWLTLVEK 92985000 0 92985000 
INFYCPGSALGR 3625500 0 3625500 
INGSALSPHPGLR 476260000 0 476260000 
INISEGNCPER 104200000 0 104200000 
INMNGINNSSGMVDAR 0 0 0 
INMNGVNSSNGVVDPR 6294300 0 6294300 
INNFSADIK 13286000 0 13286000 
INQILMEK 9663700 0 9663700 
INQLYEQAK 63517000 0 63517000 
INSAPQQIEVFPPFR 10204000 0 10204000 
INSITVDNCK 50910000 0 50910000 
INTQEYLDVLGR 10074000 0 10074000 
INVLAAQYQSLLNSYGEPVDDK 2464100 0 2464100 
INVSGLTTK 12236000 0 12236000 
INYTEGR 163810000 0 163810000 
IPALDLLIK 31319000 0 31319000 
IPDEIIDMVK 21656000 0 21656000 
IPDPEAVKPDDWDEDAPAK 5385200 0 5385200 
IPDWFLNR 99971000 0 99971000 
IPDYLWMGLDGMK 4472100 0 4472100 
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IPEGLFDPSNVK 1699400 0 1699400 
IPEISIQDMTAQVTSPSGK 2094800 0 2094800 
IPETLEEDQQFMLK 7637200 0 7637200 
IPGGIIEDSCVLR 8142200 0 8142200 
IPGLLGVFQK 21406000 0 21406000 
IPGSPPESMGR 84410000 0 84410000 
IPLLSDLTHQISK 15205000 0 15205000 
IPLNNGAGCR 0 0 0 
IPLNTEQK 25028000 0 25028000 
IPNPDFFEDLEPFR 23146000 0 23146000 
IPSEQEQLR 11024000 0 11024000 
IPVDTYNNILTVLK 7019000 0 7019000 
IPVENILGEVGDGFK 5259900 0 5259900 
IQASTMAFK 11021000 0 11021000 
IQDFNDTFYR 4481900 0 4481900 
IQDKEGIPPDQQR 232390000 0 232390000 
IQEAGTEVVK 691450000 0 691450000 
IQEEGTEVELTGK 14718000 14718000 0 
IQEGVFDINNEANGIK 0 0 0 
IQEPNTFPAILR 35552000 0 35552000 
IQEVADELQK 60735000 0 60735000 
IQFVGACNPPTDPGR 0 0 0 
IQGLTVEQAEAVVR 0 0 0 
IQLIFER 3092100 0 3092100 
IQLINNMLDK 72551000 0 72551000 
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IQLLVFK 9377600 0 9377600 
IQLQDAGR 12284000 0 12284000 
IQNTLHCCGVTDYR 16906000 0 16906000 
IQQEIAVQNPLVSER 0 0 0 
IQQGALELLR 2657200 0 2657200 
IQQLAISGLK 10226000 0 10226000 
IQSGQCLR 26142000 0 26142000 
IQSLLDIQEK 0 0 0 
IQSTVTQPGGK 14456000 0 14456000 
IQTLTSSVR 20880000 0 20880000 
IQTQPGYANTLR 25206000 0 25206000 
IQVLQQQADDAEER 6585500 0 6585500 
IRDEMVATEQER 16621000 0 16621000 
ISAPQER 16019000 0 16019000 
ISATSIFFESMPYK 38904000 0 38904000 
ISAVSVAER 138700000 3447500 135250000 
ISDDLMQK 12506000 0 12506000 
ISDEDWDIIHR 0 0 0 
ISDIQSQLEK 32578000 0 32578000 
ISEACSLAQQSGDHR 3530800 0 3530800 
ISEQFTAMFR 462860000 10770000 452090000 
ISESPSEIMESLTK 3346100 0 3346100 
ISGAIGPCVSLNSK 0 0 0 
ISGETIFVTAPHEATAGIIGVNR 23468000 0 23468000 
ISGLIYEETR 701940000 4408700 697530000 
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ISLGLPVGAVINCADNTGAK 177470000 0 177470000 
ISLQAIQQLVR 11260000 0 11260000 
ISNYGWDQSDK 33835000 0 33835000 
ISSDLDGHPVPK 58957000 0 58957000 
ISSIQSIVPALEIANAHR 141500000 0 141500000 
ISSMVVMENVGQQK 978490 0 978490 
ISSTLYQAAAPVLTPAK 1136800 0 1136800 
ISVAAASK 27024000 0 27024000 
ISVGSDSDLVIWDPDAVK 14172000 0 14172000 
ISVNDFIIK 33874000 0 33874000 
ITADLLSNGIDVYPQK 1421400 0 1421400 
ITAEEMYDIFGK 36547000 0 36547000 
ITAFVVER 0 0 0 
ITCLCQVPQNAANR 9972000 0 9972000 
ITDGTMLQAIER 4591500 0 4591500 
ITDVALDFWR 10351000 0 10351000 
ITEFCHR 37445000 0 37445000 
ITENIGCVMTGMTADSR 6117700 0 6117700 
ITFDDYIACCVK 55632000 0 55632000 
ITFDVAPSR 7943700 0 7943700 
ITIADCGQLE 0 0 0 
ITITNDK 371390000 3436500 367950000 
ITITNDQNR 0 0 0 
ITLPVDFVTADK 57794000 0 57794000 
ITLPVDFVTADKFDENAK 382210000 0 382210000 
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ITNNINVLIK 0 0 0 
ITNQVHGLK 10617000 0 10617000 
ITNQVIYLNPPIEECR 1186100 0 1186100 
ITPSYVAFTPEGER 0 0 0 
ITQDIFQQLLK 4363600 0 4363600 
ITSAPDMEDILTESEIK 0 0 0 
ITSDEPLTK 27190000 0 27190000 
ITSEALLVTQQLVK 35067000 0 35067000 
ITSEMGSASQANIR 10102000 0 10102000 
ITSPLMEPSSIEK 0 0 0 
ITVPGNFQGHSGAQCITCSYK 18825000 0 18825000 
ITVTSEVPFSK 54965000 0 54965000 
ITWSNPPAQGAR 9105700 0 9105700 
IVADKDYSVTANSK 685340000 0 685340000 
IVAERPGTNSTGPAPMAPPR 3950200 0 3950200 
IVALSSSLSNAK 16466000 0 16466000 
IVASTLSNPELFEEWTGNVK 14888000 0 14888000 
IVAVTGAEAQK 69036000 0 69036000 
IVCTPGQGLGDLR 8199700 0 8199700 
IVDDWANDGWGLK 124840000 0 124840000 
IVEDEPNKICEADR 23288000 0 23288000 
IVEMSTSK 251950000 0 251950000 
IVEPPENIQEK 12632000 0 12632000 
IVEWNGK 87128000 0 87128000 
IVFNLCPLQTEDDK 16470000 0 16470000 
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IVFQEFR 11923000 3165000 8757600 
IVGPSGAAVPCK 40619000 0 40619000 
IVIGLFGK 22047000 0 22047000 
IVILEYQPSK 85362000 0 85362000 
IVIVPSLNPDGR 0 0 0 
IVLANDPDADR 39684000 0 39684000 
IVLDNSVFSEHR 0 0 0 
IVLEDGTLHVTEGSGR 9015300 0 9015300 
IVLTNPVCTEVGEK 0 0 0 
IVLVDDSIVR 0 0 0 
IVNSAQTGSFK 61694000 0 61694000 
IVNSSMELAQTAK 0 0 0 
IVPGQFLAVDPK 54090000 0 54090000 
IVPNVLLEQGK 45776000 0 45776000 
IVQAEGEAEAAK 3835400 0 3835400 
IVQMTEAEVR 31663000 0 31663000 
IVVEMIK 0 0 0 
IVVFQYSDGK 29714000 0 29714000 
IVVLFYK 0 0 0 
IVVNLTGR 96537000 0 96537000 
IVVSNTPR 25081000 0 25081000 
IVVVTAGVR 746730000 13444000 733290000 
IVYLYTK 8884700 0 8884700 
IWDLEGK 0 0 0 
IWDTASGQCLK 27948000 0 27948000 
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IWGDCTVR 34425000 0 34425000 
IYADTFGDINYQEFAK 25105000 0 25105000 
IYAMHWGTDSR 11594000 0 11594000 
IYANFFPYGDASK 23229000 0 23229000 
IYDLNKPEAEPK 2865000 0 2865000 
IYELAAGGTAVGTGLNTR 11491000 0 11491000 
IYFMAGSSR 0 0 0 
IYGISFPDPK 18896000 0 18896000 
IYGLGSLALYEK 32607000 0 32607000 
IYIGDQVQK 5006200 0 5006200 
IYLDMLNVYK 16481000 0 16481000 
IYLYLTK 0 0 0 
IYNDDKNTYIR 9656600 0 9656600 
IYQIYEGTSQIQR 0 0 0 
IYQTEELR 0 0 0 
IYSYVVSR 6253700 0 6253700 
IYVISLAEPR 52003000 0 52003000 
KACADATLSQITNNIDPVGR 0 0 0 
KAEEIANEMIEAAK 0 0 0 
KALAAAGYDVEK 8894500 0 8894500 
KDCEVVMMIGLPGAGK 657010 0 657010 
KDDEVQVVR 9798600 0 9798600 
KDDPVTNLNNAFEVAEK 20857000 0 20857000 
KDLYANTVLSGGTTMYPGIADR 667900000 0 667900000 
KEAAENSLVAYK 4800500 0 4800500 
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KEGGLGPLNIPLLADVTR 1688600 0 1688600 
KESYSVYVYK 65569000 0 65569000 
KEVVEEAENGR 71172000 0 71172000 
KGDIFLVR 0 0 0 
KGIVDQSQQAYQEAFEISK 0 0 0 
KIPNPDFFEDLEPFR 23206000 0 23206000 
KITIADCGQLE 161910000 0 161910000 
KLELSDNR 61936000 0 61936000 
KPEDVLDDDDAGSAPLK 12160000 0 12160000 
KPEDWDEEMDGEWEPPVIQNPEYK 23623000 0 23623000 
KPITDDDVDR 9906400 0 9906400 
KQSLGELIGTLNAAK 26739000 0 26739000 
KQTIDNSQGAYQEAFDISK 0 0 0 
KSDVEAIFSK 9436700 0 9436700 
KVDWLTEK 0 0 0 
KVEDMMK 85073000 0 85073000 
KVESLQEEIAFLK 118240000 0 118240000 
KVMDLCFSK 1360600000 0 1360600000 
KVMHLQDVEVK 31252000 2330000 28922000 
KVPQVSTPTLVEVSR 127250000 127250000 0 
KVTGTLDANR 7097400 0 7097400 
KYDAFLASESLIK 145150000 0 145150000 
KYEDICPSTHNMDVPNIK 10568000 0 10568000 
LAAIAESGVER 22396000 0 22396000 
LAAIVAK 133870000 0 133870000 
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LAALNPESNTAGLDIFAK 25426000 0 25426000 
LAASGEGGLQELSGHFENQK 15451000 0 15451000 
LAATNALLNSLEFTK 127510000 0 127510000 
LAAVDATVNQVLASR 94415000 0 94415000 
LAAVVSACK 54977000 0 54977000 
LACDVDQVTR 206350000 18869000 187480000 
LACTSCTFVTSVGDAMAK 0 0 0 
LADFGLAR 28921000 0 28921000 
LAEAEETAR 4020000 0 4020000 
LAECCIAANK 3268100 0 3268100 
LAELCGVLK 0 0 0 
LAEQAER 1256700 0 1256700 
LAETVFNFQEK 5172800 0 5172800 
LAETYLHR 5339700 0 5339700 
LAEVGQYEQVK 23825000 0 23825000 
LAFLNVQAAEEALPR 32581000 7071000 25510000 
LAGEELAGEEAPQEK 3726500 0 3726500 
LAGESESNLR 47977000 0 47977000 
LAGFLDLTEQEFR 18054000 0 18054000 
LAGTQPLEVLEAVQR 10275000 0 10275000 
LALFNPDVCWDR 112670000 4057500 108610000 
LALGDDSPALK 47835000 0 47835000 
LALGIPLPELR 1890600 0 1890600 
LALLAHPR 83760000 0 83760000 
LAMQEFMILPVGAANFR 3445800 0 3445800 
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LANDAAQVK 26094000 0 26094000 
LANILFTQELAR 16673000 0 16673000 
LAPEYEK 12593000 0 12593000 
LAPGTIVEVWK 0 0 0 
LAPITSDPTEATAVGAVEASFK 9503100 0 9503100 
LAQAAQSSVATITR 0 0 0 
LAQFEPSQR 16216000 0 16216000 
LAQLAGDHECGSSSQR 0 0 0 
LAQLDDVK 75115000 0 75115000 
LAQLEEAK 197250000 0 197250000 
LAQMFSDMVLK 33637000 0 33637000 
LAQQISDEASR 6283000 0 6283000 
LAQVSPELLLASVR 13272000 0 13272000 
LASALDLPLLR 0 0 0 
LASDLLEWIR 23970000 0 23970000 
LASEEPPDDEEALATIR 6207200 0 6207200 
LASGEDDPFDSDFSCPVK 1213900 0 1213900 
LASQANIAQVLAELK 14264000 0 14264000 
LASTLVHLGEYQAAVDGAR 0 0 0 
LASVLGSEPSLDSEVTSK 0 0 0 
LATALQK 17830000 0 17830000 
LATQLTGPVMPVR 20365000 0 20365000 
LAVDEEENADNNTK 22154000 0 22154000 
LAVEALSSLDGDLAGR 23986000 0 23986000 
LAVNMVPFPR 540920000 0 540920000 
 
 
318 | P a g e  
 
LAVNNIAGIEEVNMIK 5787500 0 5787500 
LAVSAQSEPAR 0 0 0 
LAVVDPLFGMQPIR 63341000 0 63341000 
LAYINPDLALEEK 10144000 0 10144000 
LCAAAASILGK 7185200 0 7185200 
LCDEQLSSQSHYDFGLR 0 0 0 
LCFSTAQHAS 0 0 0 
LCGDTSLNNMQR 48495000 0 48495000 
LCGQDLNK 22699000 0 22699000 
LCIEVTPQSK 0 0 0 
LCLISTFLEDGIR 11747000 0 11747000 
LCMSLMQNK 10356000 0 10356000 
LCQIFSDLNATYR 1580800 0 1580800 
LCSLFYTNEEVAK 0 0 0 
LCSLLDSEDYNTCEGAFGALQK 16525000 0 16525000 
LCTSATESEVAR 15624000 0 15624000 
LCVLHEK 27033000 27033000 0 
LCVQNSPQEAR 0 0 0 
LCYDAFTENMAGENQLLER 2439800 0 2439800 
LCYVALDFEQEMATAASSSSLEK 6283200 0 6283200 
LCYYIGATDDAATK 0 0 0 
LDDFVETGDIR 1775900 0 1775900 
LDECEEAFQGTK 9043700 0 9043700 
LDEFGEQLSK 11354000 0 11354000 
LDELEELLTNNR 51696000 0 51696000 
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LDEQYQK 0 0 0 
LDFGNSQGK 17441000 0 17441000 
LDFVCSFLQK 22127000 0 22127000 
LDGEASINNR 115100000 2728800 112370000 
LDGFPLLR 11077000 0 11077000 
LDGFSVLMR 22273000 0 22273000 
LDGNLLTQPGQAR 0 0 0 
LDHVVTIIK 14012000 0 14012000 
LDILDMFTEIK 930790 0 930790 
LDLQQGQNLLQGLSK 0 0 0 
LDNLMLELDGTENK 5248600 0 5248600 
LDNLVAILDINR 3191800 0 3191800 
LDPHLVLDQLR 41437000 0 41437000 
LDPSIFESLQK 4390000 0 4390000 
LDQPMTEIVSR 13161000 0 13161000 
LDQVSSEIK 0 0 0 
LDSSAVLDTGK 77795000 0 77795000 
LDTAMWLSR 5451500 0 5451500 
LDTMNTTCVDR 69971000 0 69971000 
LDVGNAEVK 41956000 0 41956000 
LDVPQNLMFGK 27150000 0 27150000 
LDVQFSGLTK 4942100 0 4942100 
LDYGQHVVAGTPGR 41039000 0 41039000 
LDYILGLK 140890000 0 140890000 
LDYLSSLK 33982000 0 33982000 
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LEAADEGSGDVK 3166700 0 3166700 
LEAEIATYRR 12782000 0 12782000 
LEAGDYADLVK 3982500 0 3982500 
LEAIEDDSVKETDSSSASAATPSK 0 0 0 
LEALEEK 21000000 0 21000000 
LEALSVK 16140000 0 16140000 
LEATGELVDK 18430000 0 18430000 
LECSEELGDLVK 0 0 0 
LECVEPNCR 15868000 0 15868000 
LEDCTPQR 62894000 0 62894000 
LEDLVCDVVDR 51954000 0 51954000 
LEDSEVR 17101000 0 17101000 
LEEDAEMK 0 0 0 
LEELTMDGAK 0 0 0 
LEELYTK 78973000 0 78973000 
LEEPESTK 7290000 0 7290000 
LEETLPVIR 0 0 0 
LEGGSGGDSEVQR 14120000 0 14120000 
LEGNSPQGSNQGVK 3154700 0 3154700 
LEGQGDVPTPK 12540000 0 12540000 
LEGQMGEDGNSIK 9408000 0 9408000 
LEGTNVQEAQK 6543600 0 6543600 
LELEAAQK 14251000 0 14251000 
LELFLPEEYPMAAPK 1779900 0 1779900 
LELNYCVPMGVQTGDR 3612000 0 3612000 
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LEMDYYQLR 41703000 0 41703000 
LEMYVLNPVK 0 0 0 
LENDQIESLR 0 0 0 
LENEHLNNCGEFR 7125500 0 7125500 
LENGEIETIAR 0 0 0 
LENPDEACAVSQK 1757900 0 1757900 
LENYPIPEPGPNEVLLR 10702000 0 10702000 
LEQGQAIDDLMPAQK 40561000 0 40561000 
LEQLASR 95430000 0 95430000 
LEQSEAQLGR 13112000 0 13112000 
LESCGVTSDNCR 9120100 0 9120100 
LESEEEGVPSTAIR 7111800 0 7111800 
LETHMTPEMFR 23270000 0 23270000 
LETLGIGQR 8807000 0 8807000 
LEVEANNAFDQYR 3072800 0 3072800 
LEVNIDR 131500000 0 131500000 
LEVQATDREENK 1781900 0 1781900 
LEYCEALAMLR 102520000 0 102520000 
LFCVGFTK 23816000 0 23816000 
LFDDCTQQFK 0 0 0 
LFDFVNAK 32563000 0 32563000 
LFDHPESPTPNPTEPLFLAQAEVYK 6426600 0 6426600 
LFDSICNNK 42723000 0 42723000 
LFEFAGYDVLR 45081000 8044700 37036000 
LFEGNALLR 120230000 0 120230000 
 
 
322 | P a g e  
 
LFELLEK 22916000 0 22916000 
LFEVGGSPANTR 0 0 0 
LFFPVIYDVK 6015400 0 6015400 
LFFVGSR 4777000 0 4777000 
LFFWMQEPK 20471000 0 20471000 
LFGAAEVQR 15660000 0 15660000 
LFGNMEGDCPSDWK 0 0 0 
LFGQESGPSAEK 30879000 0 30879000 
LFGYEMAEFK 8032100 0 8032100 
LFGYEPTIYYPK 105320000 0 105320000 
LFIYNPTTGEFLGR 15443000 0 15443000 
LFLAGYDPTPTMR 41950000 5429500 36521000 
LFLNETQTQEITEDIPVK 12440000 0 12440000 
LFLVQLQEK 52509000 0 52509000 
LFNTAVCESK 12951000 0 12951000 
LFPDTPLALDANK 5004700 0 5004700 
LFPGFEIETVK 71071000 0 71071000 
LFPNMLPSTFETQSLK 6581800 0 6581800 
LFQECCPHSTDR 154020000 1022700 153000000 
LFQEDDEIPLYLK 67034000 0 67034000 
LFQPNLNMDR 17719000 0 17719000 
LFQSNDQTLR 2390000 0 2390000 
LFQSVAQCCMGQK 0 0 0 
LFSDEAANIYER 5103300 0 5103300 
LFSQETVMK 48605000 0 48605000 
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LFSSVTFETVEESK 0 0 0 
LFTAESLIGLK 0 0 0 
LFTEVEGTCTGK 20731000 0 20731000 
LFTFHADICTLPDTEK 38003000 38003000 0 
LFTLTALR 14370000 0 14370000 
LFTTMELMR 25898000 0 25898000 
LFVGNLPADITEDEFK 19599000 0 19599000 
LFVGNLPPDITEEEMR 36789000 0 36789000 
LFVGSIPK 16986000 0 16986000 
LFVVPADEAQAR 8046400 0 8046400 
LGAQALLGAAK 5287500 0 5287500 
LGAVDESLSEETQK 41226000 0 41226000 
LGAVFNQVAFPLQYTPR 3922800 0 3922800 
LGDLLISQFSGPSAEQMCK 0 0 0 
LGDLYEEEMR 36953000 0 36953000 
LGDPEELMFQYFK 6314200 0 6314200 
LGEDLNK 23055000 0 23055000 
LGEHNIDVLEGNEQFINAAK 1650900000 1650900000 0 
LGEHNIEVLEGNEQFINAAK 116600000 116600000 0 
LGELPSWILMR 4967200 0 4967200 
LGEMWNNLNDSEK 8581400 0 8581400 
LGEMWNNTAADDK 1595700 0 1595700 
LGEMWNNTAADDKQPYEK 233060000 0 233060000 
LGEMWSEQSAK 57713000 0 57713000 
LGEQVFGTTGK 0 0 0 
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LGEYGFQNALIVR 36518000 36518000 0 
LGFEEFK 12509000 0 12509000 
LGGIGQFLAK 111180000 0 111180000 
LGGSLADSYLDEGFLLDK 10065000 0 10065000 
LGGSPFGPAGTGK 66656000 0 66656000 
LGGSPTSLGTWGSWIGPDHDK 16850000 0 16850000 
LGGSQEDQIK 25053000 0 25053000 
LGGTCVNVGCVPK 18480000 0 18480000 
LGIGQSQEMNTLFR 28224000 0 28224000 
LGIHEDSQNR 1538200000 34964000 1503200000 
LGIHEDSTNR 1741400000 93951000 1647400000 
LGLDYEER 15003000 0 15003000 
LGLENAEALIR 34546000 0 34546000 
LGLPPLTPEQQEALQK 17414000 0 17414000 
LGLQNDLFSLAR 7119900 0 7119900 
LGLSIPDLTPK 895970 0 895970 
LGMLSPEGTCK 103230000 0 103230000 
LGNNCVFAPADVTSEK 0 0 0 
LGNPIVPLNIR 18383000 0 18383000 
LGNTISSLFGGGTTPDAK 36479000 0 36479000 
LGNYAGAVQDCER 8875100 0 8875100 
LGPALATGNVVVMK 19322000 0 19322000 
LGPEGELLIR 0 0 0 
LGPLLDILADSR 9806600 0 9806600 
LGPNDQYK 152550000 0 152550000 
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LGQASLGVIK 12507000 0 12507000 
LGQEATVGK 15148000 0 15148000 
LGQIYQSWLDK 38478000 0 38478000 
LGSAVVTR 4578600 0 4578600 
LGVELGLK 419750000 0 419750000 
LGVENCYFPMFVSQSALEK 26573000 0 26573000 
LGVIEDHSNR 756160000 9295400 746870000 
LGVTANDVK 142310000 0 142310000 
LGYILTCPSNLGTGLR 23123000 0 23123000 
LGYTPVCR 50215000 0 50215000 
LHEEGIIYR 6746400 0 6746400 
LIAEEGVDSLNVK 0 0 0 
LIAEQPPHLTPGIR 3725800 0 3725800 
LIAINANDPEASK 8828900 0 8828900 
LIANMPESGPSYEFHLTR 34687000 0 34687000 
LIANNTTVER 0 0 0 
LIAPVAEEEATVPNNK 3739100 0 3739100 
LICCDILDVLDK 133570000 1167100 132400000 
LIDDMVAQAMK 221500000 0 221500000 
LIDDMVAQVLK 38730000 0 38730000 
LIDFLESGK 0 0 0 
LIDVLENR 0 0 0 
LIEGLSHEVIVSAACGR 8701100 0 8701100 
LIEVANLACSISNNEEGVK 3206300 0 3206300 
LIFYDLR 12572000 0 12572000 
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LIINELSNVMEANAAR 12865000 0 12865000 
LIINSLYK 57154000 0 57154000 
LIIWDSYTTNK 195310000 0 195310000 
LILDLSMK 17051000 0 17051000 
LILIESR 149140000 0 149140000 
LIMAMQTLIPIDEAK 6089400 0 6089400 
LIPTLVSIMQAPADK 25666000 0 25666000 
LIPVLVNGMK 0 0 0 
LIQEQHPEEELIK 11854000 0 11854000 
LIQESPTLSK 2420200 0 2420200 
LIQQQLEK 11956000 0 11956000 
LIQYCQSK 65159000 0 65159000 
LISTLIYK 12977000 0 12977000 
LISWYDNEFGYSNR 502160000 13140000 489020000 
LITEDVQGK 110190000 6385600 103800000 
LITPAEK 14592000 0 14592000 
LITPAVVSER 204550000 0 204550000 
LITTQQWLIK 64578000 0 64578000 
LIVDEAINEDNSVVSLSQPK 68262000 0 68262000 
LIVDHNIADYMTAK 11226000 0 11226000 
LKDDEVAQLK 70194000 0 70194000 
LKPDPNTLCDEFK 0 0 0 
LLADQAEAR 79381000 0 79381000 
LLAEMSSFCGDMEK 56594000 0 56594000 
LLALNSLYSPK 31078000 0 31078000 
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LLAPDCEIIQEVGK 16686000 0 16686000 
LLAQDQGQGAPLLEPAP 0 0 0 
LLATGSQDR 10581000 0 10581000 
LLCGLLAER 860320000 3229800 857090000 
LLCTVAR 14333000 0 14333000 
LLDEVFFSEK 147210000 0 147210000 
LLDSITVPVAR 0 0 0 
LLDSSTVTHLFK 23009000 0 23009000 
LLDSWFTSTQEK 5931700 0 5931700 
LLDVDNR 153680000 0 153680000 
LLDVTGGLGTDELR 11183000 0 11183000 
LLDYVPIGPR 5066000 0 5066000 
LLEAAITPETK 7378800 0 7378800 
LLEEALLR 24250000 0 24250000 
LLEELEEGQK 9778600 0 9778600 
LLEGEESR 146830000 0 146830000 
LLELFPVNR 10093000 0 10093000 
LLEPVLLLGK 31861000 0 31861000 
LLEQGLR 168150000 0 168150000 
LLESGDLSMSSIK 0 0 0 
LLETECPQYIR 0 0 0 
LLEVVQPCLQAAK 0 0 0 
LLEVYDQLFK 31739000 0 31739000 
LLEYDTVTR 48448000 0 48448000 
LLFEGAGSNPGDK 8081500 0 8081500 
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LLFPAVDDNLLK 50825000 0 50825000 
LLGAALPLLTK 3918000 0 3918000 
LLGELLQDNAK 18611000 7146400 11464000 
LLGMGDIEGLIDK 2684600 0 2684600 
LLGPNASPDGLIPWTR 7893300 0 7893300 
LLGQFSEK 41107000 0 41107000 
LLGWIQNK 38542000 0 38542000 
LLHVAVSDVNDDVR 0 0 0 
LLIAAQK 10104000 0 10104000 
LLIDEAILK 53450000 0 53450000 
LLIEMEQR 284050000 0 284050000 
LLILADMADVYK 15868000 0 15868000 
LLILALER 3473500 0 3473500 
LLIVSTTPYSEK 1874600 0 1874600 
LLLDTFEYQGLVK 11026000 0 11026000 
LLLIDWPELK 539010 0 539010 
LLLIGDSGVGK 146800000 0 146800000 
LLLLAGVDR 0 0 0 
LLLLGAGESGK 51303000 0 51303000 
LLLLGTGESGK 0 0 0 
LLLNLAENPAMTR 8224500 0 8224500 
LLLNNDNLLR 9779000 0 9779000 
LLLNNGAK 107780000 1882300 105890000 
LLLPGELAK 127750000 0 127750000 
LLLPWLEAR 134600000 0 134600000 
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LLLQVQHASK 52651000 0 52651000 
LLLSIPHSDLLDYPK 3913400 0 3913400 
LLLSSETPIEGK 14507000 0 14507000 
LLLWDTKTMK 0 0 0 
LLMLGLDNAGK 0 0 0 
LLMMAGIDDCYTSAR 23925000 0 23925000 
LLNCSDFAFTDMTK 5788700 0 5788700 
LLNDSGLTGSK 3942100 0 3942100 
LLNFPTIVER 41759000 0 41759000 
LLPDDPYEK 18911000 0 18911000 
LLPEQLIK 3893800 0 3893800 
LLPQLTYLDGYDR 1032100000 36314000 995810000 
LLPQLTYLDGYDRDDK 46497000 0 46497000 
LLQAPDTDLR 12243000 0 12243000 
LLQDFFNGK 252530000 0 252530000 
LLQDFFNGR 81814000 0 81814000 
LLQQEEEIK 33952000 0 33952000 
LLQSIGQAPESISEK 1942700 0 1942700 
LLQTGQER 6481000 0 6481000 
LLSEGADVNAK 7515400 0 7515400 
LLSGGSVLDIIK 57105000 0 57105000 
LLSLSSLYSPK 6420800 6420800 0 
LLSNDEVTIK 64142000 0 64142000 
LLSPTER 12391000 0 12391000 
LLSQEPSNGISSDPTVFLDR 0 0 0 
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LLTAEADK 12282000 0 12282000 
LLTDDGNK 43670000 0 43670000 
LLTEEGQK 7612200 0 7612200 
LLTFYNLADCIAEK 1274100 0 1274100 
LLVGLVQSR 0 0 0 
LLVPILLPEK 79308000 0 79308000 
LLVSASQDGK 461340000 0 461340000 
LLVTDMSDAEQYR 0 0 0 
LLWIDTK 53763000 0 53763000 
LLYEALVDCK 173330000 0 173330000 
LLYFMMFLKR 20661000 0 20661000 
LLYNNVSNFGR 7513500 0 7513500 
LLYVTPEK 33364000 0 33364000 
LMCPQEIVDYIADK 7626200 0 7626200 
LMDEAVLALR 5003500 0 5003500 
LMDEVAGIVAAR 86648000 0 86648000 
LMDLLADSR 0 0 0 
LMEDLDR 31226000 0 31226000 
LMELFPANK 24677000 0 24677000 
LMIEMDGTENK 7150300 0 7150300 
LMLAQDEER 39153000 5813800 33339000 
LMLISMANDLK 123120000 0 123120000 
LMMDPLSGQNR 11689000 0 11689000 
LMMDPLTGLNR 63682000 0 63682000 
LMMLQSCSGPTCR 0 0 0 
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LMNDMTAVALNYGIYK 21811000 0 21811000 
LMQGDEICLR 6522300 0 6522300 
LMSSGNEESLR 7885800 0 7885800 
LMSSNSTDLPLNIECFMNDKDVSGK 0 0 0 
LMTDTINEPILLCR 24951000 0 24951000 
LMTTGNNTVR 23122000 0 23122000 
LMVEPLQAILIR 1277000 0 1277000 
LMVMEIR 0 0 0 
LMVSMLDR 21763000 0 21763000 
LNAIYQNNLTK 0 0 0 
LNDGNEYLFQAK 878270 0 878270 
LNDYIFSFDK 5551100 0 5551100 
LNEAQPSTIATSMR 1893100 0 1893100 
LNECVDHTPK 62235000 0 62235000 
LNEILQAR 5104300 0 5104300 
LNEQASEEILK 0 0 0 
LNESTFDTQITK 66132000 0 66132000 
LNFELTDALK 10516000 0 10516000 
LNGDFAQLNLK 5631500 0 5631500 
LNILDTLSK 104530000 0 104530000 
LNIPATNVFANR 0 0 0 
LNIQPSEADYAVDIR 0 0 0 
LNLGTVGFYR 0 0 0 
LNLYELK 9275200 0 9275200 
LNMTPEEAER 48451000 0 48451000 
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LNNLVLFDK 236880000 0 236880000 
LNPEDIK 18582000 0 18582000 
LNQVCFDDDGTSSPQDR 15089000 0 15089000 
LNQVIFPVSYNDK 0 0 0 
LNQYFQK 194290000 0 194290000 
LNSGVDYR 15955000 0 15955000 
LNSLMSLVNK 50483000 0 50483000 
LNTLLQR 109870000 0 109870000 
LNVCVSK 14326000 0 14326000 
LNVEGEHCDVCK 0 0 0 
LNVTEQEK 321760000 0 321760000 
LNVWDLSK 10141000 0 10141000 
LNWTGTSK 15927000 0 15927000 
LPAAGVGDMVMATVK 155760000 0 155760000 
LPAIALDLLR 1713900 0 1713900 
LPCIFICENNR 5440800 0 5440800 
LPEADDIQYPSMLLLTADHDDR 7804700 0 7804700 
LPEGDLGK 74149000 0 74149000 
LPENYTDETWQK 7753100 0 7753100 
LPESNQTLLR 4234000 0 4234000 
LPETNLFETEETR 1636500 0 1636500 
LPFAAAQIGNSFR 0 0 0 
LPFPIIDDR 862260000 25962000 836300000 
LPGAICSLTCGGADIGTAMAK 8790100 0 8790100 
LPGLLGNFPGPFEEEMK 6904400 0 6904400 
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LPLISGFYK 17447000 0 17447000 
LPLPEPWR 26070000 0 26070000 
LPLQDVYK 331910000 0 331910000 
LPLQLDDAVRPEAEGEEEGR 18862000 0 18862000 
LPNFGFVVFDDSEPVQK 5058100 0 5058100 
LPPNTNDEVDEDPTGNK 8771900 0 8771900 
LPPTPLLLFPEEEATNGR 2938400 0 2938400 
LPQLPITNFSR 5433000 0 5433000 
LPQPPEGQCYSN 0 0 0 
LPQPPEGQTYNN 0 0 0 
LPTDLTACDNR 49777000 1262000 48515000 
LPVLAGCLK 0 0 0 
LPVPESITGFAR 86378000 0 86378000 
LQAASPELTQAAIMEK 3671900 0 3671900 
LQAENDASKEEVK 10383000 0 10383000 
LQAFSAAIESCNK 1777300 0 1777300 
LQDAEIAR 127380000 0 127380000 
LQDAINILK 14908000 0 14908000 
LQDAYYIFQEMADK 8495200 0 8495200 
LQDEEASMGASYSK 2373600 0 2373600 
LQDEFENR 3647800 0 3647800 
LQDEIQNMK 138520000 0 138520000 
LQDEIQNMKEEMAR 16603000 0 16603000 
LQDLVNR 4154200 0 4154200 
LQEEINEVK 8366500 0 8366500 
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LQEEMLQR 175640000 0 175640000 
LQEEYWDLQDMLTNR 4213000 0 4213000 
LQELSAEER 0 0 0 
LQETEMMDPELDYTLMR 3432600 0 3432600 
LQETLSAADR 14527000 0 14527000 
LQETTLVANQLR 4570500 0 4570500 
LQEVPHEGPMCDLLWSDPDDR 3315500 0 3315500 
LQGETLDQQLGR 1996000 0 1996000 
LQGINCGPDFTPSFANLGR 4521000 0 4521000 
LQGQLEQGDDTAAER 8508600 0 8508600 
LQIEDFEAR 0 0 0 
LQIVEMPLAHK 57217000 0 57217000 
LQIWDTAGQESFR 47193000 0 47193000 
LQKEEEIEFLYNENTVR 0 0 0 
LQLDSPEDAEFIVAK 46145000 0 46145000 
LQLEIDQK 10519000 0 10519000 
LQLLEDDKENR 59493000 0 59493000 
LQLWDIAGQER 10896000 0 10896000 
LQLWDTAGQER 9477000 0 9477000 
LQMEAPHIIVGTPGR 16271000 0 16271000 
LQMEQQQQLQQR 118750000 0 118750000 
LQPFATEADVEEALR 6091700 0 6091700 
LQQLPADFGR 36537000 0 36537000 
LQQVLQMESHIQSTSDR 112070000 1550800 110520000 
LQSIGTENTEENR 17944000 0 17944000 
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LQSIGTENTEENRR 58172000 0 58172000 
LQSSQEPEAPPPR 1933200 0 1933200 
LQTASDESYKDPTNIQSK 10833000 0 10833000 
LQTQGLGTALK 69079000 0 69079000 
LQTQVFK 119120000 0 119120000 
LQVMANSR 6861800 0 6861800 
LQVSQQEDITK 54512000 0 54512000 
LQVTNVLSQPLTQATVK 7440400 0 7440400 
LQVVDQPLPVR 0 0 0 
LSAAVTEAFVR 0 0 0 
LSAETLQQVNR 6562300 0 6562300 
LSAIPVSAFCNSETK 11869000 0 11869000 
LSALGNVTTCNDYVALVHPDLDR 7615900 0 7615900 
LSANQQNILK 105810000 0 105810000 
LSASDMLQVR 218910000 0 218910000 
LSCFAQTVSPAEK 100210000 0 100210000 
LSDIPEGK 0 0 0 
LSDLLAPISEQIK 17707000 0 17707000 
LSDMPLK 22379000 0 22379000 
LSEELSGGR 22152000 0 22152000 
LSEETTTSSSR 1364000 0 1364000 
LSEFGLIQEK 6219800 0 6219800 
LSESGAIMTDLEENPK 0 0 0 
LSFAVPFR 14869000 0 14869000 
LSGQDVER 6059200 0 6059200 
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LSGSNPYTTVTPQIINSK 4156300 0 4156300 
LSGTGSAGATIR 32717000 1670600 31046000 
LSILYPATTGR 213030000 0 213030000 
LSIVPVR 35202000 0 35202000 
LSKEDIER 9447300 0 9447300 
LSLDGQNIYNACCTLR 118540000 0 118540000 
LSLLCIDFNK 0 0 0 
LSLLLNDISR 0 0 0 
LSLNIDPDAK 29054000 0 29054000 
LSMSQLNEK 447010000 0 447010000 
LSNIFVIGK 0 0 0 
LSNTSPEFQEMSLLER 8125200 0 8125200 
LSNVNLQEK 16377000 0 16377000 
LSPEELLLR 10042000 0 10042000 
LSPQAVNSIAK 123500000 0 123500000 
LSPTDNLPR 36731000 0 36731000 
LSQLEGVNVER 14129000 0 14129000 
LSQMAVQGLQQFK 9046200 0 9046200 
LSQNNFALGYK 61789000 4730600 57059000 
LSQVPDNPPDYQK 12653000 0 12653000 
LSSAMSAAK 47062000 0 47062000 
LSSDVCPTSDK 11763000 0 11763000 
LSSPATLNSR 3495900000 3495900000 0 
LSSTWEGIQAGK 55974000 0 55974000 
LSSVVTQHDSK 9156600 0 9156600 
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LSTLCPSAVLQR 16252000 0 16252000 
LSTLVETTLK 6492800 0 6492800 
LSVADSQAEAK 25504000 0 25504000 
LSVDYGKK 0 0 0 
LSVEESEAAGDGVDTK 14286000 0 14286000 
LSVEGFAVDK 0 0 0 
LSVENVPCIVTLCK 0 0 0 
LSVLGAITSVQQR 2349800 0 2349800 
LSVNSVTAGDYSR 21840000 0 21840000 
LSYNTASNK 17012000 0 17012000 
LTDADAMK 57473000 0 57473000 
LTDCVVMR 19978000 0 19978000 
LTDIQYGR 27609000 2185200 25424000 
LTDQLPLIIVCDR 130890000 24398000 106500000 
LTEGCSFR 6029700 0 6029700 
LTEMETLQSQLMAEK 37495000 0 37495000 
LTFDSSFSPNTGK 0 0 0 
LTFDTTFSPNTGK 0 0 0 
LTFSCLGGSDNFK 2963300 0 2963300 
LTGADGTPPGFLLK 0 0 0 
LTGMAFR 844580000 29289000 815290000 
LTGSLSGWSSPK 9576000 0 9576000 
LTGSVLEDAWK 0 0 0 
LTGVFAPR 245120000 0 245120000 
LTIAEER 11618000 0 11618000 
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LTLDTIFVPNTGK 10852000 0 10852000 
LTLHGLQQYYVK 8027400 0 8027400 
LTLSALLDGK 12115000 0 12115000 
LTLSALVDGK 4609500 0 4609500 
LTLSQFQK 0 0 0 
LTNFPEMMNR 0 0 0 
LTNVAATSGDGYR 11684000 0 11684000 
LTPEFSQR 87688000 0 87688000 
LTPITYPQGLAMAK 99841000 0 99841000 
LTPQMFQQLMK 51143000 0 51143000 
LTPTEVK 9514400 0 9514400 
LTQDQDVDVK 14291000 0 14291000 
LTQEQVSDSQVLIR 3437500 0 3437500 
LTQVSPR 2419600 0 2419600 
LTSDSTVYDYAGK 3189800 0 3189800 
LTSEPQPQR 66247000 0 66247000 
LTTLPSDFCGLTHLVK 347710000 347710000 0 
LTVAENEAETK 46878000 16569000 30309000 
LTVEDPVTVEYITR 57497000 0 57497000 
LTVNDFVR 2403500 0 2403500 
LTVNPGTK 65033000 0 65033000 
LVAGEMGQNEPDQGGQR 16587000 0 16587000 
LVAIVDVIDQNR 4150800 0 4150800 
LVALAVIDEK 12637000 0 12637000 
LVALLNTLDR 42067000 0 42067000 
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LVARPEPATGYTLEFR 76028000 0 76028000 
LVASAEQLLK 9178300 0 9178300 
LVCSGLLQASK 436890000 411250000 25644000 
LVDAGEECDCGTPK 1607100 0 1607100 
LVDEYSLNAGK 0 0 0 
LVDVICEK 22354000 0 22354000 
LVEAISR 30964000 0 30964000 
LVEALAAATEK 0 0 0 
LVEALCAEHQINLIK 0 0 0 
LVEDEER 21584000 780440 20803000 
LVEDMENK 26457000 0 26457000 
LVEQYTK 38354000 0 38354000 
LVFDEYLK 57209000 0 57209000 
LVFLGLDNAGK 286960000 0 286960000 
LVFPQDLLEK 91464000 0 91464000 
LVFSNVNLK 3721100 0 3721100 
LVGMPAK 17949000 0 17949000 
LVGPEEALSPGEAR 8768000 0 8768000 
LVGQGASAVLLDLPNSGGEAQAK 73556000 0 73556000 
LVGSVNLFSDENVPR 13365000 0 13365000 
LVIEEAER 121970000 0 121970000 
LVIITAGAR 154040000 0 154040000 
LVILANNCPALR 34743000 0 34743000 
LVILEGELER 0 0 0 
LVINGNPITIFQER 1216100000 128410000 1087700000 
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LVIPSELGYGER 16328000 0 16328000 
LVIVGDGACGK 160740000 7526300 153220000 
LVKPGNQNTQVTEAWNK 16869000 0 16869000 
LVLEAEER 47989000 0 47989000 
LVLLGESAVGK 101540000 0 101540000 
LVLMSATGDNER 12684000 0 12684000 
LVLVGDGGTGK 282140000 0 282140000 
LVMELSGEMVR 0 0 0 
LVNANGEAVYCK 14833000 0 14833000 
LVNELTEFAK 138380000 138380000 0 
LVNLADCLCNEDLESR 5497400 0 5497400 
LVPADNEK 6772600 0 6772600 
LVPDLLAIVQR 1697200 0 1697200 
LVPEAVGDQK 30299000 0 30299000 
LVPLLDTGDIIIDGGNSEYR 1248600 0 1248600 
LVPLNQESVEER 29105000 0 29105000 
LVPQLVR 3067600 0 3067600 
LVPSQEETK 16954000 0 16954000 
LVPTGLDFGQEGFTR 1887400 0 1887400 
LVQAFQFTDK 34015000 0 34015000 
LVQAFQYTDK 33514000 0 33514000 
LVQGSILK 80155000 0 80155000 
LVQLGQAEK 6585300 0 6585300 
LVQSPNSYFMDVK 85456000 19077000 66379000 
LVQTAAQQVAEDK 18804000 0 18804000 
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LVSDGNINSDR 11734000 0 11734000 
LVSEYMSK 117920000 0 117920000 
LVSIDSK 41041000 0 41041000 
LVSIGAEEIVDGNAK 21653000 0 21653000 
LVSIGAEEIVDGNVK 0 0 0 
LVSLGTCFGK 5987900 0 5987900 
LVSLIGSK 99144000 0 99144000 
LVSLYFDTK 24785000 0 24785000 
LVSPGSANETSSILVESVTR 3010900 0 3010900 
LVTDEDVFPTK 0 0 0 
LVTMQIWDTAGQER 47917000 0 47917000 
LVVECVMNNVTCTR 29260000 0 29260000 
LVVLGSGGVGK 18589000 0 18589000 
LVVLGSSQESNSK 0 0 0 
LVVPATQCGSLIGK 0 0 0 
LVWIETPTNPTQK 0 0 0 
LVYLVENPGGYVAYSK 0 0 0 
LWAPDSPNR 11004000 0 11004000 
LWDFQGFECIR 2926600 0 2926600 
LWDIGGQPR 0 0 0 
LWDLTTGTTTR 54512000 0 54512000 
LWDLVAGK 0 0 0 
LWEEQLAAAK 28003000 0 28003000 
LWGDIYFNPK 3745200 0 3745200 
LWGLTEMFPER 2314800 0 2314800 
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LWNLLMPTK 0 0 0 
LWNTLGVCK 0 0 0 
LWVPDEEVSPETMVK 5714400 0 5714400 
LYAMQTGMK 19574000 0 19574000 
LYCPVEFSK 0 0 0 
LYDAYELK 19145000 0 19145000 
LYDLVAGSNCLK 5652900 0 5652900 
LYDMADVWVK 6502600 0 6502600 
LYDVVAVFPK 0 0 0 
LYELIITR 0 0 0 
LYENFISEFEHR 44975000 0 44975000 
LYEQLSGK 102620000 0 102620000 
LYEWTTEK 19101000 0 19101000 
LYGDDALDNALQTFIK 1799900 0 1799900 
LYGEFADPFK 3130100 0 3130100 
LYGPSSVSFADDFVR 1437900 0 1437900 
LYGSAGPPPTGEEDTAEKDEL 12957000 0 12957000 
LYIDSYEK 9258900 0 9258900 
LYLVSDVLYNSSAK 5007400 0 5007400 
LYNNHEIR 35302000 0 35302000 
LYPEGLAQLAR 32950000 0 32950000 
LYQPEYQEVSTEEQR 16554000 0 16554000 
LYQVEYAFK 18450000 0 18450000 
LYSEDELPAEFK 2680000 0 2680000 
LYSESLAR 258950000 0 258950000 
 
 
343 | P a g e  
 
LYTLQDK 119710000 0 119710000 
LYTLVLTDPDAPSR 17639000 0 17639000 
LYVYNTDTDNCR 7359900 0 7359900 
MADLHAVPR 118750000 0 118750000 
MADMQNLVER 0 0 0 
MAEDEAETIGNLIEECGGLEK 3403000 0 3403000 
MAGAIPLVTAGSQK 0 0 0 
MAGATPVFIPLR 16437000 0 16437000 
MAGTAFDFENMK 0 0 0 
MAILQIMK 30748000 0 30748000 
MAIMVQSPMFDGK 28277000 0 28277000 
MAIQTQQSK 20278000 0 20278000 
MALLMAEMSR 40313000 0 40313000 
MASTFIGNSTAIQELFK 3112900 0 3112900 
MATEVAADALGEEWK 23554000 0 23554000 
MATFEIDEK 0 0 0 
MAVLALLAK 12273000 0 12273000 
MAVQDAVDALMQK 0 0 0 
MCQGGDFTR 6065700 0 6065700 
MDASTGDAIK 41920000 0 41920000 
MDATANDVPSDR 93987000 0 93987000 
MDCQECPEGYR 25708000 0 25708000 
MDDREDLVYQAK 216740000 0 216740000 
MDELQLFR 145610000 4054600 141560000 
MDENQFVAVTSTNAAK 14535000 0 14535000 
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MDGTYACSYTPVK 15223000 0 15223000 
MDKNELVQK 37824000 0 37824000 
MDLVTYFGK 7052300 0 7052300 
MDMEEIIQR 2863600 0 2863600 
MDPNTIIEALR 7164600 0 7164600 
MDQAIIFCR 15486000 0 15486000 
MDQYFNQMEK 11051000 0 11051000 
MDSTANEVEAVK 131650000 0 131650000 
MDSTEPPYSQK 22362000 0 22362000 
MEADPDGQQPEK 2505600 0 2505600 
MEAEDYVMAVVDK 8048500 0 8048500 
MEANIDR 8595500 0 8595500 
MEEADALIESLCR 48569000 0 48569000 
MEEANIQPNR 65120000 0 65120000 
MEEETEVR 14831000 0 14831000 
MEEVVIAGMSGK 15617000 0 15617000 
MEGGTENDLR 5308700 0 5308700 
MEGVEEK 1388300 0 1388300 
MELITILEK 12258000 0 12258000 
MELVQVLK 4660700 0 4660700 
MESVLGAGGK 10916000 7250800 3665600 
MESYHKPDQQK 16039000 0 16039000 
METLGENEYFR 5389800 0 5389800 
MFDVGGQR 22516000 0 22516000 
MFEFYER 8523300 0 8523300 
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MFGMVLEK 109060000 0 109060000 
MFIGGLSWDTTK 27733000 0 27733000 
MFLSFPTTK 12727000 12727000 0 
MFLYADNEDR 826350 0 826350 
MFQDIGVSK 0 0 0 
MFVLDEADEMLSR 166700000 0 166700000 
MFVTPGAGR 29771000 0 29771000 
MGESDDSILR 12765000 0 12765000 
MGGDIANR 19210000 0 19210000 
MGGEEAEIR 98586000 0 98586000 
MGITEYNNQCR 65513000 0 65513000 
MGPGAASGGER 405580 0 405580 
MGPGAASGGERPNLK 7699200 0 7699200 
MGPGATAGGAEK 18309000 0 18309000 
MGPNIYELR 32174000 0 32174000 
MGVVECAK 0 0 0 
MIAAVDTDSPR 103700000 0 103700000 
MIAILTENYGGK 97031000 0 97031000 
MIDLIIPR 5277400 0 5277400 
MIDLSGNPVLR 29210000 0 29210000 
MIFDVESMK 102990000 0 102990000 
MIFVGIK 6096700 0 6096700 
MIIEEAK 10595000 0 10595000 
MILELFSK 52946000 0 52946000 
MINTDLSR 56407000 0 56407000 
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MIPCDFLIPVQTQHPIR 96956000 0 96956000 
MISDAIPELK 136240000 0 136240000 
MISGMYLGEIVR 15622000 0 15622000 
MISLTDTQK 6511400 0 6511400 
MIVDPVEPHGEMK 8495600 0 8495600 
MLAEDELR 90673000 0 90673000 
MLALALLDR 6321400 0 6321400 
MLAQQAVK 14484000 0 14484000 
MLDAEDIVGTARPDEK 0 0 0 
MLDAEDIVNTARPDEK 20801000 0 20801000 
MLENTDNSSPSTEHSQGLEK 0 0 0 
MLEQLDMR 1750900 0 1750900 
MLFDYLADK 75500000 0 75500000 
MLLADQGQSWK 0 0 0 
MLLCEAVAAVMAK 17429000 0 17429000 
MLLNDFLNDQNR 9531600 0 9531600 
MLLQSSEGR 13389000 0 13389000 
MLLSLPEK 23008000 0 23008000 
MLLVDELR 149500000 889910 148610000 
MLLYTEVTR 31384000 0 31384000 
MLPLIWSK 2279600 0 2279600 
MLQIQPEK 7467400 0 7467400 
MLQPCGPPADKPEEN 3035000 0 3035000 
MLQPSSSPLWGK 0 0 0 
MLSCAGADR 65334000 0 65334000 
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MLTAQDMSYDEAR 6002900 0 6002900 
MLTGPVYSQSTALTHK 25769000 0 25769000 
MLVIEQCK 52197000 0 52197000 
MLVLDEADEMLNK 118440000 0 118440000 
MLVNENFEEYLR 98589000 0 98589000 
MLVQCMQDQEHPSIR 4402500 0 4402500 
MLVVGGIDR 3211100 0 3211100 
MMADEALGSGLVSR 0 0 0 
MMCGAPSATQPATAETQHIADQVR 39269000 0 39269000 
MMMQSGR 14129000 0 14129000 
MMVAGFK 24983000 0 24983000 
MNEFLENFEK 35762000 0 35762000 
MNGMLLNDR 20297000 0 20297000 
MNGMSVLMK 2215700 0 2215700 
MNLGVGAYR 115550000 0 115550000 
MNLSAIQDR 128480000 28973000 99507000 
MNPEYDYLFK 10517000 0 10517000 
MNYSDAIVWLK 16062000 0 16062000 
MPCTEDYLSLILNR 24269000 24269000 0 
MPPYDEQTQAFIDAAQEAR 120960000 0 120960000 
MPSLPSYK 12133000 0 12133000 
MPTTQETDGFQVK 0 0 0 
MQASIEK 70051000 0 70051000 
MQGQSPPAPTR 2110500 0 2110500 
MQLSGEGAK 14744000 0 14744000 
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MQVDPQK 50087000 0 50087000 
MQVDQEEPHVEEQQQQTPAENK 36283000 0 36283000 
MREDYDSVEQDGDEPGPQR 1666800 0 1666800 
MSAEDIEK 31531000 0 31531000 
MSASDPNSSIFLTDTAK 20251000 0 20251000 
MSATFIGNSTAIQELFK 3112900 0 3112900 
MSPDEGQEELEEVQAELK 3089300 0 3089300 
MSSFGDFVALSDVCDVPTAK 7063600 0 7063600 
MSTMTPK 7801900 0 7801900 
MSTSPEAFLALR 2126200 0 2126200 
MSVIWDK 63771000 0 63771000 
MTALAQDFAVGLGPR 1132500 0 1132500 
MTDSFTEQADQVTAEVGK 0 0 0 
MTFTSNK 12163000 0 12163000 
MTLSNPSELDELMSEEAYEK 6048300 0 6048300 
MTQNPNYYNLQGISHR 0 0 0 
MTTETASEDDNFGTAQSNK 0 0 0 
MTVDESGQLISCSMDDTVR 2901000 0 2901000 
MVCSSTCYR 4074000 0 4074000 
MVDVGGQR 23700000 0 23700000 
MVEGYQGLR 5260500 0 5260500 
MVGSQDILCSENK 0 0 0 
MVGVPAALDMMLTGR 2439300 0 2439300 
MVLVGDVK 15660000 0 15660000 
MVMAEGTAVLR 0 0 0 
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MVNHFIAEFK 25604000 0 25604000 
MVQQCCTYVEEITDLPIK 0 0 0 
MVRPNQDGTLIASCSNDQTVR 7243800 0 7243800 
MVSDEYEQLSSEALEAAR 3346400 0 3346400 
MVVESAYEVIK 436950000 0 436950000 
MVVLSLPR 7098900 0 7098900 
MVVPAALK 0 0 0 
MVYDMEK 8628400 0 8628400 
MWFQWSEQR 35899000 0 35899000 
MYVGECQGPGVR 3379800 0 3379800 
NAAPCAVSYLLFDQNDK 5473100 0 5473100 
NACIECSVNQNSIR 38589000 0 38589000 
NADMSEDMQQDAVDCATQAMEK 36381000 0 36381000 
NADMSEEMQQDSVECATQALEK 161020000 0 161020000 
NAENAIEALK 48628000 0 48628000 
NAENAIEALKEYEPEMGK 12251000 0 12251000 
NAFMMLIHADQDR 7185600 0 7185600 
NAGFTPQER 187360000 0 187360000 
NAGNCLSPAVIVGLLK 22303000 0 22303000 
NAGNEQDLGIQYK 4170600 0 4170600 
NAIQEIQR 0 0 0 
NALDLLLPK 44146000 0 44146000 
NALDPMSVLLAR 6014200 0 6014200 
NALESYAFNMK 36851000 0 36851000 
NALLQLTDSQIADVAR 2556700 0 2556700 
 
 
350 | P a g e  
 
NALSSLWGK 32054000 0 32054000 
NAPNDASYDAVR 17881000 0 17881000 
NAQAIEDMVGYAQETQHEK 11809000 0 11809000 
NASNDIVR 73908000 0 73908000 
NATNVEQAFMTMAAEIK 3820900 0 3820900 
NATNVEQSFMTMAAEIK 0 0 0 
NAYVWSQK 10258000 0 10258000 
NCAAYLK 62602000 0 62602000 
NCAVEFNFGQR 5845700 0 5845700 
NCETDTLINYMAK 2143300 0 2143300 
NCFASVFEK 10465000 0 10465000 
NCGQMSEIEAK 4976900 0 4976900 
NCIDITGVR 35526000 0 35526000 
NCISTVVHQGLIR 6651400 0 6651400 
NCIVLIDSTPYR 10596000 0 10596000 
NCLTNFHGMDLTR 76703000 0 76703000 
NCNDFQYESK 41661000 0 41661000 
NCPHIVVGTPGR 41358000 0 41358000 
NCTIVSPDAGGAK 6461200 0 6461200 
NDCEENGLAK 2743100 0 2743100 
NDEELNK 1119000 0 1119000 
NDEELNKLLGK 0 0 0 
NDFTEEEEAQVR 0 0 0 
NDGAAILAAVSSIAQK 25777000 0 25777000 
NDGVLLLQALTR 20772000 0 20772000 
 
 
351 | P a g e  
 
NDLAVVDVR 29018000 0 29018000 
NDLDDPER 0 0 0 
NDLSPASSGNAVYDFFIGR 3725700 0 3725700 
NDNDTFTVK 29396000 0 29396000 
NDQCYDDIR 29062000 0 29062000 
NDQCYEDIR 16292000 0 16292000 
NDQDTWDYTNPNLSGQGDPGSNPNKR 0 0 0 
NEAIQAAHDAVAQEGQCR 5934100 0 5934100 
NEALAALLR 45539000 0 45539000 
NECFLSHK 43885000 43885000 0 
NEDITEPQSILAAAEK 0 0 0 
NEDLNAEDVYSR 4529300 0 4529300 
NEEDAAELVALAQAVNAR 164420000 0 164420000 
NEEEGNSEEIK 10170000 0 10170000 
NEFIPTNFEILPLEK 0 0 0 
NEGNIFPNPEATFVK 96875000 0 96875000 
NELEIPGQYDGR 8479000 0 8479000 
NELSGALTGLTR 111790000 0 111790000 
NENQLIIFADDTYPR 0 0 0 
NEPQNATGAPGR 12327000 0 12327000 
NETGGGEGIEVLK 0 0 0 
NETLGGTCLNVGCIPSK 29473000 0 29473000 
NFALLGVGTSK 20194000 0 20194000 
NFATSLYSMIK 5955300 0 5955300 
NFDEILR 24892000 0 24892000 
 
 
352 | P a g e  
 
NFDFEDVFVK 27695000 0 27695000 
NFEDVAFDEK 0 0 0 
NFGAENPDPFVPVLNTAVK 1814200 0 1814200 
NFGASLLLPGLK 14428000 0 14428000 
NFGDQPDIR 35386000 0 35386000 
NFGEDMDDER 8044300 0 8044300 
NFGIWLR 17986000 0 17986000 
NFGLYNER 0 0 0 
NFGSYVTHETK 46039000 0 46039000 
NFIEFVFPYR 76003000 5501100 70502000 
NFILDQCNVYNSGQR 0 0 0 
NFILDQTNVSAAAQR 0 0 0 
NFLSTPQFLYR 5245700 0 5245700 
NFNETFLK 4918800 0 4918800 
NFPQTALVSFATTGEK 0 0 0 
NFVDSPIIVDITK 47112000 0 47112000 
NGAPIIMSFPHFYQADER 2165400 0 2165400 
NGDYLCVK 8381300 0 8381300 
NGETELCMEGR 9398600 0 9398600 
NGGQILIADLR 17256000 0 17256000 
NGLSLAALK 18032000 0 18032000 
NGQDLGVAFK 52208000 0 52208000 
NGQVIGIGAGQQSR 25284000 0 25284000 
NGYELSPTAAANFTR 6332200 0 6332200 
NHDEESLECLCR 33682000 0 33682000 
 
 
353 | P a g e  
 
NHQSAAEYNIFEGMELR 19986000 0 19986000 
NICFTVWDVGGQDK 22034000 0 22034000 
NICFTVWDVGGQDR 39740000 0 39740000 
NIDEHANEDVER 109650000 0 109650000 
NIEDVIAQGIGK 140830000 0 140830000 
NIEEHASADVEK 4020800 0 4020800 
NIEIDSPYEISR 2565500 0 2565500 
NIEMTQEDVR 2700400 0 2700400 
NIFLLFK 6549200 0 6549200 
NIFPSNLVSAAFR 4581600 0 4581600 
NIGWGTDQGIGGFGEEPGIK 66142000 7918400 58223000 
NIIGYFEQK 6545600 0 6545600 
NIIHGSDSVESAEK 121120000 0 121120000 
NIIHGSDSVK 213230000 0 213230000 
NILGGTVFR 62762000 0 62762000 
NILIDFTK 20694000 0 20694000 
NILTEIYR 60038000 0 60038000 
NINDAWVCTNDMFR 15721000 0 15721000 
NINLIVQK 0 0 0 
NIPGITLLNVSK 135650000 0 135650000 
NIQESNFDR 4471400 0 4471400 
NISFTVWDVGGQDK 133960000 693010 133260000 
NISPIEVEYSQAEMK 39724000 0 39724000 
NIVEAAAVR 266740000 2460400 264280000 
NIVLSGGSTMFR 41313000 0 41313000 
 
 
354 | P a g e  
 
NIYSEELR 8414500 0 8414500 
NIYVLQELDNPGAK 117420000 0 117420000 
NKFDVDAADEK 0 0 0 
NLAMGVNLTSMSK 5451900 0 5451900 
NLANTVTEEILEK 61428000 0 61428000 
NLATTVTEEILEK 138810000 0 138810000 
NLDCPELISEFMK 3412700 0 3412700 
NLDDGIDDER 19661000 0 19661000 
NLDEQLSAPK 6580300 0 6580300 
NLDGISHAPNAVK 9939000 0 9939000 
NLDIERPTYTNLNR 52563000 0 52563000 
NLDKEYLPIGGLAEFCK 78639000 0 78639000 
NLDLAVLELMQSSVDNTK 0 0 0 
NLDPDVFNQIVK 16907000 0 16907000 
NLEAMNPPLFLR 2987300 0 2987300 
NLEAVETLGSTSTICSDK 0 0 0 
NLEGYVGFANLPNQVYR 4437900 0 4437900 
NLFEDQNTLTSICEK 98873000 0 98873000 
NLGESEIR 12138000 0 12138000 
NLGLYVK 17902000 0 17902000 
NLIDAGVDALR 72892000 0 72892000 
NLIDEDGNNQWPEGLK 27690000 0 27690000 
NLIEWLNK 15000000 0 15000000 
NLLDVIDQAR 2215700 0 2215700 
NLLQNIH 0 0 0 
 
 
355 | P a g e  
 
NLLQVDLTK 5872200 0 5872200 
NLLSVAYK 220780000 0 220780000 
NLLTPLMEK 62585000 0 62585000 
NLLTVTSSDEMMK 0 0 0 
NLLVAFR 0 0 0 
NLMFLVLR 3493600 0 3493600 
NLNEDDTFLVFSK 5891100 0 5891100 
NLPIYSENIIEMYR 9220000 0 9220000 
NLPPEEQMISALPDIK 19548000 0 19548000 
NLQEAEEWYK 10469000 0 10469000 
NLQEVLGEEK 0 0 0 
NLQLFMENK 15300000 0 15300000 
NLQNLLILTAIK 14304000 0 14304000 
NLQYYDISAK 41589000 0 41589000 
NLSGQPNFPCR 93315000 0 93315000 
NLSSNEAISLEEIR 9161600 0 9161600 
NLTEDNSQNQDLIAK 10543000 0 10543000 
NLTWIDSPAPER 9570900 0 9570900 
NLVDSYVAIINK 1707600 0 1707600 
NLVTEDVMR 23991000 0 23991000 
NLVVIPK 82703000 0 82703000 
NLYIISVK 41585000 0 41585000 
NLYVTFPIPDLQK 19098000 0 19098000 
NMAALDAADR 28037000 0 28037000 
NMACVQR 12135000 0 12135000 
 
 
356 | P a g e  
 
NMALSIAER 20155000 0 20155000 
NMDPLNDNIATLLHQSSDK 12488000 0 12488000 
NMGLYGER 32388000 0 32388000 
NMGYVQQR 8310800 0 8310800 
NMMAACDPR 153140000 1767700 151370000 
NMSGSLYEMVSR 45470000 0 45470000 
NMVPQQALVIR 4279900 0 4279900 
NNALNQVVLWDK 47678000 0 47678000 
NNASTDYDLSDK 237990000 0 237990000 
NNAYLAQSPQLYK 0 0 0 
NNDFYVTGESYAGK 7007000 0 7007000 
NNDLCYWVPELVR 5791300 0 5791300 
NNFAVGYR 67288000 0 67288000 
NNFEGEVTK 242410000 0 242410000 
NNFSDGFR 14007000 0 14007000 
NNIIQTWR 10421000 0 10421000 
NNIPYFETSAK 40500000 0 40500000 
NNLCPSGSNIISNLFK 28114000 0 28114000 
NNNQQLAQLQK 24431000 0 24431000 
NNNSNQNFFK 12183000 0 12183000 
NNNTDLMILK 0 0 0 
NNPEPWNK 79395000 0 79395000 
NNQFQALLQYADPVSAQHAK 137340000 0 137340000 
NNSELLNNLGNFINR 47031000 0 47031000 
NNSGLSFEELYR 3409300 0 3409300 
 
 
357 | P a g e  
 
NNSPMAANQTPTLR 2787200 0 2787200 
NNTQVLINCR 73251000 1639500 71612000 
NNVNVASLTQSEIR 0 0 0 
NNWEVSALSR 0 0 0 
NNYENYIDIVK 17545000 0 17545000 
NPASPYNLAYK 25373000 3722700 21650000 
NPAVQAGSIVVLQGGEETQR 6380700 0 6380700 
NPDDITNEEYGEFYK 51116000 0 51116000 
NPDDITQEEYGEFYK 360230000 0 360230000 
NPDGTMNLMNWECAIPGK 8520200 0 8520200 
NPELPNAAQAQK 7306900 0 7306900 
NPELQNLLLDDFFK 6362600 0 6362600 
NPEPELLVR 0 0 0 
NPQNSSQSADGLR 1023000 0 1023000 
NPSNCYGEESNAVCEK 5477600 5477600 0 
NPTIVNFPITNVDLR 46375000 0 46375000 
NPVMELNEK 29894000 0 29894000 
NPYYGGESASITPLEDLYK 125160000 0 125160000 
NPYYGGESSSITPLEELYK 77305000 0 77305000 
NQDLAPNSAEQASILSLVTK 47464000 0 47464000 
NQGGGLSSSGAGEGQGPK 7511800 0 7511800 
NQGIEEALK 30133000 0 30133000 
NQKDDVAQTDLLQIDPNFGSK 0 0 0 
NQNIQKPEYSE 4510700 0 4510700 
NQSETLNWLSNAIK 16966000 0 16966000 
 
 
358 | P a g e  
 
NQSFCPTVNLDK 0 0 0 
NQTAEKEEFEHQQK 59734000 0 59734000 
NQVAMNPTNTVFDAK 0 0 0 
NQVFEPSCLDAFPNLK 22095000 0 22095000 
NQYDNDVTVWSPQGR 3894800 0 3894800 
NREPVQLETLSIR 21350000 808520 20541000 
NSAFESLYQDK 2790300 0 2790300 
NSAQGNVYVK 8542500 0 8542500 
NSILFLNSLDAK 8636600 0 8636600 
NSIVNSQPPEK 14344000 0 14344000 
NSLDCEIVSAK 36411000 0 36411000 
NSLESYAFNMK 267370000 0 267370000 
NSNILEDLETLR 0 0 0 
NSNPALNDNLEK 11460000 0 11460000 
NSQFAGGPLGNPNTTAK 20062000 0 20062000 
NSSTYWEGK 5245500 0 5245500 
NSSYFVEWIPNNVK 775650000 2511500 773140000 
NSTFSEIFK 78970000 0 78970000 
NSTTDQVYQAIAAK 0 0 0 
NSVFQQGMK 37186000 0 37186000 
NSVTPDMMEEMYK 0 0 0 
NSVVEASEAAYK 23317000 0 23317000 
NSYLEVLLK 73482000 0 73482000 
NSYVAGQYDDAASYQR 2379600 0 2379600 
NTCTSVYTK 25885000 0 25885000 
 
 
359 | P a g e  
 
NTDQASMPDNTAAQK 18033000 0 18033000 
NTGIICTIGPASR 0 0 0 
NTISLLVAGLK 18849000 0 18849000 
NTLANSCGTGIR 1623800 0 1623800 
NTLCAPEVISLINTR 9652400 0 9652400 
NTLIQFEDFGNHNAFR 6414800 0 6414800 
NTNDANSCQIIIPQNQVNR 88772000 0 88772000 
NTNPNFVR 73000000 0 73000000 
NTPLCDSFVFR 5650400 0 5650400 
NTPSFLIACNK 0 0 0 
NTTGALTTR 5022300 0 5022300 
NTVANSPQTLLAGMNK 1525200 0 1525200 
NTVCSLSSGK 15124000 0 15124000 
NTVVATGGYGR 30011000 0 30011000 
NTVVLFVPQQEAWVVER 6391300 0 6391300 
NTWDCGLQILK 15485000 0 15485000 
NVAQYNANHPDFPMQIEQLER 29545000 0 29545000 
NVDILKDPETVK 1523500 0 1523500 
NVDLLSDMVQEHDEPILK 23409000 0 23409000 
NVEAMNFADIER 0 0 0 
NVEDFTGPR 70633000 0 70633000 
NVEGQDMLYQSLK 13914000 0 13914000 
NVEMFMNIEK 0 0 0 
NVFDEAILAALEPPEPK 4895700 0 4895700 
NVFLLGFIPAK 1649400 0 1649400 
 
 
360 | P a g e  
 
NVFNALIR 29566000 0 29566000 
NVGQFSGFPFEK 22093000 0 22093000 
NVIDGDLCEQFNSMEPNK 0 0 0 
NVIIWGNHSSTQYPDVNHAK 5087900 0 5087900 
NVIQSVLQAIR 2156800 0 2156800 
NVIVNGLVLASDGQK 64313000 0 64313000 
NVLCSACSGQGGK 19511000 0 19511000 
NVLDSEDEIEELSK 20641000 0 20641000 
NVLIVEDIIDTGK 5444100 0 5444100 
NVMTIITGYPTPGSK 233970000 0 233970000 
NVNSNLITWNR 6716600 0 6716600 
NVQGIIEILK 3233000 0 3233000 
NVQLTENEIR 93480000 0 93480000 
NVTELNEPLSNEER 175890000 2127500 173770000 
NVVAECLGK 0 0 0 
NVVTIFSAPNYCYR 20523000 0 20523000 
NVVVVDGVR 26165000 0 26165000 
NWADVQSQLR 0 0 0 
NWFGLPGR 19584000 19584000 0 
NWQYQETIK 39119000 0 39119000 
NYAQVFNK 43075000 0 43075000 
NYDVMKDFEEMR 16852000 0 16852000 
NYDYYASR 8141800 0 8141800 
NYELLCGDNTR 2795300 2795300 0 
NYFLEEDNYK 0 0 0 
 
 
361 | P a g e  
 
NYILDQTNVYGSAQR 3326400 0 3326400 
NYIMDFQVGK 186320000 0 186320000 
NYLEPGKECVQPATK 26695000 0 26695000 
NYLLQCTR 27460000 0 27460000 
NYLSIFR 15350000 0 15350000 
NYLSLAPLFFK 2612000 0 2612000 
NYMMPAK 10295000 0 10295000 
NYNECIR 22415000 0 22415000 
NYPDPVSIIQK 5191800 0 5191800 
NYTDEAIETDDLTIK 29233000 0 29233000 
NYVLQTLGTETYR 63109000 0 63109000 
NYYEQWGK 75542000 0 75542000 
PAAPPAPGPGQLTLR 8444800 0 8444800 
PAAVVLQTK 34072000 0 34072000 
PADEIAVDR 256410000 0 256410000 
PADTEPPPLLVYK 1972600 0 1972600 
PADVYLIDEPSAYLDSEQR 3970900 0 3970900 
PAEIDSLWEISK 1930500 0 1930500 
PAGQNLQGIEDK 2733900 0 2733900 
PALELLEPIEQK 36014000 0 36014000 
PASGCEAETQTEELK 4934100 0 4934100 
PASPATETVPAFSER 2457300 0 2457300 
PDISPYFGLFYEK 1293000 0 1293000 
PEPATGYTLEFR 0 0 0 
PGDGEFVEVISLPK 22976000 0 22976000 
 
 
362 | P a g e  
 
PLSSGGEEEEKPR 8449100 0 8449100 
PMEIFVDDETK 11702000 0 11702000 
PMFIVNTNVPR 4199200 1978800 2220400 
PPSAASAAPSSSK 247390000 0 247390000 
PPYTVVYFPVR 77904000 0 77904000 
PSQVVAETR 23951000 0 23951000 
PVAVGPYGQSQPSCFDR 0 0 0 
PVDFTGYWK 19198000 0 19198000 
PVIDNPNYK 105690000 0 105690000 
PVNLGLWDTAGQEDYDR 4018700 0 4018700 
QEYDESGPSIVHR 175740000 6090200 169650000 
QIDNPDYK 12724000 0 12724000 
QMFLTQTDTGDDR 0 0 0 
QSLGELIGTLNAAK 5851100 0 5851100 
QVHPDTGISSK 11858000 0 11858000 
QVTIFINSGGK 32214000 32214000 0 
QVVESAYEVIK 2989200 0 2989200 
RAPFDLFENK 42689000 0 42689000 
RAPFDLFENR 73188000 0 73188000 
RFDDAVVQSDMK 61628000 0 61628000 
RFPGYDSESK 5995600 0 5995600 
RGTGGVDTAAVGGVFDVSNADR 11007000 0 11007000 
RLTDADAMK 0 0 0 
RPCFSALTPDETYVPK 14356000 14356000 0 
RPTPQDSPIFLPVDDTSFR 42122000 0 42122000 
 
 
363 | P a g e  
 
RQVDQLTNDK 6564200 0 6564200 
RYDDPEVQK 29489000 0 29489000 
SAADLISQAR 54151000 0 54151000 
SAADSISESVPVGPK 27043000 0 27043000 
SADESGQALLAAGHYASDEVR 11203000 0 11203000 
SADGSAPAGEGEGVTLQR 84883000 2759600 82123000 
SADTLWDIQK 27606000 0 27606000 
SADTLWGIQK 22893000 0 22893000 
SAEAYENFLR 17476000 0 17476000 
SAGACTAAAFLK 0 0 0 
SAHLQWMVVR 0 0 0 
SALALAIK 0 0 0 
SALLDFYMK 33849000 0 33849000 
SALQSINEWAAQTTDGK 34410000 0 34410000 
SALYYVDLIGGK 36831000 0 36831000 
SANSELGGIWSVGQR 5147300 0 5147300 
SANVNEFPVLK 0 0 0 
SASAPAAEGEGTPTQPASEKEPEMPGPR 0 0 0 
SASVVSVISR 1562600 0 1562600 
SATLLQLITK 15727000 0 15727000 
SATQFTGR 29983000 0 29983000 
SATYVNTEGR 11129000 0 11129000 
SAVDAGFLQK 0 0 0 
SAVEDEGLK 43095000 0 43095000 
SAVENCQDSWR 99572000 0 99572000 
 
 
364 | P a g e  
 
SAVVAAGGGSSGQVTSNGSIGR 5607400 0 5607400 
SAYDSTMETMNYAQIR 0 0 0 
SCAAAGTECLISGWGNTK 50230000 50230000 0 
SCDGNQELLNFLR 18038000 5011100 13026000 
SCNCLLLK 465070000 0 465070000 
SCQFVAVR 0 0 0 
SCSGVEFSTSGSSNTDTGK 34029000 0 34029000 
SCSPELQQK 11801000 0 11801000 
SCSSSCAVHDLIFWR 26848000 0 26848000 
SCTTESCDFVR 14310000 0 14310000 
SCYDLSCHAR 79969000 0 79969000 
SDAAVDTSSEITTK 7710700 0 7710700 
SDALETLGFLNHYQMK 39529000 0 39529000 
SDASPSSIR 24135000 0 24135000 
SDATADDLIDVVEGNR 8450400 0 8450400 
SDGGYTYDTSDLAAIK 11657000 2975000 8682500 
SDGIYIINLK 254260000 0 254260000 
SDHPGISITDLSK 0 0 0 
SDIGEVILVGGMTR 6373300 0 6373300 
SDLLLEGFNNYR 0 0 0 
SDPGLLTNTMDVFVK 18386000 0 18386000 
SDPLLIGIPTSENPFK 23832000 0 23832000 
SDPVVSYR 34466000 0 34466000 
SDQDYILK 57334000 0 57334000 
SDTIANIQLNK 6694400 6694400 0 
 
 
365 | P a g e  
 
SDTPLIYK 65617000 0 65617000 
SDVEAIFSK 70929000 0 70929000 
SDVLELTDDNFESR 21320000 0 21320000 
SDVLQPGAEVTTDDR 2064500 0 2064500 
SDVLVEYQGEGR 13424000 0 13424000 
SDYDMVDYLNELR 179220000 0 179220000 
SDYLNTFEFMDK 38464000 0 38464000 
SEALPTDLPAPSAPDLTEPK 2062400 0 2062400 
SEAVVEYVFSGSR 0 0 0 
SEDFSLPAYMDR 109290000 0 109290000 
SEDGEIVSTPR 7341700 0 7341700 
SEDLLDYGPFR 22947000 0 22947000 
SEEEFIHINNK 32950000 0 32950000 
SEENEEPMETDQNAKEEEK 4019200 0 4019200 
SEEPEVPDQEGLQR 0 0 0 
SEEQLKEEGIEYK 125310000 0 125310000 
SEETNQQEVANSLAK 5348200 0 5348200 
SEGALELADVSNELPGLK 0 0 0 
SEGDSVGESVHGK 22907000 0 22907000 
SEGDSVGESVHGKPSVVYR 31611000 0 31611000 
SEGFDTYR 101920000 0 101920000 
SEGGFIWACK 5220400 0 5220400 
SEGTYCCGPVPVR 3561400 0 3561400 
SEGVVAVLLTK 100110000 13524000 86590000 
SEHPGLSIGDTAK 337470000 0 337470000 
 
 
366 | P a g e  
 
SEIDLFNIR 42568000 0 42568000 
SEIEYYAMLAK 34528000 0 34528000 
SEISLLPSDIDR 2971400 0 2971400 
SELDMLDIR 10742000 0 10742000 
SELDQLRQEAEQLK 20263000 0 20263000 
SEMEVQDAELK 53486000 0 53486000 
SEMTPEELQK 65106000 0 65106000 
SENENQEQIEESK 4233100 0 4233100 
SENFEELLK 93172000 0 93172000 
SENGLEFTSSGSANTETTK 2931800 0 2931800 
SEPIPESNDGPVK 25899000 0 25899000 
SEQDQAENEGEDSAVLMER 0 0 0 
SESPKEPEQLR 0 0 0 
SESVTTQAELEEK 3370700 0 3370700 
SETELKDTYAR 3808300 0 3808300 
SETITEEELVGLMNK 38042000 0 38042000 
SEVATLTAAGK 70869000 0 70869000 
SEVSSDEDIQFR 9796800 0 9796800 
SFAFVGPSR 0 0 0 
SFAVGMFK 4580800 0 4580800 
SFDLLILK 6359000 0 6359000 
SFDLLVK 121980000 0 121980000 
SFDVNKPGCEVDDLK 17820000 0 17820000 
SFEEAFQK 8157500 0 8157500 
SFENISK 30088000 0 30088000 
 
 
367 | P a g e  
 
SFGGGTGSGFTSLLMER 44457000 0 44457000 
SFITTDVNPYYDSFVR 16286000 0 16286000 
SFLDDPIWR 0 0 0 
SFLEDIR 0 0 0 
SFLEDIRK 0 0 0 
SFLLDLLNATGK 0 0 0 
SFQDYLGK 22837000 0 22837000 
SFYPEEVSSMVLTK 57118000 0 57118000 
SFYQGEK 10412000 0 10412000 
SGALDVLQMK 566640000 0 566640000 
SGALDVLQMKEEDVLK 11632000 0 11632000 
SGANVLICGPNGCGK 636580 0 636580 
SGAYLIPLLER 8558400 0 8558400 
SGCIVNNLAEFTVDPK 16695000 0 16695000 
SGDETPGSEVPGDK 15893000 0 15893000 
SGDSEVYQLGDVSQK 93839000 0 93839000 
SGEENPASKPTPVQDVQGDGR 52652000 0 52652000 
SGELLAK 9244900 0 9244900 
SGENAASLANELAK 0 0 0 
SGFQINLNPLK 4878900 0 4878900 
SGGGGGGGLGSGGSIR 4488900 4488900 0 
SGGVGGSNTNWK 2346500 0 2346500 
SGLGELILPENEPGSSIMPGK 42640000 0 42640000 
SGNELPLAVASTADLIR 11841000 0 11841000 
SGNYPSSLSNETDR 20268000 0 20268000 
 
 
368 | P a g e  
 
SGPGAYESGIMVSK 2076900 0 2076900 
SGSAAQAEGLCK 0 0 0 
SGSGTMNLGGSLTR 28527000 0 28527000 
SGSMATAEASGSDGK 32100000 0 32100000 
SGSMSAYEMR 16013000 0 16013000 
SGTVDPQELQK 100870000 0 100870000 
SGVGNIFIK 0 0 0 
SGVGTALLLK 0 0 0 
SGVNSELVK 51231000 0 51231000 
SGVSLAALK 70327000 0 70327000 
SHCIAEVEK 126130000 126130000 0 
SHMMDVQGSTQDSAIK 3242400 0 3242400 
SHQTGIQASEDVK 0 0 0 
SIAFPSIGSGR 16179000 0 16179000 
SIAPSIFGGTDMK 0 0 0 
SIASEPTEK 15786000 0 15786000 
SICTTVLELLDK 10842000 0 10842000 
SIDMSWDSVTMK 25206000 0 25206000 
SIDSNPYDTDK 12450000 0 12450000 
SIDTGMGLER 1820900 0 1820900 
SIEDFAHSSFQMALSK 7013200 0 7013200 
SIEEQLGTEIKPIPSNIDK 11682000 0 11682000 
SIEVIENR 17616000 0 17616000 
SIFDFSALK 34793000 0 34793000 
SIFLFLDR 4569400 0 4569400 
 
 
369 | P a g e  
 
SIFSLDTPEQYQEAFQK 7766800 0 7766800 
SIGTANRPMGAGEALR 113630000 0 113630000 
SIIECVDDFR 0 0 0 
SIIQEVAR 10479000 0 10479000 
SIISMFDR 4565200 0 4565200 
SILYDER 86257000 0 86257000 
SIMSYNGGAVMAMK 3010800 0 3010800 
SINNPDMR 59435000 0 59435000 
SINPDEAVAYGAAVQAAILSGDK 10085000 0 10085000 
SINSILDYISTSK 14553000 0 14553000 
SIPMTVDFIR 48684000 0 48684000 
SIPVLAK 10413000 0 10413000 
SIQFVDWCPTGFK 118260000 0 118260000 
SISFIPPDGEFELMR 8881300 0 8881300 
SITCWTLSR 0 0 0 
SIVEHVASK 51733000 0 51733000 
SIYGEKFEDENFILK 240040000 0 240040000 
SIYSLILGQDNAADQSR 0 0 0 
SKFDEMAK 29693000 0 29693000 
SKFDNLYGCR 0 0 0 
SLAASSSFYGQR 1101000 0 1101000 
SLADELALVDVLEDK 122510000 0 122510000 
SLAEGYFDAAGR 0 0 0 
SLAGSSGPGASSGTSGDHGELVVR 30893000 0 30893000 
SLANVILGGYGTTSTAGGK 16800000 0 16800000 
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SLAPSLLDR 46623000 0 46623000 
SLCNLEESITSAGR 0 0 0 
SLDDSQCGITYK 0 0 0 
SLDECCHSESSTACLNAK 3821900 3821900 0 
SLDFYTR 39557000 0 39557000 
SLDLDISK 27518000 0 27518000 
SLDLFNCEITNLEDYR 1480900 0 1480900 
SLDLFNCEVTNLNDYR 273000000 9924200 263080000 
SLDLIESLLR 576360 0 576360 
SLDLVTMK 0 0 0 
SLDTSEEGGR 0 0 0 
SLEDQVEMLR 10106000 0 10106000 
SLEEGEGPIAVIMTPTR 5622100 0 5622100 
SLEEIYLFSLPIK 3983000 0 3983000 
SLESINSR 117660000 0 117660000 
SLETCMYDHK 8750500 0 8750500 
SLETENAGLR 0 0 0 
SLFNNAER 10810000 0 10810000 
SLFSNVVTK 0 0 0 
SLFSSIGEVESAK 4023600 0 4023600 
SLFTDVVAEK 36724000 36724000 0 
SLGNVIHPDVVVNGGQDQSK 16422000 0 16422000 
SLGPPQGEEDSVPR 188070000 0 188070000 
SLGTDLMNEMR 1760100 0 1760100 
SLHDALCVIR 33803000 0 33803000 
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SLHTLFGDELCK 446270000 446270000 0 
SLIEEGGDWDR 0 0 0 
SLIGCFNLDPNR 1997700 0 1997700 
SLILTALQR 35628000 0 35628000 
SLLDFLPR 16009000 0 16009000 
SLLDGNIDSSQYEDSLR 0 0 0 
SLLEGEGSSGGGGR 18852000 16446000 2406100 
SLLINAVEASCIR 22986000 0 22986000 
SLLIPYLDNLVK 4255600 0 4255600 
SLLQGTILQYVK 6372700 0 6372700 
SLLSILQR 8155200 0 8155200 
SLLVQTK 102870000 0 102870000 
SLLVTELGSSR 19083000 0 19083000 
SLMEQDVK 10645000 0 10645000 
SLPVEEQPK 13035000 0 13035000 
SLQMYLER 0 0 0 
SLQSVAEER 79397000 0 79397000 
SLQSYYFYDELR 3694800 0 3694800 
SLSFVPGNDFEMSK 15879000 0 15879000 
SLTAEIDR 25340000 0 25340000 
SLTNDWEDHLAVK 227230000 0 227230000 
SLTYLSILR 14807000 923020 13884000 
SLVASLAEPDFVVTDFAK 17444000 0 17444000 
SLVDLTAVDVPTR 94911000 0 94911000 
SLVEIADTVPK 64510000 0 64510000 
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SLVQEMVGSFGK 9236200 0 9236200 
SLYQSAGVAPESFEYIEAHGTGTK 30099000 0 30099000 
SLYYYIQQDTK 3370500 0 3370500 
SMEEDPQTSR 40064000 0 40064000 
SMENYYQESGR 23078000 0 23078000 
SMFAGVPTMR 5010600 0 5010600 
SMQGFPFYDK 39219000 0 39219000 
SMSTEGLMK 217350000 88855000 128490000 
SMVAVMDSDTTGK 32617000 0 32617000 
SMVNLMDR 3949800 0 3949800 
SNDEEAFTFAR 0 0 0 
SNEILTAIIQGMR 39254000 0 39254000 
SNELWTEIK 0 0 0 
SNFGYNIPLK 59554000 0 59554000 
SNGLICGGNGVCK 27507000 0 27507000 
SNILTLMYQCMQDK 0 0 0 
SNIWLAAVTK 11045000 0 11045000 
SNLNSLDEQEGVK 25197000 0 25197000 
SNLQVSNEPGNR 9280800 0 9280800 
SNNSMAQAMK 9314400 0 9314400 
SNPEDQILYQTER 1911500 0 1911500 
SNQQNLGTIK 4918900 0 4918900 
SNTPILVDGK 191010000 0 191010000 
SNVSDAVAQSTR 592780000 16717000 576060000 
SNVVDDMVQSNPVLYTPGEEPDHCVVIK 22889000 0 22889000 
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SPAAECLSEK 0 0 0 
SPAESCDLLGDIQTCIR 15069000 0 15069000 
SPAGSIVHELNPNFQPPK 0 0 0 
SPASDTYIVFGEAK 27952000 0 27952000 
SPDTNYLFMGDYVDR 82684000 1347300 81336000 
SPEACCELTLQPLR 0 0 0 
SPEDLER 268630000 5052300 263580000 
SPELVQAMFPK 1763400 0 1763400 
SPEVLSGGEDGAVR 2016400 0 2016400 
SPFLQVFNNSPDESSYYR 6764400 0 6764400 
SPFSVAVSPSLDLSK 0 0 0 
SPFTVGVAAPLDLSK 24984000 0 24984000 
SPIEFLENAYEK 10579000 0 10579000 
SPLIIFSDCDMNNAVK 29744000 0 29744000 
SPLSWIEEK 20797000 0 20797000 
SPLVMDVLNIQGVQR 72773000 0 72773000 
SPNDFALWK 3852800 0 3852800 
SPPGQVTEAVK 170260000 0 170260000 
SPPTVLVICGPGNNGGDGLVCAR 16279000 0 16279000 
SPVYLTVLK 1613500 0 1613500 
SPYTVTVGQACNPSACR 29284000 0 29284000 
SQADQFCQR 6048100 0 6048100 
SQAIDLLYWR 54281000 0 54281000 
SQDIYLR 254830000 4399400 250430000 
SQETECTYFSTPLLLGK 205650000 0 205650000 
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SQFEELCAELLQK 38875000 0 38875000 
SQGGEPTYNVAVGR 59206000 0 59206000 
SQICDNAALYAQK 72849000 0 72849000 
SQIFSTASDNQPTVTIK 0 0 0 
SQIHDIVLVGGSTR 130150000 0 130150000 
SQLSCVVVDDIER 27396000 0 27396000 
SQMDGLIPGVEPR 0 0 0 
SQNFDILQSAISK 33513000 0 33513000 
SQSPTCQMCGEK 4862800 0 4862800 
SQVEPADYK 29027000 0 29027000 
SQYEQLAEQNR 15278000 15278000 0 
SQYPEIIFLGTGSAIPMK 1697200 0 1697200 
SSAEVIAQAR 13660000 0 13660000 
SSALQWLTPEQTSGK 4018300 0 4018300 
SSAQDPQAVLGALGR 22577000 0 22577000 
SSAYESLMEIVK 196210000 0 196210000 
SSDSADPFYWMR 9886000 0 9886000 
SSEAVIWEVLR 26426000 0 26426000 
SSEHINEGETAMLVCK 20468000 0 20468000 
SSFLPSYIIDVR 2402800 0 2402800 
SSFTVDCSK 117340000 0 117340000 
SSFYVNGLTLGGQK 126280000 0 126280000 
SSGEIVYCGQVFEK 0 0 0 
SSGGFVWACK 1821400 0 1821400 
SSGSALTVWGTGNPR 0 0 0 
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SSGSSYPSLLQCLK 496300000 496300000 0 
SSIDSEPALVLGPLK 8295800 0 8295800 
SSIGTGYDLSASTFSPDGR 16370000 0 16370000 
SSLAEFISER 4461700 0 4461700 
SSLNPILFR 45298000 0 45298000 
SSLQSQCLNEVLK 0 0 0 
SSLSSAQADFNQLAELDR 23469000 0 23469000 
SSMNPEYDYLFK 2496900 0 2496900 
SSPSGPSNPSNPSVEEK 23916000 0 23916000 
SSSGLLEWESK 0 0 0 
SSSSSSASAAAAAAAASSSASCSR 9883700 0 9883700 
SSVNCPFSSQDMK 5307100 0 5307100 
SSYPGQITGNMICVGFLEGGK 34914000 34914000 0 
STAGDTHLGGEDFDNR 912900000 27369000 885540000 
STCIYGGAPK 28940000 0 28940000 
STELLIR 1596300000 21217000 1575000000 
STESLQANVQR 19982000 0 19982000 
STFVLDEFKR 12530000 0 12530000 
STGEAFVQFASQEIAEK 25111000 0 25111000 
STGGAPTFNVTVTK 244240000 0 244240000 
STGSFVGELMYK 30566000 0 30566000 
STGTFVVSQPLNYR 11460000 0 11460000 
STIIGESISR 21838000 0 21838000 
STLEPVEK 17292000 0 17292000 
STLINSLFLTDLYPER 877140 0 877140 
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STLINTLFK 40091000 0 40091000 
STLMDTLFNTK 10878000 0 10878000 
STNCFGDNDPIDVCEIGSK 0 0 0 
STNGDTFLGGEDFDQALLR 24571000 0 24571000 
STPAITLESPDIK 0 0 0 
STPEYFAER 30181000 0 30181000 
STPVTVVLPDTK 5511600 0 5511600 
STPYECGFDPMSPAR 10901000 0 10901000 
STQFEYAWCLVR 6850600 0 6850600 
STSLETQDDDNIR 13020000 0 13020000 
STTELPLTVSYDK 1887900 0 1887900 
STTQVADSGYQR 7233800 0 7233800 
STTTGHLIYK 384790000 0 384790000 
STVAQLVK 84055000 0 84055000 
STVNCSTTPVAER 23133000 0 23133000 
STVVQLLER 18248000 0 18248000 
STYIESSTK 3044800 0 3044800 
SVAGGFVYTYK 8101800 0 8101800 
SVDETLR 147810000 1939600 145870000 
SVDIPENR 7485700 0 7485700 
SVEEISTLVQK 0 0 0 
SVEETLR 137630000 2299600 135330000 
SVESVPK 33272000 0 33272000 
SVILEAFSSPSEEVK 26779000 0 26779000 
SVLDAAQIVGLNCLR 41468000 0 41468000 
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SVLGEADQK 71930000 0 71930000 
SVLIGEFLEK 9315800 0 9315800 
SVLQAVQK 134240000 0 134240000 
SVMDATQIAGLNCLR 0 0 0 
SVMEELKR 14336000 0 14336000 
SVNELIYK 30146000 0 30146000 
SVPLAATSMLITQGLISK 2027700 0 2027700 
SVQTTLQTDEVK 57744000 0 57744000 
SVSAFAPICNPVLCPWGK 14993000 0 14993000 
SVSFSDVFFK 17835000 0 17835000 
SVSGTDVQEECR 19614000 0 19614000 
SVTEQGAELSNEER 213790000 6371600 207420000 
SVVALHNLINNK 9990400 0 9990400 
SVVSQSVCDYFFEAQEK 6459500 0 6459500 
SVVTSIFGVK 6943100 0 6943100 
SVVYQETNGETR 1684600 0 1684600 
SVYQDNESETGK 5851800 0 5851800 
SWCPDCVQAEPVVR 0 0 0 
SWLLPVIR 2433200 0 2433200 
SWLPQNCTLVDMK 103770000 0 103770000 
SWNDCLNK 27487000 0 27487000 
SWQDELAQQAEEGSAR 1604800 0 1604800 
SWVNQMESQTGEASK 1547600 0 1547600 
SYAEELAK 51847000 0 51847000 
SYCAEIAHNVSSK 142780000 0 142780000 
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SYCNDQSTGDIK 33689000 0 33689000 
SYCSNLVR 0 0 0 
SYDYQSVCEPGAAPK 42096000 0 42096000 
SYEECIIESR 5136700 0 5136700 
SYELPDGQVITIGNER 8771300000 290650000 8480600000 
SYEPLEDPGVK 45630000 0 45630000 
SYGATATSPGER 6142600 0 6142600 
SYLMTNYESAPPSPQYK 918940 0 918940 
SYSEDDIHR 6670400 0 6670400 
SYSPYDMLESIR 66282000 1993700 64288000 
SYSSGGEDGYVR 12692000 0 12692000 
SYVDLLK 14387000 0 14387000 
SYVTTSTR 7806200 0 7806200 
TAAYVNAIEK 35985000 0 35985000 
TAEENLDR 1300900 0 1300900 
TAEEVAALIR 0 0 0 
TAEVLANK 15808000 0 15808000 
TAFDDAIAELDTLNEDSYK 715830 0 715830 
TAFDEAIAELDTLNEDSYK 13361000 0 13361000 
TAFDEAIAELDTLNEESYK 13996000 0 13996000 
TAIEEVQAER 11080000 0 11080000 
TALAATNPAVR 22723000 0 22723000 
TALALAIAQELGSK 3184100 0 3184100 
TALAMGADR 2664100 0 2664100 
TALNLFFK 32430000 0 32430000 
 
 
379 | P a g e  
 
TAMNVNEIFMAIAK 7401100 0 7401100 
TAPGPATTQAGDAAR 2493000 0 2493000 
TAPYVVTGSVDQTVK 0 0 0 
TAQCFLR 17111000 0 17111000 
TASSVIELTCTK 0 0 0 
TASTNNIAQAR 3662100 0 3662100 
TATPQQAQEVHEK 857320000 4588000 852730000 
TATQLAVNK 91994000 0 91994000 
TATTQETDGFQVK 35068000 0 35068000 
TATVYPEPQNK 0 0 0 
TAVAPIER 351180000 7035100 344150000 
TAVCDIPPR 771120000 0 771120000 
TAVETAVLLLR 23061000 0 23061000 
TAVVVGTITDDVR 0 0 0 
TAWGQQPDLAANEAQLLR 15744000 0 15744000 
TAWLDGK 249730000 0 249730000 
TCAAQLVSYPGK 0 0 0 
TCDGVQCAFEELVEK 4619600 0 4619600 
TCEESSFCK 102100000 0 102100000 
TCGFDFTGAVEDISK 163250000 0 163250000 
TCLICADTFR 2888600 0 2888600 
TCNCETEDYGEK 84483000 0 84483000 
TCNTMNQFVNK 13435000 0 13435000 
TCTTVAFTQVNSEDK 67383000 0 67383000 
TCTTVAFTQVNSEDKGALAK 21208000 0 21208000 
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TCVADESHAGCEK 173200000 173200000 0 
TDAPQPDVK 2594300 0 2594300 
TDDEVVQR 13654000 0 13654000 
TDDYLDQPCLETVNR 18973000 0 18973000 
TDDYLDQPCYETINR 0 0 0 
TDEATFSK 6854900 0 6854900 
TDEGIAYR 135190000 0 135190000 
TDFEEFFLR 11901000 0 11901000 
TDGCHAYLSK 61866000 0 61866000 
TDGFGIDTCR 9260500 0 9260500 
TDITYPAGFMDVISIDK 27200000 0 27200000 
TDLLLEPYNK 0 0 0 
TDLVPAFQNLMK 30785000 0 30785000 
TDMDNQIVVSDYAQMDR 0 0 0 
TDPALNPADTLAPADYTGANAALK 39721000 39721000 0 
TDSDIIAK 0 0 0 
TDTESELDLISR 0 0 0 
TDTLEDLFPTTK 105030000 0 105030000 
TDTVLILCR 32490000 0 32490000 
TDYMVGSYGPR 143960000 0 143960000 
TDYNASVSVPDSSGPER 50151000 0 50151000 
TECGCQFTSK 1608500 0 1608500 
TEEEEIDR 10076000 1429600 8646500 
TEELKPQVEEK 4898700 0 4898700 
TEFLGFFYK 9016800 0 9016800 
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TEIIILATR 8188300 0 8188300 
TELAEPIAIRPTSETVMYPAYAK 0 0 0 
TEQAISFAK 0 0 0 
TEQGPQIDQK 0 0 0 
TEQGPQVDETQFK 14632000 0 14632000 
TESSGGWQNR 7008400 0 7008400 
TETVEEPMEEEEAAK 49883000 0 49883000 
TETVEEPMEEEEAAKEEK 75454000 0 75454000 
TEWLDGK 14398000 0 14398000 
TEYTVAVQTASK 15864000 0 15864000 
TFAPEEISAMVLTK 31049000 0 31049000 
TFCQLILDPIFK 74735000 0 74735000 
TFDHYCEYR 2792300 0 2792300 
TFDSIVMDPK 0 0 0 
TFDTNGDGTIDFR 0 0 0 
TFEGIDPK 25852000 0 25852000 
TFEGVDPQTTSMR 101300000 0 101300000 
TFESLVDFSK 32379000 0 32379000 
TFEVTPIR 0 0 0 
TFFSFPAVVAPFK 25284000 0 25284000 
TFIAIKPDGVQR 359010000 0 359010000 
TFLVGER 92130000 2399500 89731000 
TFLVWVNEEDHLR 13125000 0 13125000 
TFNMDEYVGLPR 67973000 0 67973000 
TFPTVNPSTGEVICQVAEGDKEDVDK 0 0 0 
 
 
382 | P a g e  
 
TFQGPNCPATCGR 3849600 0 3849600 
TFSEACLMVR 0 0 0 
TFSEILNR 11748000 0 11748000 
TFSYAGFEMQPK 11643000 0 11643000 
TFTDCFNCLPIAAIVDEK 40460000 0 40460000 
TFTTQETITNAETAK 172940000 0 172940000 
TFVNITPAEVGVLVGK 0 0 0 
TGAAPIIDVVR 0 0 0 
TGCNVLLIQK 48010000 0 48010000 
TGDLGDINAEQLPGR 0 0 0 
TGEAIVDAALSALR 17477000 0 17477000 
TGENVEDAFLEAAK 7294200 0 7294200 
TGFFEFQAAK 18836000 0 18836000 
TGGQVPDTNYIFMGDFVDR 3465900 0 3465900 
TGIEQGSDAGYLCESQK 11764000 0 11764000 
TGIYEEK 89559000 0 89559000 
TGLYNYYDDEK 10551000 0 10551000 
TGLYNYYDDEKEK 152270000 0 152270000 
TGNIPALVR 63590000 0 63590000 
TGPNLHGLFGR 29266000 0 29266000 
TGQAAELGGLLK 0 0 0 
TGQAPGYSYTAANK 203290000 0 203290000 
TGQATVASGIPAGWMGLDCGPESSK 61821000 0 61821000 
TGQATVASGIPAGWMGLDCGPESSKK 33130000 0 33130000 
TGQEVVFVAEPDNK 24029000 0 24029000 
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TGQYSGIYDCAK 30319000 0 30319000 
TGTSCALDCGAGIGR 2160100 0 2160100 
TGTVSLEVR 18196000 0 18196000 
TGVAVNKPAEFTVDAK 62792000 0 62792000 
TGVVTDGVK 10806000 0 10806000 
TGWISTSSIWK 3240100 0 3240100 
TGYTLDVTTGQR 86444000 0 86444000 
TGYTPDEK 1829200 0 1829200 
THINAVVAK 73374000 0 73374000 
THLPGFVEQAEALK 21230000 0 21230000 
THNSSLEYNIFEGMECR 10161000 0 10161000 
THVADFAPEVAWVTR 6110000 0 6110000 
TIADHCPDSACK 6414900 0 6414900 
TIAECLADELINAAK 19083000 0 19083000 
TIAEIFGNPNYLR 13759000 0 13759000 
TIAPALVSK 893420000 0 893420000 
TIAQDYGVLK 64778000 0 64778000 
TIAQGNLSNTDVQAAK 2100200 0 2100200 
TIAVDFASEDIYDK 56669000 0 56669000 
TICSSVDK 7558200 0 7558200 
TIDDLEEK 28926000 0 28926000 
TIDPELLGK 17146000 0 17146000 
TIEAEAAHGTVTR 4207100 0 4207100 
TIEEYAVCPDLK 2130900 0 2130900 
TIEKFEK 10266000 0 10266000 
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TIELDGK 27592000 0 27592000 
TIFAYFTGSK 5517800 0 5517800 
TIFQGIAAK 22742000 0 22742000 
TIGGGDDSFNTFFSETGAGK 44482000 0 44482000 
TIIPLISQCTPK 288570000 0 288570000 
TIIQNPTDQQK 14901000 0 14901000 
TIISYIDEQFER 12790000 0 12790000 
TILATGELGTLTNVYK 8764500 0 8764500 
TILPAAAQDVYYR 0 0 0 
TINLYPLTNYTFGTK 13597000 0 13597000 
TIPGTALVEMGDEYAVER 0 0 0 
TIPIDGDFFSYTR 5197900 0 5197900 
TIQEMQQK 37159000 0 37159000 
TIQVDNTDAEGR 55782000 0 55782000 
TIQVSDFVR 4710700 0 4710700 
TISETIER 22719000 1260000 21459000 
TITLEVEPSDTIENVK 3908300000 0 3908300000 
TITVALADGGRPDNTGR 35426000 0 35426000 
TIVTDVFQGSMR 24314000 0 24314000 
TKVEAFQTTISK 7998800 0 7998800 
TLADAEGDVFR 0 0 0 
TLADIIMEK 2335000 0 2335000 
TLAMDTILANAR 45278000 0 45278000 
TLAQLNPESSLFIIASK 36693000 0 36693000 
TLASAGGPDNLVLLNPEK 2773900 0 2773900 
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TLATWATK 11869000 0 11869000 
TLDELGIHLTK 6335500 0 6335500 
TLDNLGYR 7237000 0 7237000 
TLDPDPAIR 22219000 0 22219000 
TLEDPDLNVR 4588000 0 4588000 
TLEEDEEELFK 10613000 0 10613000 
TLETANCMSSQTK 21567000 0 21567000 
TLFATEDALEVR 0 0 0 
TLFLAVQVQNEEGK 0 0 0 
TLFNELR 6723700 0 6723700 
TLFPLIEAK 30681000 0 30681000 
TLGECGFTSQTAR 35539000 0 35539000 
TLGILGLGR 79924000 0 79924000 
TLGLYGK 446880000 0 446880000 
TLGVDLVALATR 4947300 0 4947300 
TLHPDLGTDK 8015400 0 8015400 
TLIDDDNPPVSFVK 24607000 0 24607000 
TLIEFLLR 2501100 0 2501100 
TLIQNCGASTIR 22484000 4022300 18462000 
TLLDSLR 0 0 0 
TLLEFLK 13619000 0 13619000 
TLLENTAITIGR 0 0 0 
TLLETLQK 0 0 0 
TLLVNNNR 20694000 0 20694000 
TLLYNPFPPTNESDVIR 8065700 0 8065700 
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TLMNTIMQLR 6428000 0 6428000 
TLNAGAYSK 16547000 0 16547000 
TLQEVLTMEYR 10403000 0 10403000 
TLQLDNNFEVK 0 0 0 
TLQSLLTPQPPLLK 12982000 0 12982000 
TLQTISLLGYMK 7342200 0 7342200 
TLSDYNIQK 13498000 0 13498000 
TLSGLEVSMVTAVPGR 0 0 0 
TLSPTGNISSAPK 5216900 0 5216900 
TLTDELAALQITGVK 12938000 0 12938000 
TLTLVDTGIGMTK 57511000 0 57511000 
TLTTMAPYLSTEDVPLAR 11070000 0 11070000 
TLVECWK 11386000 0 11386000 
TLVEDLFADK 12735000 0 12735000 
TLVLLDNLNVR 16927000 0 16927000 
TLVLLMGK 69690000 0 69690000 
TLVSVTK 142200000 0 142200000 
TLYNNQPIDFLK 64298000 0 64298000 
TMGFCYQILTEPNADPR 1837100 0 1837100 
TMLESAGGLIQTAR 0 0 0 
TMQNTNDVETAR 24338000 0 24338000 
TMQNTSDLDTAR 2314100 0 2314100 
TMQTLLSLVR 3213800 0 3213800 
TMSIVSYNHLGNNDGENLSAPLQFR 4231000 0 4231000 
TMTITETADK 41659000 0 41659000 
 
 
387 | P a g e  
 
TMVQELLDFK 3793300 0 3793300 
TNADTDGMVK 25305000 0 25305000 
TNAENEFVTIK 4862000 4862000 0 
TNDEVIHGIFK 0 0 0 
TNEAQAIETAR 251120000 2441800 248680000 
TNHIYVSSDDIK 3881800 0 3881800 
TNIVTASVDAINFHDK 77465000 0 77465000 
TNLDESDVQPVK 2270100 0 2270100 
TNNPLPLEQR 20167000 0 20167000 
TNSTFNQVVLK 148560000 0 148560000 
TNTLAVTGGEDDK 2453800 0 2453800 
TNYNDRYDEIR 20987000 0 20987000 
TPADCPVIAIDSFR 28282000 0 28282000 
TPAFAESVTEGDVR 0 0 0 
TPAQYDASELK 58577000 0 58577000 
TPCEEILVK 95395000 0 95395000 
TPCNAGTFSQPEK 30938000 0 30938000 
TPEEYPESAK 9540100 0 9540100 
TPEGLTLLFK 341030000 0 341030000 
TPELNLDQFHDK 2121600 0 2121600 
TPEQCPSVVSLLSESYNPHVR 19895000 0 19895000 
TPLLLMLGQEDR 62725000 0 62725000 
TPPLLENSLPQCYQR 0 0 0 
TPSALAILENANVLAR 1217500 0 1217500 
TPTEALASFDYIVR 10961000 0 10961000 
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TPTLLNEGAVR 0 0 0 
TPVEEVPAAIAPFQGR 95737000 0 95737000 
TPVIVTLK 5600700 0 5600700 
TPVPSDIDISR 32875000 0 32875000 
TPVSITEHPK 9642600 0 9642600 
TPVTDPATGAVK 13268000 0 13268000 
TPVTQVNEVTGTLR 0 0 0 
TPYTDVNIVTIR 0 0 0 
TQEEIVAK 129130000 0 129130000 
TQGFLALFSGDTGEIK 3327000 0 3327000 
TQIDHYVGIAR 126520000 0 126520000 
TQIIQDFLR 8223800 0 8223800 
TQIPTQR 97129000 0 97129000 
TQLEELEDELQATEDAK 3345700 0 3345700 
TQLVSNLK 217580000 0 217580000 
TQLYEYLQNR 4582100 0 4582100 
TQMTSAVR 70414000 2152700 68262000 
TQNVLGEK 143160000 0 143160000 
TQPVQGEPSAPK 2012300 0 2012300 
TQPYDVYDQVEFDVPVGSR 0 0 0 
TQQYDDLIDEFMK 25351000 0 25351000 
TQSSLVPALTDFVR 21668000 0 21668000 
TQVTVQYMQDR 19062000 0 19062000 
TQYACPPFDLTECSFK 4019300 0 4019300 
TSAPITCELLNK 0 0 0 
 
 
389 | P a g e  
 
TSDANINWNNLK 9791900 9791900 0 
TSDFNTFLAQEGCTK 1740400 0 1740400 
TSDLIVLGLPWK 0 0 0 
TSDQTWVK 12611000 0 12611000 
TSEFTAAFVGR 8097300 0 8097300 
TSESLCQNNMVILK 5210000 0 5210000 
TSFVNFTDICK 63291000 0 63291000 
TSGNVEDDLIIFPDDCEFK 9646000 0 9646000 
TSIAIDTIINQK 0 0 0 
TSIDAYDNFDNISLAQR 57139000 0 57139000 
TSLDWWITDK 187410000 0 187410000 
TSLMNQYVNK 68150000 0 68150000 
TSNSYLR 15148000 0 15148000 
TSQTVATFLDELAQK 4158600 0 4158600 
TSSAETPTIPLGSAVEAIK 3210500 0 3210500 
TSSAFVGK 6185400 0 6185400 
TSSDPTCVEK 42159000 0 42159000 
TSSQPGFLER 39108000 0 39108000 
TSTSQAVFR 40042000 0 40042000 
TSVETALR 25160000 0 25160000 
TSYGWIEIVGCADR 35565000 0 35565000 
TTAAMWALQTVEK 0 0 0 
TTANAIYCPPK 4447400 0 4447400 
TTAQVLIR 2119000 0 2119000 
TTDGYLLR 37410000 0 37410000 
 
 
390 | P a g e  
 
TTECSNTFK 9564900 0 9564900 
TTEINFK 13929000 0 13929000 
TTETQVFVATPQK 1361200 0 1361200 
TTETQVLVASAQK 38553000 0 38553000 
TTGEVVSGVVSK 13228000 0 13228000 
TTGFGMIYDSLDYAK 127680000 0 127680000 
TTGIVMDSGDGVTHTVPIYEGYALPHAILR 88773000 0 88773000 
TTIAQQVK 17824000 0 17824000 
TTIFTDAK 10018000 0 10018000 
TTLVIMER 52845000 0 52845000 
TTNFAGILSQGLR 66120000 0 66120000 
TTPECGPTGYVEK 0 0 0 
TTPLNQESDR 28432000 0 28432000 
TTPSVVAFTADGER 2507000 0 2507000 
TTPSYVAFTDTER 4498000 0 4498000 
TTPTFFPK 10163000 0 10163000 
TTQFSCTLGEK 10419000 0 10419000 
TTQVPQFILDDFIQNDR 9235100 0 9235100 
TTTGSYIANR 43672000 0 43672000 
TTVVYPATEK 4337500 0 4337500 
TTYQALPCLPSMYGYPNR 9240400 0 9240400 
TVAGGAWTYNTTSAVTVK 0 0 0 
TVALWDLR 40263000 0 40263000 
TVAQSQQLETNSQR 2994300 0 2994300 
TVCGVVSR 13946000 0 13946000 
 
 
391 | P a g e  
 
TVDFTQDSNYLLTGGQDK 36887000 0 36887000 
TVDNFVALATGEK 1824000000 13330000 1810700000 
TVEAEAAHGTVTR 17833000 0 17833000 
TVEALYK 0 0 0 
TVEDVFLR 21168000 0 21168000 
TVELLSGVVDQTK 21383000 0 21383000 
TVENFVALATGEK 34048000 0 34048000 
TVENVTVFGTASASK 0 0 0 
TVESEAASYLDQISR 0 0 0 
TVESITDIR 124060000 0 124060000 
TVFAEHISDECK 169250000 0 169250000 
TVGAALDILCPSGPIK 26382000 0 26382000 
TVGALQVLGTEAQSSLLK 84789000 0 84789000 
TVGATALPR 26555000 0 26555000 
TVGQCLETTAQR 22129000 0 22129000 
TVGQLYK 15925000 0 15925000 
TVIDYNGER 69209000 0 69209000 
TVIGCSGFHGDCLTLTK 0 0 0 
TVLDPVTGDLSDTR 26730000 4740200 21990000 
TVLDQQQTPSR 74997000 0 74997000 
TVLGTPEVLLGALPGAGGTQR 9148700 0 9148700 
TVLIMELINNVAK 1254400 0 1254400 
TVLLLADQMISR 7526100 0 7526100 
TVLMLADQMISR 5136000 0 5136000 
TVMENFVAFVDK 656740000 656740000 0 
 
 
392 | P a g e  
 
TVNTFSQSVSSLFGEDNVR 4256900 0 4256900 
TVNVVQFEPSK 0 0 0 
TVPWEQPATK 5196300 0 5196300 
TVQIEASTVEIEER 2696900 0 2696900 
TVQLTSSELESTLETLK 21541000 0 21541000 
TVQSNSPISALAPTGK 36044000 0 36044000 
TVQVSATEDGNVTK 22065000 0 22065000 
TVSQIISLQTLK 46471000 0 46471000 
TVTAEVQPQCGR 5413800 0 5413800 
TVTAMDVVYALK 38353000 0 38353000 
TVTATFGYPFR 40887000 0 40887000 
TVTEIDEK 20984000 0 20984000 
TVTNAVVTVPAYFNDSQR 8476100 0 8476100 
TVVAPSAVAGK 15229000 0 15229000 
TVVSGSCAAHSLLITTEGK 0 0 0 
TWIEVSGSSAK 17795000 0 17795000 
TWNDPSVQQDIK 5749000 0 5749000 
TWTVVDAK 43935000 0 43935000 
TYADYESVNECMEGVCK 0 0 0 
TYCCDLK 33885000 0 33885000 
TYDATTHFETTCDDIK 28323000 0 28323000 
TYDLLFK 36737000 0 36737000 
TYDSYLGDDYVR 1561300 1561300 0 
TYGGCEGPDAMYVK 0 0 0 
TYIPPKGETK 2562400 0 2562400 
 
 
393 | P a g e  
 
TYIQCIAAISR 21487000 0 21487000 
TYLPSQVSR 29127000 0 29127000 
TYLQALPYFDR 51876000 0 51876000 
TYSWDNAQVLLVGNK 0 0 0 
TYSYLTPDLWK 3562700 0 3562700 
TYTDELTPIESAVSVFK 0 0 0 
VAAAESMPLLLECAR 0 0 0 
VAAALPGMESTQDR 19678000 0 19678000 
VAADMFSDGNFNWGR 9674900 0 9674900 
VAAGLQIK 46849000 0 46849000 
VAAIEALNDGELQK 9591200 0 9591200 
VAALIQK 9893600 0 9893600 
VAALQNLVK 137280000 0 137280000 
VAALTGLPFVTAPNK 16968000 0 16968000 
VAAPDVVVPTLDTVR 86351000 0 86351000 
VAASCGAIQYIPTELDQVR 46303000 0 46303000 
VAASNIVQMK 176900000 0 176900000 
VAASPEDIK 5893900 0 5893900 
VACITEQVLTLVNK 6389700 0 6389700 
VADGGGAGGTFQPYLDTLR 24305000 0 24305000 
VADIGLAAWGR 45530000 0 45530000 
VADISGDTQK 115120000 1180300 113940000 
VAECSTGTLDYILQR 1088200 0 1088200 
VAEDEAEAAAAAK 60635000 0 60635000 
VAEITELILK 17624000 0 17624000 
 
 
394 | P a g e  
 
VAEQTPLTALYVANLIK 5432100 0 5432100 
VAEQVLNAVNK 29429000 0 29429000 
VAFITGGGTGLGK 12712000 0 12712000 
VAFTGSTEIGR 10385000 0 10385000 
VAGDCLDEK 45549000 0 45549000 
VAGSPGWVR 0 0 0 
VAGTQACATETIDTSR 6348800 0 6348800 
VAGYAALLEQYQK 10028000 0 10028000 
VAHALAEGLGVIACIGEK 2509200 0 2509200 
VAIEPGAPR 27786000 0 27786000 
VAIFIEK 0 0 0 
VALDMTTLTIMR 12107000 0 12107000 
VALIGSPVDLTYTYDHLGDSPK 7605700 0 7605700 
VAMGAFDK 20376000 0 20376000 
VANPSGNLTETYVQDR 0 0 0 
VANVELYYR 35061000 0 35061000 
VAPADGFSDLAMQVMTSPSK 5700700 0 5700700 
VAPDEHPILLTEAPLNPK 10104000 0 10104000 
VAPEEHPILLTEAPLNPK 612900000 612900000 0 
VAPEEHPVLLTEAPLNPK 1422000000 0 1422000000 
VAPPGLTQIPQIQK 12577000 0 12577000 
VAQGVSGAVQDK 83945000 0 83945000 
VAQLEQVYIR 60974000 0 60974000 
VAQPTITDNK 3587600 0 3587600 
VAQVAEITYGQK 0 0 0 
 
 
395 | P a g e  
 
VASGCLDINSSVK 9564800 0 9564800 
VASQGEVVR 3811500 0 3811500 
VASVEMVK 61287000 0 61287000 
VATMLATGGNR 21614000 0 21614000 
VATPVDWK 95334000 0 95334000 
VATSSLDQTVK 7689100 0 7689100 
VATVSLPR 4869700000 4869700000 0 
VATWFNQPAR 0 0 0 
VAVAIPNRPPDAVLTDTTSLNQAALYR 6322700 0 6322700 
VAVEYLDPSPEVQK 0 0 0 
VAVLSQNR 8975000 0 8975000 
VAVTPPGLAR 1488500 0 1488500 
VAVYVPGSK 17696000 0 17696000 
VCALLSCTSHK 2899800 0 2899800 
VCDIAAELAR 38012000 0 38012000 
VCEEIAIIPSK 0 0 0 
VCEEIAIIPSKK 0 0 0 
VCENIPIVLCGNK 254180000 0 254180000 
VCGSDGVTYGNECQLK 1677600 0 1677600 
VCLLGCGISTGYGAAVNTAK 89195000 0 89195000 
VCMDFNIIR 31016000 0 31016000 
VCMVYDLYK 4049300 0 4049300 
VCNYGLTFTQK 3002300 0 3002300 
VCNYVNWIQQTIAAN 0 0 0 
VCQCDSNGDCTDVDR 6232100 0 6232100 
 
 
396 | P a g e  
 
VCQGIGMVNR 11517000 0 11517000 
VCTLAIIDPGDSDIIR 85693000 0 85693000 
VDALLSAQPK 30504000 0 30504000 
VDATADYICK 53480000 0 53480000 
VDATAETDLAK 163170000 0 163170000 
VDATEESDLAQQYGVR 0 0 0 
VDCDQHSDIAQR 10598000 0 10598000 
VDCQAYAQTCQK 2288700 0 2288700 
VDCTAHSDVCSAQGVR 21273000 0 21273000 
VDCTQHYELCSGNQVR 22777000 0 22777000 
VDDESMQR 3062900 0 3062900 
VDDFLANEAK 9946000 0 9946000 
VDDQIAIVFK 0 0 0 
VDDSSGSIGR 106530000 5266000 101260000 
VDEFVTHNLSFDEINK 26389000 0 26389000 
VDFPQDQLTALTGR 349840000 0 349840000 
VDFTEEEINNMK 16073000 0 16073000 
VDGALCTEK 10300000 10300000 0 
VDGMDILCVR 19443000 0 19443000 
VDIIENQVMDFR 52185000 3564700 48620000 
VDLGVLGK 0 0 0 
VDNDENEHQLSLR 23070000 0 23070000 
VDNIQAGELTEGIWR 7285500 0 7285500 
VDQETLTEMVKPSIDYVR 13229000 0 13229000 
VDQIQEIVTGNPTVIK 3427300 0 3427300 
 
 
397 | P a g e  
 
VDQSTTSMAK 1600500 0 1600500 
VDSDKEDDITELK 12151000 0 12151000 
VDSLLENLEK 66627000 0 66627000 
VDTILEFSQNMNTK 5099600 0 5099600 
VDVGKDQEFTVK 0 0 0 
VDVTEQPGLSGR 72199000 0 72199000 
VEAFQTTISK 12411000 0 12411000 
VEDLTFTSPFCLQVK 16296000 0 16296000 
VEDPTFLNQLQSGVNR 0 0 0 
VEDVVVSDECR 38795000 0 38795000 
VEEIAASK 30236000 0 30236000 
VEEQEPELTSTPNFVVEVIK 29213000 0 29213000 
VEESSWLIEDGK 10525000 0 10525000 
VEEVEDVSPGPWGLVK 25634000 25634000 0 
VEEVELPVEK 7030900 0 7030900 
VEEVGPYTYR 57031000 0 57031000 
VEFILEQMR 21178000 0 21178000 
VEFNVNYTQDLDK 1158300 0 1158300 
VEGELEEMER 48382000 0 48382000 
VEGFPTIYFAPSGDK 67198000 0 67198000 
VEIATLTR 53225000 865490 52360000 
VEILANDQGNR 85840000 12170000 73670000 
VEITYTPSDGTQK 120610000 0 120610000 
VELDNMPLR 10148000 0 10148000 
VELSEQQLQLWPSDVDK 9926600 0 9926600 
 
 
398 | P a g e  
 
VELVPPTPAEIPR 64314000 0 64314000 
VENFIQK 70935000 0 70935000 
VENQENVSNLVIEDTELK 91610000 0 91610000 
VEPGLGADNSVVR 39751000 0 39751000 
VEQDLAMGTDAEGEK 13994000 0 13994000 
VEQIEAGTPGR 103240000 0 103240000 
VESLQEEIAFLK 36159000 0 36159000 
VESVEPSENEASK 10114000 0 10114000 
VETGVLKPGMVVTFAPVNVTTEVK 41724000 0 41724000 
VETPLEEAIK 12031000 0 12031000 
VETYNDESR 9088200 0 9088200 
VEVCCFDK 25012000 0 25012000 
VEVGKDQEFTVDTR 6807300 0 6807300 
VEVTEFEDIK 49661000 0 49661000 
VEYPIMYSTDPENGHIFNCIQR 17959000 0 17959000 
VEYTLGEESEAPGQR 0 0 0 
VFDAIMNFK 249920000 0 249920000 
VFDFTFSPEEMK 17410000 0 17410000 
VFDGIPPPYDK 0 0 0 
VFDPQNDKPSK 25104000 0 25104000 
VFDPVPVGVTK 16161000 0 16161000 
VFEDESGK 10294000 0 10294000 
VFEEDALSWEDK 6846600 0 6846600 
VFEGNRPTNSIVFTK 41295000 0 41295000 
VFEISPFEPWITR 11186000 0 11186000 
 
 
399 | P a g e  
 
VFFDLMR 34090000 0 34090000 
VFIGNLNTLVVK 219350000 0 219350000 
VFITDDFHDMMPK 114810000 0 114810000 
VFIWTCDDASSNTWSPK 28309000 0 28309000 
VFLATNSDYK 18003000 0 18003000 
VFLDFFTYAPPK 9616700 0 9616700 
VFLDVLMK 8416300 0 8416300 
VFLENVIR 2003000000 56058000 1947000000 
VFLLGEEVAQYDGAYK 12029000 0 12029000 
VFMQEFK 21683000 0 21683000 
VFNCISYSPLCK 9806000 0 9806000 
VFNDTCR 6078100 0 6078100 
VFNLYPR 0 0 0 
VFQFLNAK 0 0 0 
VFQSSTSQEQVYNDCAK 1618900 0 1618900 
VFSGLVSTGLK 0 0 0 
VFSIGPVFR 27739000 0 27739000 
VFSLSSEFK 9451000 0 9451000 
VFTAGSEER 6147000 0 6147000 
VFVDLLPATQCTK 0 0 0 
VFVMPNGMLK 0 0 0 
VFVPLPGSTVMLCDYK 9640400 0 9640400 
VFYYLVQDLK 96489000 0 96489000 
VGAEELTADQNLK 26934000 0 26934000 
VGDAIPAVEVFEGEPGNK 6412800 0 6412800 
 
 
400 | P a g e  
 
VGDPQELNGITR 12155000 0 12155000 
VGEEFEEQTVDGRPCK 28214000 0 28214000 
VGEFSGANK 88438000 0 88438000 
VGEGFEEETVDGR 8079900 0 8079900 
VGEGPGVCWLAPEQTAGK 565500 0 565500 
VGEIEFEGLMR 22032000 0 22032000 
VGEIVVFR 37442000 0 37442000 
VGENADSQIK 0 0 0 
VGFLPSAGK 17298000 0 17298000 
VGGDVPETNYLFMGDFVDR 4610700 0 4610700 
VGGTSDVEVNEK 2202400 0 2202400 
VGGVQSLGGTGALR 43962000 0 43962000 
VGINYQPPTVVPGGDLAK 398710000 0 398710000 
VGIPVTDENGNR 25919000 0 25919000 
VGLVASQK 31178000 0 31178000 
VGMVETNSQDRPVDDVK 46876000 0 46876000 
VGNLTVVGK 39937000 0 39937000 
VGPGAGESPGTPPFR 0 0 0 
VGQALELPLR 20450000 0 20450000 
VGQAMASTEEK 59930000 0 59930000 
VGQAVDVVGQAGKPK 18967000 0 18967000 
VGQDPVLR 113400000 0 113400000 
VGQEIEVRPGIVSK 20618000 0 20618000 
VGQLSEGAIAAIMQK 56984000 0 56984000 
VGSTSENITQK 7277200 0 7277200 
 
 
401 | P a g e  
 
VGSVEEFQGQER 9521300 0 9521300 
VGTVIGSNK 96191000 0 96191000 
VGVNGFGR 978150000 23371000 954780000 
VGWEQLLTTIAR 1428000 0 1428000 
VGYTPDWIFLLR 5107200 0 5107200 
VHAAVQPGSLDSESGIFACAFDQSESR 3005600 0 3005600 
VHAPEVDWIK 0 0 0 
VHLVGIDIFTGK 3012100 0 3012100 
VHPVSTMIK 176870000 0 176870000 
VHVDCMTSQK 2553300 0 2553300 
VIAALLQTMEDQGNQR 96434000 0 96434000 
VIADNVK 81450000 0 81450000 
VIAINVDDPDAANYNDINDVKR 7203900 0 7203900 
VIATDINESK 8325900 0 8325900 
VIATFTCSGEK 10733000 0 10733000 
VIAYNSEGK 8791900 0 8791900 
VIDQQNGLYR 15044000 0 15044000 
VIECSYTSADGQR 32517000 0 32517000 
VIEDIYEK 0 0 0 
VIEDNEYTAR 1981500 0 1981500 
VIEEQLEPAVEK 18065000 0 18065000 
VIFGLFGK 238500000 1831500 236670000 
VIFLENYR 13517000 0 13517000 
VIGIECSSISDYAVK 0 0 0 
VIGNQSLVNELAFTAR 12965000 0 12965000 
 
 
402 | P a g e  
 
VIGSGCNLDSAR 3695700000 126600000 3569100000 
VIISAPSADAPMFVMGVNHEK 2399400000 8282500 2391100000 
VIISCDLISPSVPPK 812010000 812010000 0 
VIITGDAFVPGER 3625300 0 3625300 
VILDLTPNYR 57838000 0 57838000 
VILGSEAAQQHPEEVR 17469000 0 17469000 
VIMGEEVEPVGLMTGSGVVGVK 9315000 0 9315000 
VIMVGSGGVGK 13403000 0 13403000 
VINEPTAAALAYGLDK 71714000 0 71714000 
VIPAADLSQQISTAGTEASGTGNMK 0 0 0 
VIPELNGK 1365900000 3445700 1362500000 
VIPGAAEK 38040000 0 38040000 
VIPSFMCQAGDFTNHNGTGGK 0 0 0 
VIQALAMK 7568000 0 7568000 
VIQCFAETGQVQK 102000000 0 102000000 
VIQDCEDENIQR 18139000 0 18139000 
VIQEGLEGLVLK 2351400 0 2351400 
VIQEIVDK 31175000 0 31175000 
VIQVAAGSSNLK 52289000 0 52289000 
VISELNGK 85267000 0 85267000 
VISLEDFMEK 46446000 0 46446000 
VISTLEEPTPQCPTSQGR 9650000 0 9650000 
VISYEEGK 15203000 0 15203000 
VIVDFSSPNIAK 0 0 0 
VIVVGNPANTNCLTASK 0 0 0 
 
 
403 | P a g e  
 
VKNPEDLSAETMAK 3129800 0 3129800 
VLAGETLSVNDPPDVLDR 9252400 0 9252400 
VLANNSLSFEK 6534900 0 6534900 
VLANPGNSQVAR 101540000 0 101540000 
VLANQYK 6355200 0 6355200 
VLATAFDTTLGGR 21290000 0 21290000 
VLAVNQENEHLMEDYEK 7435600 0 7435600 
VLAVNQENEQLMEDYEK 30838000 0 30838000 
VLDMPTQELGLPAYR 5494700 0 5494700 
VLDNAIETEK 73013000 0 73013000 
VLDPASSDFTR 0 0 0 
VLDPFTIKPLDR 43191000 0 43191000 
VLEACSIACNK 12063000 0 12063000 
VLECLASGIVMPDGSGIYDPCEK 27980000 0 27980000 
VLEDNKLPGAICSLTCGGADIGTAMAK 7160000 0 7160000 
VLEEYGAGVCSTR 7830200 0 7830200 
VLEFNCR 6489800 0 6489800 
VLEGMEVVR 516530000 0 516530000 
VLEGNEQFINAAK 4707900 4707900 0 
VLELVSITANK 55657000 0 55657000 
VLENAEGAR 25615000 0 25615000 
VLENIELNK 7308800 0 7308800 
VLEQLIVAHFPMQSR 18435000 0 18435000 
VLEQLTGQTPVFSK 62177000 0 62177000 
VLESLDR 8653600 0 8653600 
 
 
404 | P a g e  
 
VLESVAR 36067000 0 36067000 
VLFDNTGR 34067000 0 34067000 
VLFLLGADGGCITR 0 0 0 
VLFPGNSTQYNILEGLEK 4192400 0 4192400 
VLFSSNGGVVK 11124000 0 11124000 
VLGATLLPDLIQK 42102000 0 42102000 
VLGGSFADQK 0 0 0 
VLGLVLLR 17420000 0 17420000 
VLGMDPLPSK 0 0 0 
VLGMTLIQK 0 0 0 
VLGQLTETGVVSPEQFMK 18156000 0 18156000 
VLGSDTNCSAPR 240650000 12979000 227670000 
VLGTAFDPFLGGK 179510000 0 179510000 
VLGTEELYGYLK 18645000 0 18645000 
VLIDPVSVQDK 25528000 0 25528000 
VLIFSQMTK 29575000 0 29575000 
VLIFSQMTR 5087200 0 5087200 
VLIGGDETPEGQR 2371200 0 2371200 
VLIGVGK 20668000 0 20668000 
VLITTDLLAR 11756000 0 11756000 
VLLDNVENK 0 0 0 
VLLDQLR 13083000 0 13083000 
VLLSALER 0 0 0 
VLLVPGPEKEN 0 0 0 
VLNLGQALER 5013900 0 5013900 
 
 
405 | P a g e  
 
VLNNMEIGTSLFDEEGAK 80756000 0 80756000 
VLNSYWVGEDSTYK 9042600 0 9042600 
VLNTNIDGR 357970000 0 357970000 
VLPGSSVLFLCDMQEK 1885500 0 1885500 
VLPMNTGVEAGETACK 7684100 0 7684100 
VLPQEAEEENR 12817000 0 12817000 
VLPSITTEILK 21528000 0 21528000 
VLPSIVNEVLK 35124000 0 35124000 
VLQALEGLK 7274600 0 7274600 
VLQATVVAVGSGSK 7359900 0 7359900 
VLQDMGLPTGAEGR 13107000 0 13107000 
VLQGDLVMNVYR 31702000 0 31702000 
VLQNMEQCQK 4743700 0 4743700 
VLQQTMTK 1667100 0 1667100 
VLQSALAAIR 29498000 0 29498000 
VLQSDEYEEVEDK 9224400 0 9224400 
VLSECSPLMNDIFNK 96073000 0 96073000 
VLSGQDTEDR 5000800 0 5000800 
VLSQQAASVVK 11502000 0 11502000 
VLSSIEQK 322240000 0 322240000 
VLSTPDLEVR 13253000 0 13253000 
VLTEIIASR 15435000 0 15435000 
VLTGVAGEDAECHAAK 113620000 0 113620000 
VLTIDPTEFK 22088000 0 22088000 
VLTNITVSCQEK 1019000 0 1019000 
 
 
406 | P a g e  
 
VLTSDIEK 39423000 0 39423000 
VLTTAGSYVR 19011000 8437700 10573000 
VLTVINQTQK 60583000 0 60583000 
VLVDSLVEDDR 3318500 0 3318500 
VLVEGPLNNLR 9090500 0 9090500 
VLVEPDAGAGVAVMK 0 0 0 
VLVEWLR 9504400 0 9504400 
VLVIGAGGLGCELLK 2142500 0 2142500 
VLVLSQDYGK 18200000 0 18200000 
VLVPATDR 67954000 0 67954000 
VLVSPTNPPGATSSCQK 14394000 0 14394000 
VLVWDLR 25406000 0 25406000 
VLYAYGYYTGEPSK 12930000 0 12930000 
VLYPNDNFFEGK 43594000 0 43594000 
VLYSNMLGEENTYLWR 5680300 0 5680300 
VLYVQDSLEGEAR 0 0 0 
VMATTGGTNLR 16336000 0 16336000 
VMEIVDADEK 106000000 0 106000000 
VMEMYQPSAVVLQCGADSLSGDR 24032000 0 24032000 
VMEYINR 63094000 0 63094000 
VMFEVWR 35965000 0 35965000 
VMLGETNPADSK 56688000 0 56688000 
VMLGETNPADSKPGTIR 643710000 0 643710000 
VMQQQQQTTQQQLPQK 2566300 0 2566300 
VMQVLNADAIVVK 105040000 0 105040000 
 
 
407 | P a g e  
 
VMVELLGSYTEDNASQAR 7434900 0 7434900 
VMVLDFVTPTPLGTR 6364100 0 6364100 
VMVQPINLIFR 53352000 1100300 52251000 
VNAELQAR 0 0 0 
VNASASSLK 8299900 0 8299900 
VNEAAPEKPQDDSGTAGGISSTSASVNR 0 0 0 
VNEALLQR 17492000 0 17492000 
VNEIVETNRPDSK 1971800 0 1971800 
VNEVNQFAAK 37475000 0 37475000 
VNFAMNVGK 44866000 0 44866000 
VNFDDYTVNLGGLK 12532000 0 12532000 
VNFTVDQIR 0 0 0 
VNGDASPAAAESGAK 17664000 0 17664000 
VNIFGVESGK 0 0 0 
VNIIGEVVDQGSTNLK 30281000 0 30281000 
VNIIPLIAK 63869000 0 63869000 
VNIVPVIAK 3573100 0 3573100 
VNLAELFK 101770000 0 101770000 
VNLFTDFDK 56334000 0 56334000 
VNLGVGAYR 10070000 0 10070000 
VNLLQIVR 12639000 0 12639000 
VNLLSVLEAAK 16648000 0 16648000 
VNNSTMLGASGDYADFQYLK 64903000 0 64903000 
VNPIQGLASK 162520000 0 162520000 
VNQAIWLLCTGAR 14195000 0 14195000 
 
 
408 | P a g e  
 
VNQIGSVTESLQACK 85137000 0 85137000 
VNTLIRPDGEK 18588000 0 18588000 
VNVPVIGGHAGK 136740000 0 136740000 
VPADTEVVCAPPTAYIDFAR 300830000 6179700 294650000 
VPAGLEK 25075000 0 25075000 
VPAGNWVLIEGVDQPIVK 3152700 0 3152700 
VPAINVNDSVTK 317880000 0 317880000 
VPDVLVADPPIAR 5869600 0 5869600 
VPEANSSWMDTVIR 20566000 0 20566000 
VPEILQLSDALR 5676000 0 5676000 
VPELNVQNGVLK 0 0 0 
VPEPGVPTETIK 19573000 0 19573000 
VPEWVDTVK 2311800 0 2311800 
VPFLPGDSDLDQLTR 6966200 0 6966200 
VPFLVLECPNLK 126250000 0 126250000 
VPGLPTPIENMILR 7788000 0 7788000 
VPLAIVNK 15377000 0 15377000 
VPLQGFAALEGMNGIQK 7476900 0 7476900 
VPLVAPEDLR 12455000 0 12455000 
VPMASCDFSIR 0 0 0 
VPPAINQFTQALDR 163550000 0 163550000 
VPQVSTPTLVEVSR 24003000 24003000 0 
VPSENVLGEVGSGFK 39656000 0 39656000 
VPSLVGSFIR 6362100 0 6362100 
VPSTETEALASNLMGMFEK 15156000 0 15156000 
 
 
409 | P a g e  
 
VPTANVSVVDLTCR 596670000 0 596670000 
VPTWGPLR 0 0 0 
VPVNLLR 23591000 0 23591000 
VQAHAAAALINFTEDCPK 64245000 0 64245000 
VQAQGPGLK 5066700 0 5066700 
VQAQVIQETIVPK 1230400 0 1230400 
VQEGETIEDGAR 4777400 0 4777400 
VQEMVESNEAK 10773000 0 10773000 
VQENCIDLVGR 0 0 0 
VQEQLGNDVVEK 11336000 0 11336000 
VQESADELQK 119080000 2285200 116790000 
VQIAANEETQER 28175000 0 28175000 
VQIPIMLVGNK 31271000 0 31271000 
VQIQESVR 15325000 0 15325000 
VQQTVQDLFGR 25349000 0 25349000 
VQSDGQIVLVDDWIK 3310100 0 3310100 
VQTAALR 15800000 0 15800000 
VQTGEEGMPLSTIR 2568200 0 2568200 
VQVALEELQDLK 14839000 0 14839000 
VQVMVPEAETR 3553700 0 3553700 
VQVQDNEGCPVEALVK 0 0 0 
VQVYQEPNR 5332600 0 5332600 
VQYPQSQACK 7545600 0 7545600 
VSASPLLYTLIEK 23600000 0 23600000 
VSEEIEDIIK 14797000 0 14797000 
 
 
410 | P a g e  
 
VSEYVPEIVNFVQK 13838000 0 13838000 
VSFELFADK 527320000 0 527320000 
VSGGLEVLAEK 244530000 0 244530000 
VSGVDGYETEGIR 2157300 0 2157300 
VSQAAADLK 5487500 0 5487500 
VSQAAAELLAFCETHAK 46733000 0 46733000 
VSQGQLVVMQPEK 73658000 0 73658000 
VSQGSKDPAEGDGAQPEETPR 17246000 0 17246000 
VSQMAQYFEPLTLAAVGAASK 1563100 0 1563100 
VSQPIEGHAASFAQFK 14988000 0 14988000 
VSSDNVADLHEK 52752000 3431700 49320000 
VSSFEEK 65337000 363020 64974000 
VSTEVDAR 65966000 0 65966000 
VSYGIGDEEHDQEGR 43178000 0 43178000 
VSYYENVIK 41015000 0 41015000 
VTAQGPGLEPSGNIANK 68648000 0 68648000 
VTAVPTLLK 12715000 0 12715000 
VTCIDPNPNFEK 29172000 0 29172000 
VTDDLVCLVYK 15566000 0 15566000 
VTDFGDKVEDPTFLNQLQSGVNR 20618000 0 20618000 
VTDLVQFLLFK 927410 0 927410 
VTEGGEPYR 3997200 0 3997200 
VTEGLTDVILYHQPDDK 16250000 0 16250000 
VTEGLVDVILYHQPDDK 52960000 0 52960000 
VTEGSFVYK 117800000 0 117800000 
 
 
411 | P a g e  
 
VTELALTASDR 47932000 0 47932000 
VTGQFPWSSLR 20044000 0 20044000 
VTGTLDANR 375860000 3169600 372690000 
VTIAQGGVLPNIQAVLLPK 1108400 0 1108400 
VTLGTQPTVLR 16655000 0 16655000 
VTLLDLMIAK 6029800 0 6029800 
VTLMQLPTR 12727000 0 12727000 
VTLNPPGTFLEGVAK 1879400 0 1879400 
VTLPGQEEPWDIR 0 0 0 
VTLTSEEEAR 585000000 6797400 578200000 
VTMNFEPNK 6207800 0 6207800 
VTMQNLNDR 3581800 3581800 0 
VTNGAFTGEISPGMIK 54036000 0 54036000 
VTNLLMLK 14885000 0 14885000 
VTNLSEDTR 35782000 0 35782000 
VTPPAVTGSPEFER 18374000 0 18374000 
VTQDELK 40231000 0 40231000 
VTQSNFAVGYK 86022000 0 86022000 
VTQVDGNSPVR 7380500 0 7380500 
VTSAVEALLSADSASR 11427000 0 11427000 
VTSEGAGLQLQK 11920000 0 11920000 
VTTGTSNTTAIK 8433700 0 8433700 
VTWDSSFCAVNPR 0 0 0 
VTYMEEER 2825500 0 2825500 
VVAEPVELAQEFR 10683000 0 10683000 
 
 
412 | P a g e  
 
VVAIGECGLDFDR 6768600 0 6768600 
VVAPTISSPVCQEQLVEAGR 0 0 0 
VVDLLNQAALITNDSK 7534000 0 7534000 
VVDLMAHMASK 37282000 0 37282000 
VVDLMAHMASKE 0 0 0 
VVDYTTAK 6452500 0 6452500 
VVEDGILK 33806000 0 33806000 
VVEGSFVYK 34737000 4537600 30199000 
VVEGTPLIDGR 14589000 0 14589000 
VVEQLEK 11969000 0 11969000 
VVESGGPEILK 5265800 0 5265800 
VVFEQTK 515270000 0 515270000 
VVFQEFR 0 0 0 
VVFVFGPDK 96302000 710660 95591000 
VVGAMQLYSVDR 0 0 0 
VVGAQSLK 49971000 0 49971000 
VVHIMDFQR 12996000 0 12996000 
VVHVNGYGK 1690900 0 1690900 
VVIEDEQLVLGASQEPVGR 2643600 0 2643600 
VVIFQQEQENK 0 0 0 
VVIIGAGK 26897000 0 26897000 
VVINGQEVK 21514000 0 21514000 
VVLAYEPVWAIGTGK 173230000 0 173230000 
VVLIGDSGVGK 15381000 0 15381000 
VVLIGGKPDR 8842900 0 8842900 
 
 
413 | P a g e  
 
VVLLGEFLHPCEDDIVCK 15664000 0 15664000 
VVLLTGETSTDLK 7242500 0 7242500 
VVLPIEAPIR 73277000 1666200 71611000 
VVLVLAGR 3834900 0 3834900 
VVMDGVISDHECQELQR 2841400 0 2841400 
VVNDEEVVR 5358600 0 5358600 
VVNEINIEDLCLTK 46666000 0 46666000 
VVNIVPVIAK 27480000 0 27480000 
VVSLSEYR 0 0 0 
VVSPWNSEDAK 18062000 0 18062000 
VVSSIEQK 801880000 3677800 798200000 
VVSTQAPDR 1602900 0 1602900 
VVSVHPGDVLITSCTYNTEDR 18233000 0 18233000 
VVTDTDETELAR 7483200 0 7483200 
VVTGVANALAHR 32775000 32775000 0 
VVTQNICQYR 71519000 0 71519000 
VVTVGQFK 31602000 0 31602000 
VVTYGMANLLTGPK 64069000 0 64069000 
VVVLGLLPR 34601000 0 34601000 
VVVLNCEPSK 16865000 0 16865000 
VVVQVLAEEPEAVLK 8211800 0 8211800 
VVVVTGANTGIGK 19979000 0 19979000 
VVYIFGPPVK 0 0 0 
VVYTGTYDTEGVTPTK 0 0 0 
VWDISGLR 17394000 0 17394000 
 
 
414 | P a g e  
 
VWNLANCK 68614000 0 68614000 
VWQLQDLSFQTAAR 10772000 0 10772000 
VYATILNAGTNTDGFK 12498000 0 12498000 
VYAVATSTNTPCAR 6480400 0 6480400 
VYEGERPLTK 13135000 0 13135000 
VYIYSSGSVEAQK 10799000 0 10799000 
VYLQNEYK 0 0 0 
VYMGEMGR 16080000 0 16080000 
VYNVTQHAVGIVVNK 5131100 0 5131100 
VYPSSLSK 37824000 0 37824000 
VYQVTEQQISEK 0 0 0 
VYSYALALK 0 0 0 
VYTPVGK 22682000 0 22682000 
VYVGNLGTGAGK 14277000 0 14277000 
VYVVEGSK 19439000 0 19439000 
VYYVSEK 8263500 0 8263500 
WADNFMAEGCGGSK 0 0 0 
WAPNENK 24509000 0 24509000 
WCEYGLTFTEK 18873000 0 18873000 
WDPTANEDPEWILVEK 5947500 0 5947500 
WDTGENPIYK 1649700 0 1649700 
WDVLIQQATQCLNR 33936000 22246000 11691000 
WDYLTQVEK 39905000 0 39905000 
WELNSGDGAFYGPK 30752000 0 30752000 
WFEENASQSTVK 61736000 0 61736000 
 
 
415 | P a g e  
 
WFLTCINQPQFR 38642000 0 38642000 
WFVLDAETR 24453000 0 24453000 
WGEEEAELNK 8955000 0 8955000 
WGLGGTCVNVGCIPK 20497000 0 20497000 
WGSNELPAEEGK 34362000 0 34362000 
WGTLTDCVVMR 22849000 0 22849000 
WIDETPPVDQPSR 15684000 0 15684000 
WIDFDNDYK 24312000 0 24312000 
WIDLTMEDIR 32765000 0 32765000 
WISDWNLTTEK 7118900 0 7118900 
WISIMTER 27318000 0 27318000 
WLAIDANAR 0 0 0 
WLAPDGLIFPDR 111470000 0 111470000 
WLDESDAEMELR 16849000 0 16849000 
WLLLCNPGLADTIVEK 1885700 0 1885700 
WLLLTGISAQQNR 6840100 0 6840100 
WLNENAVEK 176890000 0 176890000 
WMVSSWLPSEVHPDINR 6855600 0 6855600 
WNFDDLLEK 0 0 0 
WNSPAEEGSSDCEVFSK 1819000 0 1819000 
WPFSLSEQQLDAR 8388100 0 8388100 
WSLQSEAHR 18388000 0 18388000 
WSPLENK 0 0 0 
WSSLACNIALDAVK 18596000 0 18596000 
WSTISENLFATTGYPGK 8849600 0 8849600 
 
 
416 | P a g e  
 
WSTLVEDYGMELR 28444000 0 28444000 
WTDENIDTVALK 46146000 0 46146000 
WTELAGCTADFR 5069600 0 5069600 
WTEYGLTFTEK 3756300 0 3756300 
WTGMIIGPPR 34891000 0 34891000 
WTMSSWTMKMMR 1512500 1512500 0 
WTNQLNSLNQAVVSK 0 0 0 
WTSQDSLLGMEFSGR 19386000 0 19386000 
WTTEQQQR 26464000 0 26464000 
WVTTASLLDYDTVAGADK 27742000 0 27742000 
WYVVQTNYDR 1986400 0 1986400 
YAACNAVGQMATDFAPGFQK 12256000 0 12256000 
YADLTEDQLPSCESLK 10901000 0 10901000 
YAEAVTR 251570000 0 251570000 
YAILNEPFK 3897200 0 3897200 
YALPLVGHR 6560800 0 6560800 
YALTGDEVK 304170000 0 304170000 
YALTTTLSAR 0 0 0 
YAMEQSIK 14071000 0 14071000 
YANEVNSDAGAFK 17931000 0 17931000 
YASACQMK 1903600 0 1903600 
YASICQQNGIVPIVEPEILPDGDHDLK 36030000 0 36030000 
YATLATVSR 3443100 1367500 2075600 
YAVLYQPLFDK 20553000 0 20553000 
YAVPSAGLR 62757000 0 62757000 
 
 
417 | P a g e  
 
YCALLLPLLK 4402800 0 4402800 
YCAQDAFFQVK 3185400 0 3185400 
YCFGVEDTLK 0 0 0 
YCGLCDSIITIYR 0 0 0 
YCTDTGVLFR 10677000 0 10677000 
YDAFLASESLIK 50485000 0 50485000 
YDDAIQLYDR 1023100 0 1023100 
YDDMAAAMK 127630000 0 127630000 
YDDMAACMK 78805000 0 78805000 
YDDPEVQK 16286000 0 16286000 
YDEEFQR 19203000 0 19203000 
YDEMVESMK 332520000 0 332520000 
YDGLVGMFDPK 32734000 0 32734000 
YDGQVAVFGSDLQEK 12734000 0 12734000 
YDLSPITVK 0 0 0 
YDLTVPFAR 111770000 0 111770000 
YDPTIEDSYR 0 0 0 
YDQNYDIR 5131400 0 5131400 
YDYEEVEAEGANK 36076000 0 36076000 
YDYNSGEELESYK 9897200 0 9897200 
YEAAGTLVTLSSAPTAIK 60425000 0 60425000 
YEAAYGK 7063800 0 7063800 
YEDAYQYQNIFGPLVK 2927800 0 2927800 
YEDICPSTHNMDVPNIK 14311000 0 14311000 
YEDLAPCITLK 11765000 0 11765000 
 
 
418 | P a g e  
 
YEFLWGPR 2163500 0 2163500 
YEGGYPALTEVMNK 4799800 0 4799800 
YEILTPNSIPK 8652800 0 8652800 
YEIMDGAPVR 2397500 0 2397500 
YEITEQR 21919000 0 21919000 
YENNVMNIR 24989000 0 24989000 
YEPIVTK 86068000 0 86068000 
YEQGTGCWQGPNR 64454000 1986600 62468000 
YESLTDPSK 374300000 0 374300000 
YEWDVAEAR 0 0 0 
YFAYDCEASFPGISTGPMK 5895300 0 5895300 
YFDEISQDTGK 11889000 0 11889000 
YFDPANGK 204540000 0 204540000 
YFDSCNGDLDPEIVK 9037400 0 9037400 
YFDTVPVAAAMCVLK 10365000 0 10365000 
YFEGVSPK 55628000 0 55628000 
YFEVEEADGNK 2206400 0 2206400 
YFFDFLDEQAEK 2909400 0 2909400 
YFFFDDGNGLK 51014000 0 51014000 
YFGDIISVGQR 0 0 0 
YFGGTEDR 17463000 0 17463000 
YFLFYDGETVSGK 1108200 0 1108200 
YFPFMDLK 11353000 0 11353000 
YFPTQALNFAFK 48074000 0 48074000 
YFQFQEEGK 6268500 0 6268500 
 
 
419 | P a g e  
 
YFTLGLPTGSTPLGCYK 18683000 0 18683000 
YFTWDPSR 111240000 0 111240000 
YFVISNTTGYNDR 2333500 0 2333500 
YGALALQEIFDGIQPK 5192200 0 5192200 
YGDAFIR 12418000 0 12418000 
YGDSGEQIAGFVK 0 0 0 
YGEPGEVFINK 33241000 0 33241000 
YGEYFPGTGDLR 58809000 0 58809000 
YGGPPPDSVYSGVQPGIGTEVFVGK 8450000 0 8450000 
YGGQPVPNFPSK 5294800 0 5294800 
YGIENVK 14412000 0 14412000 
YGIEPTMVVQGVK 0 0 0 
YGIVDYMIEQSGPPSK 90441000 0 90441000 
YGLECLFR 5889000 0 5889000 
YGMGTSVER 38175000 0 38175000 
YGPADVEDTTGSGATDSK 2879300 0 2879300 
YGPFVADFADK 70265000 0 70265000 
YGPMEEPLVIEK 0 0 0 
YGQFSGLNPGGR 19276000 0 19276000 
YGSPGNVSK 34310000 0 34310000 
YGSQVEDQR 4473900 0 4473900 
YGTCPHGGYGLGLER 42667000 0 42667000 
YGVSGYPTLK 55705000 0 55705000 
YHNVGLSK 12124000 0 12124000 
YHTSQSGDEMTSLSEYVSR 249460000 3814800 245650000 
 
 
420 | P a g e  
 
YIAENGTDPINNQPLSEEQLIDIK 17760000 0 17760000 
YIAIVSTTVETK 0 0 0 
YICDNQDTISSK 444840000 444840000 0 
YIDQEELNK 835800000 4810400 830980000 
YIETSELCGGAR 14601000 0 14601000 
YIIIGDMGVGK 27163000 0 27163000 
YIIIGDTGVGK 24858000 0 24858000 
YILAATLDNTLK 6506900 0 6506900 
YIMVPSGNMGVFDPTEIHNR 15532000 0 15532000 
YIQAEPPTNK 18343000 0 18343000 
YIQELWR 2876500 0 2876500 
YISLIYTNYEAGK 46440000 0 46440000 
YISLIYTNYEAGKDDYVK 13631000 0 13631000 
YISPDQLADLYK 513920000 0 513920000 
YITDWQNVFR 0 0 0 
YITGDQLGALYQDFVR 1783200 0 1783200 
YITGTDILDMK 23064000 0 23064000 
YITQNGDYQLR 2351600 0 2351600 
YIYIMGIQER 18584000 0 18584000 
YKPESEELTAER 158420000 0 158420000 
YLAADKDGNVTCER 62896000 0 62896000 
YLAEFATGNDR 832040000 20466000 811580000 
YLAEFATGNDRK 108760000 0 108760000 
YLAEVAAGDDK 164080000 0 164080000 
YLAEVAAGDDKK 254090000 0 254090000 
 
 
421 | P a g e  
 
YLAEVACGDDR 163520000 4253200 159270000 
YLAEVACGDDRK 44125000 0 44125000 
YLAEVASGEK 73870000 0 73870000 
YLAEVATGEK 321680000 0 321680000 
YLAIAPPIIK 39389000 0 39389000 
YLCDEQK 17177000 0 17177000 
YLDLILNDFVR 8225500 0 8225500 
YLDSIPPGQYMDSSLVK 10496000 0 10496000 
YLEAGAAGLR 28549000 0 28549000 
YLEANMTQSALPK 7041000 0 7041000 
YLEAVEK 31879000 0 31879000 
YLEMIYSMCK 19452000 0 19452000 
YLEPLYNDYR 15380000 0 15380000 
YLFLGDYVDR 25946000 0 25946000 
YLGLLENLR 9557800 0 9557800 
YLIANATNPESK 86709000 0 86709000 
YLIATSEQPIAALHR 34769000 0 34769000 
YLIPNATQPESK 82193000 0 82193000 
YLLADCNEAFIK 20932000 0 20932000 
YLLAMER 3154000 0 3154000 
YLLDSCAPLLR 0 0 0 
YLLGDMEGR 0 0 0 
YLLLMDLQDR 1721600 0 1721600 
YLMEEDEDAYKK 28042000 0 28042000 
YLNIFGESQPNPK 0 0 0 
 
 
422 | P a g e  
 
YLQQIFESQR 10926000 0 10926000 
YLQSLLAEVER 7392500 0 7392500 
YLSEVASGDNK 63057000 0 63057000 
YLSNAYAR 11530000 0 11530000 
YLTGTYVQEESPEGGR 4921800 0 4921800 
YLTLDGFDAMFR 8953000 0 8953000 
YLTMDDLTTALEGNR 37091000 0 37091000 
YLTTAVITNK 25344000 0 25344000 
YLYEIAR 57818000 57818000 0 
YMACCLLYR 64515000 0 64515000 
YMDAWNTVSR 2157700 0 2157700 
YMEENDQLKK 27235000 0 27235000 
YMLPLDNLK 18057000 0 18057000 
YMMIVDPAISSSGPAGSYRPYDEGLR 3582100 0 3582100 
YMSPEQISSQDYGK 0 0 0 
YMTDGMLLR 0 0 0 
YNACILEYK 2981200 0 2981200 
YNAQCQETIR 7905600 0 7905600 
YNDTFWK 16939000 0 16939000 
YNGVFQECCQAEDK 192620000 192620000 0 
YNILGTNTIMDK 171090000 0 171090000 
YNPNVLPVQCTGK 10868000 0 10868000 
YNPTWHCIVGR 11302000 0 11302000 
YNQPFFVTSLPDDK 4460100 0 4460100 
YPEAPPFVR 0 0 0 
 
 
423 | P a g e  
 
YPEETLSLMTK 14056000 0 14056000 
YPENFFLLR 53089000 0 53089000 
YPIEHGIITNWDDMEK 1145800000 1647100 1144200000 
YPQLLPGIR 22897000 0 22897000 
YPSATNNTPAK 3378800 0 3378800 
YPSPFFVFGEK 15548000 0 15548000 
YPVNSVNILK 0 0 0 
YQAVTATLEEK 64369000 0 64369000 
YQEALAK 31951000 0 31951000 
YQEALHLGSQLLR 35457000 0 35457000 
YQEELNFDNPLGMR 2602700 0 2602700 
YQETFNVIER 0 0 0 
YQEVTNNLEFAK 2419900 0 2419900 
YQILPLHSQIPR 17017000 0 17017000 
YQLDKDGVVLFK 92681000 0 92681000 
YQLNLPPYPDTECVYR 0 0 0 
YQQGDFGYCPR 46491000 0 46491000 
YQQLFEDIR 0 0 0 
YQSHDYAFSSVEK 5030000 0 5030000 
YQYVDCGR 44602000 0 44602000 
YRPGTVALR 232180000 0 232180000 
YRVPDVLVADPPIAR 0 0 0 
YSDIEPSTEGEVIFR 13140000 0 13140000 
YSDSLVQK 13305000 0 13305000 
YSEEGVYNVQYSFIK 3289000 0 3289000 
 
 
424 | P a g e  
 
YSELTTVQQQLIR 25125000 0 25125000 
YSEVFEAINITNNEK 11428000 0 11428000 
YSFLQFDPAPR 46563000 0 46563000 
YSGDQILIR 7982800 0 7982800 
YSIDQEFLK 1691800 0 1691800 
YSLEPVAVELK 108060000 0 108060000 
YSNDPVVASLAQDIFK 7006300 0 7006300 
YSNSALGHVNCTIK 74053000 0 74053000 
YSNSEVVTGSGR 11542000 0 11542000 
YSQVLANGLDNK 61341000 0 61341000 
YSQYQQAIYK 24320000 0 24320000 
YSSTEEVLVAAK 6572500 0 6572500 
YSTDVSVDEVK 19862000 0 19862000 
YSTSGSSGLTTGK 8191700 0 8191700 
YSVQTADHR 321780000 5065600 316710000 
YSYQYTVANK 31384000 0 31384000 
YSYVCPDLVK 0 0 0 
YTAESSDTLCPR 10981000 0 10981000 
YTCGEAPDYDR 18904000 0 18904000 
YTCSFCGK 18246000 0 18246000 
YTEGVQSLNWTK 0 0 0 
YTFEEIQQETDIPER 1164800 0 1164800 
YTGEDFDEDLR 9616100 0 9616100 
YTGTLDCAK 12864000 0 12864000 
YTMGDAPDYDR 1118600 0 1118600 
 
 
425 | P a g e  
 
YTPEEIAMATVTALR 1983000 0 1983000 
YTQGGLENLELSR 0 0 0 
YTQSNSVCYAK 28907000 0 28907000 
YTSQIVGR 28727000 0 28727000 
YTTPEDATPEPGEDPR 13941000 0 13941000 
YTTTQQVVK 1312800 0 1312800 
YTVQDESHSEWVSCVR 9249300 0 9249300 
YVAAAFPSACGK 0 0 0 
YVAEIEK 63688000 0 63688000 
YVALTSLLK 30023000 0 30023000 
YVALVQEK 12154000 0 12154000 
YVANLFPYK 6251700 0 6251700 
YVASYLLAALGGNSSPSAK 3588300 0 3588300 
YVECSALTQK 0 0 0 
YVENFGLIDGR 0 0 0 
YVIYIER 14645000 0 14645000 
YVLCTAPR 7260900 0 7260900 
YVLEPEISFTSDNSFAK 6762400 0 6762400 
YVLGDTAMQK 0 0 0 
YVLINWVGEDVPDAR 5631800 0 5631800 
YVMTTTTLER 5248300 0 5248300 
YVPYVGDSK 52850000 0 52850000 
YVQLPADEVDTQLLQDAAR 33097000 0 33097000 
YVQQLQR 6759000 0 6759000 
YVVEMAEGSNGNK 777120 0 777120 
 
 
426 | P a g e  
 
YVVVTGITPTPLGEGK 22298000 0 22298000 
YWLCAATGPSIK 177680000 0 177680000 
YWTLTATGGVQSTASSK 0 0 0 
YWYLGPLK 8640000 0 8640000 
YYAVNFPMR 56276000 0 56276000 
YYDDTYPSVK 53441000 0 53441000 
YYDQICSIEPK 18388000 0 18388000 
YYEAADTVTQFDNVR 973740 0 973740 
YYGLQILENVIK 1621200 0 1621200 
YYMNQVEETR 28287000 0 28287000 
YYNAESYEVER 1506400 0 1506400 
YYNDYGDIIK 0 0 0 
YYPTEDVPR 41146000 0 41146000 
YYTEFPTVLDITAEDPSK 10138000 0 10138000 
YYTPTISR 117820000 0 117820000 
YYTSASGDEMVSLK 431650000 1249500 430400000 
YYVLNALK 2847200 0 2847200 
YYVTIIDAPGHR 461920000 0 461920000 
   
 
 
427 | P a g e  
 
Appendix 2 
Dysregulated SILAC proteins 
Uniprot 
accession # 






A0AVT1 UBA6 ubiquitin-like modifier activating 
enzyme 6 
1.105 0.006  
A6ZKI3 FAM127A family with sequence similarity 
127, member A 
1.273  0.021 
B1AKJ5 NRD1 nardilysin (N-arginine dibasic 
convertase) 
1.074  0.002 
B1AKZ3 PEA15 phosphoprotein enriched in 
astrocytes 15 
1.075  0.004 
B1AVU8     -1.195  0.017 
B3KQV7 SLC29A1 solute carrier family 29 
(equilibrative nucleoside 
transporter), member 1 
1.230 0.02  
B3KS98 EIF3H eukaryotic translation initiation 
factor 3, subunit H 
-1.203 0.035  
B4DNJ6 STRAP serine/threonine kinase receptor 
associated protein 
1.049  0.003 
B4DR61 SEC61A1 Sec61 alpha 1 subunit (S. 
cerevisiae) 
1.123 0.008  
B4E1G6 GALK1 galactokinase 1 -1.100 0  
B7Z254 PDIA6 protein disulfide isomerase family 
A, member 6 
1.245 0.003 0.001 
B7Z7Q0 PITPNB phosphatidylinositol transfer 
protein, beta 
1.391  0.02 
B9A064 IGLL1/IGLL5 immunoglobulin lambda-like 
polypeptide 1 
-5.039  0.001 
C9IZQ1 SSR1 signal sequence receptor, alpha 1.131 0.021  
C9JEA7 PLCD4 phospholipase C, delta 4 1.131  0.002 
C9JEH3 AAMP angio-associated, migratory cell 
protein 
-1.078  0.026 
C9JWM7 ARPC4 actin related protein 2/3 complex, 
subunit 4, 20kDa 
1.098  0.014 
D3DQV9 EIF4G2 eukaryotic translation initiation 
factor 4 gamma, 2 
1.121 0.029  
E7EPA7 TKT transketolase 1.258 0.023 0.046 
E7EX17 EIF4B eukaryotic translation initiation 
factor 4B 
-1.112  0.021 
E9PCK7 RRP12 ribosomal RNA processing 12 
homolog 
1.032  0.02 
E9PFM1 EIF4G1 eukaryotic translation initiation 
factor 4 gamma, 1 
1.048  0.038 
E9PHK9     -1.245 0.03  
E9PK25 CFL1 cofilin 1 (non-muscle) 1.018 0.017  
E9PNQ8 THY1 Thy-1 cell surface antigen -1.282 0.019  
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F5H3A1 ATP1A1 ATPase, Na+/K+ transporting, 
alpha 1 polypeptide 
1.061 0.018  
F5H3J8     6.521  0.028 
F5HFY4 NAP1L4 nucleosome assembly protein 1-
like 4 
-1.062  0.027 
F8W7C6 RPL10 ribosomal protein L10 -1.078 0.004  
F8W8S0     1.089  0.037 
G3V2N0 GNG2 guanine nucleotide binding protein 
(G protein), gamma 2 
-1.205 0  
G3V4T6 GSTZ1 glutathione S-transferase zeta 1 -1.194 0.004  
G3V5Z7 PSMA6 proteasome (prosome, macropain) 
subunit, alpha type, 6 
1.048  0.048 
H0YBA3 NRG1 neuregulin 1 1.012 0.002  
H0YHU6     -23.605 0.036  
H3BPE7 FUS FUS RNA binding protein -1.093 0.004  
H7BYM6     -1.091  0.038 
H7C2I1 PRMT1 protein arginine methyltransferase 
1 
1.048 0.008  
I3NI00     -1.108 0.021  




NODAL modulator 1 1.075 0.021  
J3KPP7     1.117  0.018 
J3KPV7 MPST mercaptopyruvate 
sulfurtransferase 
1.035 0.009  
J3KTA4 DDX5 DEAD (Asp-Glu-Ala-Asp) box 
helicase 5 
1.063 0.016  
J3QLS3 MRPS7 mitochondrial ribosomal protein 
S7 
-1.050 0.02  
J3QT22 PPME1 protein phosphatase 
methylesterase 1 
-1.058 0.027  
O00116 AGPS alkylglycerone phosphate synthase 1.073 0.013  
O00571 DDX3X DEAD (Asp-Glu-Ala-Asp) box 
helicase 3, X-linked 
1.084 0.029 0.011 
O00629 KPNA4 karyopherin alpha 4 (importin 
alpha 3) 
-1.016  0.039 
O14579 COPE coatomer protein complex, subunit 
epsilon 
1.087  0.004 
O14979 HNRNPDL heterogeneous nuclear 
ribonucleoprotein D-like 
-1.047  0.015 
O14980 XPO1 exportin 1 -1.008 0.032  
O15116 LSM1 LSM1 homolog, mRNA degradation 
associated 
1.264  0.017 
O15143 ARPC1B actin related protein 2/3 complex, 
subunit 1B, 41kDa 
1.137 0.016  
O15144 ARPC2 actin related protein 2/3 complex, 
subunit 2, 34kDa 
1.056 0.047  
O15397 IPO8 importin 8 -1.067  0.012 
O15511 ARPC5 actin related protein 2/3 complex, 
subunit 5, 16kDa 
1.089 0.032  
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O43175 PHGDH phosphoglycerate dehydrogenase -1.076 0.015  
O43447 PPIH peptidylprolyl isomerase H 
(cyclophilin H) 
-1.128 0  
O43633 CHMP2A charged multivesicular body 
protein 2A 
1.087  0.047 
O43707 ACTN4 actinin, alpha 4 1.119  0 
O43760 SYNGR2 synaptogyrin 2 1.193 0  
O60763-2 USO1 USO1 vesicle transport factor 1.097  0.039 
O75083 WDR1 WD repeat domain 1 1.209 0.015  
O75367 H2AFY H2A histone family, member Y 1.004 0.026  
O75369-8 FLNB filamin B, beta 1.254  0.038 
O75475 PSIP1 PC4 and SFRS1 interacting protein 
1 
-1.179  0.049 
O75569 PRKRA protein kinase, interferon-
inducible double stranded RNA 
dependent activator 
-1.173  0.035 
O75688 PPM1B protein phosphatase, Mg2+/Mn2+ 
dependent, 1B 
-1.159  0.044 
O75718 CRTAP cartilage associated protein 1.119  0.031 
O75874 IDH1 isocitrate dehydrogenase 1 
(NADP+), soluble 
1.101 0.009  
O75915 ARL6IP5 ADP-ribosylation factor-like 6 
interacting protein 5 
1.172 0.045  
O75976 CPD carboxypeptidase D 1.050 0.02  
O94888 UBXN7 UBX domain protein 7 -3.555 0.004  
O94925-3 GLS glutaminase -1.181 0.029  
O95372 LYPLA2 lysophospholipase II 1.147 0.016  
O95399-2 UTS2 urotensin 2 1.134  0.015 
O95433 AHSA1 AHA1, activator of heat shock 
90kDa protein ATPase homolog 1 
(yeast) 
1.025  0.042 
O95864 FADS2 fatty acid desaturase 2 1.248 0.006  
O96019 ACTL6A actin-like 6A -1.193 0.017  
P00338-3 LDHA lactate dehydrogenase A 1.105  0.001 
P00374     -1.289 0.038  
P01040 CSTA cystatin A (stefin A) -4.740 0.037  
P01876 IGHA1 immunoglobulin heavy constant 
alpha 1 
-9.966 0.032 0.022 
P02786 TFRC transferrin receptor 1.240 0.041 0.027 
P05109 S100A8 S100 calcium binding protein A8 -5.529 0.021  
P05141 SLC25A5 solute carrier family 25 
(mitochondrial carrier; adenine 
nucleotide translocator), member 
5 
1.091 0.026  
P05198 EIF2S1 eukaryotic translation initiation 
factor 2, subunit 1 alpha, 35kDa 
1.036  0.047 
P05386 RPLP1 ribosomal protein, large, P1 -1.078 0.011  
P05388 RPLP0 ribosomal protein, large, P0 -1.053 0.013  
P05455 SSB Sjogren syndrome antigen B 
(autoantigen La) 
1.045  0.018 
P06493 CDK1 cyclin-dependent kinase 1 -1.229 0.019 0.008 
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P06730-2 EIF4E eukaryotic translation initiation 
factor 4E 
1.070 0.013 0.041 
P06753-2 TPM3 tropomyosin 3 1.041  0.028 
P07339 CTSD cathepsin D -1.247  0.017 
P07814 EPRS glutamyl-prolyl-tRNA synthetase -1.024 0.042  
P07900-2 HSP90AA1 heat shock protein 90kDa alpha 
(cytosolic), class A member 1 
-1.035  0.002 
P07954 FH fumarate hydratase -1.048 0.014  
P08107     -1.162  0.011 
P08133 ANXA6 annexin A6 -1.119  0.024 
P08183 ABCB1 ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
1.271 0.035  
P08195-4 SLC3A2 solute carrier family 3 (amino acid 
transporter heavy chain), member 
2 
1.202 0.046  
P08243 ASNS asparagine synthetase (glutamine-
hydrolyzing) 
1.272 0.036  
P08559-4 PDHA1 pyruvate dehydrogenase 
(lipoamide) alpha 1 
1.037 0.049  
P08754 GNAI3 guanine nucleotide binding protein 
(G protein), alpha inhibiting 
activity polypeptide 3 
1.113 0.034  
P08865 RPSA ribosomal protein SA -1.032 0.016  
P09172 DBH dopamine beta-hydroxylase 
(dopamine beta-monooxygenase) 
1.672  0.028 
P09211 GSTP1 glutathione S-transferase pi 1 -1.197 0.01  
P09429 HMGB1 high mobility group box 1 -1.048  0.016 
P09936 UCHL1 ubiquitin carboxyl-terminal 
esterase L1 (ubiquitin 
thiolesterase) 
1.127 0.003  
P0C0S5 H2AFZ H2A histone family, member Z -1.091 0  
P10412 HIST1H1E histone cluster 1, H1e -1.251 0.006  
P10645 CHGA chromogranin A 2.095  0.009 
P11142 HSPA8 heat shock 70kDa protein 8 -1.016  0.019 
P11166 SLC2A1 solute carrier family 2 (facilitated 
glucose transporter), member 1 
-1.340 0.02  
P11233 RALA v-ral simian leukemia viral 
oncogene homolog A (ras related) 
-1.064 0.028  
P11413-2 G6PD glucose-6-phosphate 
dehydrogenase 
1.137 0.034  
P11498 PC pyruvate carboxylase -1.026 0.011  






-1.033 0.021  
P12004 PCNA proliferating cell nuclear antigen -1.056 0.04  
P12956 XRCC6 X-ray repair complementing 
defective repair in Chinese 
hamster cells 6 
1.054  0.039 
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P13073 COX4I1 cytochrome c oxidase subunit IV 
isoform 1 
1.217 0.01  
P13591 NCAM1 neural cell adhesion molecule 1 -1.243 0.037  
P13639 EEF2 eukaryotic translation elongation 
factor 2 
-1.117 0.012 0.017 
P13667 PDIA4 protein disulfide isomerase family 
A, member 4 
1.122  0.017 
P13674-2 P4HA1 prolyl 4-hydroxylase, alpha 
polypeptide I 
1.116  0.011 
P14324 FDPS farnesyl diphosphate synthase 1.168 0.019  
P14618 PKM pyruvate kinase, muscle 1.035 0  
P14625 HSP90B1 heat shock protein 90kDa beta 
(Grp94), member 1 
1.109  0.032 
P14868 DARS aspartyl-tRNA synthetase 1.040 0.019  
P15121 AKR1B1 aldo-keto reductase family 1, 
member B1 (aldose reductase) 
-1.183 0.023  
P15311 EZR ezrin 1.096  0.005 
P15880 RPS2 ribosomal protein S2 -1.011 0.032  
P15924 DSP desmoplakin -5.506  0 
P16401 HIST1H1B histone cluster 1, H1b -1.256 0.014 0.007 
P16403 HIST1H1C histone cluster 1, H1c -1.227 0.003  
P17987 TCP1 t-complex 1 1.037 0.015  
P18077 RPL35A ribosomal protein L35a 1.064 0.006 0 
P18085 ARF4 ADP-ribosylation factor 4 1.064 0.021  
P18669 PGAM1 phosphoglycerate mutase 1 (brain) -1.111  0.007 
P18754-2 RCC1 regulator of chromosome 
condensation 1 
1.151  0.026 
P20700 LMNB1 lamin B1 -1.106  0.019 
P21266 GSTM3 glutathione S-transferase mu 3 
(brain) 
1.059 0.038  






1.064 0.009  




1.039 0.02  
P22626 HNRNPA2B1 heterogeneous nuclear 
ribonucleoprotein A2/B1 
-1.052 0.008 0 
P22695 UQCRC2 ubiquinol-cytochrome c reductase 
core protein II 
1.101 0.024  
P23284 PPIB peptidylprolyl isomerase B 
(cyclophilin B) 
1.132  0.046 
P23396 RPS3 ribosomal protein S3 1.062  0.004 
P24386 CHM choroideremia (Rab escort protein 
1) 
1.282  0.03 
P24534 EEF1B2 eukaryotic translation elongation 
factor 1 beta 2 
-1.091  0.018 
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P25205 MCM3 minichromosome maintenance 
complex component 3 
-1.291 0.017 0.006 
P25789 PSMA4 proteasome (prosome, macropain) 
subunit, alpha type, 4 
-1.093 0.007  
P26583 HMGB2 high mobility group box 2 -1.091  0.008 
P26641 EEF1G eukaryotic translation elongation 
factor 1 gamma 
-1.023  0.008 
P27348 YWHAQ tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
theta 
-1.075 0.006  
P27797 CALR calreticulin 1.087  0.035 
P28070 PSMB4 proteasome (prosome, macropain) 
subunit, beta type, 4 
1.047  0.041 
P28074 PSMB5 proteasome (prosome, macropain) 
subunit, beta type, 5 
1.037  0.028 
P30044 PRDX5 peroxiredoxin 5 1.094 0.041  
P31944 CASP14 caspase 14, apoptosis-related 
cysteine peptidase 
-2.454  0.028 
P32119 PRDX2 peroxiredoxin 2 -1.112 0.009  
P33316 DUT deoxyuridine triphosphatase -1.168  0.043 
P33947 KDELR2 KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein 
retention receptor 2 
1.177 0.005  
P33991 MCM4 minichromosome maintenance 
complex component 4 
-1.124 0.048  
P33992 MCM5 minichromosome maintenance 
complex component 5 
-1.171  0.031 
P33993 MCM7 minichromosome maintenance 
complex component 7 
-1.213  0.018 
P34932 HSPA4 heat shock 70kDa protein 4 -1.008  0.026 
P35030 PRSS3 protease, serine, 3 -11.081 0.009 0.043 
P35611-3 ADD1 adducin 1 (alpha) -1.152  0.049 
P35908 KRT2 keratin 2, type II -6.462  0.031 
P35998 PSMC2 proteasome (prosome, macropain) 
26S subunit, ATPase, 2 
-1.068 0.002 0.019 
P36543 ATP6V1E1 ATPase, H+ transporting, lysosomal 
31kDa, V1 subunit E1 
1.084 0.016  
P38606 ATP6V1A ATPase, H+ transporting, lysosomal 
70kDa, V1 subunit A 
1.060 0.04  
P38646 HSPA9 heat shock 70kDa protein 9 
(mortalin) 
-1.048  0.045 
P39019 RPS19 ribosomal protein S19 1.082 0.003  
P40227 CCT6A chaperonin containing TCP1, 
subunit 6A (zeta 1) 
1.038 0.004  
P40616 ARL1 ADP-ribosylation factor-like 1 1.142 0.029  
P40926 MDH2 malate dehydrogenase 2, NAD 
(mitochondrial) 
-1.121 0.033  
P41091 EIF2S3 eukaryotic translation initiation 
factor 2, subunit 3 gamma, 52kDa 
1.091  0.044 
P43304 GPD2 glycerol-3-phosphate -1.219 0.033  
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dehydrogenase 2 (mitochondrial) 
P43487 RANBP1 RAN binding protein 1 -1.032  0.001 
P43490 NAMPT nicotinamide 
phosphoribosyltransferase 
1.148 0.009  
P46108 CRK v-crk avian sarcoma virus CT10 
oncogene homolog 
1.016  0.001 
P46778 RPL21 ribosomal protein L21 -1.014 0.047  
P46782 RPS5 ribosomal protein S5 1.213  0.049 
P46783 RPS10 ribosomal protein S10 -1.067 0.043  
P47914 RPL29 ribosomal protein L29 -1.275 0.025  
P48643 CCT5 chaperonin containing TCP1, 
subunit 5 (epsilon) 
-1.092  0.04 
P48735 IDH2 isocitrate dehydrogenase 2 
(NADP+), mitochondrial 
-1.103 0  
P49006 MARCKSL1 MARCKS-like 1 -1.162 0.046  
P49321 NASP nuclear autoantigenic sperm 
protein (histone-binding) 
-1.087  0.012 
P49327 FASN fatty acid synthase 1.142  0.028 
P49354 FNTA farnesyltransferase, CAAX box, 
alpha 
1.145  0 
P49366 DHPS deoxyhypusine synthase -1.059  0.021 
P49589-3 CARS cysteinyl-tRNA synthetase 1.127 0.002  
P49643 PRIM2 primase, DNA, polypeptide 2 
(58kDa) 
-1.247  0.01 
P49720 PSMB3 proteasome (prosome, macropain) 
subunit, beta type, 3 
1.045  0.018 
P49959 MRE11A MRE11 homolog A, double strand 
break repair nuclease 
-1.073 0.037  
P50148 GNAQ guanine nucleotide binding protein 
(G protein), q polypeptide 
-1.089 0.024  
P50213 IDH3A isocitrate dehydrogenase 3 (NAD+) 
alpha 
1.112 0.003  
P50897 PPT1 palmitoyl-protein thioesterase 1 1.062 0  
P51114 FXR1 fragile X mental retardation, 
autosomal homolog 1 
-1.027  0.007 
P51659 HSD17B4 hydroxysteroid (17-beta) 
dehydrogenase 4 
1.087 0.007  
P51809 VAMP7 vesicle-associated membrane 
protein 7 
-1.091 0.021  
P51991 HNRNPA3 heterogeneous nuclear 
ribonucleoprotein A3 
-1.027  0.036 
P52298 NCBP2 nuclear cap binding protein 
subunit 2, 20kDa 
1.110  0.015 
P52565 ARHGDIA Rho GDP dissociation inhibitor 
(GDI) alpha 
-1.046  0.036 
P52732 KIF11 kinesin family member 11 -1.188 0.042  
P53396 ACLY ATP citrate lyase 1.158  0.033 
P53634 CTSC cathepsin C 1.091  0.038 
P53999 SUB1 SUB1 homolog (S. cerevisiae) 1.165  0.03 
P54136 RARS arginyl-tRNA synthetase 1.047 0.01  
P54727 RAD23B RAD23 homolog B, nucleotide 1.178  0.001 
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excision repair protein 
P54920 NAPA N-ethylmaleimide-sensitive factor 
attachment protein, alpha 
1.087 0.035  
P55060 CSE1L CSE1 chromosome segregation 1-
like (yeast) 
-1.084 0.001 0.008 
P55072 VCP valosin containing protein 1.037  0.015 
P60468 SEC61B Sec61 beta subunit 1.073 0.041  
P60953 CDC42 cell division cycle 42 -1.027 0.024  
P61081 UBE2M ubiquitin-conjugating enzyme E2M 1.118 0.049  
P61158 ACTR3 ARP3 actin-related protein 3 
homolog (yeast) 
1.042  0.007 
P61163 ACTR1A ARP1 actin-related protein 1 
homolog A, centractin alpha 
(yeast) 
1.087 0.021  
P61289-2 PSME3 proteasome (prosome, macropain) 
activator subunit 3 (PA28 gamma; 
Ki) 
1.117 0.049  
P61513 RPL37A ribosomal protein L37a 1.075 0.037  
P62191 PSMC1 proteasome (prosome, macropain) 
26S subunit, ATPase, 1 
-1.092  0.016 
P62263 RPS14 ribosomal protein S14 -1.092 0.001  
P62277 RPS13 ribosomal protein S13 -1.036 0.041  
P62333 PSMC6 proteasome (prosome, macropain) 
26S subunit, ATPase, 6 
1.097 0.037  
P62424 RPL7A ribosomal protein L7a -1.001 0  
P62753 RPS6 ribosomal protein S6 -1.047 0.021  
P62805     -1.056 0.001  
P62820 RAB1A RAB1A, member RAS oncogene 
family 
1.108 0.041  
P62913 RPL11 ribosomal protein L11 -1.078 0.005 0.009 
P62917 RPL8 ribosomal protein L8 1.017 0.016  
P62937 PPIA peptidylprolyl isomerase A 
(cyclophilin A) 
-1.053  0.009 
P62979 RPS27A ribosomal protein S27a -1.076 0.006  
P63173 RPL38 ribosomal protein L38 -1.010  0 
P67775 PPP2CA protein phosphatase 2, catalytic 
subunit, alpha isozyme 
-1.129  0.004 
P68104 EEF1A1 eukaryotic translation elongation 
factor 1 alpha 1 
1.017 0.042  
P78347 GTF2I general transcription factor IIi -1.116  0.038 
P78371 CCT2 chaperonin containing TCP1, 
subunit 2 (beta) 
1.018 0.019  
P81605 DCD dermcidin -10.770 0.002  
P82663 MRPS25 mitochondrial ribosomal protein 
S25 
1.139 0.031  
P82921 MRPS21 mitochondrial ribosomal protein 
S21 
1.167 0.048  
P83916 CBX1 chromobox homolog 1 -1.082  0.013 
P84090 ERH enhancer of rudimentary homolog 
(Drosophila) 
-1.064 0.033  
Q00534 CDK6 cyclin-dependent kinase 6 1.253 0.006 0.019 
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Q00577 PURA purine-rich element binding 
protein A 
1.095  0.048 
Q00610 CLTC clathrin, heavy chain (Hc) 1.050 0.03  
Q01105-2 SET SET nuclear proto-oncogene -1.012  0.022 
Q01581 HMGCS1 3-hydroxy-3-methylglutaryl-CoA 
synthase 1 (soluble) 
1.155 0.038  
Q01844-5 EWSR1 EWS RNA-binding protein 1 -1.085 0.008  
Q02543 RPL18A ribosomal protein L18a 1.065 0.002  
Q02790 FKBP4 FK506 binding protein 4, 59kDa -1.067  0.006 
Q04323 UBXN1 UBX domain protein 1 1.121  0.023 
Q04837 SSBP1 single-stranded DNA binding 
protein 1, mitochondrial 
1.110  0.042 
Q05639 EEF1A2 eukaryotic translation elongation 
factor 1 alpha 2 
-1.163 0.04  
Q06323 PSME1 proteasome (prosome, macropain) 
activator subunit 1 (PA28 alpha) 
1.235  0.006 
Q08499-6 PDE4D phosphodiesterase 4D, cAMP-
specific 
-15.232 0.016  
Q12904-2 AIMP1 aminoacyl tRNA synthetase 
complex-interacting 
multifunctional protein 1 
1.048 0.002  
Q12905 ILF2 interleukin enhancer binding factor 
2 
-1.070 0.041 0.026 





Q13151 HNRNPA0 heterogeneous nuclear 
ribonucleoprotein A0 
-1.040 0.033 0.025 
Q13257 MAD2L1 MAD2 mitotic arrest deficient-like 
1 (yeast) 
-1.138 0.003 0.042 
Q13263 TRIM28 tripartite motif containing 28 -1.078 0.013  
Q13630 TSTA3 tissue specific transplantation 
antigen P35B 
1.196 0.017  
Q13813 SPTAN1 spectrin, alpha, non-erythrocytic 1 -1.123 0.003  
Q13838 DDX39B DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 39B 
-1.011  0.01 
Q14103 HNRNPD heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 
37kDa) 
-1.179 0.01 0.017 
Q14108 SCARB2 scavenger receptor class B, 
member 2 
1.169 0.027  
Q14152 EIF3A eukaryotic translation initiation 
factor 3, subunit A 
1.102 0.038  
Q14194-2 CRMP1 collapsin response mediator 
protein 1 
-1.754 0.026  
Q14195-2 DPYSL3 dihydropyrimidinase-like 3 1.094 0.015  
Q14204 DYNC1H1 dynein, cytoplasmic 1, heavy chain 
1 
1.090 0.006  
Q14566 MCM6 minichromosome maintenance 
complex component 6 
-1.164 0.047 0.019 
Q14683 SMC1A structural maintenance of -1.132 0.015  
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chromosomes 1A 
Q15008 PSMD6 proteasome (prosome, macropain) 
26S subunit, non-ATPase, 6 
1.118 0.038  
Q15056 EIF4H eukaryotic translation initiation 
factor 4H 
1.126  0.039 
Q15149 PLEC plectin 1.048  0.007 
Q15181 PPA1 pyrophosphatase (inorganic) 1 1.101 0.025  
Q15291 RBBP5 retinoblastoma binding protein 5 1.079  0.031 
Q15293 RCN1 reticulocalbin 1, EF-hand calcium 
binding domain 
1.073  0.011 
Q15365 PCBP1 poly(rC) binding protein 1 1.016 0.016  
Q15393 SF3B3 splicing factor 3b, subunit 3, 
130kDa 
-1.109  0.044 
Q15691 MAPRE1 microtubule-associated protein, 
RP/EB family, member 1 
-1.031  0 
Q15738 NSDHL NAD(P) dependent steroid 
dehydrogenase-like 
1.142 0.003  
Q15785 TOMM34 translocase of outer mitochondrial 
membrane 34 
-1.300 0.014  
Q15904 ATP6AP1 ATPase, H+ transporting, lysosomal 
accessory protein 1 
1.236 0.044  
Q16539 MAPK14 mitogen-activated protein kinase 
14 
1.052  0 
Q16555 DPYSL2 dihydropyrimidinase-like 2 -1.149 0.011 0.003 
Q16629 SRSF7 serine/arginine-rich splicing factor 
7 
1.135 0.026  
Q16630-2 CPSF6 cleavage and polyadenylation 
specific factor 6, 68kDa 
-1.069  0 
Q16658 FSCN1 fascin actin-bundling protein 1 -1.041 0.024  
Q16836-2 HADH hydroxyacyl-CoA dehydrogenase -1.140 0.02  
Q16850 CYP51A1 cytochrome P450, family 51, 
subfamily A, polypeptide 1 
1.125 0.036  
Q16878 CDO1 cysteine dioxygenase type 1 1.446 0.005  
Q1KMD3 HNRNPUL2 heterogeneous nuclear 
ribonucleoprotein U-like 2 
-1.090  0.006 
Q4KWH8 PLCH1 phospholipase C, eta 1 1.185  0.013 
Q53EL6 PDCD4 programmed cell death 4 
(neoplastic transformation 
inhibitor) 
1.055  0.019 
Q5SSJ5 HP1BP3 heterochromatin protein 1, 
binding protein 3 
-1.207 0.01  
Q5T4U5 ACADM acyl-CoA dehydrogenase, C-4 to C-
12 straight chain 
1.208 0.031  
Q68D91 MBLAC2 metallo-beta-lactamase domain 
containing 2 
-1.067 0.041  
Q69YN4 KIAA1429 KIAA1429 -1.454 0  
Q6GMV2 SMYD5 SMYD family member 5 -1.374 0.013  
Q6IBS0 TWF2 twinfilin actin binding protein 2 1.100  0.044 
Q6JUT2 TICAM2 toll-like receptor adaptor molecule 
2 
1.202 0.022  
Q7Z2Z2 EFTUD1 elongation factor Tu GTP binding 1.119  0.042 
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domain containing 1 
Q8IUE6 HIST2H2AB histone cluster 2, H2ab -1.149  0.01 
Q8IZ81 ELMOD2 ELMO/CED-12 domain containing 2 1.090 0.01  
Q8N0U8 VKORC1L1 vitamin K epoxide reductase 
complex, subunit 1-like 1 
1.050 0.043  
Q8N183 NDUFAF2 NADH dehydrogenase 
(ubiquinone) complex I, assembly 
factor 2 
-1.071 0.011  
Q8N5I4 DHRSX dehydrogenase/reductase (SDR 
family) X-linked 
-1.034 0.032  
Q8NC51 SERBP1 SERPINE1 mRNA binding protein 1 -1.081  0.011 
Q8NE71 ABCF1 ATP-binding cassette, sub-family F 
(GCN20), member 1 
1.084  0.021 
Q8NFH5 NUP35 nucleoporin 35kDa -1.061 0  
Q8NFQ8 TOR1AIP2 torsin A interacting protein 2 1.179  0.048 
Q8TBQ9 TMEM167A transmembrane protein 167A 1.043 0.028  
Q8TF72 SHROOM3 shroom family member 3 -
103.752 
0.002 0.014 
Q8WVY7 UBLCP1 ubiquitin-like domain containing 
CTD phosphatase 1 
1.058  0.036 
Q8WWC4 C2orf47 chromosome 2 open reading frame 
47 
-1.087 0.044  
Q8WWM9 CYGB cytoglobin 1.273  0.011 
Q8WWY3 PRPF31 pre-mRNA processing factor 31 1.079  0.009 
Q8WXE1 ATRIP ATR interacting protein -1.033  0.045 
Q8WY54 PPM1E protein phosphatase, Mg2+/Mn2+ 
dependent, 1E 
1.076  0.045 
Q92522 H1FX H1 histone family, member X -1.081 0  
Q92598 HSPH1 heat shock 105kDa/110kDa protein 
1 
1.254 0.002  
Q92616 GCN1 GCN1 eIF2 alpha kinase activator 
homolog 
-1.055 0.003  
Q969X5 ERGIC1 endoplasmic reticulum-golgi 
intermediate compartment 1 
1.050 0.032  
Q96DA0 ZG16B zymogen granule protein 16B -11.811  0.023 
Q96DR8 MUCL1 mucin-like 1 -6.653  0.001 
Q96E39 RBMXL1 RNA binding motif protein, X-
linked-like 1 
1.201  0 
Q96FX7 TRMT61A tRNA methyltransferase 61A -1.007 0.045  
Q96HE7 ERO1A endoplasmic reticulum 
oxidoreductase alpha 
1.070  0.018 
Q96ND0 FAM210A family with sequence similarity 
210, member A 
1.089  0.035 
Q96P70 IPO9 importin 9 1.039  0.026 
Q96PE2 ARHGEF17 Rho guanine nucleotide exchange 
factor (GEF) 17 
-8.556 0.035  
Q96QK1 VPS35 VPS35 retromer complex 
component 
1.022 0.021  
Q96RP9-2 GFM1 G elongation factor, mitochondrial 
1 
-1.097 0.002  
Q96S97 MYADM myeloid-associated differentiation -1.075 0.029  
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marker 
Q96SI1 KCTD15 potassium channel tetramerization 
domain containing 15 
-1.331  0.026 
Q96SI9 STRBP spermatid perinuclear RNA binding 
protein 
-1.067  0.011 
Q96SL4 GPX7 glutathione peroxidase 7 -1.030 0.023  
Q99470 SDF2 stromal cell-derived factor 2 1.138  0.005 
Q99627 COPS8 COP9 signalosome subunit 8 -1.219 0.023 0.024 
Q99714 HSD17B10 hydroxysteroid (17-beta) 
dehydrogenase 10 
-1.027 0  
Q99729-2 HNRNPAB heterogeneous nuclear 
ribonucleoprotein A/B 
-1.040  0.029 
Q99832 CCT7 chaperonin containing TCP1, 
subunit 7 (eta) 
1.035 0.042  
Q99986 VRK1 vaccinia related kinase 1 -1.131 0.004  
Q9BPX5 ARPC5L actin related protein 2/3 complex, 
subunit 5-like 
1.175  0.035 
Q9BQA1 WDR77 WD repeat domain 77 -1.117  0.046 
Q9BRJ2 MRPL45 mitochondrial ribosomal protein 
L45 
-1.002 0.017  
Q9BRX8 FAM213A family with sequence similarity 
213, member A 
1.064  0.011 
Q9BUJ2 HNRNPUL1 heterogeneous nuclear 
ribonucleoprotein U-like 1 
-1.044  0.047 
Q9BUL8 PDCD10 programmed cell death 10 -1.065 0.023  
Q9BV86 NTMT1 N-terminal Xaa-Pro-Lys N-
methyltransferase 1 
1.153  0.003 
Q9BVA1 TUBB2B tubulin, beta 2B class IIb -1.078  0.028 
Q9BVG4 PBDC1 polysaccharide biosynthesis 
domain containing 1 
1.074  0.043 
Q9BWD1 ACAT2 acetyl-CoA acetyltransferase 2 1.048 0.002  
Q9BY50 SEC11C SEC11 homolog C, signal peptidase 
complex subunit 
1.200 0.023  
Q9BYD1 MRPL13 mitochondrial ribosomal protein 
L13 
1.077 0.007  
Q9BYD6 MRPL1 mitochondrial ribosomal protein L1 -1.039  0.007 
Q9BZC1 CELF4 CUGBP, Elav-like family member 4 1.123  0.016 
Q9H3U1 UNC45A unc-45 myosin chaperone A 1.050 0.012  
Q9H444 CHMP4B charged multivesicular body 
protein 4B 
-1.073  0.017 
Q9HAV7 GRPEL1 GrpE-like 1, mitochondrial (E. coli) -1.138 0.028  
Q9HBD4 SMARCA4 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
a, member 4 
-1.201 0.037  
Q9HCC0 MCCC2 methylcrotonoyl-CoA carboxylase 
2 (beta) 
1.180 0.031  
Q9NP55 BPIFA1 BPI fold containing family A, 
member 1 
-26.410 0.009 0.011 
Q9NPD8 UBE2T ubiquitin-conjugating enzyme E2T -1.234  0.003 
Q9NPL8 TIMMDC1 translocase of inner mitochondrial 1.218  0.019 
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membrane domain containing 1 
Q9NQ48 LZTFL1 leucine zipper transcription factor-
like 1 
1.169  0.022 
Q9NQ50 MRPL40 mitochondrial ribosomal protein 
L40 
-1.035  0.009 
Q9NR28 DIABLO diablo, IAP-binding mitochondrial 
protein 
1.081  0.034 
Q9NSD9 FARSB phenylalanyl-tRNA synthetase, 
beta subunit 
-1.127 0.048  
Q9NTJ3 SMC4 structural maintenance of 
chromosomes 4 
-1.202 0.013  
Q9NTX5 ECHDC1 ethylmalonyl-CoA decarboxylase 1 -1.211 0.019  
Q9NVP1 DDX18 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 18 
-1.056  0.027 
Q9NZL4 HSPBP1 HSPA (heat shock 70kDa) binding 
protein, cytoplasmic cochaperone 
1 
1.166  0.018 
Q9P0J7 KCMF1 potassium channel modulatory 
factor 1 
1.138 0.02  
Q9P258 RCC2 regulator of chromosome 
condensation 2 
-1.048  0.04 
Q9P2R7 SUCLA2 succinate-CoA ligase, ADP-forming, 
beta subunit 
-1.089 0.007  
Q9P2X0-2 DPM3 dolichyl-phosphate 
mannosyltransferase polypeptide 3 
1.228 0.032  
Q9UBE0 SAE1 SUMO1 activating enzyme subunit 
1 
-1.106 0.049 0.002 
Q9UBK7-3 RABL2A RAB, member of RAS oncogene 
family-like 2A 
1.230  0.019 
Q9UBP6 METTL1 methyltransferase like 1 -1.097 0  
Q9UBT2 UBA2 ubiquitin-like modifier activating 
enzyme 2 
-1.053  0.035 
Q9UEU0 VTI1B vesicle transport through 
interaction with t-SNAREs 1B 
-1.222 0.002  
Q9UHD8-5 SEPT9 septin 9 1.155 0.047 0.041 
Q9UHN1 POLG2 polymerase (DNA directed), 
gamma 2, accessory subunit 
1.095 0.024  
Q9UL46 PSME2 proteasome (prosome, macropain) 
activator subunit 2 (PA28 beta) 
1.400 0 0.004 
Q9UQ80 PA2G4 proliferation-associated 2G4, 
38kDa 
-1.034  0.031 
Q9Y266 NUDC nudC nuclear distribution protein 1.144 0.013  
Q9Y285 FARSA phenylalanyl-tRNA synthetase, 
alpha subunit 
-1.081 0.049  
Q9Y291 MRPS33 mitochondrial ribosomal protein 
S33 
1.186 0  
Q9Y295 DRG1 developmentally regulated GTP 
binding protein 1 
-1.176  0.036 
Q9Y3A5 SBDS Shwachman-Bodian-Diamond 
syndrome 
-1.115 0.003  
Q9Y3B4 SF3B6 splicing factor 3b, subunit 6, 14kDa 1.085 0.031  
 
 





Q9Y3D9 MRPS23 mitochondrial ribosomal protein 
S23 
1.075 0.006  
Q9Y3E7 CHMP3 charged multivesicular body 
protein 3 
-1.021  0.043 
Q9Y3L5 RAP2C RAP2C, member of RAS oncogene 
family 
-1.052 0.013  
Q9Y4L1 HYOU1 hypoxia up-regulated 1 1.103 0.043  
Q9Y520-7 PRRC2C proline-rich coiled-coil 2C -31.889 0.019  
Q9Y5K8 ATP6V1D ATPase, H+ transporting, lysosomal 
34kDa, V1 subunit D 
1.061 0  
Q9Y5L0 TNPO3 transportin 3 1.059 0.049  
Q9Y5M8 SRPRB signal recognition particle 
receptor, B subunit 
1.058 0.043  
Q9Y5S9 RBM8A RNA binding motif protein 8A 1.053  0.001 
Q9Y6E2 BZW2 basic leucine zipper and W2 
domains 2 
1.206   
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Appendix 3 
Dysregulated gene expression genes 
Gene Symbol Gene Name fold change p-value 
7-Sep septin 7 -1.4984401 0.00608128 
A1CF APOBEC1 complementation factor 1.40399642 0.00257006 
AADAT aminoadipate aminotransferase -1.6651491 0.00993689 
AATF apoptosis antagonizing transcription factor -1.5335361 0.00467496 
ABAT 4-aminobutyrate aminotransferase 1.32180711 0.00720804 
ABCA5 ATP-binding cassette, sub-family A (ABC1), 
member 5 
1.50720344 0.00209641 
ABHD11 abhydrolase domain containing 11 1.45037732 0.00616103 
ABLIM2 actin binding LIM protein family, member 2 1.70232289 0.00815331 
ACADVL acyl-CoA dehydrogenase, very long chain 1.44375247 0.00437243 
ACAT1 acetyl-CoA acetyltransferase 1 -1.4087298 0.00808636 
ACD adrenocortical dysplasia homolog (mouse) 1.38843469 0.00633468 
ACHE acetylcholinesterase 1.4125532 0.00280107 
ACOT2 acyl-CoA thioesterase 2 1.40818223 0.00349595 
ACR acrosin 1.36912597 0.00351268 
ACSL5 acyl-CoA synthetase long-chain family 
member 5 
-1.5060511 0.0016866 
ACTL6B actin-like 6B 1.43279035 0.00764492 
ACTL9 actin-like 9 1.488417 0.00605686 
ACTRT3 actin-related protein T3 1.38756845 0.00298979 
ADAM20 ADAM metallopeptidase domain 20 1.61847785 0.00247439 
ADAM28 ADAM metallopeptidase domain 28 1.36116056 0.00752962 
ADAM29 ADAM metallopeptidase domain 29 1.36611509 0.0039063 
ADM adrenomedullin 1.53747418 0.00199026 
ADSS adenylosuccinate synthase -1.6332631 0.00682018 
AFAP1 actin filament associated protein 1 1.34664961 0.004574 
AGAP3 ArfGAP with GTPase domain, ankyrin repeat 
and PH domain 3 
1.36901629 0.00130042 
AGGF1 angiogenic factor with G patch and FHA 
domains 1 
-1.3011144 0.00594638 
AGRN agrin 1.41911852 0.00288114 
AGT angiotensinogen (serpin peptidase inhibitor, 
clade A, member 8) 
-1.383402 0.00889442 
AGTR2 angiotensin II receptor, type 2 1.47805562 0.00497075 
AHR aryl hydrocarbon receptor 1.52516676 0.00739662 
AKAP5 A kinase (PRKA) anchor protein 5 -1.4289685 0.00372443 
ALG5 ALG5, dolichyl-phosphate beta-
glucosyltransferase 
-1.4734871 0.00490963 
ALKBH1 alkB, alkylation repair homolog 1 (E. coli) -1.3183499 0.00425537 
ANKRD20A11P ankyrin repeat domain 20 family, member 
A11, pseudogene 
-1.3887586 0.00261117 
ANKRD20A8P ankyrin repeat domain 20 family, member 
A8, pseudogene 
-2.0980388 0.0034523 
ANKRD24 ankyrin repeat domain 24 1.39065038 0.00593802 
ANKRD36 ankyrin repeat domain 36 -1.3519997 0.00703186 
ANKRD36B ankyrin repeat domain 36B -1.4952863 0.00903325 
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ANXA3 annexin A3 -1.3593938 0.00329835 
ANXA7 annexin A7 1.3879872 0.00861895 
AP1S2 adaptor-related protein complex 1, sigma 2 
subunit 
-1.4852222 0.00754761 
APH1B anterior pharynx defective 1 homolog B (C. 
elegans) 
1.34792774 0.00330927 
API5 apoptosis inhibitor 5 -1.9076431 0.00256648 
APIP APAF1 interacting protein 1.4747703 0.00823354 
APOBEC3B apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3B 
1.36878993 0.00308093 
APOBEC3F apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3F 
1.35529586 0.0072492 
APOC1 apolipoprotein C-I 1.2949613 0.00709404 
APOL4 apolipoprotein L, 4 -1.3302259 0.00396969 
AQP2 aquaporin 2 (collecting duct) 1.51969647 0.00732511 
AQP4 aquaporin 4 1.33282589 0.00865278 
AQP6 aquaporin 6, kidney specific 1.48499542 0.00296404 
ARHGAP36 Rho GTPase activating protein 36 -1.4976739 0.0012076 
ARRDC3 arrestin domain containing 3 1.43125423 0.00358846 
ARSG arylsulfatase G -1.3183171 0.00820076 
ARSI arylsulfatase family, member I 1.40122219 0.0063748 
ARV1 ARV1 homolog (S. cerevisiae) -1.5342957 0.00334069 
ASAP1 ArfGAP with SH3 domain, ankyrin repeat 
and PH domain 1 
-1.3351206 0.00503114 
ASCL1 achaete-scute complex homolog 1 
(Drosophila) 
-1.9005652 0.00480802 
ASIC2 acid-sensing (proton-gated) ion channel 2 1.46177904 0.00817559 
ASIP agouti signaling protein 1.45381678 0.00768403 
ASMT acetylserotonin O-methyltransferase 1.46262452 0.00265487 
ASMT acetylserotonin O-methyltransferase 1.39635483 0.00377306 
ATG10 autophagy related 10 -1.3860079 0.00463556 
ATP1B3 ATPase, Na+/K+ transporting, beta 3 
polypeptide 
-1.6961035 0.0055613 
ATP6V0C ATPase, H+ transporting, lysosomal 16kDa, 
V0 subunit c 
1.58077695 0.00172218 
ATP8A2 ATPase, aminophospholipid transporter, 
class I, type 8A, member 2 
1.33934957 0.00987716 
AVIL advillin -1.4720667 0.00534935 
B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 4 
1.43925088 0.00960861 
B3GALT4 UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 4 
1.43925088 0.00960861 
B3GALT6 UDP-Gal:betaGal beta 1,3-





BAAT bile acid CoA: amino acid N-acyltransferase 
(glycine N-choloyltransferase) 
1.34871741 0.00526872 
BAG5 BCL2-associated athanogene 5 -1.7306534 0.00087346 
BAIAP2-AS1 BAIAP2 antisense RNA 1 (head to head) 1.49395372 0.00845472 
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BCL2L2 BCL2-like 2 1.31212254 0.00668409 
BCL7C B-cell CLL/lymphoma 7C 1.60381277 0.0028725 
BMP10 bone morphogenetic protein 10 -1.4691914 0.00131576 
BMP8B bone morphogenetic protein 8b -1.6078147 0.00444957 
BMS1P4 BMS1 pseudogene 4 -1.5559773 0.00578774 
BRCA2 breast cancer 2, early onset -1.4770358 0.00074779 
BSPRY B-box and SPRY domain containing 1.24937758 0.0097779 
BST2 bone marrow stromal cell antigen 2 1.61629272 0.0001938 
BTF3L4 basic transcription factor 3-like 4 -1.5678655 0.00641156 
BTF3P11 basic transcription factor 3 pseudogene 11 -1.3259101 0.0041633 
C10orf107 chromosome 10 open reading frame 107 -1.5162638 0.00857738 
C10orf55 chromosome 10 open reading frame 55 1.30532068 0.00753963 
C12orf40 chromosome 12 open reading frame 40 1.4014459 0.00466736 
C12orf76 chromosome 12 open reading frame 76 -1.6305819 0.00823317 
C14orf169 chromosome 14 open reading frame 169 -1.4850804 0.00746659 
C14orf180 chromosome 14 open reading frame 180 1.63106991 0.00203119 
C14orf37 chromosome 14 open reading frame 37 -1.6401752 0.00081278 
C15orf27 chromosome 15 open reading frame 27 1.35307939 0.00884666 
C19orf66 chromosome 19 open reading frame 66 1.35430929 0.00603134 
C1orf63 chromosome 1 open reading frame 63 -1.3277417 0.00539741 
C1orf64 chromosome 1 open reading frame 64 1.27409371 0.00745309 
C1RL-AS1 C1RL antisense RNA 1 1.38351101 0.00743235 
C21orf119 chromosome 21 open reading frame 119 1.49057083 0.00311083 
C2orf27A chromosome 2 open reading frame 27A 1.34125981 0.00269092 
C2orf54 chromosome 2 open reading frame 54 1.44893254 0.00275162 
C3 complement component 3 1.38248576 0.0083961 
C3orf67 chromosome 3 open reading frame 67 -1.3201351 0.0070835 
C4orf21 chromosome 4 open reading frame 21 -1.4462947 0.0032078 
C5AR1 complement component 5a receptor 1 1.71196499 0.00480311 
C5orf34 chromosome 5 open reading frame 34 -1.40708 0.00347049 
C5orf54 chromosome 5 open reading frame 54 -1.6470839 0.00228177 
C5orf63 chromosome 5 open reading frame 63 -1.5581383 0.00234503 
C7orf13 chromosome 7 open reading frame 13 1.49351643 0.00908752 
C7orf61 chromosome 7 open reading frame 61 1.45028055 0.00276623 
C7orf69 chromosome 7 open reading frame 69 -1.8157076 0.00483134 
C9orf57 chromosome 9 open reading frame 57 1.41127778 0.00619903 
C9orf64 chromosome 9 open reading frame 64 -1.3627049 0.0075531 
C9orf66 chromosome 9 open reading frame 66 1.9172585 0.00680794 
C9orf72 chromosome 9 open reading frame 72 -1.3983 0.00534874 
CA5A carbonic anhydrase VA, mitochondrial 1.3107483 0.0090998 
CA5B carbonic anhydrase VB, mitochondrial -1.2934834 0.0060258 
CABP1 calcium binding protein 1 -1.3602423 0.00348499 
CACNA1C calcium channel, voltage-dependent, L type, 
alpha 1C subunit 
1.63876109 0.00396931 
CALD1 caldesmon 1 -1.5088737 0.00738752 
CALY calcyon neuron-specific vesicular protein 1.60071309 0.00399234 
CASP7 caspase 7, apoptosis-related cysteine 
peptidase 
1.42146028 0.00775724 
CBLN2 cerebellin 2 precursor -2.0585125 0.00321421 
CC2D2B coiled-coil and C2 domain containing 2B 1.98785278 0.00795639 
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CCDC105 coiled-coil domain containing 105 1.36741386 0.00912022 
CCDC111 coiled-coil domain containing 111 -1.3868754 0.0078463 
CCDC125 coiled-coil domain containing 125 -1.6005917 0.00210689 
CCDC130 coiled-coil domain containing 130 1.33314167 0.00478115 
CCDC15 coiled-coil domain containing 15 -1.4132657 0.00353545 
CCDC157 coiled-coil domain containing 157 1.32041743 0.0092776 
CCDC23 coiled-coil domain containing 23 -1.5998012 0.00171056 
CCDC59 coiled-coil domain containing 59 -1.9050684 0.00568834 
CCDC85B coiled-coil domain containing 85B 1.73615813 0.00326807 
CCDC97 coiled-coil domain containing 97 -1.2775654 0.00677263 
CCL2 chemokine (C-C motif) ligand 2 6.458198 0.00896644 
CCL27 chemokine (C-C motif) ligand 27 1.42775251 0.0027912 
CCNB1 cyclin B1 -1.3905987 0.00654906 
CCT6A chaperonin containing TCP1, subunit 6A 
(zeta 1) 
-1.6108124 0.00918703 
CCT8 chaperonin containing TCP1, subunit 8 
(theta) 
-1.3019616 0.00652346 
CD40 CD40 molecule, TNF receptor superfamily 
member 5 
1.42851339 0.00083145 
CD83 CD83 molecule 1.40233474 0.00101099 
CD99 CD99 molecule -1.3174832 0.00734419 
CDC123 cell division cycle 123 -1.366842 0.0092751 
CDC42EP2 CDC42 effector protein (Rho GTPase 
binding) 2 
1.32872277 0.00711512 
CDH9 cadherin 9, type 2 (T1-cadherin) 1.48060011 0.00937582 
CDK5R2 cyclin-dependent kinase 5, regulatory 
subunit 2 (p39) 
1.49163182 0.00410361 
CDKL4 cyclin-dependent kinase-like 4 -1.5971317 0.00648699 
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, 
inhibits CDK4) 
1.45764553 0.00312511 
CELP carboxyl ester lipase pseudogene 1.55045311 0.00460831 
CEMP1 cementum protein 1 1.6356154 0.00349869 
CEP290 centrosomal protein 290kDa -1.4888556 0.00102782 
CHMP2A charged multivesicular body protein 2A 1.32885604 0.00636408 
CHORDC1 cysteine and histidine-rich domain (CHORD) 
containing 1 
-1.5063194 0.00078603 
CHP2 calcineurin-like EF-hand protein 2 1.59184573 0.00524852 
CHRM1 cholinergic receptor, muscarinic 1 1.3192699 0.00884907 
CHRNA4 cholinergic receptor, nicotinic, alpha 4 
(neuronal) 
1.30875715 0.00731808 
CHRNA5 cholinergic receptor, nicotinic, alpha 5 
(neuronal) 
-1.5958122 0.0040677 
CHRNB1 cholinergic receptor, nicotinic, beta 1 
(muscle) 
1.54829912 0.00575994 
CHRNE cholinergic receptor, nicotinic, epsilon 
(muscle) 
1.35489472 0.00913969 
CHST12 carbohydrate (chondroitin 4) 
sulfotransferase 12 
1.4633345 0.00881797 
CIRBP-AS1 CIRBP antisense RNA 1 1.37470967 0.00528761 
CLEC11A C-type lectin domain family 11, member A 1.54520065 0.00649744 
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CLEC3B C-type lectin domain family 3, member B 1.2624645 0.00869212 
CLGN calmegin -1.3504835 0.00558512 
CLHC1 clathrin heavy chain linker domain 
containing 1 
-1.4331775 0.00720207 
CLNS1A chloride channel, nucleotide-sensitive, 1A -1.5241125 0.0055801 
CLP1 cleavage and polyadenylation factor I 
subunit 1 
1.53066795 0.00960602 
CMTM3 CKLF-like MARVEL transmembrane domain 
containing 3 
1.44262758 0.00558042 
CNTNAP3 contactin associated protein-like 3 -2.2148939 0.00336497 
CNTNAP3 contactin associated protein-like 3 -2.2148939 0.00336497 
CNTNAP4 contactin associated protein-like 4 1.46528097 0.00118182 
COL11A2 collagen, type XI, alpha 2 1.41880415 0.00221912 
COL11A2 collagen, type XI, alpha 2 1.41880415 0.00221912 
COL8A1 collagen, type VIII, alpha 1 1.7937738 0.0008596 
COLEC10 collectin sub-family member 10 (C-type 
lectin) 
1.49982659 0.00205082 
CORO1A coronin, actin binding protein, 1A 1.74995054 0.00308974 
CPXM2 carboxypeptidase X (M14 family), member 2 -1.4630577 0.00175754 
CRABP2 cellular retinoic acid binding protein 2 2.04259509 0.00040643 
CSF1 colony stimulating factor 1 (macrophage) 1.33213696 0.00635303 
CSNK1G3 casein kinase 1, gamma 3 -1.4132806 0.00542341 
CSPG4 chondroitin sulfate proteoglycan 4 1.50334185 0.00878242 
CSPG4P1Y chondroitin sulfate proteoglycan 4 
pseudogene 1, Y-linked 
1.40630483 0.0067943 
CSPG4P1Y chondroitin sulfate proteoglycan 4 
pseudogene 1, Y-linked 
1.40630483 0.0067943 
CSRP2 cysteine and glycine-rich protein 2 1.45401889 0.00191152 
CST7 cystatin F (leukocystatin) 1.40451305 0.00737404 
CSTB cystatin B (stefin B) 1.39686613 0.00556535 
CT47A1 cancer/testis antigen family 47, member A1 -2.1145286 0.0007563 
CT47A1 cancer/testis antigen family 47, member A1 -2.1145286 0.0007563 
CT47A1 cancer/testis antigen family 47, member A1 -1.7790009 0.00163196 
CT47A10 cancer/testis antigen family 47, member 
A10 
-2.1145286 0.0007563 
CTAGE4 CTAGE family, member 4 -1.7717865 0.00300301 
CTAGE4 CTAGE family, member 4 -2.2499671 0.00445651 
CTAGE6P CTAGE family, member 6, pseudogene -1.8224788 0.00642042 
CTAGE6P CTAGE family, member 6, pseudogene -1.7496182 0.00959033 
CTBP2 C-terminal binding protein 2 1.32923091 0.00927575 
CTRL chymotrypsin-like 1.41886492 0.00385596 
CTSB cathepsin B 1.41956895 0.00793897 
CTSL3P cathepsin L family member 3, pseudogene -1.4041411 0.00592271 
CWF19L2 CWF19-like 2, cell cycle control (S. pombe) 1.30034654 0.00750656 
CXADR coxsackie virus and adenovirus receptor -1.6140047 0.00282615 
CXCL16 chemokine (C-X-C motif) ligand 16 1.69772233 0.00689009 
CXCR6 chemokine (C-X-C motif) receptor 6 1.35796347 0.00192341 
CXXC11 CXXC finger protein 11 1.3771677 0.00694307 
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CYP2C18 cytochrome P450, family 2, subfamily C, 
polypeptide 18 
1.360413 0.00342202 
CYP4F30P cytochrome P450, family 4, subfamily F, 
polypeptide 30, pseudogene 
-1.5124396 0.00994937 
CYP4F30P cytochrome P450, family 4, subfamily F, 
polypeptide 30, pseudogene 
-1.5118029 0.00995343 
DAB2IP DAB2 interacting protein 1.39833554 0.00408515 
DAPL1 death associated protein-like 1 -1.5213054 0.00203877 
DARC Duffy blood group, chemokine receptor -1.6685878 0.00203222 
DARS aspartyl-tRNA synthetase -1.3490682 0.00996349 
DBF4B DBF4 homolog B (S. cerevisiae) -1.2904874 0.00873128 
DCAF13 DDB1 and CUL4 associated factor 13 -1.4742775 0.0047464 
DCLRE1A DNA cross-link repair 1A -1.379613 0.00908365 
DCP1B DCP1 decapping enzyme homolog B (S. 
cerevisiae) 
-2.0860606 0.00248041 
DCTN4 dynactin 4 (p62) -1.4243972 0.00883326 
DDR1 discoidin domain receptor tyrosine kinase 1 1.42115861 0.00143806 
DDR1 discoidin domain receptor tyrosine kinase 1 1.37493496 0.00524051 
DDR1 discoidin domain receptor tyrosine kinase 1 1.35094709 0.00676501 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 1.38267202 0.00320914 
DEFB127 defensin, beta 127 1.43552994 0.00189834 
DEFB132 defensin, beta 132 1.60853438 0.00673306 
DEK DEK oncogene -1.3201203 0.00515759 
DEPDC7 DEP domain containing 7 1.43919931 0.00707205 
DEXI Dexi homolog (mouse) 1.41242428 0.00382427 
DEXI Dexi homolog (mouse) 1.41242428 0.00382427 
DHFR dihydrofolate reductase -1.7358712 0.00719605 
DHRS3 dehydrogenase/reductase (SDR family) 
member 3 
1.46097631 0.0062481 
DHRS7C dehydrogenase/reductase (SDR family) 
member 7C 
1.41439583 0.00160991 
DHX9 DEAH (Asp-Glu-Ala-His) box polypeptide 9 -1.5584467 0.00377462 
DLEU7 deleted in lymphocytic leukemia, 7 -1.7198129 0.00826711 
DLK1 delta-like 1 homolog (Drosophila) 1.46805722 0.0081591 
DLL3 delta-like 3 (Drosophila) 1.58841027 0.00403631 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, 
member 4 
1.29654171 0.00631861 
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, 
member 1 
1.707447 0.00478467 
DNAJC12 DnaJ (Hsp40) homolog, subfamily C, 
member 12 
-1.5329817 0.00752884 
DNAJC15 DnaJ (Hsp40) homolog, subfamily C, 
member 15 
-1.5891888 0.00368321 
DNAJC19 DnaJ (Hsp40) homolog, subfamily C, 
member 19 
-1.6480697 0.00688969 
DNAJC2 DnaJ (Hsp40) homolog, subfamily C, 
member 2 
-1.3726308 0.00871237 
DNAJC4 DnaJ (Hsp40) homolog, subfamily C, 
member 4 
1.4289938 0.00441396 
DNAL1 dynein, axonemal, light chain 1 1.44219731 0.00198364 
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DPY19L3 dpy-19-like 3 (C. elegans) -1.416202 0.00740495 
DRD4 dopamine receptor D4 1.36312751 0.00339405 
DUOXA1 dual oxidase maturation factor 1 1.45333388 0.00734303 
DUSP15 dual specificity phosphatase 15 1.40349034 0.00129605 
DYNC1LI1 dynein, cytoplasmic 1, light intermediate 
chain 1 
-1.4536471 0.00892579 
E2F5 E2F transcription factor 5, p130-binding -1.7964338 0.0076987 
E4F1 E4F transcription factor 1 1.57362678 0.00997376 
EDEM1 ER degradation enhancer, mannosidase 
alpha-like 1 
1.46055622 0.00532533 
EFEMP2 EGF containing fibulin-like extracellular 
matrix protein 2 
1.42547617 0.0033326 
EFHA1 EF-hand domain family, member A1 -1.3260019 0.00468515 
EFHD2 EF-hand domain family, member D2 1.33964624 0.00286356 
EFNA1 ephrin-A1 1.57769161 0.00023888 
EIF3E eukaryotic translation initiation factor 3, 
subunit E 
-1.4484499 0.0087005 
EIF4B eukaryotic translation initiation factor 4B -1.9230901 0.00219707 
EIF4B eukaryotic translation initiation factor 4B -1.4264988 0.00681525 
ELMO3 engulfment and cell motility 3 1.52645526 0.00534868 
ELOVL2-AS1 ELOVL2 antisense RNA 1 1.63848915 0.00433533 
EME1 essential meiotic endonuclease 1 homolog 1 
(S. pombe) 
-1.3270693 0.00337762 
EMILIN1 elastin microfibril interfacer 1 1.54017784 0.00050776 
EML3 echinoderm microtubule associated protein 
like 3 
1.31209933 0.00600673 
ENGASE endo-beta-N-acetylglucosaminidase 1.41250267 0.00238552 
EPHA1 EPH receptor A1 1.4674116 0.00413348 
EPHA2 EPH receptor A2 1.46136946 0.00190208 
EPHA7 EPH receptor A7 1.36845249 0.00510077 
EPHX1 epoxide hydrolase 1, microsomal 
(xenobiotic) 
1.41816857 0.00203623 
EPS8L2 EPS8-like 2 1.50639134 0.00247935 
EQTN equatorin, sperm acrosome associated 1.37320394 0.00371442 
ERAS ES cell expressed Ras 1.41960967 0.00636028 
ERCC6L excision repair cross-complementing rodent 
repair deficiency, complementation group 
6-like 
1.39565452 0.00140245 
ERCC6L2 excision repair cross-complementing rodent 
repair deficiency, complementation group 
6-like 2 
-1.3681732 0.00692221 
ERVFC1-1 endogenous retrovirus group FC1, member 
1 
-1.4655461 0.00121988 
ESR2 estrogen receptor 2 (ER beta) -1.5617064 0.00126234 
EXOC3L2 exocyst complex component 3-like 2 1.45093729 0.00240619 
FADD Fas (TNFRSF6)-associated via death domain 1.35225764 0.00431984 
FAF2 Fas associated factor family member 2 -1.5132243 0.00345403 
FAM115C family with sequence similarity 115, 
member C 
-1.4252672 0.00716198 
FAM129A family with sequence similarity 129, 1.36310846 0.00157227 
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member A 
FAM136A family with sequence similarity 136, 
member A 
-1.7674728 0.00445093 
FAM185A family with sequence similarity 185, 
member A 
-1.5247677 0.00414397 
FAM209B family with sequence similarity 209, 
member B 
-1.4630168 0.00933243 
FAM221A family with sequence similarity 221, 
member A 
-1.6049817 0.00532264 
FAM3A family with sequence similarity 3, member 
A 
1.4714046 0.00583562 
FAM46A family with sequence similarity 46, member 
A 
1.79445762 0.00433952 
FAM65A family with sequence similarity 65, member 
A 
1.44720088 0.0033097 
FAM86B1 family with sequence similarity 86, member 
B1 
-1.3604455 0.00905306 
FAM86DP family with sequence similarity 86, member 
D, pseudogene 
1.28026391 0.0092316 
FAM90A10P putative protein FAM90A10 -1.8280389 0.00498387 
FAM92B family with sequence similarity 92, member 
B 
1.30662303 0.0090668 
FAM98C family with sequence similarity 98, member 
C 
1.50010248 0.00840963 
FBL fibrillarin 1.49126141 0.00646627 
FBXL6 F-box and leucine-rich repeat protein 6 1.37595072 0.00221666 
FBXL8 F-box and leucine-rich repeat protein 8 1.46982553 0.0087072 
FBXO25 F-box protein 25 -1.9463862 0.00171204 
FBXO5 F-box protein 5 -1.7847546 0.00900986 
FBXO9 F-box protein 9 -1.2782382 0.00541704 
FBXW5 F-box and WD repeat domain containing 5 1.32319329 0.00656749 
FCGR2A Fc fragment of IgG, low affinity IIa, receptor 
(CD32) 
-1.6495348 0.00832779 
FER1L5 fer-1-like 5 (C. elegans) 1.48256544 0.00257805 
FHIT fragile histidine triad 1.53404805 0.00402755 
FIBIN fin bud initiation factor homolog (zebrafish) 1.35599533 0.00501094 
FKTN fukutin -1.3956176 0.00412904 
FLJ00290 FLJ00290 protein 1.52515281 0.00453387 
FLJ16124 FLJ16124 protein -1.7418576 7.16E-05 
FLJ40852 uncharacterized LOC285962 -1.8054055 0.00215123 
FLJ46010 FLJ46010 protein 1.4487022 0.00225245 
FN1 fibronectin 1 -1.3736624 0.00293406 
FNDC5 fibronectin type III domain containing 5 1.59671738 0.00101517 
FOXE1 forkhead box E1 (thyroid transcription 
factor 2) 
1.55931804 0.00688943 
FOXG1 forkhead box G1 1.53894988 0.007729 
FOXN1 forkhead box N1 1.6681649 0.00392401 
FOXN3-AS2 FOXN3 antisense RNA 2 1.37860911 0.00822837 
FOXP4 forkhead box P4 1.3407025 0.00454256 
FRAT2 frequently rearranged in advanced T-cell -1.2957657 0.00836044 
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lymphomas 2 
FUT11 fucosyltransferase 11 (alpha (1,3) 
fucosyltransferase) 
1.34367056 0.00589971 
FZD2 frizzled family receptor 2 1.38438984 0.00744227 
GABPA GA binding protein transcription factor, 
alpha subunit 60kDa 
-1.3623306 0.00615479 
GABRA2 gamma-aminobutyric acid (GABA) A 
receptor, alpha 2 
1.32804344 0.00492319 
GABRA5 gamma-aminobutyric acid (GABA) A 
receptor, alpha 5 
1.36064086 0.00669276 
GAFA3 FGF-2 activity-associated protein 3 -1.7600028 0.00726059 
GAGE12B G antigen 12B -1.572379 0.00615968 
GAGE12G G antigen 12G -1.9396781 0.00544343 
GAREML GRB2 associated, regulator of MAPK1-like 1.36089057 0.00390282 
GAS6 growth arrest-specific 6 1.48624367 0.00806804 
GATSL3 GATS protein-like 3 1.4847895 0.00064202 
GBAP1 glucosidase, beta, acid pseudogene 1 -1.9873666 0.00203203 
GCFC2 GC-rich sequence DNA-binding factor 2 -1.5057776 0.00947834 
GCSH glycine cleavage system protein H 
(aminomethyl carrier) 
-1.5826448 0.00636755 
GDF15 growth differentiation factor 15 2.31406546 0.00015991 
GDF2 growth differentiation factor 2 -1.4440709 0.00194197 
GET4 golgi to ER traffic protein 4 homolog (S. 
cerevisiae) 
1.41244627 0.00444028 
GFOD1 glucose-fructose oxidoreductase domain 
containing 1 
1.61610342 0.00556383 
GFRA1 GDNF family receptor alpha 1 1.37344454 0.00876855 
GINM1 glycoprotein integral membrane 1 -1.6341205 0.00392617 
GJB4 gap junction protein, beta 4, 30.3kDa 1.37927908 0.00534821 
GLI1 GLI family zinc finger 1 1.57201614 0.00131998 
GLUL glutamate-ammonia ligase 1.48196185 0.00415082 
GM2A GM2 ganglioside activator -1.3751475 0.00279776 
GNG11 guanine nucleotide binding protein (G 
protein), gamma 11 
-2.3585267 0.00342451 
GNPDA2 glucosamine-6-phosphate deaminase 2 -1.4574169 0.00333011 
GOLGA6A golgin A6 family, member A -1.7096381 0.00188026 
GOLGA6A golgin A6 family, member A -1.6265027 0.00287806 
GOLGA6B golgin A6 family, member B -1.7126347 0.00073422 
GOLGA6B golgin A6 family, member B -1.6230647 0.00218616 
GOLGA7B golgin A7 family, member B 1.4952246 0.00059627 
GOLGA8CP golgin A8 family, member C, pseudogene -1.678006 0.00293306 
GOLGA8DP golgin A8 family, member D, pseudogene -1.779009 0.00161121 
GOLGA8DP golgin A8 family, member D, pseudogene -1.6518255 0.00293684 
GOLGA8EP golgin A8 family, member E, pseudogene -1.7444265 0.00137293 
GOLGA8F golgin A8 family, member F -1.9352733 0.00053522 
GOLGA8F golgin A8 family, member F -1.6924449 0.00271074 
GOLGA8G golgin A8 family, member G -1.7804466 0.00188902 
GOLGA8G golgin A8 family, member G -1.7804466 0.00188902 
GOLGA8I golgin A8 family, member I -1.3641628 0.00270222 
GOLGA8I golgin A8 family, member I -1.4977994 0.00627908 
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GP9 glycoprotein IX (platelet) 1.66180114 0.00032157 
GPAM glycerol-3-phosphate acyltransferase, 
mitochondrial 
-4.759574 0.00717223 
GPC2 glypican 2 1.64693456 0.0075887 
GPR125 G protein-coupled receptor 125 -1.5266338 0.00771512 
GPR87 G protein-coupled receptor 87 -1.5929989 0.00194725 
GRAMD2 GRAM domain containing 2 1.29447278 0.00692641 
GREM1 gremlin 1, DAN family BMP antagonist 1.32903588 0.00762051 
GRWD1 glutamate-rich WD repeat containing 1 1.30629598 0.00523252 
GSPT1 G1 to S phase transition 1 -1.5684938 0.00313961 
GSTM1 glutathione S-transferase mu 1 1.31207878 0.00659851 
GTF3A general transcription factor IIIA -1.3804047 0.00958578 
GTPBP10 GTP-binding protein 10 (putative) -1.6148176 0.00049488 
GUCA1C guanylate cyclase activator 1C -1.582679 0.00980018 
GUCY1B3 guanylate cyclase 1, soluble, beta 3 1.38543556 0.0043242 
GULP1 GULP, engulfment adaptor PTB domain 
containing 1 
-1.4634208 0.00918897 
GZMH granzyme H (cathepsin G-like 2, protein h-
CCPX) 
1.37546617 0.00794708 
H3F3C H3 histone, family 3C -1.6823724 0.00382094 
HAS1 hyaluronan synthase 1 1.41519769 0.00992248 
HAUS6 HAUS augmin-like complex, subunit 6 -1.8477691 0.00795401 
HBE1 hemoglobin, epsilon 1 -1.5284297 0.00056329 
HBZ hemoglobin, zeta 1.92565434 0.00057246 
HCFC1R1 host cell factor C1 regulator 1 (XPO1 
dependent) 
1.49173279 0.00183157 
HCG27 HLA complex group 27 (non-protein coding) 1.56250825 0.00335795 
HCLS1 hematopoietic cell-specific Lyn substrate 1 1.38988023 0.00532845 
HCRTR2 hypocretin (orexin) receptor 2 1.51845962 0.00916578 
HES1 hairy and enhancer of split 1, (Drosophila) 1.47571979 0.00855364 
HES6 hairy and enhancer of split 6 (Drosophila) 1.38612243 0.00932072 
HHEX hematopoietically expressed homeobox 1.75030403 0.00282441 
HIF3A hypoxia inducible factor 3, alpha subunit 1.30562014 0.00457406 
HIST1H1B histone cluster 1, H1b -1.535788 0.0060165 
HIST1H2AK histone cluster 1, H2ak -1.6132711 0.00056287 
HIST1H2BE histone cluster 1, H2be -1.5123396 0.00374242 
HIST1H2BF histone cluster 1, H2bf -2.2472862 0.00235658 
HIST1H2BM histone cluster 1, H2bm -1.3689334 0.00743264 
HIST1H3G histone cluster 1, H3g -2.263027 0.00303331 
HIST1H4D histone cluster 1, H4d -1.4654363 0.00905834 
HIST1H4E histone cluster 1, H4e -1.3594196 0.002829 
HIST1H4I histone cluster 1, H4i -1.7975941 0.00467047 
HIST1H4L histone cluster 1, H4l -1.3410717 0.00684357 
HIST2H2AB histone cluster 2, H2ab -1.3630564 0.00510716 
HLA-A major histocompatibility complex, class I, A 1.56363877 0.00063651 
HLA-A major histocompatibility complex, class I, A 1.53365882 0.0008735 
HLA-C major histocompatibility complex, class I, C 1.34192597 0.00244172 
HLA-C major histocompatibility complex, class I, C 1.42304192 0.00299471 
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HLA-H major histocompatibility complex, class I, H 
(pseudogene) 
1.51814758 0.00522171 
HNRNPA1 heterogeneous nuclear ribonucleoprotein 
A1 
-1.4376811 0.00520577 
HNRNPCL1 heterogeneous nuclear ribonucleoprotein 
C-like 1 
-1.4814942 0.00614308 
HNRNPF heterogeneous nuclear ribonucleoprotein F 1.33321998 0.00345261 
HNRNPH2 heterogeneous nuclear ribonucleoprotein 
H2 (H') 
-1.4524954 0.00222474 
HNRPDL heterogeneous nuclear ribonucleoprotein 
D-like 
-1.3431189 0.00680819 
HOXB8 homeobox B8 1.28594309 0.00633524 
HOXC10 homeobox C10 1.5462776 0.00150971 
HOXD12 homeobox D12 1.60087824 0.00096138 
HOXD9 homeobox D9 1.43285396 0.00150592 
HS3ST2 heparan sulfate (glucosamine) 3-O-
sulfotransferase 2 
-1.9846779 0.00561259 
HS6ST2 heparan sulfate 6-O-sulfotransferase 2 -1.4053567 0.00387087 
HSD17B6 hydroxysteroid (17-beta) dehydrogenase 6 -1.3156976 0.00347008 
HSPA1A heat shock 70kDa protein 1A 1.72426529 0.00363717 
HSPA1B heat shock 70kDa protein 1B 1.88830445 0.0065915 
HSPB2 heat shock 27kDa protein 2 1.8551688 0.00149319 
ICAM1 intercellular adhesion molecule 1 2.39147761 0.00019756 
IDI2 isopentenyl-diphosphate delta isomerase 2 -1.3436748 0.00442506 
IFIH1 interferon induced with helicase C domain 1 1.45435091 0.00432776 
IFIT1B interferon-induced protein with 
tetratricopeptide repeats 1B 
-1.9139157 0.00244303 
IFITM1 interferon induced transmembrane protein 
1 
1.51286565 0.00204425 
IFNA14 interferon, alpha 14 1.70719931 0.00025261 
IFNA16 interferon, alpha 16 1.45914449 0.00734769 
IGF2BP3 insulin-like growth factor 2 mRNA binding 
protein 3 
-1.9498267 0.00358878 
IGFBP6 insulin-like growth factor binding protein 6 1.40837088 0.00536374 
IGK@ immunoglobulin kappa locus 1.37239261 0.0050714 
IL12A interleukin 12A (natural killer cell 
stimulatory factor 1, cytotoxic lymphocyte 
maturation factor 1, p35) 
1.46324993 0.00313229 
IL16 interleukin 16 -1.4779732 0.0019272 
IL17D interleukin 17D 1.36329967 0.00605238 
IL17REL interleukin 17 receptor E-like 1.48870221 0.00781906 
IL27RA interleukin 27 receptor, alpha 1.40220621 0.00120901 
IMP3 IMP3, U3 small nucleolar ribonucleoprotein, 
homolog (yeast) 
1.60611058 0.0027704 
IMPAD1 inositol monophosphatase domain 
containing 1 
-1.7274307 0.00063132 
INO80C INO80 complex subunit C 1.55243986 0.00516809 
INSRR insulin receptor-related receptor 1.4060464 0.00537082 
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IPO11 importin 11 -1.3423521 0.00716138 
IRAK1 interleukin-1 receptor-associated kinase 1 1.49286546 0.00742093 
IRF1 interferon regulatory factor 1 1.91788448 0.00090356 
IRF7 interferon regulatory factor 7 1.49339277 0.00457725 
IRX2 iroquois homeobox 2 1.47034547 0.00821892 
ISCA1 iron-sulfur cluster assembly 1 homolog (S. 
cerevisiae) 
-1.6565667 0.00229221 
ITPA inosine triphosphatase (nucleoside 
triphosphate pyrophosphatase) 
1.254876 0.00843721 
JAKMIP2 janus kinase and microtubule interacting 
protein 2 
-1.6737238 0.0017846 
JKAMP JNK1/MAPK8-associated membrane protein -1.2723758 0.00641461 
JUNB jun B proto-oncogene 1.38850101 0.00711351 
KBTBD3 kelch repeat and BTB (POZ) domain 
containing 3 
1.64771659 0.0005275 
KCNJ3 potassium inwardly-rectifying channel, 
subfamily J, member 3 
1.58606947 0.00108532 
KCNJ5 potassium inwardly-rectifying channel, 
subfamily J, member 5 
1.4005271 0.0086741 
KCNK10 potassium channel, subfamily K, member 10 -1.257699 0.00985841 
KCNQ1DN KCNQ1 downstream neighbor (non-protein 
coding) 
1.58414366 0.00957277 
KDM4D lysine (K)-specific demethylase 4D -1.5036161 0.00248182 
KDM6B lysine (K)-specific demethylase 6B 1.29050416 0.00811393 
KERA keratocan 1.53515126 0.00729617 
KIAA0947 KIAA0947 -1.3011333 0.00751556 
KIAA1143 KIAA1143 -1.4715957 0.00731705 
KIAA1586 KIAA1586 -1.7882312 0.00150098 
KIAA1671 KIAA1671 1.68718788 0.00233698 
KIAA1804 mixed lineage kinase 4 -1.5361622 0.00740112 
KIF11 kinesin family member 11 -2.0951566 0.00175736 
KIF17 kinesin family member 17 1.55583395 0.00753366 
KIF18A kinesin family member 18A -1.4441497 0.00991971 
KIF1A kinesin family member 1A 1.35109502 0.00194876 
KIF25-AS1 KIF25 antisense RNA 1 1.40402907 0.00969577 
KIF4A kinesin family member 4A -1.489318 0.00260038 
KIF4B kinesin family member 4B -1.3546668 0.00723938 
KLF17 Kruppel-like factor 17 1.77478947 0.00102835 
KLF6 Kruppel-like factor 6 1.60932411 0.00079512 
KLHDC10 kelch domain containing 10 -1.6346608 0.00030588 
KLK2 kallikrein-related peptidase 2 -1.3431813 0.00562813 
KNTC1 kinetochore associated 1 -1.510823 0.0044797 
KPNA3 karyopherin alpha 3 (importin alpha 4) -1.7303641 0.00525414 
KRCC1 lysine-rich coiled-coil 1 -1.870309 0.00391615 
KRT6C keratin 6C -1.4216889 0.00912623 
KRT72 keratin 72 -1.3264305 0.00581181 
KRT79 keratin 79 1.37945574 0.00616254 
KRTAP1-1 keratin associated protein 1-1 -1.325578 0.00531899 
KRTAP4-2 keratin associated protein 4-2 -1.4842331 0.00402215 
KRTAP4-7 keratin associated protein 4-7 -1.4406273 0.00697999 
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KRTAP4-9 keratin associated protein 4-9 -1.3548083 0.00729224 
KRTAP9-2 keratin associated protein 9-2 -2.8523007 0.00327308 
KRTAP9-4 keratin associated protein 9-4 -1.4936662 0.00434703 
L3MBTL2 l(3)mbt-like 2 (Drosophila) 1.68197215 0.00311585 
LATS2 LATS, large tumour suppressor, homolog 2 
(Drosophila) 
1.37800108 0.0038231 
LBX1 ladybird homeobox 1 1.56433088 0.00035289 
LCE1F late cornified envelope 1F 1.3278228 0.00817019 
LCE3C late cornified envelope 3C 1.55088577 0.00462421 
LCE4A late cornified envelope 4A 1.37132554 0.00587565 
LENG1 leukocyte receptor cluster (LRC) member 1 1.70075471 0.00047482 
LGALS1 lectin, galactoside-binding, soluble, 1 1.52084084 0.00454816 
LGALS2 lectin, galactoside-binding, soluble, 2 1.2866337 0.00681117 
LGALS3 lectin, galactoside-binding, soluble, 3 1.49789804 0.00362271 
LGALS8 lectin, galactoside-binding, soluble, 8 1.47635865 0.00390088 
LGALS9 lectin, galactoside-binding, soluble, 9 1.31894271 0.0055027 
LIF leukemia inhibitory factor 1.63742325 0.00224831 
LILRA6 leukocyte immunoglobulin-like receptor, 
subfamily A (with TM domain), member 6 
1.60948964 0.00800949 
LIMD1-AS1 LIMD1 antisense RNA 1 -2.9987612 0.0014607 
LIN7A lin-7 homolog A (C. elegans) 1.40496514 0.00702178 
LINC00083 long intergenic non-protein coding RNA 83 1.4480573 0.00184392 
LINC00161 long intergenic non-protein coding RNA 161 1.51438514 0.00352098 
LINC00324 long intergenic non-protein coding RNA 324 -1.4150558 0.00270479 
LINC00326 long intergenic non-protein coding RNA 326 1.80331777 0.00430523 
LINC00328 long intergenic non-protein coding RNA 328 -1.561099 0.00621697 
LINC00334 long intergenic non-protein coding RNA 334 1.41292223 0.00495078 
LINC00470 long intergenic non-protein coding RNA 470 1.48930379 0.00886861 
LINC00652 long intergenic non-protein coding RNA 652 -1.6462011 0.00223502 










LMNE6487 1.52616314 0.00947376 
LOC10013087
6 
uncharacterized LOC100130876 -1.7583144 0.0061228 
LOC10013231
9 
uncharacterized LOC100132319 -1.5413939 0.00342226 
LOC149373 uncharacterized LOC149373 -1.6067554 0.00155708 
LOC157740 uncharacterized protein C8orf9 1.49149715 0.00165635 
LOC1720 dihydrofolate reductase pseudogene -2.6252688 0.00226471 
LOC286359 uncharacterized LOC286359 1.46330034 0.00568533 
LOC349196 uncharacterized LOC349196 -2.6553267 0.00378863 
LOC349196 uncharacterized LOC349196 -2.6553267 0.00378863 
LOC349196 uncharacterized LOC349196 -2.6188928 0.00431395 
LOC349196 uncharacterized LOC349196 -2.6188928 0.00431395 
LOC349196 uncharacterized LOC349196 -1.8389346 0.00692405 
LOC349196 uncharacterized LOC349196 -1.6917143 0.00696358 
LOC440461 Rho GTPase activating protein 27 1.5425584 0.00640761 
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pseudogene 
LOC440518 golgin A2 pseudogene 1.54903821 0.00157767 
LOC441233 uncharacterized LOC441233 -1.453047 0.00165581 
LOC441601 septin 7 pseudogene -1.574438 0.00125853 
LOC728093 putative POM121-like protein 1-like -2.8302117 0.00207992 
LOC728093 putative POM121-like protein 1-like -2.3596391 0.00222753 
LOC728093 putative POM121-like protein 1-like -2.4893059 0.00347276 
LOC728093 putative POM121-like protein 1-like -2.5346682 0.00405898 
LOC728093 putative POM121-like protein 1-like -2.5899449 0.00624563 
LOC729866 hCG1994895 -1.2495077 0.00962286 
LRRC37A2 leucine rich repeat containing 37, member 
A2 
-1.7499196 0.00615896 
LRRC37A2 leucine rich repeat containing 37, member 
A2 
-1.7258521 0.00878025 
LRRC37A4P leucine rich repeat containing 37, member 
A4, pseudogene 
-2.0324506 0.00379769 
LRRC37A4P leucine rich repeat containing 37, member 
A4, pseudogene 
-1.6011804 0.00829862 
LRRFIP1 leucine rich repeat (in FLII) interacting 
protein 1 
-1.6428484 0.00089113 
LRRFIP1 leucine rich repeat (in FLII) interacting 
protein 1 
-1.4372556 0.00499763 
LRRN4 leucine rich repeat neuronal 4 1.40567939 0.00337612 
LSM5 LSM5 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
-2.0118102 4.83E-05 
LYVE1 lymphatic vessel endothelial hyaluronan 
receptor 1 
-1.4640346 0.00758696 
LYZL2 lysozyme-like 2 -1.4001227 0.00697368 
MAG myelin associated glycoprotein 1.39009697 0.0064814 
MAGEC3 melanoma antigen family C, 3 1.37428423 0.00978512 
MAGED2 melanoma antigen family D, 2 1.36221039 0.00496031 
MAL mal, T-cell differentiation protein 1.79307625 0.00637814 
MAML3 mastermind-like 3 (Drosophila) -1.6547906 0.007928 
MANSC1 MANSC domain containing 1 -1.4001226 0.00717139 
MAP3K8 mitogen-activated protein kinase kinase 
kinase 8 
1.40791861 0.00295065 
MAP9 microtubule-associated protein 9 -1.4694117 0.00139462 
MATK megakaryocyte-associated tyrosine kinase 1.32979381 0.00237734 
MBL1P mannose-binding lectin (protein A) 1, 
pseudogene 
1.46393234 0.0016882 
MBOAT2 membrane bound O-acyltransferase domain 
containing 2 
-1.5002044 0.00823811 
MC3R melanocortin 3 receptor -1.3504471 0.0021511 
MCM4 minichromosome maintenance complex 
component 4 
-1.583085 0.00940137 
MECOM MDS1 and EVI1 complex locus 1.68820312 0.00162863 
MED11 mediator complex subunit 11 1.38848832 0.00785458 
METTL17 methyltransferase like 17 -1.3259692 0.00831058 
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MFSD12 major facilitator superfamily domain 
containing 12 
1.46004333 0.00578763 
MGC2752 CENPB DNA-binding domains containing 1 
pseudogene 
1.57841007 0.00301383 
MIOX myo-inositol oxygenase 1.58155366 0.00019451 
MIR101-2 microRNA 101-2 -1.450115 0.00468929 
MIR124-2 microRNA 124-2 1.57538479 0.00685616 
MIR127 microRNA 127 -1.717711 0.00038283 
MIR132 microRNA 132 1.44681707 0.00845629 
MIR194-1 microRNA 194-1 1.38033729 0.00324537 
MIR199A1 microRNA 199a-1 1.4838612 0.00094699 
MIR200A microRNA 200a 1.65129884 0.00046954 
MIR217 microRNA 217 1.72579811 0.00297348 
MIR24-2 microRNA 24-2 1.64948761 0.00157753 
MIR331 microRNA 331 1.62489997 0.0097712 
MIR9-1 microRNA 9-1 1.33770284 0.00631658 
MIRLET7A2 microRNA let-7a-2 -1.91675 0.00103118 
MIS18BP1 MIS18 binding protein 1 -1.63245 0.00331005 
MKNK1 MAP kinase interacting serine/threonine 
kinase 1 
1.52856379 0.00994782 
MLF1IP MLF1 interacting protein -2.0947479 0.0027028 
MLYCD malonyl-CoA decarboxylase 1.44228622 0.00178723 
MMADHC methylmalonic aciduria (cobalamin 
deficiency) cblD type, with homocystinuria 
-1.6050085 0.00464214 
MMP15 matrix metallopeptidase 15 (membrane-
inserted) 
1.50356421 0.00739363 
MORN2 MORN repeat containing 2 -1.7053174 0.00682951 
MPLKIP M-phase specific PLK1 interacting protein -1.6346498 0.00697653 
MPLKIP M-phase specific PLK1 interacting protein -1.6251707 0.00979526 
MRE11A MRE11 meiotic recombination 11 homolog 
A (S. cerevisiae) 
-1.434089 0.00350256 
MRPL36 mitochondrial ribosomal protein L36 -1.3477643 0.00638591 
MRPL42 mitochondrial ribosomal protein L42 -1.8062143 0.00344433 
MRPL43 mitochondrial ribosomal protein L43 1.43490952 0.00745007 
MRPS16 mitochondrial ribosomal protein S16 -1.3824089 0.00153061 
MS4A10 membrane-spanning 4-domains, subfamily 
A, member 10 
-1.448379 0.00206776 
MS4A5 membrane-spanning 4-domains, subfamily 
A, member 5 
-1.5262421 0.00431019 
MSANTD3 Myb/SANT-like DNA-binding domain 
containing 3 
1.3132095 0.00750806 
MT1IP metallothionein 1I, pseudogene 1.56545655 0.00916121 
MT1P2 metallothionein 1H-like -1.7032556 0.0086519 
MTERF mitochondrial transcription termination 
factor 
-1.7032065 4.08E-05 
MTF1 metal-regulatory transcription factor 1 -1.3340475 0.00906641 
MTHFD1L methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
-1.9765297 0.00742429 
MTHFD1L methylenetetrahydrofolate dehydrogenase 
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MTHFD1L methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
-1.7744804 0.00810297 
MTSS1L metastasis suppressor 1-like 1.40796112 0.00387123 
MYC v-myc myelocytomatosis viral oncogene 
homolog (avian) 
-1.5293125 0.00144542 
MYL3 myosin, light chain 3, alkali; ventricular, 
skeletal, slow 
1.4229427 0.00379969 
MYO1F myosin IF 1.34349144 0.00491486 
MZF1 myeloid zinc finger 1 1.4015913 0.00342834 
NAA30 N(alpha)-acetyltransferase 30, NatC 
catalytic subunit 
1.38611291 0.00874639 
NAALAD2 N-acetylated alpha-linked acidic dipeptidase 
2 
-1.4439501 0.00149197 
NAB2 NGFI-A binding protein 2 (EGR1 binding 
protein 2) 
1.36139019 0.00665619 
NANOGP1 Nanog homeobox pseudogene 1 -1.427557 0.00317513 
NARFL nuclear prelamin A recognition factor-like 1.62211979 0.00227088 
NARG2 NMDA receptor regulated 2 -1.6981767 0.00397781 
NBPF15 neuroblastoma breakpoint family, member 
15 
-1.4531656 0.00495607 
NBPF3 neuroblastoma breakpoint family, member 
3 
-1.7415064 0.00556132 
NCOR1P1 nuclear receptor corepressor 1 pseudogene 
1 
-1.263402 0.00978249 
NDOR1 NADPH dependent diflavin oxidoreductase 
1 
1.48046061 0.00587505 
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 7, 14.5kDa 
1.3531688 0.00839612 
NEBL nebulette -1.4208168 0.00665693 
NEDD9 neural precursor cell expressed, 
developmentally down-regulated 9 
1.33779803 0.00601474 
NET1 neuroepithelial cell transforming 1 -1.4640557 0.00937576 
NEUROD2 neuronal differentiation 2 1.96644622 0.00291419 
NF1 neurofibromin 1 -1.5079174 0.00483154 
NF1 neurofibromin 1 -1.5079174 0.00483154 
NFIA nuclear factor I/A -1.4665809 0.00881149 
NFKB2 nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 2 (p49/p100) 
1.84070992 0.00321834 
NFKBIA nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, alpha 
1.7531713 0.00257873 
NFKBIE nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, epsilon 
1.41831309 0.00527512 
NGEF neuronal guanine nucleotide exchange 
factor 
1.49417589 0.00869222 
NMU neuromedin U 1.56099287 0.00060394 
NOBOX NOBOX oogenesis homeobox 1.64413558 7.37E-05 
NOL7 nucleolar protein 7, 27kDa -1.4421621 0.00649029 
NOS3 nitric oxide synthase 3 (endothelial cell) 1.34222472 0.00757502 
NPPA natriuretic peptide A 1.26857443 0.00664999 
NPTX2 neuronal pentraxin II 1.35667558 0.00224272 
NR4A1 nuclear receptor subfamily 4, group A, 1.35130357 0.00808884 
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member 1 
NR5A1 nuclear receptor subfamily 5, group A, 
member 1 
1.59169884 0.0059521 
NRM nurim (nuclear envelope membrane 
protein) 
1.7354009 0.00214796 
NSMAF neutral sphingomyelinase (N-SMase) 
activation associated factor 
-1.6719728 0.00417878 
NSRP1 nuclear speckle splicing regulatory protein 1 -1.6125228 0.00470031 
NT5C3 5'-nucleotidase, cytosolic III 1.45312089 0.00909778 
NUF2 NUF2, NDC80 kinetochore complex 
component, homolog (S. cerevisiae) 
-1.673213 0.00130638 
NUP107 nucleoporin 107kDa -1.4960766 0.00774131 
NUP37 nucleoporin 37kDa -1.3838821 0.00765852 
NXF4 nuclear RNA export factor 4 pseudogene 1.32129466 0.00660328 
OCIAD1 OCIA domain containing 1 -1.4659436 0.00935387 
OGDHL oxoglutarate dehydrogenase-like 1.3766824 0.0065033 
OGFOD2 2-oxoglutarate and iron-dependent 
oxygenase domain containing 2 
1.29189231 0.00548823 
OIT3 oncoprotein induced transcript 3 1.39035564 0.00594665 
OK/SW-CL.36 OK/SW-CL.36 1.80690112 0.00251412 
OR10A4 olfactory receptor, family 10, subfamily A, 
member 4 
1.36045724 0.00307227 
OR10A7 olfactory receptor, family 10, subfamily A, 
member 7 
1.38487134 0.00734019 
OR10G3 olfactory receptor, family 10, subfamily G, 
member 3 
-1.3730261 0.00477705 
OR10H5 olfactory receptor, family 10, subfamily H, 
member 5 
-1.5041112 0.00204324 
OR2B11 olfactory receptor, family 2, subfamily B, 
member 11 
-1.5288092 0.00639621 
OR2T11 olfactory receptor, family 2, subfamily T, 
member 11 
1.32432744 0.00655848 
OR2T29 olfactory receptor, family 2, subfamily T, 
member 29 
1.38156558 0.00698807 
OR2T5 olfactory receptor, family 2, subfamily T, 
member 5 
1.34198452 0.00768327 
OR3A1 olfactory receptor, family 3, subfamily A, 
member 1 
1.56202554 0.00120887 
OR4K17 olfactory receptor, family 4, subfamily K, 
member 17 
1.51869215 0.00483456 
OR4K5 olfactory receptor, family 4, subfamily K, 
member 5 
1.47721168 0.00654816 
OR4S1 olfactory receptor, family 4, subfamily S, 
member 1 
1.63160583 0.00780147 
OR52E2 olfactory receptor, family 52, subfamily E, 
member 2 
1.51517958 0.00122487 
OR52N4 olfactory receptor, family 52, subfamily N, 
member 4 
1.42003733 0.00403946 
OR5M9 olfactory receptor, family 5, subfamily M, 
member 9 
1.41642243 0.00206395 
OR6C1 olfactory receptor, family 6, subfamily C, 1.29796113 0.00646662 
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member 1 
OR8G5 olfactory receptor, family 8, subfamily G, 
member 5 
1.63997691 0.00786227 
OTX2 orthodenticle homeobox 2 1.31161593 0.00463197 
OVOS ovostatin -1.4968429 0.00937502 
OXR1 oxidation resistance 1 -1.3910238 0.00188538 
PAGE5 P antigen family, member 5 (prostate 
associated) 
-1.7145755 0.00875443 
PAPL iron/zinc purple acid phosphatase-like 
protein 
1.2908762 0.00852893 
PAQR5 progestin and adipoQ receptor family 
member V 
1.53823354 0.00349553 
PAQR9 progestin and adipoQ receptor family 
member IX 
1.35331256 0.00937692 
PARP12 poly (ADP-ribose) polymerase family, 
member 12 
-1.5751495 0.00238174 
PARP14 poly (ADP-ribose) polymerase family, 
member 14 
-1.534117 0.00756498 
PAX1 paired box 1 1.37632675 0.00511245 
PAX7 paired box 7 1.33140805 0.00499699 
PBK PDZ binding kinase -1.8980533 0.00518191 
PCBP1 poly(rC) binding protein 1 1.40954459 0.00707651 
PCDH8 protocadherin 8 1.33689978 0.00325469 
PCDHA8 protocadherin alpha 8 1.36943955 0.00565029 
PDLIM7 PDZ and LIM domain 7 (enigma) 1.41179562 0.00319649 
PDS5B PDS5, regulator of cohesion maintenance, 
homolog B (S. cerevisiae) 
-1.3458781 0.00714099 
PDXDC2P pyridoxal-dependent decarboxylase domain 
containing 2, pseudogene 
-1.4340272 0.00551439 
PFKL phosphofructokinase, liver 1.31330404 0.00928331 
PGAM1 phosphoglycerate mutase 1 (brain) -1.5187871 0.00680149 
PHF1 PHD finger protein 1 1.45882846 0.0034018 
PHF6 PHD finger protein 6 -1.3391933 0.00358065 
PHLDA3 pleckstrin homology-like domain, family A, 
member 3 
1.58904443 0.00833364 
PHOX2B paired-like homeobox 2b -1.9186995 0.00037861 
PIEZO1 piezo-type mechanosensitive ion channel 
component 1 
1.61231735 0.00350699 
PIGA phosphatidylinositol glycan anchor 
biosynthesis, class A 
-1.6351627 0.00341186 
PIGW phosphatidylinositol glycan anchor 
biosynthesis, class W 
-1.9345698 0.00201181 
PIM3 pim-3 oncogene 1.33392885 0.00474499 
PINX1 PIN2/TERF1 interacting, telomerase 
inhibitor 1 
-1.3345843 0.0086471 
PIWIL3 piwi-like RNA-mediated gene silencing 3 -1.3698656 0.00487864 
PLAG1 pleiomorphic adenoma gene 1 -1.5802292 0.00075659 
PLEC plectin 1.42493828 0.00434097 
PLEK2 pleckstrin 2 1.33459652 0.00893016 
PLIN3 perilipin 3 1.35921699 0.0068674 
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PMM1 phosphomannomutase 1 1.36014741 0.00562909 
PMS2P5 postmeiotic segregation increased 2 
pseudogene 5 
-1.4492919 0.00737318 
PNLIPRP1 pancreatic lipase-related protein 1 -1.4463829 0.00888997 
POLR3K polymerase (RNA) III (DNA directed) 
polypeptide K, 12.3 kDa 
-1.4319111 0.00422938 
POTEE POTE ankyrin domain family, member E -1.9021442 0.00458446 
POU1F1 POU class 1 homeobox 1 1.48075686 0.00342383 
PP7080 uncharacterized LOC25845 1.42000423 0.0023527 
PPAPDC1B phosphatidic acid phosphatase type 2 
domain containing 1B 
1.33097883 0.00854024 
PPBPP2 pro-platelet basic protein pseudogene 2 1.59275099 0.00190216 
PPDPF pancreatic progenitor cell differentiation 
and proliferation factor homolog (zebrafish) 
1.58908589 0.00405252 
PPIP5K2 diphosphoinositol pentakisphosphate 
kinase 2 
-1.4963792 0.0049785 
PPP1R14C protein phosphatase 1, regulatory 
(inhibitor) subunit 14C 
1.50470617 0.00945794 
PPP1R2P9 protein phosphatase 1, regulatory 
(inhibitor) subunit 2 pseudogene 9 
-1.3179065 0.00764159 
PRAME preferentially expressed antigen in 
melanoma 
1.30881928 0.00979463 
PRAMEF24P PRAME family member 24, pseudogene 1.41045915 0.0073604 
PRAMEF3 PRAME family member 3 -1.3712788 0.00362342 
PRAP1 proline-rich acidic protein 1 1.40158517 0.00210265 
PRELP proline/arginine-rich end leucine-rich 
repeat protein 
-1.2831075 0.00767429 
PRH1 proline-rich protein HaeIII subfamily 1 1.35080916 0.00597129 
PRICKLE3 prickle homolog 3 (Drosophila) 1.39723334 0.0063454 
PRIM2 primase, DNA, polypeptide 2 (58kDa) -1.3915371 0.005428 
PRKAG1 protein kinase, AMP-activated, gamma 1 
non-catalytic subunit 
-1.2934552 0.00942534 
PRKD3 protein kinase D3 -1.4473024 0.00397071 
PRM2 protamine 2 1.38121441 0.00428374 
PROCA1 protein interacting with cyclin A1 1.54721086 0.00517252 
PROM1 prominin 1 -1.5004625 0.00523099 
PRORSD1P prolyl-tRNA synthetase associated domain 
containing 1, pseudogene 
1.29014823 0.00711071 
PRR25 proline rich 25 1.46600522 0.00785079 
PRTN3 proteinase 3 1.38999153 0.00733455 
PS1TP4 HBV preS1-transactivated protein 4 -1.4758125 0.00355916 
PSMB6 proteasome (prosome, macropain) subunit, 
beta type, 6 
1.30293645 0.00606505 
PTGES prostaglandin E synthase 1.69442917 0.0026536 
PTGES2 prostaglandin E synthase 2 1.2818581 0.00560912 
PTPLAD2 protein tyrosine phosphatase-like A domain 
containing 2 
1.3687682 0.00160185 
PTPN12 protein tyrosine phosphatase, non-receptor 
type 12 
-1.5686677 0.00901474 
PURG purine-rich element binding protein G 1.30422311 0.00951276 
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PUS7 pseudouridylate synthase 7 homolog (S. 
cerevisiae) 
-1.6901236 0.00557966 
PYDC1 PYD (pyrin domain) containing 1 1.43569886 0.0018279 
PYY2 peptide YY, 2 (pseudogene) 1.63744248 0.00317913 
RAB14 RAB14, member RAS oncogene family -1.2915067 0.00888837 
RAB19 RAB19, member RAS oncogene family 1.64965203 0.00609239 
RAB27A RAB27A, member RAS oncogene family 1.43318218 0.00360747 
RAB42 RAB42, member RAS oncogene family 1.31382673 0.00958148 
RAB4A RAB4A, member RAS oncogene family -1.3561917 0.00819289 
RABL3 RAB, member of RAS oncogene family-like 3 -1.3432457 0.00864677 
RAD51 RAD51 homolog (S. cerevisiae) -1.5156276 0.00651326 
RAG2 recombination activating gene 2 -1.354598 0.00289187 
RANBP6 RAN binding protein 6 -1.7880422 0.00510804 
RAP1A RAP1A, member of RAS oncogene family -1.337501 0.00744466 
RAP1GAP2 RAP1 GTPase activating protein 2 1.31380105 0.00310572 
RARG retinoic acid receptor, gamma 1.35476562 0.00324248 
RBBP6 retinoblastoma binding protein 6 -1.4090555 0.00583859 
RBM11 RNA binding motif protein 11 1.52910124 0.00359926 
RBM38 RNA binding motif protein 38 1.34503441 0.00363068 
RBMS1 RNA binding motif, single stranded 
interacting protein 1 
-1.7175682 0.00951117 
RBMY1A1 RNA binding motif protein, Y-linked, family 
1, member A1 
1.8539554 0.00801024 
RBPJ recombination signal binding protein for 
immunoglobulin kappa J region 
1.41361912 0.00809874 
RCN1 reticulocalbin 1, EF-hand calcium binding 
domain 
-1.515104 0.00678496 
RD3 retinal degeneration 3 1.30390824 0.0080413 
REG1P regenerating islet-derived 1 pseudogene 1.33162613 0.00792155 
REM2 RAS (RAD and GEM)-like GTP binding 2 1.34968204 0.00462349 
REN renin 1.44590412 0.00475158 
RET ret proto-oncogene 1.26585469 0.00713909 
RETNLB resistin like beta 1.29320572 0.00889996 
RFC1 replication factor C (activator 1) 1, 145kDa -7.2552632 0.00527569 
RFK riboflavin kinase -1.4953205 0.00359816 
RFPL3 ret finger protein-like 3 -1.3269688 0.00726742 
RFPL4A ret finger protein-like 4A -1.476346 0.00791465 
RFT1 RFT1 homolog (S. cerevisiae) 1.3952342 0.00287894 
RFX1 regulatory factor X, 1 (influences HLA class II 
expression) 
1.58346735 0.00867333 
RGCC regulator of cell cycle 1.47637621 0.00722517 
RGPD4 RANBP2-like and GRIP domain containing 4 -1.3038347 0.00378976 
RGS14 regulator of G-protein signaling 14 1.35304669 0.00486376 
RGS20 regulator of G-protein signaling 20 1.33421915 0.00783578 
RGS8 regulator of G-protein signaling 8 -2.0691151 0.00084814 
RHBDF2 rhomboid 5 homolog 2 (Drosophila) 1.28935138 0.0056114 
RHPN2 rhophilin, Rho GTPase binding protein 2 1.36015241 0.00509987 
RIMKLB ribosomal modification protein rimK-like 
family member B 
-1.4352475 0.00396861 
RLTPR RGD motif, leucine rich repeats, 1.43561157 0.008175 
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tropomodulin domain and proline-rich 
containing 
RNASEH2B ribonuclease H2, subunit B -1.4996089 0.00482342 
RNF113A ring finger protein 113A 1.62304463 0.00465788 
RNF128 ring finger protein 128, E3 ubiquitin protein 
ligase 
1.32013923 0.00786633 
RNF130 ring finger protein 130 -1.3814472 0.00192864 
RNF207 ring finger protein 207 2.44355276 0.00106254 
RNF39 ring finger protein 39 1.76726332 0.00116754 
RNF39 ring finger protein 39 1.3303209 0.0099667 
RNF7 ring finger protein 7 1.36223459 0.00819957 
RNU105C RNA, U105C small nucleolar 1.35588643 0.00429825 
RNU4-1 RNA, U4 small nuclear 1 1.46850289 0.0012848 
RNY4P8 RNA, Ro-associated Y4 pseudogene 8 2.17829883 0.00260147 
RP1 retinitis pigmentosa 1 (autosomal 
dominant) 
-1.3788828 0.00821927 
RPF2 ribosome production factor 2 homolog (S. 
cerevisiae) 
-1.6113262 0.00715953 
RPL13P5 ribosomal protein L13 pseudogene 5 1.59037257 0.00764284 
RPL15 ribosomal protein L15 -1.3448405 0.00888981 
RPL17 ribosomal protein L17 -1.7196792 0.00735713 
RPL21 ribosomal protein L21 -1.5732435 0.00310483 
RPL21 ribosomal protein L21 -1.3868593 0.00731918 
RPL23AP7 ribosomal protein L23a pseudogene 7 -1.3259939 0.0045243 
RPL23AP82 ribosomal protein L23a pseudogene 82 -1.3902583 0.00892742 
RPL41 ribosomal protein L41 -1.5784134 0.00762604 
RPL7 ribosomal protein L7 -2.1837556 0.005671 
RPS12 ribosomal protein S12 1.3201093 0.00680787 
RPS18P9 ribosomal protein S18 pseudogene 9 -1.2980697 0.00840981 
RPS4Y2 ribosomal protein S4, Y-linked 2 1.42324841 0.00484915 
RPS8 ribosomal protein S8 1.41301781 0.00501818 
RRAS related RAS viral (r-ras) oncogene homolog 1.51736198 0.00041811 
RSPO2 R-spondin 2 1.42088121 0.00353461 
S100A10 S100 calcium binding protein A10 1.36525336 0.00711731 
SAA2 serum amyloid A2 -1.3730322 0.00337943 
SACS spastic ataxia of Charlevoix-Saguenay 
(sacsin) 
-1.4809056 0.00269208 
SART1 squamous cell carcinoma antigen 
recognized by T cells 
1.37693948 0.00913641 
SASS6 spindle assembly 6 homolog (C. elegans) -2.0661429 0.0019406 
SCAND2P SCAN domain containing 2 pseudogene 1.34497816 0.00408092 
SCARNA11 small Cajal body-specific RNA 11 1.31937452 0.00923161 
SCARNA4 small Cajal body-specific RNA 4 -1.3060213 0.00902797 
SCARNA9L small Cajal body-specific RNA 9-like -1.8012527 0.002488 
SCRG1 stimulator of chondrogenesis 1 1.31446062 0.0074904 
SEC14L2 SEC14-like 2 (S. cerevisiae) 1.35376988 0.00393954 
SEC61G Sec61 gamma subunit -1.620669 0.00367282 
SELT selenoprotein T -1.5993055 0.006961 
SEMA3E sema domain, immunoglobulin domain (Ig), 
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3E 
SEMG2 semenogelin II 1.26795925 0.0091194 
SERF2 small EDRK-rich factor 2 1.63545225 0.00244993 
SERPINA5 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 5 
1.5675072 0.00092058 
SERPINA7 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 7 
1.46611768 0.00587476 
SERPINB11 serpin peptidase inhibitor, clade-B 
(ovalbumin), member 11 
(gene/pseudogene) 
-1.3802507 0.00305391 
SETD9 SET domain containing 9 -1.2850054 0.00818042 
SFMBT2 Scm-like with four mbt domains 2 1.34111786 0.00410599 
SFRP1 secreted frizzled-related protein 1 1.47104681 0.00056471 
SH2D6 SH2 domain containing 6 1.3404933 0.00378496 
SH3KBP1 SH3-domain kinase binding protein 1 -1.504401 0.00590555 
SHC3 SHC (Src homology 2 domain containing) 
transforming protein 3 
-1.3120228 0.00873297 
SHH sonic hedgehog 1.45585993 0.00656163 
SIKE1 suppressor of IKBKE 1 -1.3388263 0.00802696 
SIRPG signal-regulatory protein gamma -1.5527818 0.00240301 
SIX5 SIX homeobox 5 1.3669927 0.00629323 
SKA2 spindle and kinetochore associated complex 
subunit 2 
-1.4885727 0.00322029 
SKP2 S-phase kinase-associated protein 2, E3 
ubiquitin protein ligase 
-1.2682071 0.00977842 
SLC16A3 solute carrier family 16, member 3 
(monocarboxylic acid transporter 4) 
-1.4473994 0.00072852 
SLC17A9 solute carrier family 17, member 9 1.41618011 0.00778823 
SLC24A5 solute carrier family 24, member 5 1.63362584 0.00555133 
SLC25A32 solute carrier family 25 (mitochondrial 
folate carrier) , member 32 
-1.2585664 0.00992027 
SLC25A35 solute carrier family 25, member 35 1.29761502 0.00853233 
SLC2A3 solute carrier family 2 (facilitated glucose 
transporter), member 3 
-1.9464176 9.12E-05 
SLC2A6 solute carrier family 2 (facilitated glucose 
transporter), member 6 
1.42111487 0.0038238 
SLC30A2 solute carrier family 30 (zinc transporter), 
member 2 
1.47578691 0.00795333 
SLC30A7 solute carrier family 30 (zinc transporter), 
member 7 
-1.2903243 0.00902701 
SLC34A3 solute carrier family 34 (sodium phosphate), 
member 3 
1.30802151 0.0078593 
SLC35B2 solute carrier family 35, member B2 1.48209054 0.00200942 
SLC38A9 solute carrier family 38, member 9 -1.5667527 0.00247208 
SLC43A2 solute carrier family 43, member 2 1.4601023 0.00096276 
SLC45A2 solute carrier family 45, member 2 1.45526895 0.00620841 
SLC7A4 solute carrier family 7 (orphan transporter), 
member 4 
1.32406 0.00411189 
SLCO6A1 solute carrier organic anion transporter 
family, member 6A1 
1.4338976 0.00891736 
SLED1 proteoglycan 3 pseudogene -1.4765682 0.0061134 
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SLITRK4 SLIT and NTRK-like family, member 4 1.46804986 0.00967883 
SLPI secretory leukocyte peptidase inhibitor 1.38786264 0.00775953 
SMIM11 small integral membrane protein 11 1.76415226 0.0037342 
SMIM8 small integral membrane protein 8 1.33019823 0.00658544 
SMR3B submaxillary gland androgen regulated 
protein 3B 
1.62169363 0.0084304 
SNORA24 small nucleolar RNA, H/ACA box 24 1.29909036 0.00927678 
SNORA40 small nucleolar RNA, H/ACA box 40 -1.5253876 0.00903804 
SNORA73A small nucleolar RNA, H/ACA box 73A -1.9718843 0.005879 
SNORA80B small nucleolar RNA, H/ACA box 80B 1.427043 0.0070032 
SNORD114-26 small nucleolar RNA, C/D box 114-26 1.93853041 0.00066389 
SNORD114-6 small nucleolar RNA, C/D box 114-6 1.45298892 0.00789582 
SNORD116-21 small nucleolar RNA, C/D box 116-21 -1.8655778 0.00494818 
SNORD116-22 small nucleolar RNA, C/D box 116-22 -1.784712 0.00287197 
SNORD28 small nucleolar RNA, C/D box 28 -2.5267856 0.00537802 
SNORD32A small nucleolar RNA, C/D box 32A 1.47125976 0.00613069 
SNORD47 small nucleolar RNA, C/D box 47 -2.765056 0.00415733 
SNORD53 small nucleolar RNA, C/D box 53 1.4480991 0.00110322 
SNORD54 small nucleolar RNA, C/D box 54 -1.4986839 0.00867576 
SNORD83A small nucleolar RNA, C/D box 83A 1.41092744 0.00995603 
SNORD83B small nucleolar RNA, C/D box 83B 1.42814595 0.00395453 
SNRNP25 small nuclear ribonucleoprotein 25kDa 
(U11/U12) 
-1.4662124 0.00753144 
SNRNP35 small nuclear ribonucleoprotein 35kDa 
(U11/U12) 
-1.3707088 0.00700775 
SNRPB2 small nuclear ribonucleoprotein 
polypeptide B 
-1.4427687 0.00836926 
SNRPE small nuclear ribonucleoprotein 
polypeptide E 
-1.8486403 0.00662544 
SNX14 sorting nexin 14 -1.7011032 0.00815084 
SNX29P2 sorting nexin 29 pseudogene 2 -1.4904836 0.00624199 
SNX29P2 sorting nexin 29 pseudogene 2 -1.4901777 0.00686328 
SOS1 son of sevenless homolog 1 (Drosophila) -1.3383185 0.00597408 
SOX8 SRY (sex determining region Y)-box 8 1.5408732 0.00909677 
SPA17 sperm autoantigenic protein 17 -1.9149208 0.00469728 
SPAG7 sperm associated antigen 7 1.41376129 0.0007959 
SPATA31C1 SPATA31 subfamily C, member 1 -1.4574866 0.00447166 
SPATA31C1 SPATA31 subfamily C, member 1 -1.433493 0.00838289 
SPC25 SPC25, NDC80 kinetochore complex 
component, homolog (S. cerevisiae) 
-1.8092176 0.00540351 
SPDL1 spindle apparatus coiled-coil protein 1 -1.7985188 0.00522621 
SPDYE4 speedy homolog E4 (Xenopus laevis) -1.5408145 0.00103508 
SPG21 spastic paraplegia 21 (autosomal recessive, 
Mast syndrome) 
-1.3780475 0.00632969 
SPINK9 serine peptidase inhibitor, Kazal type 9 1.47378834 0.00551911 
SPINT3 serine peptidase inhibitor, Kunitz type, 3 1.62702221 0.00666778 
SQSTM1 sequestosome 1 1.48262713 0.00595664 
SRSF10 serine/arginine-rich splicing factor 10 -1.2960057 0.00856662 
SSC5D scavenger receptor cysteine-rich domain 




464 | P a g e  
 









STARD10 StAR-related lipid transfer (START) domain 
containing 10 
1.49107363 0.0008294 
STK3 serine/threonine kinase 3 -1.3846451 0.0018806 
STK33 serine/threonine kinase 33 1.33745193 0.00255048 
STMN4 stathmin-like 4 1.29553666 0.00601313 
STPG1 sperm-tail PG-rich repeat containing 1 -1.3828801 0.00176296 
SUCNR1 succinate receptor 1 1.42610767 0.00813748 
SULT1A1 sulfotransferase family, cytosolic, 1A, 
phenol-preferring, member 1 
1.92884127 0.00086885 
SUMO1 SMT3 suppressor of mif two 3 homolog 1 (S. 
cerevisiae) 
-2.1213541 0.00208169 
SUMO1P3 SUMO1 pseudogene 3 -1.7127261 0.00242378 
SUPT7L suppressor of Ty 7 (S. cerevisiae)-like -1.4939791 0.00612014 
SYNPO synaptopodin 1.31865022 0.00949869 
SYNPO2L synaptopodin 2-like 1.30501233 0.00372278 
SYT5 synaptotagmin V 1.26285709 0.00929044 
TAB2 TGF-beta activated kinase 1/MAP3K7 
binding protein 2 
-1.6617923 0.00011505 
TAS2R38 taste receptor, type 2, member 38 -1.3884273 0.00839776 
TAS2R45 taste receptor, type 2, member 45 1.61375704 0.00242476 
TBC1D21 TBC1 domain family, member 21 1.61730397 0.00050047 
TBC1D2B TBC1 domain family, member 2B -1.3459318 0.00565615 
TBCA tubulin folding cofactor A -1.5293579 0.00731506 
TBCE tubulin folding cofactor E -1.395743 0.0067436 
TBX10 T-box 10 1.45086373 0.00772717 
TBX2 T-box 2 1.44814986 0.00832134 
TBXA2R thromboxane A2 receptor 1.36438974 0.00528757 
TCF7L1 transcription factor 7-like 1 (T-cell specific, 
HMG-box) 
1.30948469 0.00331539 
TCTE1 t-complex-associated-testis-expressed 1 1.30828204 0.00585674 
TCTE3 t-complex-associated-testis-expressed 3 -1.4036072 0.00385406 
TEAD2 TEA domain family member 2 1.37822941 0.00437832 
TECTA tectorin alpha -1.3435151 0.00492826 
TENM3 teneurin transmembrane protein 3 -1.2692944 0.0098579 
TERF1 telomeric repeat binding factor (NIMA-
interacting) 1 
-1.5291117 0.00165372 
TET1 tet methylcytosine dioxygenase 1 -1.3351282 0.00833343 
TET2 tet methylcytosine dioxygenase 2 -1.486639 0.00318103 
TEX30 testis expressed 30 -1.555587 0.0075745 
TEX35 testis expressed 35 -1.3467975 0.00319399 
TFAP2B transcription factor AP-2 beta (activating 
enhancer binding protein 2 beta) 
-1.4505479 0.00891461 
TFDP2 transcription factor Dp-2 (E2F dimerization -1.4233727 0.00580582 
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partner 2) 
TFE3 transcription factor binding to IGHM 
enhancer 3 
1.29237942 0.0073865 
TFPI2 tissue factor pathway inhibitor 2 1.34645625 0.00550187 
THAP5 THAP domain containing 5 -1.877235 0.003309 
THBS1 thrombospondin 1 -1.5170703 0.00442329 
THSD7B thrombospondin, type I, domain containing 
7B 
1.30895332 0.00559285 
TIMD4 T-cell immunoglobulin and mucin domain 
containing 4 
1.46649258 0.00972391 
TLR2 toll-like receptor 2 1.64211905 0.00606061 
TMA7 translation machinery associated 7 homolog 
(S. cerevisiae) 
-1.3928834 0.007475 
TMC4 transmembrane channel-like 4 1.63392816 0.00217606 
TMEM11 transmembrane protein 11 1.4180403 0.00420597 
TMEM115 transmembrane protein 115 1.62280795 0.00549541 
TMEM171 transmembrane protein 171 1.36285049 0.00855559 
TMEM176B transmembrane protein 176B 1.3930882 0.0014476 
TMEM177 transmembrane protein 177 1.98955487 0.00614044 
TMEM194A transmembrane protein 194A -1.3879439 0.00993134 
TMEM204 transmembrane protein 204 1.43163773 0.00888 
TMEM209 transmembrane protein 209 -1.4436199 0.00867761 
TMEM225 transmembrane protein 225 1.5085165 0.00149641 
TMEM243 transmembrane protein 243, mitochondrial -1.5778268 0.00316234 
TMEM254 transmembrane protein 254 -1.8876126 0.00158038 
TMEM256 transmembrane protein 256 1.37153361 0.00668196 
TMEM5 transmembrane protein 5 -1.2904889 0.00559558 
TMOD4 tropomodulin 4 (muscle) -1.2916232 0.00785128 
TMPRSS5 transmembrane protease, serine 5 1.40191466 0.00944558 
TMSB15A thymosin beta 15a 1.49996513 0.00225184 
TMSB4X thymosin beta 4, X-linked -1.5713019 0.00747261 
TMX1 thioredoxin-related transmembrane protein 
1 
-1.4590948 0.00325232 
TNF tumour necrosis factor 1.82325585 0.00072702 
TNF tumour necrosis factor 1.82325585 0.00072702 
TNF tumour necrosis factor 1.82325585 0.00072702 
TNFAIP8L3 tumour necrosis factor, alpha-induced 
protein 8-like 3 
1.35518061 0.00803936 
TNFRSF12A tumour necrosis factor receptor 
superfamily, member 12A 
1.54373297 0.00218968 
TNFSF9 tumour necrosis factor (ligand) superfamily, 
member 9 
1.68404209 0.00138506 
TOMM20L translocase of outer mitochondrial 
membrane 20 homolog (yeast)-like 
1.38014745 0.00287146 
TOMM22 translocase of outer mitochondrial 
membrane 22 homolog (yeast) 
-1.6306566 0.00988361 
TOP1 topoisomerase (DNA) I -1.6673634 0.00672314 
TP53I3 tumour protein p53 inducible protein 3 1.66905815 0.00402356 
TP53TG3 TP53 target 3 -1.9318329 8.78E-05 
TP53TG3 TP53 target 3 -1.6287949 0.0009121 
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TP53TG3 TP53 target 3 -1.6287949 0.0009121 
TPP1 tripeptidyl peptidase I 1.45244389 0.00641158 
TPST1 tyrosylprotein sulfotransferase 1 1.44451452 0.00733 
TRA2A transformer 2 alpha homolog (Drosophila) -1.5328577 0.00804863 
TRAF1 TNF receptor-associated factor 1 1.55324292 0.00061575 
TRAF3IP1 TNF receptor-associated factor 3 interacting 
protein 1 
-1.2780399 0.00699101 
TREML3P triggering receptor expressed on myeloid 
cells-like 3, pseudogene 
1.66003587 0.00287719 
TRERF1 transcriptional regulating factor 1 -1.3912537 0.00763847 
TRIAP1 TP53 regulated inhibitor of apoptosis 1 1.59804827 0.00329516 
TRIM16 tripartite motif containing 16 1.41190575 0.00179349 
TRIM64 tripartite motif containing 64 -1.3495948 0.00449859 
TRIM73 tripartite motif containing 73 1.48081582 0.00483609 
TRIM73 tripartite motif containing 73 1.39492202 0.00710298 
TRIM9 tripartite motif containing 9 -1.4913546 0.00641607 
TRIML1 tripartite motif family-like 1 -1.3552718 0.00509419 
TSC22D1 TSC22 domain family, member 1 1.37398511 0.00562496 
TSC22D2 TSC22 domain family, member 2 1.38974221 0.00798312 
TTC23L tetratricopeptide repeat domain 23-like 1.37299446 0.00425825 
TTC8 tetratricopeptide repeat domain 8 -1.4693999 0.00260307 
TTR transthyretin 1.44484577 0.00976102 
TTTY9A testis-specific transcript, Y-linked 9A (non-
protein coding) 
1.49342992 0.0078765 
TTTY9A testis-specific transcript, Y-linked 9A (non-
protein coding) 
1.49342992 0.0078765 
TUBA3E tubulin, alpha 3e -1.3872365 0.00291494 
TUBB7P tubulin, beta 7, pseudogene 1.35601924 0.00364905 
TUBGCP5 tubulin, gamma complex associated protein 
5 
1.27890851 0.00727431 
TXNL4B thioredoxin-like 4B -1.6051395 0.00779487 
TXNRD2 thioredoxin reductase 2 1.34274581 0.00953194 




pyrophosphorylase 1-like 1 
1.34907951 0.00799782 
UBE2D2 ubiquitin-conjugating enzyme E2D 2 -1.3275287 0.00910058 
UBE2E2 ubiquitin-conjugating enzyme E2E 2 -1.3276831 0.00839816 
UBE2G1 ubiquitin-conjugating enzyme E2G 1 -1.4353923 0.00913833 
UBE2V2 ubiquitin-conjugating enzyme E2 variant 2 -1.3019873 0.00461406 
UCA1 urothelial cancer associated 1 (non-protein 
coding) 
-1.4823698 0.00224772 
UGP2 UDP-glucose pyrophosphorylase 2 -1.4987398 0.00559773 
UPF2 UPF2 regulator of nonsense transcripts 
homolog (yeast) 
-1.2824097 0.00870346 
UQCR11 ubiquinol-cytochrome c reductase, complex 
III subunit XI 
-1.3592465 0.00862442 
UQCRB ubiquinol-cytochrome c reductase binding 
protein 
1.34193808 0.00568602 
UQCRQ ubiquinol-cytochrome c reductase, complex -1.3673093 0.00930787 
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III subunit VII, 9.5kDa 
USP14 ubiquitin specific peptidase 14 (tRNA-
guanine transglycosylase) 
-1.579024 0.00494022 
USP17L2 ubiquitin specific peptidase 17-like family 
member 2 
-2.2207348 0.00740727 
USP17L2 ubiquitin specific peptidase 17-like family 
member 2 
-2.2207348 0.00740727 
USP45 ubiquitin specific peptidase 45 -1.3385195 0.00808387 
UTP20 UTP20, small subunit (SSU) processome 
component, homolog (yeast) 
-1.3717251 0.00789091 
UXT ubiquitously-expressed, prefoldin-like 
chaperone 
1.33168676 0.00594137 
VASN vasorin 1.39630102 0.00794552 
VASP vasodilator-stimulated phosphoprotein 1.50416798 0.00804549 
VEGFA vascular endothelial growth factor A 1.24902079 0.00913782 
VPS18 vacuolar protein sorting 18 homolog (S. 
cerevisiae) 
1.38912296 0.005355 
VSX2 visual system homeobox 2 1.59156912 0.00909056 
VWA5B1 von Willebrand factor A domain containing 
5B1 
1.38829849 0.0048921 
WASF3 WAS protein family, member 3 -1.5654037 0.00093818 
WASH1 WAS protein family homolog 1 1.34409994 0.00950598 
WBSCR27 Williams Beuren syndrome chromosome 
region 27 
1.41031331 0.0094696 
WDR35 WD repeat domain 35 -1.4454092 0.00661542 
WDR63 WD repeat domain 63 1.68327869 0.00211679 
WDSUB1 WD repeat, sterile alpha motif and U-box 
domain containing 1 
-1.3518602 0.00295526 
WNT6 wingless-type MMTV integration site family, 
member 6 
1.40519357 0.00865265 
WSB1 WD repeat and SOCS box containing 1 1.4090423 0.00720225 
XAF1 XIAP associated factor 1 1.33882372 0.00468846 
XAGE2 X antigen family, member 2 -1.6098678 0.0023911 
XAGE2 X antigen family, member 2 -1.6098678 0.0023911 
XAGE5 X antigen family, member 5 -1.5601156 0.00286432 
XCL1 chemokine (C motif) ligand 1 -1.284046 0.00996633 
XPNPEP1 X-prolyl aminopeptidase (aminopeptidase 
P) 1, soluble 
1.30114391 0.00849348 
XRCC2 X-ray repair complementing defective repair 
in Chinese hamster cells 2 
-1.8648728 0.00176591 
YAE1D1 Yae1 domain containing 1 -2.1929167 0.00526492 
YEATS4 YEATS domain containing 4 -1.8012026 0.00739336 
YY2 YY2 transcription factor 1.42602643 0.00714733 
ZBED3 zinc finger, BED-type containing 3 1.57525522 0.00033457 
ZBTB32 zinc finger and BTB domain containing 32 1.56160979 0.00897679 
ZBTB33 zinc finger and BTB domain containing 33 -1.8679142 6.00E-05 
ZBTB4 zinc finger and BTB domain containing 4 1.40499132 0.00214602 
ZFAND2B zinc finger, AN1-type domain 2B 1.46027419 0.00245805 
ZFAND5 zinc finger, AN1-type domain 5 1.33062735 0.00497071 
ZFP30 ZFP30 zinc finger protein -1.4637022 0.00561004 
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ZFP36 ZFP36 ring finger protein 1.75330753 0.00087569 
ZFP37 ZFP37 zinc finger protein -1.5327128 0.0059632 
ZNF100 zinc finger protein 100 -1.3551788 0.00959488 
ZNF219 zinc finger protein 219 1.44279837 0.00411836 
ZNF253 zinc finger protein 253 -1.8274146 0.00239955 
ZNF257 zinc finger protein 257 -1.8850459 8.25E-05 
ZNF29P zinc finger protein 29, pseudogene 1.31390376 0.00674269 
ZNF320 zinc finger protein 320 -1.6288505 0.00370094 
ZNF385C zinc finger protein 385C 1.39273293 0.00596903 
ZNF428 zinc finger protein 428 1.50080629 0.00917844 
ZNF474 zinc finger protein 474 1.76398737 0.00196361 
ZNF493 zinc finger protein 493 -1.3924263 0.00974746 
ZNF516 zinc finger protein 516 1.33961751 0.00487458 
ZNF558 zinc finger protein 558 -1.4043754 0.00708913 
ZNF585B zinc finger protein 585B -1.4414827 0.00149728 
ZNF587 zinc finger protein 587 1.3198051 0.00575996 
ZNF599 zinc finger protein 599 1.26968155 0.00941448 
ZNF610 zinc finger protein 610 -1.5649062 0.00327722 
ZNF618 zinc finger protein 618 1.41839742 0.0089143 
ZNF624 zinc finger protein 624 1.37589647 0.0092119 
ZNF69 zinc finger protein 69 -1.4420076 0.00441717 
ZNF695 zinc finger protein 695 -1.3716037 0.00348576 
ZNF724P zinc finger protein 724, pseudogene -2.1577577 9.39E-05 
ZNF777 zinc finger protein 777 1.66307478 0.00805479 
ZNF780B zinc finger protein 780B -1.6066267 0.00909869 
ZNF808 zinc finger protein 808 -1.308982 0.006736 
ZNF93 zinc finger protein 93 -1.3084894 0.00987301 
ZNF98 zinc finger protein 98 -1.6267553 0.00384123 











Symbol Entrez gene name Log2 Ratio p-value 
B0UX83     0.082  
B1AKZ5 PEA15 phosphoprotein enriched in 
astrocytes 15 
-0.428 0.045443598 
B1ANR0 PABPC4 poly(A) binding protein, 
cytoplasmic 4 (inducible form) 
-0.514 0.001105763 
B4DGU4 CTNNB1 catenin (cadherin-associated 
protein), beta 1, 88kDa 
-0.554 0.01856624 
B4DJP7 SNRPD3 small nuclear ribonucleoprotein 
D3 polypeptide 18kDa 
0.593 0.025934802 
B4DT77 ANXA7 annexin A7 0.230 0.019274764 
B4DVY1 EIF3D eukaryotic translation initiation 
factor 3, subunit D 
0.363 0.019730813 
B7Z254 PDIA6 protein disulfide isomerase 
family A, member 6 
0.569 3.85E-05 
B7Z972 PCMT1 protein-L-isoaspartate (D-
aspartate) O-methyltransferase 
0.245 0.005413453 
B7Z9I1 ACADM acyl-CoA dehydrogenase, C-4 to 
C-12 straight chain 
-0.230 0.040270643 
C9J2Y9 POLR2B polymerase (RNA) II (DNA 
directed) polypeptide B, 140kDa 
0.059 0.037345812 
C9JAZ1 MTX2 metaxin 2 0.970 0.012058425 
C9JQV0 C7orf50 chromosome 7 open reading 
frame 50 
0.354 0.019054514 
E5RIW3 TBCA tubulin folding cofactor A -0.289 0.000376615 
E7EQ72 TMED2 transmembrane emp24 domain 
trafficking protein 2 
-0.689 0.001651738 
E7ESY4 MTA1 metastasis associated 1 0.072 0.003827555 
E9PC52 RBBP7 retinoblastoma binding protein 7 -0.287 0.022834008 
E9PID8 CSTF2 cleavage stimulation factor, 3' 
pre-RNA, subunit 2, 64kDa 
-0.472 0.000723888 
F5H2Q7     -0.325 0.023732276 
F5H669 CPSF7 cleavage and polyadenylation 
specific factor 7, 59kDa 
-0.616 0.018739581 
F5H8E5     -0.405 0.008226516 
F8VQE1 LIMA1 LIM domain and actin binding 1 -0.497 0.001412543 
F8W7S5 RRBP1 ribosome binding protein 1 -0.330 0.014946706 
F8WBH3     -0.467 0.035213753 
G5EA52     -0.183 0.001501007 
G8JLB2 XPNPEP1 X-prolyl aminopeptidase 
(aminopeptidase P) 1, soluble 
0.224 0.01806039 
H0YNG3 SEC11A SEC11 homolog A, signal 
peptidase complex subunit 
0.475 0.005757513 
H7BXW3     0.150 0.005826958 
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J3KNU8 ALDH6A1 aldehyde dehydrogenase 6 
family, member A1 
0.308 0.016323129 
J3KSI4 MPDU1 mannose-P-dolichol utilization 
defect 1 
0.158 0.038081134 
J3KTL7 CDK11B cyclin-dependent kinase 11B 0.441 0.012701995 
J3QLE5 SNRPN small nuclear ribonucleoprotein 
polypeptide N 
0.181 0.043153114 
J3QQT2 RPL17 ribosomal protein L17 0.256 0.001907946 
M0QX07 BABAM1 BRISC and BRCA1 A complex 
member 1 
-1.173 0.012172722 
M0R366 FSD1 fibronectin type III and SPRY 
domain containing 1 
-0.847 0.00106746 
O00159-2 MYO1C myosin IC 0.649 0.029072883 
O00170 AIP aryl hydrocarbon receptor 
interacting protein 
-0.324 0.032252991 
O00231 PSMD11 proteasome (prosome, 
macropain) 26S subunit, non-
ATPase, 11 
0.210 0.009084319 
O00267-2 SUPT5H suppressor of Ty 5 homolog (S. 
cerevisiae) 
-0.389 0.028515076 
O00303 EIF3F eukaryotic translation initiation 
factor 3, subunit F 
0.368 0.006535552 
O00425 IGF2BP3 insulin-like growth factor 2 mRNA 
binding protein 3 
0.082 1.45E-05 
O00429 DNM1L dynamin 1-like 0.395 0.024417694 
O00505 KPNA3 karyopherin alpha 3 (importin 
alpha 4) 
0.200 0.006959562 
O00746 NME4 NME/NM23 nucleoside 
diphosphate kinase 4 
-0.487 0.011667398 
O14617 AP3D1 adaptor-related protein complex 
3, delta 1 subunit 
-0.642 0.027695712 
O14737 PDCD5 programmed cell death 5 -0.412 0.032949515 
O14745 SLC9A3R1 solute carrier family 9, subfamily 
A (NHE3, cation proton 
antiporter 3), member 3 
regulator 1 
-0.556 0.000603427 
O15020-2 SPTBN2 spectrin, beta, non-erythrocytic 2 -0.602 0.002623003 
O15145 ARPC3 actin related protein 2/3 
complex, subunit 3, 21kDa 
-0.410 0.011093358 
O15305 PMM2 phosphomannomutase 2 -0.290 0.014129737 
O15372 EIF3H eukaryotic translation initiation 
factor 3, subunit H 
-0.424 0.032432987 
O15498 YKT6 YKT6 v-SNARE homolog (S. 
cerevisiae) 
0.096 0.034785993 
O43175 PHGDH phosphoglycerate 
dehydrogenase 
0.147 0.047639549 
O43583 DENR density-regulated protein -0.771 0.029782219 
O43670-2 ZNF207 zinc finger protein 207 -0.627 3.91E-05 
O43681 ASNA1 arsA arsenite transporter, ATP-
binding, homolog 1 (bacterial) 
0.359 6.02E-05 
O43719 HTATSF1 HIV-1 Tat specific factor 1 -0.557 0.00389311 
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O43776 NARS asparaginyl-tRNA synthetase 0.269 0.034875669 
O43795-2 MYO1B myosin IB 0.142 0.003765677 
O43813 LANCL1 LanC lantibiotic synthetase 
component C-like 1 (bacterial) 
-0.256 0.011796272 
O60264 SMARCA5 SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, subfamily 
a, member 5 
-0.391 0.000584404 
O60493 SNX3 sorting nexin 3 -0.436 0.048396362 
O60762 DPM1 dolichyl-phosphate 
mannosyltransferase polypeptide 
1, catalytic subunit 
0.408 0.033786561 
O75340 PDCD6 programmed cell death 6 0.828 4.79E-05 
O75380 NDUFS6 NADH dehydrogenase 
(ubiquinone) Fe-S protein 6, 
13kDa (NADH-coenzyme Q 
reductase) 
-0.329 0.042182932 
O75475 PSIP1 PC4 and SFRS1 interacting 
protein 1 
-0.376 0.002330608 
O75531 BANF1 barrier to autointegration factor 
1 
0.531 0.001832361 
O75534-2 CSDE1 cold shock domain containing E1, 
RNA-binding 
-0.396 0.021190425 
O75947 ATP5H ATP synthase, H+ transporting, 
mitochondrial Fo complex, 
subunit d 
-0.367 0.00755882 
O76003 GLRX3 glutaredoxin 3 0.453 0.00138796 
O76031 CLPX caseinolytic mitochondrial matrix 
peptidase chaperone subunit 
0.158 0.043543373 
O94826 TOMM70A translocase of outer 
mitochondrial membrane 70 
homolog A (S. cerevisiae) 
-0.219 0.037064899 




O95336 PGLS 6-phosphogluconolactonase 0.316 1.34E-06 
O95777 LSM8 LSM8 homolog, U6 small nuclear 
RNA associated 
-0.471 0.048219459 
O96019 ACTL6A actin-like 6A -0.308 0.016686857 
P00403 MT-CO2 cytochrome c oxidase subunit II 0.654 0.001062871 
P00491 PNP purine nucleoside phosphorylase -0.796 0.005539035 
P00568 AK1 adenylate kinase 1 -0.744 0.009042188 
P02786 TFRC transferrin receptor 0.166 0.012157298 
P04632 CAPNS1 calpain, small subunit 1 -0.392 0.009963709 
P04843 RPN1 ribophorin I 0.129 0.01575029 
P05386 RPLP1 ribosomal protein, large, P1 0.840 0.046852382 
P05556 ITGB1 integrin, beta 1 (fibronectin 
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antigen CD29 includes MDF2, 
MSK12) 
P06493 CDK1 cyclin-dependent kinase 1 -0.319 0.02122772 
P06576 ATP5B ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta 
polypeptide 
0.117 0.013590792 
P06730 EIF4E eukaryotic translation initiation 
factor 4E 
-0.287 0.008713543 
P07814 EPRS glutamyl-prolyl-tRNA synthetase -0.266 0.029286659 
P07900 HSP90AA1 heat shock protein 90kDa alpha 
(cytosolic), class A member 1 
0.235 0.044852392 
P08107     0.269 0.002719511 
P08238 HSP90AB1 heat shock protein 90kDa alpha 
(cytosolic), class B member 1 
0.160 0.01038445 
P08240-2 SRPR signal recognition particle 
receptor (docking protein) 
0.278 0.039556951 
P08670 VIM vimentin 0.103 0.004665877 
P08754 GNAI3 guanine nucleotide binding 
protein (G protein), alpha 
inhibiting activity polypeptide 3 
0.297 0.01107521 
P08758 ANXA5 annexin A5 0.293 0.02942688 
P09104 ENO2 enolase 2 (gamma, neuronal) -0.330 0.005592507 
P09211 GSTP1 glutathione S-transferase pi 1 0.340 0.003381664 
P09382 LGALS1 lectin, galactoside-binding, 
soluble, 1 
-0.433 0.004883304 
P09429 HMGB1 high mobility group box 1 -0.299 0.025815199 
P09543-2 CNP 2',3'-cyclic nucleotide 3' 
phosphodiesterase 
0.245 0.002577887 
P09661 SNRPA1 small nuclear ribonucleoprotein 
polypeptide A' 
0.123 0.010740883 
P0CW22 RPS17 ribosomal protein S17 0.151 0.02656002 
P10155-3 TROVE2 TROVE domain family, member 2 -0.506 0.000505333 




P11172 UMPS uridine monophosphate 
synthetase 
0.374 0.007431418 
P11279 LAMP1 lysosomal-associated membrane 
protein 1 
-0.467 0.004927886 
P12081-4 HARS histidyl-tRNA synthetase 0.201 0.013696079 
P12235 SLC25A4 solute carrier family 25 




P12277 CKB creatine kinase, brain 0.544 0.00286631 
P13010 XRCC5 X-ray repair complementing 
defective repair in Chinese 
hamster cells 5 (double-strand-
break rejoining) 
0.248 0.001809585 
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P14324-2 FDPS farnesyl diphosphate synthase 0.535 0.039145724 
P14406 COX7A2 cytochrome c oxidase subunit 
VIIa polypeptide 2 (liver) 
0.563 0.033127375 
P14618 PKM pyruvate kinase, muscle 0.804 0.039669197 
P16152 CBR1 carbonyl reductase 1 0.457 0.038822816 
P16401 HIST1H1B histone cluster 1, H1b -0.242 0.003551272 
P16402 HIST1H1D histone cluster 1, H1d -0.139 0.001206152 
P16403 HIST1H1C histone cluster 1, H1c -0.449 0.040337038 
P16435 POR P450 (cytochrome) 
oxidoreductase 
0.469 0.000543216 
P17174 GOT1 glutamic-oxaloacetic 
transaminase 1, soluble 
0.102 0.032003235 
P18085 ARF4 ADP-ribosylation factor 4 0.188 0.005527608 
P18615 NELFE negative elongation factor 
complex member E 
-0.340 0.017185736 
P20700 LMNB1 lamin B1 -0.309 0.031811377 
P21283 ATP6V1C1 ATPase, H+ transporting, 
lysosomal 42kDa, V1 subunit C1 
0.309 0.049697488 
P23381 WARS tryptophanyl-tRNA synthetase 0.242 0.034644942 
P23588 EIF4B eukaryotic translation initiation 
factor 4B 
-0.422 0.006041669 
P24534 EEF1B2 eukaryotic translation elongation 
factor 1 beta 2 
-0.394 0.038391208 
P24539 ATP5F1 ATP synthase, H+ transporting, 
mitochondrial Fo complex, 
subunit B1 
-0.986 0.002829824 
P24752 ACAT1 acetyl-CoA acetyltransferase 1 0.237 0.025930951 
P24928 POLR2A polymerase (RNA) II (DNA 
directed) polypeptide A, 220kDa 
0.563 0.023544105 
P25398 RPS12 ribosomal protein S12 -0.293 0.001422152 
P25685 DNAJB1 DnaJ (Hsp40) homolog, subfamily 
B, member 1 
0.455 0.000284744 
P25787 PSMA2 proteasome (prosome, 
macropain) subunit, alpha type, 2 
0.515 0.010493039 
P26368-2 U2AF2 U2 small nuclear RNA auxiliary 
factor 2 
0.315 0.015725768 





P27695 APEX1 APEX nuclease (multifunctional 
DNA repair enzyme) 1 
-0.314 0.043311557 
P27824 CANX calnexin 0.253 0.003954031 
P28072 PSMB6 proteasome (prosome, 
macropain) subunit, beta type, 6 
-0.488 0.001224471 
P28838-2 LAP3 leucine aminopeptidase 3 0.095 0.001129042 
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P29401 TKT transketolase 0.142 0.000387931 
P30041 PRDX6 peroxiredoxin 6 0.089 0.000261694 
P30044-2 PRDX5 peroxiredoxin 5 0.334 0.003820306 
P30520 ADSS adenylosuccinate synthase 0.107 0.041450692 
P31150 GDI1 GDP dissociation inhibitor 1 0.109 0.007036114 
P31323 PRKAR2B protein kinase, cAMP-dependent, 
regulatory, type II, beta 
0.983 0.005932705 





P31942-2 HNRNPH3 heterogeneous nuclear 
ribonucleoprotein H3 (2H9) 
0.195 0.008746671 





P32969 RPL9 ribosomal protein L9 0.529 0.000139254 
P34897-3 SHMT2 serine hydroxymethyltransferase 
2 (mitochondrial) 
0.123 0.006594307 
P35232 PHB prohibitin 0.272 0.004338721 
P35244 RPA3 replication protein A3, 14kDa 0.556 0.000359465 
P35269 GTF2F1 general transcription factor IIF, 
polypeptide 1, 74kDa 
-0.231 0.036534819 
P35520 CBS/CBSL cystathionine-beta-synthase -0.194 0.030952861 
P35637-2 FUS FUS RNA binding protein -0.547 0.004726813 
P36404 ARL2 ADP-ribosylation factor-like 2 0.086 0.0329326 






P39748 FEN1 flap structure-specific 
endonuclease 1 
-0.245 0.005524999 
P42167 TMPO thymopoietin 0.699 0.000369519 
P43487 RANBP1 RAN binding protein 1 -0.332 0.03233675 
P43490 NAMPT nicotinamide 
phosphoribosyltransferase 
0.154 0.023995371 
P45974-2 USP5 ubiquitin specific peptidase 5 
(isopeptidase T) 
0.298 0.000881193 
P46087 NOP2 NOP2 nucleolar protein 0.376 0.005212805 
P46778 RPL21 ribosomal protein L21 0.379 0.006529396 
P46781 RPS9 ribosomal protein S9 0.111 0.001643832 
P47813 EIF1AX eukaryotic translation initiation 
factor 1A, X-linked 
-0.411 0.011437671 
P48147 PREP prolyl endopeptidase 0.301 0.001508054 
P48637 GSS glutathione synthetase -0.364 0.024064817 
P48643 CCT5 chaperonin containing TCP1, 
subunit 5 (epsilon) 
0.193 0.036522519 
P49006 MARCKSL1 MARCKS-like 1 -0.204 0.018781147 
P49189 ALDH9A1 aldehyde dehydrogenase 9 -0.240 0.046929468 
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family, member A1 
P49321 NASP nuclear autoantigenic sperm 
protein (histone-binding) 
-0.236 0.008490313 
P49327 FASN fatty acid synthase 0.169 0.003200218 
P49419-2 ALDH7A1 aldehyde dehydrogenase 7 
family, member A1 
0.209 0.000599184 
P49720 PSMB3 proteasome (prosome, 
macropain) subunit, beta type, 3 
0.246 0.000396092 
P49770 EIF2B2 eukaryotic translation initiation 
factor 2B, subunit 2 beta, 39kDa 
0.368 0.048224022 
P49773 HINT1 histidine triad nucleotide binding 
protein 1 
-0.314 0.017456701 
P50395 GDI2 GDP dissociation inhibitor 2 0.159 0.00898103 
P50416-2 CPT1A carnitine palmitoyltransferase 1A 
(liver) 
-0.404 0.00255797 
P50454 SERPINH1 serpin peptidase inhibitor, clade 
H (heat shock protein 47), 
member 1, (collagen binding 
protein 1) 
0.212 0.001632399 
P51571 SSR4 signal sequence receptor, delta 0.424 0.005549936 
P51572 BCAP31 B-cell receptor-associated 
protein 31 
-1.069 0.010820127 
P51858 HDGF hepatoma-derived growth factor -0.470 0.004108056 
P52948-6 NUP98 nucleoporin 98kDa -0.354 0.003666415 
P53396 ACLY ATP citrate lyase 0.152 0.00549645 
P53990-2 IST1 increased sodium tolerance 1 
homolog (yeast) 
-0.873 0.004194261 
P54136 RARS arginyl-tRNA synthetase 0.106 0.033211941 
P54725-2 RAD23A RAD23 homolog A, nucleotide 
excision repair protein 
-0.407 0.010940519 
P54727 RAD23B RAD23 homolog B, nucleotide 
excision repair protein 
-0.289 0.010281498 
P55010 EIF5 eukaryotic translation initiation 
factor 5 
0.314 0.000261544 
P55072 VCP valosin containing protein 0.116 0.007046351 
P56134-3 ATP5J2 ATP synthase, H+ transporting, 
mitochondrial Fo complex, 
subunit F2 
0.566 0.013201036 
P56192 MARS methionyl-tRNA synthetase 0.298 0.005426432 
P57088 TMEM33 transmembrane protein 33 0.166 0.030099849 
P59998 ARPC4 actin related protein 2/3 
complex, subunit 4, 20kDa 
0.390 0.000254598 
P60174-1 TPI1 triosephosphate isomerase 1 0.257 0.000220944 
P60900 PSMA6 proteasome (prosome, 
macropain) subunit, alpha type, 6 
0.265 0.035478676 
P60953 CDC42 cell division cycle 42 0.805 0.031915193 
P60981 DSTN destrin (actin depolymerizing 
factor) 
0.129 0.031555097 
P61457 PCBD1 pterin-4 alpha-carbinolamine 
dehydratase/dimerization 
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factor 1 alpha 
P61586 RHOA ras homolog family member A 1.049 0.022155991 
P61964 WDR5 WD repeat domain 5 -0.650 0.032739535 
P61970 NUTF2 nuclear transport factor 2 -0.252 0.039000347 
P61978-2 HNRNPK heterogeneous nuclear 
ribonucleoprotein K 
0.715 0.00051122 
P62158     -0.506 0.023916164 





P62277 RPS13 ribosomal protein S13 0.629 0.003166966 
P62304 SNRPE small nuclear ribonucleoprotein 
polypeptide E 
0.986 0.041112866 
P62333 PSMC6 proteasome (prosome, 
macropain) 26S subunit, ATPase, 
6 
0.132 0.021977644 
P62805     0.442 0.000401869 
P62851 RPS25 ribosomal protein S25 0.091 0.036012958 
P62854 RPS26 ribosomal protein S26 0.425 0.02948157 
P62906 RPL10A ribosomal protein L10a 0.328 0.003436465 
P62937 PPIA peptidylprolyl isomerase A 
(cyclophilin A) 
1.367 0.009318894 
P62993 GRB2 growth factor receptor-bound 
protein 2 
-0.217 0.041832128 
P63151 PPP2R2A protein phosphatase 2, 
regulatory subunit B, alpha 
-0.452 0.036236488 
P63173 RPL38 ribosomal protein L38 0.635 0.006371542 
P67809 YBX1 Y box binding protein 1 -0.618 0.004101063 
P67936 TPM4 tropomyosin 4 -0.654 0.014615316 
P68036 UBE2L3 ubiquitin-conjugating enzyme 
E2L 3 
-0.770 0.004876744 
P68104 EEF1A1 eukaryotic translation elongation 
factor 1 alpha 1 
0.520 0.035438597 
P78344 EIF4G2 eukaryotic translation initiation 
factor 4 gamma, 2 
0.363 0.010928649 
P78347-2 GTF2I general transcription factor IIi -0.338 0.015313238 
P78417 GSTO1 glutathione S-transferase omega 
1 
0.147 0.002584711 
P80723 BASP1 brain abundant, membrane 
attached signal protein 1 
-0.169 0.001525792 
P84090 ERH enhancer of rudimentary 
homolog (Drosophila) 
-0.623 0.000601542 
Q00534 CDK6 cyclin-dependent kinase 6 0.190 0.005641734 
Q01105-2 SET SET nuclear proto-oncogene -0.221 0.020957902 
Q01581 HMGCS1 3-hydroxy-3-methylglutaryl-CoA 
synthase 1 (soluble) 
0.556 0.022832346 
Q02880-2 TOP2B topoisomerase (DNA) II beta 
180kDa 
0.175 0.041260933 
Q04837 SSBP1 single-stranded DNA binding 




477 | P a g e  
 





Q06124-2 PTPN11 protein tyrosine phosphatase, 
non-receptor type 11 
-0.548 0.049978081 
Q06210-2 GFPT1 glutamine--fructose-6-phosphate 
transaminase 1 
-0.502 0.049062088 
Q06830 PRDX1 peroxiredoxin 1 -0.291 0.04197834 
Q07021 C1QBP complement component 1, q 
subcomponent binding protein 
1.157 0.003213479 
Q07866-3 KLC1 kinesin light chain 1 -0.347 0.035934002 
Q07955 SRSF1 serine/arginine-rich splicing 
factor 1 
-0.431 8.94E-05 
Q08211 DHX9 DEAH (Asp-Glu-Ala-His) box 
helicase 9 
0.070 0.005106558 
Q09028-3 RBBP4 retinoblastoma binding protein 4 -0.280 0.030264444 
Q12765 SCRN1 secernin 1 -0.236 0.044460004 
Q12792 TWF1 twinfilin actin binding protein 1 -0.497 0.037497558 
Q12905 ILF2 interleukin enhancer binding 
factor 2 
0.288 0.020516523 
Q13126 MTAP methylthioadenosine 
phosphorylase 
-0.474 0.016168697 
Q13185 CBX3 chromobox homolog 3 -0.548 0.012643541 
Q13242 SRSF9 serine/arginine-rich splicing 
factor 9 
-0.297 0.002083675 
Q13247-3 SRSF6 serine/arginine-rich splicing 
factor 6 
-0.340 0.015129061 
Q13283 G3BP1 GTPase activating protein (SH3 
domain) binding protein 1 
0.451 0.000636466 
Q13347 EIF3I eukaryotic translation initiation 
factor 3, subunit I 
-0.357 0.003122779 
Q13409-3 DYNC1I2 dynein, cytoplasmic 1, 
intermediate chain 2 
-0.713 8.36E-05 
Q13442 PDAP1 PDGFA associated protein 1 -0.283 0.015009881 
Q13573 SNW1 SNW domain containing 1 -0.419 0.027973685 
Q13620-3 CUL4B cullin 4B -0.348 0.044921914 
Q13630 TSTA3 tissue specific transplantation 
antigen P35B 
-0.391 0.039148057 
Q14247 CTTN cortactin -0.503 0.021203064 
Q14699 RFTN1 raftlin, lipid raft linker 1 -0.419 0.015627758 
Q14789 GOLGB1 golgin B1 0.345 0.046124634 
Q15005 SPCS2 signal peptidase complex subunit 
2 
-0.309 0.016031277 
Q15102 PAFAH1B3 platelet-activating factor 
acetylhydrolase 1b, catalytic 
subunit 3 (29kDa) 
0.120 0.04812527 
Q15435 PPP1R7 protein phosphatase 1, 
regulatory subunit 7 
0.283 0.004758079 
Q15437 SEC23B Sec23 homolog B (S. cerevisiae) -0.565 5.44E-05 
Q15631 TSN translin 0.146 0.041458753 
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Q15785 TOMM34 translocase of outer 
mitochondrial membrane 34 
-0.707 0.01154691 
Q16527 CSRP2 cysteine and glycine-rich protein 
2 
-0.492 0.010790443 
Q16531 DDB1 damage-specific DNA binding 
protein 1, 127kDa 
0.182 0.01691446 
Q16629-3 SRSF7 serine/arginine-rich splicing 
factor 7 
-0.542 0.000607116 
Q16643 DBN1 drebrin 1 -0.426 0.009415594 
Q16777 HIST2H2AC histone cluster 2, H2ac 2.064 0.049313512 
Q16836 HADH hydroxyacyl-CoA dehydrogenase -0.707 0.047898125 
Q16850 CYP51A1 cytochrome P450, family 51, 
subfamily A, polypeptide 1 
0.218 0.027623103 
Q29RF7 PDS5A PDS5 cohesin associated factor A -0.352 0.03846805 
Q2TAY7 SMU1 smu-1 suppressor of mec-8 and 
unc-52 homolog (C. elegans) 
-0.396 0.027164747 
Q3ZCM7 TUBB8 tubulin, beta 8 class VIII 1.174 0.035422051 
Q4G0J3 LARP7 La ribonucleoprotein domain 




heat shock protein 90kDa alpha 
(cytosolic), class B member 2, 
pseudogene 
4.015 0.011673008 
Q5JP53 TUBB tubulin, beta class I 1.153 0.004274 
Q5JRA6-2 MIA3 melanoma inhibitory activity 
family, member 3 
-0.774 0.034839608 
Q5VW32 BROX BRO1 domain and CAAX motif 
containing 
0.159 0.01279061 
Q5VYK3 KIAA0368 KIAA0368 -0.733 0.0005437 
Q6NUK1-2 SLC25A24 solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier), member 24 
0.546 6.60E-05 
Q6UXN9 WDR82 WD repeat domain 82 -0.772 0.017572548 
Q7L2H7 EIF3M eukaryotic translation initiation 
factor 3, subunit M 
0.426 0.013155595 
Q7RTV0 PHF5A PHD finger protein 5A -0.629 0.000657565 
Q7Z2T5 TRMT1L tRNA methyltransferase 1 
homolog (S. cerevisiae)-like 
-0.509 0.014048953 
Q86U42-2 PABPN1 poly(A) binding protein, nuclear 1 0.407 0.01029432 
Q86U44 METTL3 methyltransferase like 3 -0.442 0.025804632 
Q8IV08 PLD3 phospholipase D family, member 
3 
0.098 0.009767724 
Q8IY81 FTSJ3 FtsJ homolog 3 (E. coli) 0.362 0.00079843 
Q8N1F7 NUP93 nucleoporin 93kDa -0.292 0.001125018 
Q8NBS9-2 TXNDC5 thioredoxin domain containing 5 
(endoplasmic reticulum) 
-0.312 0.018531569 
Q8NE71-2 ABCF1 ATP-binding cassette, sub-family 
F (GCN20), member 1 
-0.329 0.004131324 
Q8NFH4 NUP37 nucleoporin 37kDa -0.509 0.035242145 
Q8NI36 WDR36 WD repeat domain 36 -0.277 7.63E-06 
Q8TEA8 DTD1 D-tyrosyl-tRNA deacylase 1 -0.605 0.045645079 
Q8TEM1 NUP210 nucleoporin 210kDa 0.797 0.020627459 
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Q8TEX9 IPO4 importin 4 0.550 0.013265677 
Q8WVC2 RPS21 ribosomal protein S21 -0.906 1.16E-06 
Q8WW12 PCNP PEST proteolytic signal containing 
nuclear protein 
-0.528 0.032298365 
Q8WZA9 IRGQ immunity-related GTPase family, 
Q 
-0.365 0.001219965 
Q92499 DDX1 DEAD (Asp-Glu-Ala-Asp) box 
helicase 1 
0.191 0.006214171 
Q92598-2 HSPH1 heat shock 105kDa/110kDa 
protein 1 
0.134 0.003464985 
Q92878 RAD50 RAD50 homolog, double strand 
break repair protein 
-0.593 0.00937218 
Q92879-2 CELF1 CUGBP, Elav-like family member 
1 
-0.565 0.003576203 
Q92896 GLG1 golgi glycoprotein 1 -0.541 0.018680487 
Q92973-2 TNPO1 transportin 1 0.255 0.045079054 
Q96AG4 LRRC59 leucine rich repeat containing 59 0.380 0.020465995 
Q96B54 ZNF428 zinc finger protein 428 -0.455 0.018265545 
Q96C01 FAM136A family with sequence similarity 
136, member A 
-0.376 0.004017361 
Q96CN7 ISOC1 isochorismatase domain 
containing 1 
0.561 0.000454077 
Q96CT7 CCDC124 coiled-coil domain containing 124 -0.400 0.011840373 
Q96DH6-2 MSI2 musashi RNA-binding protein 2 0.589 0.0054224 
Q96FC7 PHYHIPL phytanoyl-CoA 2-hydroxylase 
interacting protein-like 
-0.288 0.001842916 
Q96HS1 PGAM5 phosphoglycerate mutase family 
member 5 
-0.254 0.029029066 
Q96I25 RBM17 RNA binding motif protein 17 -0.730 0.047584769 
Q96KR1 ZFR zinc finger RNA binding protein -0.191 0.01527677 
Q96PZ0 PUS7 pseudouridylate synthase 7 
(putative) 
-0.296 0.008884381 
Q96TA2-3 YME1L1 YME1-like 1 ATPase -0.316 0.045235908 
Q99543-2 DNAJC2 DnaJ (Hsp40) homolog, subfamily 
C, member 2 
-0.717 0.018107404 
Q99733 NAP1L4 nucleosome assembly protein 1-
like 4 
-0.275 0.003225905 
Q99880 HIST1H2BL histone cluster 1, H2bl -0.305 0.028954221 
Q9BQ52-4 ELAC2 elaC ribonuclease Z 2 0.250 0.04884852 
Q9BQA1 WDR77 WD repeat domain 77 0.526 0.040263099 
Q9BRX8-2 FAM213A family with sequence similarity 
213, member A 
1.238 0.003133277 
Q9BTT0 ANP32E acidic (leucine-rich) nuclear 
phosphoprotein 32 family, 
member E 
0.346 0.027030894 
Q9BVG4 PBDC1 polysaccharide biosynthesis 
domain containing 1 
-0.489 0.009572317 
Q9H307 PNN pinin, desmosome associated 
protein 
-0.626 0.015287906 
Q9H9B4 SFXN1 sideroflexin 1 0.202 0.000283261 
Q9HAV4 XPO5 exportin 5 0.140 0.006611309 
 
 
480 | P a g e  
 
Q9NQ48-2 LZTFL1 leucine zipper transcription 
factor-like 1 
0.417 0.025634072 
Q9NR45 NANS N-acetylneuraminic acid synthase 0.588 0.000642731 
Q9NWU5 MRPL22 mitochondrial ribosomal protein 
L22 
-0.512 0.025994698 
Q9NZZ3 CHMP5 charged multivesicular body 
protein 5 
0.331 0.036155523 
Q9P258 RCC2 regulator of chromosome 
condensation 2 
-0.279 0.021193485 
Q9P2J5 LARS leucyl-tRNA synthetase 0.155 0.016734573 
Q9UBM7 DHCR7 7-dehydrocholesterol reductase 0.142 0.017369289 
Q9UHB9 SRP68 signal recognition particle 68kDa 0.282 0.013372805 
Q9UHD8-5 SEPT9 septin 9 0.192 1.49E-05 
Q9UJA5 TRMT6 tRNA methyltransferase 6 -0.328 0.015156387 




Q9UNS2 COPS3 COP9 signalosome subunit 3 0.276 0.01101695 
Q9UQ80 PA2G4 proliferation-associated 2G4, 
38kDa 
-0.339 0.024150782 
Q9Y230 RUVBL2 RuvB-like AAA ATPase 2 -0.202 0.018236837 
Q9Y265 RUVBL1 RuvB-like AAA ATPase 1 0.361 0.001286532 
Q9Y2A7 NCKAP1 NCK-associated protein 1 0.994 0.008558676 
Q9Y2W1 THRAP3 thyroid hormone receptor 
associated protein 3 
-0.224 0.00018084 
Q9Y394-2 DHRS7 dehydrogenase/reductase (SDR 
family) member 7 
0.435 0.001591339 
Q9Y3B3-2 TMED7 transmembrane emp24 protein 
transport domain containing 7 
0.419 0.010425221 
Q9Y3B7-2 MRPL11 mitochondrial ribosomal protein 
L11 
0.071 0.00760537 
Q9Y4C2 TCAF1 TRPM8 channel-associated factor 
1 
0.370 0.003850379 
Q9Y5B8-2 NME7 NME/NM23 family member 7 0.445 0.044338155 
Q9Y5K5-2 UCHL5 ubiquitin carboxyl-terminal 
hydrolase L5 
0.224 0.020980893 
Q9Y678 COPG1 coatomer protein complex, 
subunit gamma 1 
0.688 0.02646428 
Q9Y6G9 DYNC1LI1 dynein, cytoplasmic 1, light 
intermediate chain 1 
-0.390 0.010044682 
R4GNH3 PSMC3 proteasome (prosome, 
macropain) 26S subunit, ATPase, 
3 
-0.329 4.08E-05 
S4R3H4 ACIN1 apoptotic chromatin 
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Appendix 5 
Dysregulated LF_TatLivsBme proteins 
Uniprot 
accession # 
Symbol Log2 ratio p-value 
Q5JRA6-2 MIA3 -0.6913835 0 
O95782-2 AP2A1 -0.3804217 4.54E-212 
P08574 CY1 0.10743022 2.02E-13 
Q12972-2 PP1R8 -0.4955246 1.09E-08 
Q5VTU3 Q5VTU3 -0.8494605 2.85E-07 
O95202 LETM1 0.34496839 8.11E-07 
P06576 ATPB 0.27184662 1.66E-06 
P04406 G3P 0.394625 1.88E-06 
R4GNH3 R4GNH3 -0.4366067 3.87E-06 
P08670 VIME 0.19422923 4.17E-06 
P00403 COX2 0.81210021 4.26E-06 
Q7RTV0 PHF5A -1.071474 4.30E-06 
P18085 ARF4 0.40627647 4.38E-06 
Q2NL82 TSR1 0.29527683 6.99E-06 
Q9NS69 TOM22 -0.9187857 7.87E-06 
Q99832 TCPH 0.13640894 8.60E-06 
O43681 ASNA 0.29959877 1.21E-05 
Q07955 SRSF1 -0.3124895 1.88E-05 
P80723 BASP1 -0.8429613 2.08E-05 
Q13126 MTAP -0.5017758 2.20E-05 
P40227 TCPZ 0.11978615 2.23E-05 
Q8WX93-4 PALLD -0.4270714 2.24E-05 
Q16629-3 SRSF7 -0.5301607 2.38E-05 
Q8WZA9 IRGQ -0.6128187 2.39E-05 
P68402 PA1B2 -0.8240464 2.65E-05 
Q9UHD8-5 9-Sep 0.20512801 2.78E-05 
O00231 PSD11 0.36036241 2.99E-05 
O00159-2 MYO1C 0.60850023 3.02E-05 
P14406 CX7A2 1.17743944 3.04E-05 
P09543-2 CN37 0.49754354 3.68E-05 
E9PH29 E9PH29 0.3535852 3.76E-05 
Q96CN7 ISOC1 0.73326151 3.78E-05 
P67809 YBOX1 -1.1842305 4.03E-05 
Q99460 PSMD1 0.45609209 4.30E-05 
P60981 DEST 0.23838071 4.73E-05 
P62847-2 RS24 0.71227512 5.21E-05 
Q9NQT5 EXOS3 -0.199944 5.43E-05 
P51149 RAB7A 0.31675595 5.79E-05 
Q9UHB9 SRP68 0.40451927 7.09E-05 
P33993 MCM7 0.35686876 7.36E-05 
P32969 RL9 0.49312255 9.39E-05 
O95816 BAG2 0.4141795 0.00010021 
Q9ULC4 MCTS1 0.6502271 0.00010042 
P62805 H4 0.58873181 0.00010299 
Q15435 PP1R7 0.5653714 0.00012916 
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P49419-2 AL7A1 -0.3558217 0.00013573 
P62854 RS26 0.85358842 0.00013625 
O15020-2 SPTN2 -0.6219199 0.00013697 
P49327 FAS 0.18085568 0.00013993 
P35637-2 FUS -0.7959033 0.0001459 
E7ETZ4 E7ETZ4 0.42629914 0.00014615 
P13639 EF2 0.26289713 0.00016338 
Q15005 SPCS2 0.29766686 0.00017046 
Q15437 SC23B -0.5238638 0.0001718 
Q15631 TSN 0.29110765 0.00017778 
Q09028-3 RBBP4 -0.6549413 0.00020218 
Q12765 SCRN1 -0.4158813 0.00021311 
P10645 CMGA -0.5043355 0.00021611 
Q92598-2 HS105 0.14392028 0.00024121 
Q9HDC9 APMAP 0.13566251 0.00024593 
P13010 XRCC5 0.28389073 0.00026392 
Q5T6V5 CI064 0.34167259 0.00027018 
Q969Z0 TBRG4 -0.551933 0.00027558 
P50454 SERPH 0.21550018 0.00027761 
P16403 H12 -1.0704551 0.00029289 
M0R366 M0R366 -1.0472801 0.00031372 
Q96DI7 SNR40 -0.2612973 0.00032262 
P49189 AL9A1 -0.5386639 0.00033088 
P25705 ATPA 0.10089093 0.00033684 
P61313 RL15 -0.8859813 0.00036589 
Q9BRP8-2 WIBG -0.557871 0.00036781 
P35269 T2FA -0.750707 0.00039315 
B7Z1R5 B7Z1R5 0.41918661 0.00039984 
P25205 MCM3 0.2057147 0.00042497 
O75475 PSIP1 -0.3911358 0.00042856 
Q9Y678 COPG1 1.35046477 0.00043262 
P27348 1433T -0.2690067 0.00044048 
D6RGI3 D6RGI3 -0.6501962 0.00045681 
Q16850 CP51A 0.44211141 0.00046437 
Q96DH6-2 MSI2H 0.56611172 0.00047658 
O60264 SMCA5 -0.3794155 0.00048387 
P49591 SYSC 0.74228698 0.00051216 
O75439 MPPB -0.3940763 0.00052998 
Q08211 DHX9 0.12503582 0.00053439 
O43776 SYNC 0.6129039 0.00054543 
Q9Y6G9 DC1L1 -0.5967029 0.00057668 
P00491 PNPH -0.4468672 0.00058958 
P25685 DNJB1 0.40883102 0.00059779 
E9PC52 E9PC52 -0.6175613 0.00059799 
Q9BZZ5-2 API5 0.18755361 0.00065178 
Q14137 BOP1 -0.6678439 0.00070141 
P07741 APT -0.8223015 0.00071759 
Q04637-5 IF4G1 0.33946656 0.00072613 
P84090 ERH -0.4974438 0.00073588 
P53396 ACLY 0.12581246 0.00074102 
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B7Z972 B7Z972 0.48607445 0.00074664 
Q15813 TBCE 0.28057711 0.00075679 
O15173 PGRC2 0.17460716 0.00077015 
D6RIY6 D6RIY6 -0.2203475 0.00077136 
Q16527 CSRP2 -0.633395 0.00080209 
Q14699 RFTN1 -0.729051 0.00081062 
Q9UNS2 CSN3 0.36843005 0.00081642 
H3BRV0 H3BRV0 -0.3526311 0.00082685 
Q9NYF8-2 BCLF1 -0.6260714 0.00083073 
P25787 PSA2 0.88791971 0.00087008 
O43657 TSN6 -0.7004303 0.00088783 
Q14011 CIRBP -0.5904156 0.00094096 
P13591-1 NCAM1 -0.4624239 0.00097145 
P54725-2 RD23A -0.3513324 0.00098206 
Q9UJS0 CMC2 0.43969872 0.00099077 
P56192 SYMC 0.43151661 0.00105197 
O15143 ARC1B -0.3703162 0.00105317 
P30566 PUR8 0.43717649 0.00106918 
P43490 NAMPT 0.19149716 0.0010968 
Q9H2J4 PDCL3 -0.440774 0.00113636 
P29966 MARCS -0.3840245 0.00114418 
Q9BVG4 PBDC1 -0.7763724 0.0011836 
P49589-2 SYCC 0.82772412 0.00119031 
P36543 VATE1 0.42888244 0.00121953 
Q14444-2 CAPR1 -0.3828671 0.0012707 
P09211 GSTP1 0.37461177 0.00131937 
Q9BR76 COR1B -0.465043 0.00134989 
P48735 IDHP 0.23950955 0.00142385 
Q9UKD2 MRT4 -0.381532 0.00143845 
P62851 RS25 0.30495983 0.00146125 
P47897 SYQ 0.12043223 0.00146328 
P16435 NCPR 0.46421825 0.00146421 
P50395 GDIB 0.23390987 0.0014973 
B4E363 B4E363 -0.4007379 0.00152665 
P27695 APEX1 -0.4140086 0.00159289 
P27824 CALX 0.3880622 0.00162241 
O43719 HTSF1 -0.548108 0.00163042 
Q9UJZ1 STML2 -0.2170229 0.00165471 
P40222 TXLNA -0.4781395 0.00172115 
P35520 CBS -0.3297285 0.0017519 
F8VQX6 F8VQX6 0.74411293 0.00177144 
P05556 ITB1 -0.3721782 0.00177538 
J3QT28 J3QT28 -0.3692807 0.00179301 
O14980 XPO1 0.22796556 0.00183118 
P08754 GNAI3 0.39814519 0.00184264 
P51571 SSRD 0.23822864 0.00187765 
Q15126 PMVK -0.4000686 0.0019073 
Q8WWM7 ATX2L -0.4059125 0.00192826 
P09172 DOPO -0.4091666 0.00194118 
P19367 HXK1 0.09818375 0.00194851 
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O43765 SGTA -0.402194 0.00195333 
P61163 ACTZ -0.3811932 0.00198359 
P12236 ADT3 0.41996109 0.00200616 
Q8TEX9 IPO4 0.63212103 0.0020598 
H0Y9Y3 H0Y9Y3 -0.2679842 0.00209834 
Q14157 UBP2L -0.602968 0.00211704 
O14737 PDCD5 -0.5365084 0.00213991 
P42167 LAP2B 0.62035446 0.00214649 
P11940 PABP1 0.27347677 0.00218204 
Q92879-2 CELF1 -0.4805355 0.00220402 
P60174-1 TPIS 0.22767786 0.002205 
Q92896 GSLG1 -0.7413966 0.00220662 
Q13409-3 DC1I2 -0.4794948 0.00220917 
O00170 AIP -0.4327176 0.0022471 
Q9Y2W1 TR150 -0.1297525 0.00228458 
P05141 ADT2 0.63203981 0.00232517 
P15374 UCHL3 -0.3124247 0.00234625 
P35221 CTNA1 0.15767077 0.00235113 
P21266 GSTM3 -0.4476481 0.00237385 
O75531 BAF 0.40968063 0.00237661 
P62241 RS8 0.27092144 0.00242905 
Q9BUQ8 DDX23 0.14943694 0.00253154 
Q8WXF1-2 PSPC1 0.68135665 0.00255108 
P22626 ROA2 -0.2729841 0.00268263 
Q9Y2A7 NCKP1 1.93878879 0.00271167 
O14813 PHX2A -0.6629725 0.00271825 
O75691 UTP20 -0.8269714 0.00277623 
P56537 IF6 -0.6390248 0.00278537 
P61978-2 HNRPK -0.6605611 0.00286167 
Q9NPJ3-2 ACO13 0.4282369 0.00290099 
O95433 AHSA1 0.16265704 0.0029059 
O43670-2 ZN207 -0.5631164 0.00299797 
P11216 PYGB -0.2476821 0.00311436 
Q9H223 EHD4 -0.6131218 0.00312966 
Q07021 C1QBP 1.26926778 0.00313453 
P62873 GBB1 0.07908513 0.00315873 
Q13347 EIF3I -0.3753692 0.00317877 
Q9H0D6 XRN2 0.73306622 0.00336384 
Q8IY81 SPB1 0.17355028 0.00336601 
Q12788 TBL3 -0.425691 0.0033717 
O00505 IMA4 0.23250164 0.0034379 
Q00796 DHSO 0.16439367 0.0034572 
E9PB90 E9PB90 -0.5987672 0.00347569 
P00558 PGK1 0.23134701 0.00355768 
P61247 RS3A 0.19417847 0.0035776 
P07355 ANXA2 0.15504899 0.00363759 
P30044-2 PRDX5 0.4382393 0.00368916 
P53990-2 IST1 -0.7871176 0.00371996 
Q9UKN8 TF3C4 -0.4590048 0.00374872 
O43795-2 MYO1B 0.09947394 0.00376079 
 
 
485 | P a g e  
 
Q9UGI8-2 TES -0.4302656 0.00381761 
Q9Y265 RUVB1 0.32102313 0.00384167 
H7C2G3 H7C2G3 -1.4669421 0.00391854 
Q96FW1 OTUB1 -0.4695218 0.00394749 
P51858 HDGF -0.3768478 0.00395912 
Q14232 EI2BA 0.21313358 0.00396993 
P08238 HS90B 0.18087664 0.00397999 
Q9BS26 ERP44 0.16943397 0.0040288 
O43290 SNUT1 -0.4725547 0.00404638 
Q8WXI9 P66B -0.4430816 0.00406468 
P09661 RU2A 0.24548928 0.00412568 
Q8NFH4 NUP37 -0.820406 0.00414214 
Q5T3Q7 Q5T3Q7 -0.5545054 0.00416612 
P63104 1433Z 0.26411472 0.00427475 
O43324-2 MCA3 0.16495326 0.00442892 
Q96B54 ZN428 -1.1368546 0.00448403 
Q99714 HCD2 0.1771657 0.00453754 
Q9BVJ6-3 UT14A -0.4580056 0.00455009 
O95747 OXSR1 0.16401103 0.00461377 
P12277 KCRB 0.4962872 0.00462627 
Q9Y696 CLIC4 0.35594049 0.00463604 
O75822 EIF3J 0.39575154 0.00467686 
E5RHG8 E5RHG8 -0.2827243 0.00471655 
Q53EL6-2 PDCD4 -0.5651363 0.0047467 
Q29RF7 PDS5A -0.5509964 0.00475802 
P0CW22 RS17L 0.21929951 0.00476877 
P54136 SYRC 0.12583971 0.004805 
Q7Z2W4 ZCCHV -0.5470989 0.00483703 
Q969X5-2 ERGI1 -0.4495811 0.00486926 
P18615 NELFE -0.6070631 0.00487531 
P20042 IF2B 0.24356705 0.0050198 
Q14669-4 TRIPC -0.290539 0.00528327 
O00429 DNM1L 0.53488622 0.00533045 
P02545 LMNA 0.20251626 0.00543886 
O96019 ACL6A -0.3322127 0.00544566 
B7Z7F3 B7Z7F3 -0.7223731 0.00558113 
A6NNI4 A6NNI4 -0.4085948 0.00558911 
P38117 ETFB -0.3231112 0.00562632 
Q9NP72 RAB18 0.74084635 0.00569053 
Q9Y4C2 F115A 0.29572689 0.00573443 
Q9UBQ7 GRHPR -0.459955 0.00593059 
P10515 ODP2 0.24678235 0.00594362 
P50991 TCPD 0.09244949 0.0060505 
O15305 PMM2 -0.279776 0.00610123 
F8VR84 F8VR84 0.11784407 0.00617176 
Q8NE71-2 ABCF1 -0.3052054 0.00626591 
Q15365 PCBP1 0.68246099 0.00636012 
O43813 LANC1 -0.2332036 0.00636935 
F8W7S5 F8W7S5 -0.3456749 0.00647795 
B4DVE7 B4DVE7 0.07870376 0.00659698 
 
 
486 | P a g e  
 
P68036 UB2L3 -0.9579576 0.00664704 
Q9HD42 CHM1A 0.20170304 0.0066865 
P37235 HPCL1 -0.4770035 0.00669488 
P12081-4 SYHC 0.29243974 0.00680897 
P61981 1433G -0.451085 0.00689884 
Q13573 SNW1 -0.3028767 0.00703074 
P11233 RALA 0.34242002 0.00711418 
Q5T760 Q5T760 0.54801135 0.00751645 
Q09161 NCBP1 0.32402347 0.00752466 
P33991 MCM4 0.17501827 0.00763259 
P61158 ARP3 -0.1676225 0.00767887 
P32322 P5CR1 -0.3619812 0.0077413 
P06132 DCUP 0.64250357 0.0077813 
Q9UJW0 DCTN4 -0.3836373 0.00778488 
P49790 NU153 -0.3002443 0.0078699 
Q13724-2 MOGS -0.6258741 0.0078796 
Q96TA2-3 YMEL1 -0.2713002 0.00800716 
F5H669 F5H669 -0.6889427 0.00802406 
Q99627-2 CSN8 0.54311538 0.00811039 
Q9H4A4 AMPB 0.28656988 0.00812161 
Q99733 NP1L4 -0.3033602 0.00814527 
P14618 KPYM 0.85579993 0.00819258 
J3KSI4 J3KSI4 0.86514115 0.00822442 
Q9BRX8-2 F213A 0.49370444 0.00824029 
O43809 CPSF5 0.12044263 0.00828998 
I3L1P8 I3L1P8 -0.3461458 0.00833072 
Q8NBS9-2 TXND5 -0.3083553 0.00833188 
P35232 PHB 0.2961273 0.00837994 
Q15019 2-Sep 0.12700618 0.00844986 
P62277 RS13 0.50690244 0.00845313 
E5RGR0 E5RGR0 -0.3983663 0.00845585 
O75874 IDHC 0.09126657 0.00850118 
P61081 UBC12 0.21750876 0.00855251 
Q9UIA9 XPO7 -0.4437967 0.00861995 
Q13362-4 2A5G -0.4489363 0.0088225 
F5H2Q7 F5H2Q7 -0.5764061 0.00887743 
P24666 PPAC -0.4159461 0.0089195 
P62906 RL10A 0.52360575 0.00904041 
Q9NYH9 UTP6 -0.3383785 0.00904961 
P57740 NU107 -0.4823143 0.00905945 
Q9P258 RCC2 -0.3254391 0.00909171 
P28072 PSB6 -0.5312568 0.00912911 
Q9Y333 LSM2 1.42370605 0.00919397 
P78347-2 GTF2I -0.3622572 0.009364 
O00483 NDUA4 -1.0439633 0.00938736 
Q92878 RAD50 -0.2357025 0.00941604 
Q14108 SCRB2 0.32033788 0.00943686 
P12235 ADT1 0.39586674 0.00949142 
Q13151 ROA0 0.60628708 0.00961192 
P25788-2 PSA3 -0.3071643 0.00983277 
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P54577 SYYC 0.45138201 0.00989364 
P40926 MDHM 0.21476603 0.00994247 
E5RJI7 E5RJI7 -0.597278 0.01001409 
E7EU96 E7EU96 0.38112146 0.01010198 
Q04837 SSBP -0.2819044 0.01012469 
O00410 IPO5 -0.1015946 0.01023345 
P24539 AT5F1 -0.9352183 0.01024696 
P34897-3 GLYM 0.06382125 0.01026703 
P04181 OAT -0.3388927 0.01036417 
Q8TEM1 PO210 0.54121991 0.01040082 
Q8N8S7-2 ENAH -0.6264979 0.01042338 
Q99453 PHX2B -0.1727332 0.01043904 
Q86V81 THOC4 0.42407696 0.01055297 
P51148 RAB5C -0.3186011 0.01055781 
Q9Y3B3-2 TMED7 0.35647331 0.01077864 
P67936 TPM4 -0.4529101 0.01108349 
P29373 RABP2 0.47852169 0.01117547 
P53004 BIEA 0.20142911 0.01120686 
Q14257 RCN2 0.6228945 0.01130158 
O75348 VATG1 -0.3611296 0.01149301 
Q92522 H1X -0.6206284 0.01220216 
Q9ULV4 COR1C -0.2694564 0.01238347 
P35658-2 NU214 -0.417129 0.01240852 
Q14254 FLOT2 0.46130544 0.01242215 
Q9Y262 EIF3L 0.13848467 0.01257534 
O60271-4 JIP4 -0.5336622 0.0126379 
Q9NTI5-2 PDS5B -0.3011565 0.01276182 
P21283 VATC1 0.28852194 0.01285924 
P60953 CDC42 0.74285151 0.01305653 
P22059 OSBP1 -0.3744546 0.01320858 
Q13247-3 SRSF6 -0.3050024 0.01322571 
Q16555 DPYL2 0.32150776 0.01333187 
P00505 AATM 0.19262043 0.01344204 
P35244 RFA3 0.31507644 0.01369819 
O75340 PDCD6 0.38111105 0.01373106 
P26583 HMGB2 -0.3327729 0.01385569 
O00232 PSD12 0.2103367 0.01392224 
Q1KMD3 HNRL2 0.2150828 0.01405858 
Q9UKM9-2 RALY 0.24226031 0.01414952 
O75223 GGCT -0.3521439 0.01446901 
O43847 NRDC -0.1416122 0.01451422 
P22695 QCR2 -0.3081495 0.01468315 
Q9H0A0 NAT10 0.82910196 0.01486666 
P02786 TFR1 0.23754606 0.01490123 
P08621 RU17 -0.2453147 0.01496919 
Q8IZL8 PELP1 -0.3634902 0.01501083 
P55010 IF5 0.27337664 0.01502639 
G8JLB2 G8JLB2 0.17879285 0.01533227 
O60762 DPM1 0.56962807 0.01533798 
Q16401-2 PSMD5 0.49305294 0.01534479 
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P07858 CATB -0.2130324 0.01561901 
P62140 PP1B 0.32255179 0.01578671 
P62829 RL23 0.41025496 0.01581577 
Q9H3P7 GCP60 -0.389451 0.01609769 
F5H8E5 F5H8E5 -0.3043434 0.01610484 
H7BXW3 H7BXW3 0.17810516 0.01621557 
E7EVA0 E7EVA0 -0.2885021 0.01634682 
Q7KZF4 SND1 -0.1971671 0.01646028 
Q96H79 ZCCHL -0.5092706 0.01682556 
H3BV80 H3BV80 0.15234408 0.01690784 
P47813 IF1AX -0.2582713 0.0170173 
P10599 THIO 0.25052679 0.01702853 
E3W994 E3W994 -0.6317961 0.01706636 
F8VPD4 F8VPD4 0.12723512 0.01713474 
O15240 VGF 0.42540049 0.01724866 
Q16543 CDC37 -0.2184469 0.0173562 
P49736 MCM2 0.50708332 0.0175659 
P61586 RHOA 0.7291954 0.01774152 
O00461 GOLI4 -0.5442628 0.01775416 
P48147 PPCE 0.21758558 0.01799724 
B4DEK4 B4DEK4 -0.3754769 0.01803957 
Q16643 DREB -0.3170894 0.01806144 
B7Z254 B7Z254 0.20615248 0.0181571 
B4DUS9 B4DUS9 0.18896909 0.0185763 
Q13442 HAP28 -0.2282016 0.01888934 
J3QRD1 J3QRD1 -0.3801315 0.01890638 
O00299 CLIC1 0.22426383 0.0189139 
P36578 RL4 0.22025837 0.01893942 
M0QX07 M0QX07 -1.5950906 0.0194857 
O00746 NDKM -0.324535 0.01955966 
P40938-2 RFC3 -0.4032543 0.01961431 
P61964 WDR5 -0.638016 0.01975557 
P47985 UCRI 2.60047344 0.01992551 
Q7L014 DDX46 -0.1865038 0.01995713 
B4DP61 B4DP61 -0.231257 0.01997915 
O00303 EIF3F 0.21213578 0.02013508 
Q01581 HMCS1 0.58108685 0.02024099 
Q96B26 EXOS8 0.34624596 0.02102707 
P61970 NTF2 0.16422304 0.02115015 
Q96AG4 LRC59 0.37932661 0.02116035 
Q13148 TADBP -0.5056326 0.0212743 
Q9Y2Q3 GSTK1 -0.6583139 0.02129402 
Q9HB71 CYBP -0.2815207 0.02162537 
Q13526 PIN1 0.51007236 0.02169703 
Q4VC31 CCD58 -0.114858 0.02192572 
Q9Y6C9 MTCH2 -0.1879274 0.02199233 
H0Y362 H0Y362 -0.7620361 0.0220115 
Q13162 PRDX4 -0.1973549 0.02208853 
P31939 PUR9 0.08847242 0.02215771 
Q9NV06 DCA13 0.15307215 0.02217835 
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Q14498-3 RBM39 0.45535835 0.02236653 
P62266 RS23 -0.4109626 0.02244679 
O00148 DX39A 0.38479895 0.02266198 
P18859 ATP5J -1.0988631 0.02275873 
Q8TEA8 DTD1 -0.3598152 0.02280051 
P24928 RPB1 0.56164381 0.02283175 
Q9HD20 AT131 -0.5606333 0.02293079 
P20618 PSB1 0.1517247 0.02297074 
B7Z9I1 B7Z9I1 -0.2774859 0.02325851 
Q99459 CDC5L 0.29794268 0.02326376 
Q9P2J5 SYLC 0.13197715 0.02346955 
P04843 RPN1 0.11049842 0.02363949 
O00267-2 SPT5H -0.3332797 0.02366301 
Q9UNZ2 NSF1C -0.671253 0.02369701 
E2QRM6 E2QRM6 -0.6299637 0.02410387 
P09429 HMGB1 -0.3808071 0.02432337 
P15880 RS2 0.18402184 0.02453162 
Q9H2M9 RBGPR -0.7110106 0.02453565 
O95487-2 SC24B -1.2776102 0.02469893 
B7Z3Y2 B7Z3Y2 -0.1389802 0.0247272 
P62826 RAN -0.2296955 0.02495393 
O15355 PPM1G 0.12472678 0.02505325 
Q8IV08 PLD3 0.19304616 0.02508805 
P54289-5 CA2D1 -0.4235853 0.02530562 
Q01082 SPTB2 -0.2641796 0.02539493 
O00154-4 BACH 0.38720599 0.02545483 
Q5JP53 Q5JP53 0.83222482 0.02567824 
Q9NZB2 F120A -0.6030013 0.02603678 
Q86U42-2 PABP2 0.41383839 0.02604857 
P62280 RS11 0.22916979 0.02624602 
P52948-6 NUP98 -0.3547756 0.02634268 
Q9Y315 DEOC -0.1619873 0.02643924 
P61011 SRP54 0.30486451 0.02649424 
O00425 IF2B3 -0.1100721 0.02666259 
Q6NUK1-2 SCMC1 0.16252869 0.02685506 
Q13045-2 FLII -0.3962422 0.02728717 
P11047 LAMC1 -0.6461229 0.02735778 
Q9BVP2-2 GNL3 0.28730727 0.02753233 
Q99622 C10 -0.462872 0.02763465 
B7Z7Q6 B7Z7Q6 1.23090513 0.02769174 
Q9NX46 ARHL2 -0.3560116 0.02780972 
P28070 PSB4 0.27908864 0.02784361 
Q9Y394-2 DHRS7 0.19102527 0.02785022 
Q9H910 HN1L -0.3882719 0.02807951 
P19338 NUCL 0.1223577 0.0281829 
Q9Y570 PPME1 0.73716308 0.02828869 
Q15056 IF4H 0.34381821 0.02830909 
P53597 SUCA -0.5895135 0.02836441 
E7EQ72 E7EQ72 -0.340146 0.02850739 
O95881 TXD12 -0.43143 0.02851135 
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P23193 TCEA1 -0.3144191 0.02854349 
Q9H9H4 VP37B 0.43845239 0.02859007 
A6NHR9 SMHD1 -0.6833407 0.0286715 
P63151 2ABA -0.5007296 0.0291499 
Q01081 U2AF1 -0.2775706 0.03000987 
Q9UM54-6 MYO6 -0.3231186 0.03039797 
P54886-2 P5CS 0.31098732 0.0305444 
P63244 GBLP 0.25801247 0.03087214 
Q9P0J0 NDUAD 0.30410154 0.03089417 
Q9Y5M8 SRPRB -0.3251541 0.03101928 
P05388 RLA0 0.06867191 0.03120403 
P84095 RHOG -0.5556166 0.03123039 
Q9BT78 CSN4 0.49677642 0.03134711 
Q9HC38-2 GLOD4 0.24668376 0.03148872 
P59998 ARPC4 0.19196373 0.03161036 
Q16181 7-Sep -0.2492034 0.03185862 
Q7L2H7 EIF3M 0.42027179 0.03194377 
Q15717 ELAV1 0.12760223 0.03201372 
C9JG97 C9JG97 -0.5084527 0.03220341 
Q9NQ48-2 LZTL1 -0.264396 0.03232106 
Q96CW1-2 AP2M1 0.06532179 0.03320072 
P63092 GNAS2 -0.3550469 0.03325483 
Q96PK6 RBM14 -0.2897838 0.03347358 
Q53GQ0 DHB12 1.12531917 0.03353059 
Q49AR2 CE022 -0.3750434 0.03360422 
Q13363-2 CTBP1 -0.3557922 0.0336296 
P49006 MRP -0.5129918 0.03405043 
O43395 PRPF3 0.30222216 0.03450002 
P23368 MAOM 0.23961596 0.03467032 
Q99543-2 DNJC2 -0.823313 0.03499295 
F8VQE1 F8VQE1 -0.1669062 0.03517794 
Q9P289-2 MST4 0.08208894 0.03597858 
O60443 DFNA5 -0.4177737 0.03616795 
A6NKG5 RTL1 -0.3425707 0.03617421 
Q15424 SAFB1 -0.3006997 0.03633811 
P78417 GSTO1 -0.2072622 0.03641052 
Q96EK6 GNA1 0.61253634 0.03654984 
Q9NYY8-2 FAKD2 -0.9443297 0.03658897 
Q99426 TBCB -0.2930028 0.03659576 
B1ALU1 B1ALU1 -0.3315986 0.03670205 
B4DJP7 B4DJP7 0.62809837 0.03678863 
B7Z452 B7Z452 0.24349333 0.03705886 
O75396 SC22B -0.2515568 0.03729855 
P23921 RIR1 -0.2817969 0.03740107 
B9A018 B9A018 0.33971415 0.03751816 
Q9Y4L1 HYOU1 0.04644909 0.03791438 
Q14697 GANAB -0.2625225 0.03822151 
Q9NZZ3 CHMP5 0.22072787 0.03862693 
P23381 SYWC 0.18235385 0.03881231 
Q8IYB3-2 SRRM1 -0.6195964 0.03907963 
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P35579 MYH9 0.07577479 0.03909937 
P50502 F10A1 -0.3946793 0.03942084 
Q9H4M9 EHD1 0.16213619 0.03975718 
P48681 NEST -0.134334 0.03996942 
P18583-2 SON 0.2439199 0.03997056 
O60841 IF2P -0.3909038 0.04066065 
Q13155 AIMP2 -0.2628297 0.04098395 
P55263 ADK 0.07447996 0.04253146 
P49792 RBP2 -0.3511754 0.04270022 
P09525 ANXA4 -0.1629169 0.04286451 
Q9H8Y8-2 GORS2 0.46304416 0.04389657 
Q12906 ILF3 -0.1767016 0.04432012 
Q8NCW5-2 NNRE 0.30792536 0.04462927 
Q14195-2 DPYL3 0.05430598 0.04492902 
Q9UIG0-2 BAZ1B 0.31603205 0.04509509 
O14929 HAT1 -0.3393296 0.04532541 
P06730 IF4E -0.6308994 0.04570401 
E9PF19 E9PF19 -0.2223048 0.04576374 
H3BPJ9 H3BPJ9 -0.5487046 0.04657484 
Q9NRR5 UBQL4 -0.3687411 0.04674124 
Q15477 SKIV2 -0.2740043 0.04698422 
P07737 PROF1 0.29339578 0.04701896 
P46821 MAP1B -0.2355988 0.04704407 
Q9H0S4-2 DDX47 -0.4317449 0.04760638 
Q14258 TRI25 0.25492191 0.04762559 
P22314 UBA1 0.07135596 0.04780925 
Q8N1F7 NUP93 -0.1394137 0.04790679 
E9PN17 E9PN17 -0.754698 0.04790809 
Q9Y6H1 CHCH2 -0.5063266 0.04810517 
O95347 SMC2 -0.3909784 0.04810562 
Q8WWM9 CYGB -0.5002084 0.04844401 
Q86TX2 ACOT1 -0.1777046 0.04865176 
P61006 RAB8A 0.57423884 0.04894231 
P39019 RS19 0.13328324 0.04930969 
P13667 PDIA4 -0.1062504 0.04944285 
Q13620-3 CUL4B -0.2918901 0.04954965 
 
